Canopy Growth (CGC) 10-K 22 Jun 23 2023 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - CAD ($) $ in Billions	12 Months Ended
	Mar. 31, 2023	Jun. 20, 2023	Sep. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Registrant Name	Canopy Growth Corporation
Entity Central Index Key	0001737927
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Entity Well Known Seasoned Issuer	No
Entity Public Float			$ 1.3
Entity Common Stock, Shares Outstanding		586,619,644
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common shares, no par value
Trading Symbol	CGC
Security Exchange Name	NASDAQ
Entity File Number	001-38496
Entity Incorporation, State or Country Code	Z4
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	1 Hershey Drive
Entity Address, City or Town	Smiths Falls
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	K7A 0A8
City Area Code	855
Local Phone Number	558-9333
Document Annual Report	true
Document Transition Report	false
ICFR Auditor Attestation Flag	true
Auditor Firm ID	85
Auditor Name	KPMG LLP
Auditor Location	Ottawa, Canada

Consolidated Balance Sheets

Consolidated Balance Sheets - CAD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Current assets:
Cash and cash equivalents	$ 677,007	$ 776,005
Short-term investments	105,595	595,651
Restricted short-term investments	11,765	12,216
Amounts receivable, net	93,987	86,581
Inventory	148,901	204,539
Prepaid expenses and other assets	39,999	52,620
Total current assets	1,077,254	1,727,612
Other financial assets	568,292	800,328
Property, plant and equipment	499,466	942,780
Intangible assets	188,719	252,695
Goodwill	85,563	1,866,503
Other assets	19,804	15,342
Total assets	2,439,098	5,605,260
Current liabilities:
Accounts payable	76,234	64,270
Other accrued expenses and liabilities	75,991	75,278
Current portion of long-term debt and convertible debentures	556,890	9,296
Other liabilities	94,727	64,346
Total current liabilities	803,842	213,190
Long-term debt	749,991	1,491,695
Deferred income tax liabilities	357	15,991
Liability arising from Acreage Arrangement		47,000
Warrant derivative liability		26,920
Other liabilities	124,886	190,049
Total liabilities	1,679,076	1,984,845
Commitments and contingencies
Redeemable noncontrolling interest		32,500
Canopy Growth Corporation shareholders' equity:
Common shares - $nil par value; Authorized - unlimited number of shares; Issued - 517,305,551 shares and 394,422,604 shares, respectively	7,938,571	7,482,809
Additional paid-in capital	2,506,485	2,521,246
Accumulated other comprehensive loss	(13,860)	(42,282)
Deficit	(9,672,761)	(6,378,199)
Total Canopy Growth Corporation shareholders' equity	758,435	3,583,574
Noncontrolling interests	1,587	4,341
Total shareholders' equity	760,022	3,587,915
Total liabilities and shareholders' equity	$ 2,439,098	$ 5,605,260

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - shares	Mar. 31, 2023	Mar. 31, 2022
Statement of Financial Position [Abstract]
Common stock, shares issued	517,305,551	394,422,604

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenue	$ 450,901	$ 572,214	$ 607,198
Excise taxes	47,997	61,893	60,549
Net revenue	402,904	510,321	546,649
Cost of goods sold	507,044	713,457	479,689
Gross margin	(104,140)	(203,136)	66,960
Operating expenses
Selling, general and administrative expenses	456,225	472,756	575,389
Share-based compensation	31,188	47,525	91,149
Expected credit losses on financial assets and related charges			109,480
Asset impairment and restructuring costs	2,256,742	369,339	534,398
Total operating expenses	2,744,155	889,620	1,310,416
Operating loss	(2,848,295)	(1,092,756)	(1,243,456)
Loss from equity method investments		(100)	(52,629)
Other income (expense), net	(466,025)	753,341	(387,876)
Loss before income taxes	(3,314,320)	(339,515)	(1,683,961)
Income tax recovery	4,774	8,948	13,141
Net loss	(3,309,546)	(330,567)	(1,670,820)
Net (loss) income attributable to noncontrolling interests and redeemable noncontrolling interest	(31,388)	(20,524)	74,100
Net income (loss) attributable to Canopy Growth Corporation	$ (3,278,158)	$ (310,043)	$ (1,744,920)
Basic loss per share	$ (7.07)	$ (0.79)	$ (4.69)
Diluted loss per share	$ (7.07)	$ (0.79)	$ (4.69)
Basic weighted average common shares outstanding	463,724,414	391,324,285	371,662,296
Diluted weighted average common shares outstanding	463,724,414	391,324,285	371,662,296
Comprehensive income (loss):
Net loss	$ (3,309,546)	$ (330,567)	$ (1,670,820)
Other comprehensive income (loss), net of income tax effect
Fair value changes of own credit risk of financial liabilities	30,722	21,180	(100,170)
Foreign currency translation	27,207	(45,352)	(154,969)
Total other comprehensive income (loss), net of income tax effect	57,929	(24,172)	(255,139)
Comprehensive loss	(3,251,617)	(354,739)	(1,925,959)
Comprehensive (loss) income attributable to noncontrolling interests and redeemable noncontrolling interest	(31,388)	(20,524)	74,100
Comprehensive loss attributable to Canopy Growth Corporation	$ (3,220,229)	$ (334,215)	$ (2,000,059)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Beginning balance	$ 3,587,915	$ 3,486,520	$ 5,108,120
Other issuances of common shares and warrants	140,045	267,688	27,856
Replacement equity instruments from the acquisition of Supreme Cannabis		18,916
Exercise of warrants			245,186
Exercise of Omnibus Plan stock options	281	5,567	156,897
Share-based compensation	25,322	46,686	87,322
Completion of plan of arrangement with RIV Capital			(153,935)
Changes in redeemable noncontrolling interest	51,897	102,800	(65,550)
Ownership changes relating to noncontrolling interests	710	839	6,583
Redemption of redeemable noncontrolling interest	(34,012)	(2,492)
Settlement of unsecured senior notes	235,758
Disposal of consolidated entities		16,130
Comprehensive (loss) income	(3,251,617)	(354,739)	(1,925,959)
Ending balance	760,022	3,587,915	3,486,520
Cumulative effect from adoption of ASU 2020-06
Statement [Line Items]
Beginning balance	3,723
Ending balance		3,723
Common Shares
Statement [Line Items]
Beginning balance	7,482,809	7,168,557	6,373,544
Other issuances of common shares and warrants	141,996	298,145	61,809
Exercise of warrants			315,699
Exercise of Omnibus Plan stock options	1,597	8,855	244,170
Issuance and vesting of restricted share units	20,398	7,252	3,051
Completion of plan of arrangement with RIV Capital			170,284
Redemption of redeemable noncontrolling interest	26,506
Settlement of unsecured senior notes	265,265
Ending balance	7,938,571	7,482,809	7,168,557
Additional Paid-in capital | Share-based Reserve
Statement [Line Items]
Beginning balance	492,041	480,786	517,741
Other issuances of common shares and warrants	(1,951)	(30,457)	(33,953)
Replacement equity instruments from the acquisition of Supreme Cannabis		5,566
Exercise of Omnibus Plan stock options	(1,316)	(3,288)	(87,273)
Share-based compensation	25,322	46,686	87,322
Issuance and vesting of restricted share units	(20,398)	(7,252)	(3,051)
Ending balance	498,150	492,041	480,786
Additional Paid-in capital | Share-based Reserve | Cumulative effect from adoption of ASU 2020-06
Statement [Line Items]
Beginning balance	4,452
Ending balance		4,452
Additional Paid-in capital | Warrants
Statement [Line Items]
Beginning balance	2,581,788	2,568,438	2,638,951
Replacement equity instruments from the acquisition of Supreme Cannabis		13,350
Exercise of warrants			(70,513)
Ending balance	2,581,788	2,581,788	2,568,438
Additional Paid-in capital | Ownership Changes
Statement [Line Items]
Beginning balance	(509,723)	(512,340)	(501,403)
Completion of plan of arrangement with RIV Capital			(10,976)
Changes in redeemable noncontrolling interest	4,723
Ownership changes relating to noncontrolling interests			39
Redemption of redeemable noncontrolling interest	(16,961)	2,617
Ending balance	(521,961)	(509,723)	(512,340)
Additional Paid-in capital | Redeemable Noncontrolling Interest
Statement [Line Items]
Beginning balance	(42,860)	(121,234)	(40,134)
Changes in redeemable noncontrolling interest	17,630	83,483	(83,627)
Ownership changes relating to noncontrolling interests			2,527
Redemption of redeemable noncontrolling interest	(26,262)	(5,109)
Ending balance	(51,492)	(42,860)	(121,234)
Accumulated Other Comprehensive Income (Loss)
Statement [Line Items]
Beginning balance	(42,282)	(34,240)	220,899
Settlement of unsecured senior notes	(29,507)
Disposal of consolidated entities		16,130
Comprehensive (loss) income	57,929	(24,172)	(255,139)
Ending balance	(13,860)	(42,282)	(34,240)
Deficit
Statement [Line Items]
Beginning balance	(6,378,199)	(6,068,156)	(4,323,236)
Redemption of redeemable noncontrolling interest	(15,675)
Comprehensive (loss) income	(3,278,158)	(310,043)	(1,744,920)
Ending balance	(9,672,761)	(6,378,199)	(6,068,156)
Deficit | Cumulative effect from adoption of ASU 2020-06
Statement [Line Items]
Beginning balance	(729)
Ending balance		(729)
Noncontrolling Interests
Statement [Line Items]
Beginning balance	4,341	4,709	221,758
Completion of plan of arrangement with RIV Capital			(313,243)
Changes in redeemable noncontrolling interest	29,544	19,317	18,077
Ownership changes relating to noncontrolling interests	710	839	4,017
Redemption of redeemable noncontrolling interest	(1,620)
Comprehensive (loss) income	(31,388)	(20,524)	74,100
Ending balance	$ 1,587	$ 4,341	$ 4,709

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (3,309,546)	$ (330,567)	$ (1,670,820)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant and equipment	56,736	76,247	70,914
Amortization of intangible assets	27,781	38,171	56,204
Share of loss on equity method investments		100	52,629
Share-based compensation	31,188	47,525	91,149
Asset impairment and restructuring costs	2,227,989	332,949	519,209
Expected credit losses on financial assets and related charges			109,480
Income tax recovery	(4,774)	(8,948)	(13,141)
Non-cash fair value adjustments and charges related to settlement of unsecured senior notes	353,827	(866,739)	380,758
Change in operating assets and liabilities, net of effects from purchases of businesses:
Amounts receivable	(9,906)	13,603	(11,994)
Inventory	55,638	173,037	23,107
Prepaid expenses and other assets	2,484	24,552	77
Accounts payable and accrued liabilities	17,629	(35,844)	16,542
Other, including non-cash foreign currency	(6,592)	(9,897)	(89,843)
Net cash used in operating activities	(557,546)	(545,811)	(465,729)
Cash flows from investing activities:
Purchases of and deposits on property, plant and equipment	(9,217)	(36,684)	(164,502)
Purchases of intangible assets	(1,337)	(11,429)	(9,639)
Proceeds on sale of property, plant and equipment	13,609	27,279	45,921
Proceeds on sale of intangible assets			18,337
Redemption (purchases) of short-term investments	502,589	545,991	(459,834)
Cash outflow on completion of RIV Arrangement			(152,801)
Net cash proceeds on sale of subsidiaries	14,932	118,149
Net cash outflow on acquisition of subsidiaries	(24,223)	(14,947)
Sale of equity method investments			7,000
Investment in other financial assets	(67,150)	(379,414)	(44,721)
Investment in Acreage Arrangement			(49,849)
Loan advanced to Acreage Hempco			(66,995)
Other investing activities	4,176	(18,126)	(7,022)
Net cash provided by (used in) investing activities	433,379	230,819	(884,105)
Cash flows from financing activities:
Proceeds from issuance of common shares and warrants	1,049	2,700
Proceeds from exercise of stock options	281	5,567	156,897
Proceeds from exercise of warrants			245,186
Issuance of long-term debt and convertible debentures	135,160		893,160
Repayment of long-term debt	(118,179)	(50,763)	(15,619)
Other financing activities	(38,005)	(3,037)	(14,855)
Net cash (used in) provided by financing activities	(19,694)	(45,533)	1,264,769
Effect of exchange rate changes on cash and cash equivalents	44,863	(18,123)	(63,458)
Net decrease in cash and cash equivalents	(98,998)	(378,648)	(148,523)
Cash and cash equivalents, beginning of period	776,005	1,154,653	1,303,176
Cash and cash equivalents, end of period	677,007	776,005	1,154,653
Cash received during the period:
Income taxes	5,511	1,299	4,068
Interest	28,500	16,175	26,279
Cash paid during the period:
Income taxes	1,184	2,641	22,769
Interest	131,824	119,249	25,649
Noncash investing and financing activities
Additions to property, plant and equipment	$ 38	$ 1,408	$ 9,962

Description of Business

Description of Business	12 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	1 . DESCRIPTION OF BUSINESS Canopy Growth Corporation is a publicly traded corporation, incorporated in Canada, with its head office located at 1 Hershey Drive, Smiths Falls, Ontario. References in these consolidated financial statements to “Canopy Growth” or “the Company” refer to Canopy Growth Corporation and its subsidiaries. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada pursuant to the Cannabis Act , SC 2018, c 16 (the “ Cannabis Act ”) , which came into effect on October 17, 2018 and regulates both the medical and adult-use cannabis markets in Canada. The Company has also expanded to jurisdictions outside of Canada where cannabis and/or hemp is federally lawful, permissible and regulated, and the Company, through its’ subsidiaries, operates in the United States, Germany, and certain other global markets. Additionally, the Company produces, distributes and sells a range of other consumer products globally, including vaporizers; beauty, skincare, wellness and sleep products; and sports nutrition beverages.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	2 . BASIS OF PRESENTATION The consolidated financial statements have been presented in Canadian dollars and are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Canopy Growth has determined that the Canadian dollar is the most relevant and appropriate reporting currency as, despite continuing shifts in the relative size of our operations across multiple geographies, the majority of our operations are conducted in Canadian dollars and our financial results are prepared and reviewed internally by management in Canadian dollars. Our consolidated financial statements, and the financial information contained herein, are reported in thousands of Canadian dollars, except share and per share amounts or as otherwise stated. Going Concern The consolidated financial statements have been prepared in accordance with generally accepted accounting principles on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As reflected in the consolidated financial statements, the Company has certain material debt obligations coming due in the short-term, has suffered recurring losses from operations and requires additional financing to fund its business and operations. If the Company is unable to raise additional capital, it is possible that it will be unable to meet certain of its financial obligations. For example, the Company may not be able to satisfy the minimum liquidity covenant under its credit facility during its first quarter of fiscal year 2025, which breach could trigger an acceleration of its senior secured indebtedness. As of March 31, 2023, the Company had $ 467,957 in required principal repayments under debt obligations to be settled in cash due within the next 12 months, and cash flow from operations was negative throughout fiscal 2023. As of March 31, 2023, the Company had cash and cash equivalents of $ 677,007 and short-term investments of $ 105,595 , which are predominantly invested in liquid securities issued by the United States government. These matters, when considered in the aggregate raise substantial doubt about the Company’s ability to continue as a going concern for at least twelve months from the issuance of these consolidated financial statements. In view of these matters, continuation as a going concern is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financial requirements and to raise additional capital, and the success of its future operations. The consolidated financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company not continue as a going concern. Management plans to fund the operations and debt obligations of the Company through existing cash positions and proceeds from the sale of certain of the Company’s facilities. The Company is also currently evaluating several different strategies and intends to pursue actions that are expected to increase its liquidity position, including, but not limited to, pursuing additional actions under the Company's cost-savings plan, seeking additional financing from both the public and private markets through the issuance of equity and/or debt securities, and monetizing additional assets. The Company's management cannot provide assurances that the Company will be successful in accomplishing any of its proposed financing plans. Management also cannot provide any assurance as to unforeseen circumstances that could occur within the next 12 months or, if the Company raises capital, thereafter, which could increase the Company’s need to raise additional capital on an immediate basis, which capital may not be available to the Company. Restatement of Previously Issued Consolidated Financial Statements In connection with the preparation of the Company’s consolidated financial statements for the year ended March 31, 2023, management of the Company identified certain trends in the booking of sales by the BioSteel Sports Nutrition Inc. (“BioSteel”) business unit for further review. The Company, together with independent external counsel and forensic accountants, and under the oversight of the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of the Company, initiated an internal review of the financial reporting matters related to BioSteel (the “BioSteel Review”). On May 4, 2023, the Company, in consultation with the Audit Committee, concluded that the Company’s (i) audited consolidated financial statements for the fiscal year ended March 31, 2022, included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2022 (the “2022 10-K”), and (ii) unaudited consolidated financial statements for the quarterly periods ended June 30, 2022, September 30, 2022 and December 31, 2022, included in the Company’s Quarterly Reports on Form 10-Q for such quarterly periods (collectively, the “Form 10-Qs” and together with the 2022 10-K, the “Prior Financial Statements”), should no longer be relied upon because of certain material misstatements contained in the Prior Financial Statements. The BioSteel Review focused on the timing of revenue recognition in accordance with U.S. GAAP under ASC 606, Revenue from Contracts with Customers, and the correction of the misstatements has reduced certain revenues previously recognized and adjusted related balance sheet items in the Prior Financial Statements, including certain segment disclosures (the “Restatement Items”). A summary of the corrected misstatements is as follows: Revenue Recognition As a result of the BioSteel Review, misstatements in the Company's recognition of revenue pursuant to ASC 606 were identified, primarily in relation to the Company's "business-to-business" sales to customers in international markets, including wholesalers, distributors, and retailers. The Company concluded that revenue was incorrectly recognized in certain situations in which: (i) the product ordered by the customer had not been shipped, and therefore control of the product had not been transferred to the customer; (ii) the product was shipped without a legally enforceable written, oral or implied contract with the customer that specified each party's rights regarding the goods to be transferred and the payment terms; or (iii) product had been shipped, and ultimately not accepted by the customer, because the product did not have the required remaining shelf life to be sold through by the customer in a primary sales channel. Redeemable noncontrolling interest in BioSteel As a result of the misstatements related to BioSteel's recognition of revenue, the Company considered the impact on the redeemable noncontrolling interest in BioSteel and determined that its redemption value would decline for the year ended March 31, 2022, and for the quarterly periods ended June 30, 2022, September 30, 2022 and December 31, 2022. Additionally, the consideration the BioSteel shareholders and option holders received for the first tranche of the redeemable noncontrolling interest in the three months ended December 31, 2022 was based on a multiple of BioSteel's revenue which exceeded the contractual settlement consideration after correcting for the revenue misstatements. The excess has been recognized in the three months ended September 30, 2022 as an increase to the deficit for certain employee and non-employee shareholders, and as share-based compensation expense for certain employee and consultant option holders. No gain contingency has been recognized for the excess. Goodwill In considering the misstatements related to revenue recognition and the associated correction of these misstatements through the reduction of previously recognized revenue for BioSteel, the Company determined there to be an indicator of impairment for the BioSteel reporting unit as of September 30, 2022 and, as a result, the Company performed a quantitative interim goodwill impairment assessment for the BioSteel reporting unit as of September 30, 2022. The Company concluded that the carrying value of the BioSteel reporting unit was higher than its estimated fair value, and a goodwill impairment loss totaling $ 57,401 was recognized in the three months ended September 30, 2022, representing the entirety of the goodwill assigned to the BioSteel reporting unit. Accordingly, the Company has restated its Prior Financial Statements for the quarterly periods ended September 30, 2022 and December 31, 2022. Impact of Restatement The Company evaluated the materiality of these misstatements both qualitatively and quantitatively in accordance with Staff Accounting Bulletin (“SAB”) No. 99, Materiality , and SAB No. 108, Considering the Effects of Prior Year Misstatements in Current Year Financial Statements , and determined the effect of correcting these misstatements was material to the Prior Financial Statements. As a result of the material misstatements, we have restated our Prior Financial Statements in accordance with Accounting Standards Codification (“ASC”) 250, Accounting Changes and Error Corrections (the “Restated Financial Statements”). A reconciliation from the previously reported amounts in the Prior Financial Statements to the restated amounts in the Restated Financial Statements is provided for the impacted financial statement line items below for: (i) the consolidated balance sheet as of March 31, 2022; (ii) the consolidated statement of operations and comprehensive loss for the year ended March 31, 2022; (iii) the consolidated statement of shareholders’ equity for the year ended March 31, 2022; and (iv) the consolidated statement of cash flows for the year ended March 31, 2022. The previously reported amounts in the Prior Financial Statements are labeled as “As Previously Reported” in the tables below. The amounts labelled “Restatement Adjustments” represent the effects of the restatement described above. Also see Note 36, “Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements.” The following table presents the effect of the Restatement Items on the Company’s consolidated balance sheet as of March 31, 2022 (in thousands, except number of shares and per share data): March 31, 2022 As Previously Reported Restatement Adjustment As Restated Amounts receivable, net $ 96,443 $ ( 9,862 ) $ 86,581 Inventory 204,387 152 204,539 Prepaid expenses and other assets 52,700 ( 80 ) 52,620 Total current assets 1,737,402 ( 9,790 ) 1,727,612 Total assets 5,615,050 ( 9,790 ) 5,605,260 Other liabilities 64,054 292 64,346 Total current liabilities 212,898 292 213,190 Total liabilities 1,984,553 292 1,984,845 Redeemable noncontrolling interest 36,200 ( 3,700 ) 32,500 Additional paid-in capital 2,519,766 1,480 2,521,246 Deficit ( 6,370,337 ) ( 7,862 ) ( 6,378,199 ) Total Canopy Growth Corporation shareholders' equity 3,589,956 ( 6,382 ) 3,583,574 Total shareholders' equity 3,594,297 ( 6,382 ) 3,587,915 Total liabilities and shareholders' equity 5,615,050 ( 9,790 ) 5,605,260 The correction of the revenue misstatement described above resulted in a decrease of $ 9,862 in amounts receivable, net, and a corresponding increase in the deficit. Additionally, the correction of the misstatement described above resulted in a decrease in redeemable noncontrolling interest of $ 3,700 and an increase in additional paid-in-capital of $ 1,480 . The following table presents the effect of the Restatement Items on the Company’s consolidated statement of operations and comprehensive loss for the year ended March 31, 2022 (in thousands, except number of shares and per share data): Year ended March 31, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 582,218 $ ( 10,004 ) $ 572,214 Net revenue 520,325 ( 10,004 ) 510,321 Cost of goods sold 713,379 78 713,457 Gross margin ( 193,054 ) ( 10,082 ) ( 203,136 ) Operating loss ( 1,082,674 ) ( 10,082 ) ( 1,092,756 ) Loss income before income taxes ( 329,433 ) ( 10,082 ) ( 339,515 ) Net loss ( 320,485 ) ( 10,082 ) ( 330,567 ) Net loss attributable to noncontrolling interests and ( 18,304 ) ( 2,220 ) ( 20,524 ) Net loss attributable to Canopy Growth Corporation ( 302,181 ) ( 7,862 ) ( 310,043 ) Basic and diluted loss per share $ ( 0.77 ) $ ( 0.02 ) $ ( 0.79 ) Basic and diluted weighted average common shares outstanding 391,324,285 - 391,324,285 Comprehensive loss: Net loss $ ( 320,485 ) $ ( 10,082 ) $ ( 330,567 ) Comprehensive loss ( 344,657 ) ( 10,082 ) ( 354,739 ) Comprehensive loss attributable to noncontrolling interests and ( 18,304 ) ( 2,220 ) ( 20,524 ) Comprehensive loss attributable to Canopy Growth Corporation ( 326,353 ) ( 7,862 ) ( 334,215 ) The correction of the revenue misstatement described above resulted in a decrease of $ 10,004 in net revenue and an increase in the net loss attributable to noncontrolling interests and redeemable noncontrolling interest of $ 2,220 . As a result, net loss attributable to Canopy Growth Corporation and comprehensive loss attributable to Canopy Growth Corporation were each impacted by $ 7,862 . The following table presents the effect of the Restatement Items on the Company’s consolidated statement of shareholders’ equity for the year ended March 31, 2022: March 31, 2022 As Previously Reported Restatement Adjustment As Restated Additional paid-in-capital - Redeemable noncontrolling interest $ ( 44,340 ) $ 1,480 $ ( 42,860 ) Deficit ( 6,370,337 ) ( 7,862 ) ( 6,378,199 ) Total shareholders' equity 3,594,297 ( 6,382 ) 3,587,915 The correction of the revenue misstatement described above resulted in a decrease of $ 1,480 in additional paid-in-capital - redeemable noncontrolling interest, and an increase of $ 7,862 in the deficit. In total, the impact on total shareholders' equity was a decrease of $ 6,382 . The following table presents the effect of the Restatement Items on the Company’s consolidated statement of cash flows for the year ended March 31, 2022: Year ended March 31, 2022 As Previously Reported Restatement Adjustment As Restated Net loss $ ( 320,485 ) $ ( 10,082 ) $ ( 330,567 ) Change in operating assets and liabilities, net of effects from Amounts receivable 3,741 9,862 13,603 Inventory 173,189 ( 152 ) 173,037 Prepaid expenses and other assets 24,472 80 24,552 Other, including non-cash foreign currency ( 10,189 ) 292 ( 9,897 ) Net cash used in operating activities ( 545,811 ) - ( 545,811 ) The correction of the revenue misstatement described above resulted in no net change to net cash used in operating activities. The following table presents the effect of the Restatement Items on the Company’s segmented information note for the year ended March 31, 2022: Year ended March 31, 2022 As Previously Reported Restatement Adjustment As Restated Segmented net revenue Canada cannabis $ 257,910 $ - $ 257,910 Rest-of-world cannabis 79,306 - 79,306 Storz & Bickel 85,410 - 85,410 BioSteel 44,626 ( 10,004 ) 34,622 This Works 32,296 - 32,296 Other 20,777 - 20,777 $ 520,325 $ ( 10,004 ) $ 510,321 Segmented gross margin: Canada cannabis $ ( 212,820 ) $ - $ ( 212,820 ) Rest-of-world cannabis ( 28,875 ) - ( 28,875 ) Storz & Bickel 37,284 37,284 BioSteel ( 5,640 ) ( 10,082 ) ( 15,722 ) This Works 14,800 14,800 Other 2,197 - 2,197 ( 193,054 ) ( 10,082 ) ( 203,136 ) Operating loss ( 1,082,674 ) ( 10,082 ) ( 1,092,756 ) Loss before incomes taxes $ ( 329,433 ) $ ( 10,082 ) $ ( 339,515 ) The correction of the revenue misstatement described above resulted in a decrease of $ 10,004 in revenue associated with the BioSteel reportable segment. The remainder of the notes to the Company’s consolidated financial statements have been updated and restated, as applicable, to reflect the impacts of the restatement described above. Principles of consolidation The accompanying consolidated financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation. Variable interest entities A variable interest entity (“VIE”) is an entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured such that equity investors lack the ability to control the entity’s activities or do not substantially participate in the gains and losses of the entity. Upon inception of a contractual agreement, and thereafter, if a reconsideration event occurs, the Company performs an assessment to determine whether the arrangement contains a variable interest in an entity and whether that entity is a VIE. The primary beneficiary of a VIE is the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Under ASC 810 – Consolidations , where the Company concludes that it is the primary beneficiary of a VIE, the Company consolidates the accounts of that VIE. Equity method investments Investments accounted for using the equity method include those investments where the Company: (i) can exercise significant influence over the other entity and (ii) holds common stock and/or in-substance common stock of the other entity. Under the equity method, investments are carried at cost, and subsequently adjusted for the Company’s share of net income (loss), comprehensive income (loss) and distributions received from the investee. If the current fair value of an investment falls below its carrying amount, this may indicate that an impairment loss should be recorded. Any impairment losses recognized are not reversed in subsequent periods. Use of estimates The preparation of these consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ from those estimates.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3 . SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Foreign currency translation In preparing the financial statements of individual entities, transactions in currencies other than the entity’s functional currency are recognized at exchange rates in effect on the date of the transactions. At each reporting date monetary assets and liabilities denominated in foreign currencies are re-translated at the exchange rates applicable at that date. Non-monetary items carried at fair value that are denominated in foreign currencies are translated at the rates prevailing at the date when the fair value was determined. Non-monetary assets and liabilities that are measured at historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Realized and unrealized exchange gains and losses are recognized through net income (loss). For the purposes of presenting consolidated financial statements, the assets and liabilities of foreign operations are translated into Canadian dollars at the exchange rates applicable at the balance sheet date. Income and expenses, and cash flows of foreign operations are translated into Canadian dollars using average exchange rates. Exchange differences resulting from translating foreign operations are recognized in accumulated other comprehensive income (loss). Cash equivalents and short-term investments Cash equivalents consist of highly liquid investments with original maturities of three months or less. Investments with maturities or redemption dates greater than 90 days at the date of purchase are included in short-term investments. The Company’s investments in debt securities, which consist primarily of U.S. government securities and U.S. commercial paper, have been classified and accounted for using the fair value option. Unrealized gains and losses on debt securities are recognized in net income (loss). All other short-term investments are recorded at fair value with gains or losses recognized in net income (loss). Inventory Inventory consists of raw materials, supplies and consumables used in the inventory process, merchandise for sale, finished goods and work-in-process such as pre-harvested cannabis plants, by-products to be extracted, oils, gel capsules and edible products. Inventory is valued at the lower of cost and net realizable value. Costs include direct and indirect labor, consumables, materials, packaging supplies, utilities, facilities costs, quality and testing costs, production related depreciation and other overhead costs. The Company records inventory reserves for obsolete and slow-moving inventory. Inventory reserves are based on inventory obsolescence trends, age of inventory, historical experience and application of the specific identification method. The Company classifies cannabis inventory as a current asset, although part of such inventory, because of the duration of the cultivation, drying, and conversion process, ordinarily would not be utilized within one year. Property, plant and equipment Property, plant and equipment is recorded at cost less accumulated depreciation. Major additions and improvements are capitalized, while maintenance and repairs are expensed as incurred. When significant parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items or components of property, plant and equipment. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the respective accounts and any related gain or loss is recognized in net income (loss). Depreciation is calculated on a straight-line basis over the expected useful lives of the assets, which are as follows: Years Buildings and greenhouses 20 - 50 Production and warehouse equipment 5 - 30 Leasehold improvements 3 - 20 Office and lab equipment 3 - 10 Computer equipment 3 - 10 Estimates of useful life and residual value, and the method of depreciation, are reviewed only when events or changes in circumstances indicate that the current estimates or depreciation method are no longer appropriate. Any changes are accounted for on a prospective basis as a change in estimate. Intangible assets Finite lived intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Amortization is provided on a straight-line basis over the following terms: Years Intellectual property 5 - 15 Distribution channel 5 - 11 Operating licenses 5 - 8 Software and domain names 3 - 5 Brands 2 - 5 The estimated useful life and amortization method are reviewed at the end of each reporting year, with the effect of any changes in estimate being accounted for on a prospective basis. Goodwill and indefinite lived intangible assets Goodwill is allocated to the reporting unit in which the business that created the goodwill resides. A reporting unit is an operating segment, or a business unit one level below that operating segment, for which discrete financial information is prepared and regularly reviewed by segment management. The Company reviews goodwill and indefinite lived intangible assets annually for impairment in the fourth quarter, or sooner, if events or circumstances indicate that the carrying amount of an asset may not be recoverable. The Company may elect to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If factors indicate this is the case, then a quantitative test is performed and an impairment is recorded for any excess carrying value above the reporting unit’s fair value, not to exceed the amount of goodwill. Year ended March 31, 2021 Until the three months ended March 31, 2021, the Company had two operating segments, which were also its reportable segments: (i) cannabis, hemp and other consumer products; and (ii) RIV Capital Inc. (formerly Canopy Rivers Inc.) (“RIV Capital”). The goodwill associated with all acquisitions was allocated to the one reporting unit within the cannabis, hemp and other consumer products operating and reportable segment, as this reporting unit held the acquired entities. The Company changed the structure of its internal management financial reporting in the three months ended March 31, 2021 (refer to Note 35), and accordingly, identified two operating and reportable segments: (i) global cannabis; and (ii) other consumer products. The reorganization of the Company’s reporting structure changed the composition of its reporting units and required that goodwill be reassigned to the reporting units using a relative fair value allocation approach. Assets and liabilities were also reassigned to the reporting units affected based on the assets that would be employed in, or the liabilities related to, the operations of each reporting unit, and the assets or liabilities that would be considered in determining the fair value of each reporting unit. After this reorganization, the Company’s reporting units with goodwill in the global cannabis segment included: (i) cannabis operations, and (ii) C 3 Cannabinoid Compound Company GmbH (“C 3 ”); and in the other consumer products segment included: (i) Storz & Bickel GmbH (“Storz & Bickel”); (ii) This Works Products Ltd. (“This Works”); and (iii) BioSteel. Year ended March 31, 2022 In the three months ended March 31, 2022, the Company further changed the composition of its reporting units within the global cannabis segment as a result of: (i) the completion of the Company’s divestiture of its interest in C 3 (the “C 3 Divestiture”) (see Note 30(b)); and (ii) a strategic shift in the Company’s KeyLeaf Life Sciences (“KeyLeaf”) business to focus on non-cannabis extraction activities. Accordingly, goodwill was reassigned to the KeyLeaf reporting unit from the cannabis operations reporting unit, using the relative fair value allocation approach. There were no changes to the reporting units included in the Company’s other consumer products segment in the year ended March 31, 2022. The Company performed its annual goodwill impairment test in the three months ended March 31, 2022, and recognized impairment losses in relation to its KeyLeaf and This Works reporting units. Refer to Note 15 for further details. Year ended March 31, 2023 In the three months ended June 30, 2022, the Company recognized a goodwill impairment loss in relation to the cannabis operations reporting unit in the global cannabis segment, representing the entirety of the goodwill assigned to the cannabis operations reporting unit. In the three months ended September 30, 2022, following the completion of certain restructuring actions which were initiated in the three months ended March 31, 2022, and which were aligned with the Company’s strategic review of its business, the Company changed the structure of its internal management financial reporting and began reporting its financial results for the following five reportable segments: (i) Canada cannabis; (ii) Rest-of-world cannabis; (iii) Storz & Bickel; (iv) BioSteel; (v) This Works (see Note 35). There were no changes to the composition of the Company’s reporting units to which goodwill remains assigned resulting from the change in reportable segments. The Company recognized goodwill impairment losses in the three months ended September 30, 2022 in relation to its This Works reporting unit and BioSteel reporting unit. In the three months ended March 31, 2023, the Company performed its annual goodwill impairment test and noted no additional impairments. Refer to Note 15 for further details. Indefinite lived intangible assets are comprised of certain acquired brand names and operating licenses, which are carried at cost less accumulated impairment losses. The Company reviews the classification each reporting period to decide whether the assessment made about the useful life as indefinite or finite is still appropriate. Any change is accounted for on a prospective basis as a change in estimate. Impairment of long-lived assets The Company evaluates the recoverability of long-lived assets, including property, plant and equipment and finite lived intangible assets whenever events or changes in circumstances indicate a potential impairment exists. The Company groups assets at the lowest level for which cash flows are separately identifiable, referred to as an asset group. When indicators of potential impairment are present the Company prepares a projected undiscounted cash flow analysis for the respective asset or asset group. If the sum of the undiscounted cash flow is less than the carrying value of the asset or asset group, an impairment loss is recognized equal to the excess of the carrying value over the fair value, if any. Restricted short-term investments The Company considers short-term investments to be restricted when withdrawal or general use is legally restricted. The Company records restricted short-term investments as current or non-current in the consolidated balance sheets based on the classification of the underlying securities. Redeemable noncontrolling interest Redeemable noncontrolling interest is presented as mezzanine equity. The balance of the redeemable noncontrolling interest is reported at the greater of the initial carrying amount adjusted for the redeemable noncontrolling interest’s share of earnings or losses and other comprehensive income or loss, or its estimated redemption value. The Company adjusts the carrying amount of the redeemable interest to the redemption amount each period, assuming the interest was redeemable at the balance sheet date with changes in fair value recorded in equity. Revenue recognition The Company’s cannabis revenue is comprised of sales of: (i) adult-use cannabis products in Canada, either to government agencies or third-party retailers under a “business-to-business” wholesale model, or directly to consumers through the Company’s network of retail stores and e-commerce platforms; and (ii) medical and other cannabis products in Canada and certain other countries. The Company’s other revenue is comprised of sales of vaporizers, beauty, wellness and sleep products, sports nutrition beverages, merchandise, and revenue from other sources. The Company’s revenue-generating activities have a single performance obligation and revenue is recognized at the point in time when control of the product transfers and the Company’s obligations have been fulfilled. This generally occurs when the product is shipped or delivered to the customer, depending upon the method of distribution and shipping terms set forth in the customer contract. In accordance with contracts with certain of the Company’s Canadian provincial customers, the Company fulfills its obligations only when the customer transfers control of the product to the end consumer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for the sale of the Company’s product. Certain of the Company’s customer contracts, most notably those with the Canadian provincial and territorial agencies, may provide the customer with a right of return. In certain circumstances the Company may also provide a retrospective price adjustment to a customer. These items give rise to variable consideration, which is recognized as a reduction of the transaction price based upon the expected amounts of the product returns and price adjustments at the time revenue for the corresponding product sale is recognized. The determination of the reduction of the transaction price for variable consideration requires that the Company make certain estimates and assumptions that affect the timing and amounts of revenue recognized. The Company estimates this variable consideration by taking into account factors such as historical information, current trends, forecasts, provincial and territorial inventory levels, availability of actual results and expectations of demand. The Company recognizes a liability for sales refunds within other current liabilities, and an asset for the value of inventory which is expected to be returned is recognized within prepaid expenses and other assets on the consolidated balance sheets. Sales of products are for cash or otherwise agreed-upon credit terms. The Company’s payment terms vary by location and customer; however, the time period between when revenue is recognized and when payment is due is not significant. The Company estimates and reserves for its bad debt exposure based on its experience with past due accounts and collectability, write-off history, the aging of accounts receivable and an analysis of customer data. Cost of goods sold The types of costs included in cost of goods sold are raw materials, packaging materials, manufacturing costs, plant facilities administrative support and overheads, and freight and warehouse costs, including distribution costs. Advertising Advertising costs are expensed as incurred. Advertising expenses totaled $ 134,403 , $ 104,221 and $ 72,377 in the years ended March 31, 2023, 2022, and 2021 , respectively. Research and development Research and development costs are expensed as incurred. Research and development expenses totaled $ 21,718 , $ 32,344 , and $ 57,582 in the years ended March 31, 2023, 2022, and 2021 , respectively. Asset impairment and restructuring costs Asset impairment and restructuring costs consist of property, plant and equipment, intangible asset and goodwill impairment charges, asset abandonment costs, contractual and other settlement costs, and employee-related and other restructuring costs recognized in connection with: (i) the restructuring of the Company’s global operations that commenced in the year ended March 31, 2020 and continued during the years ended March 31, 2021, March 31, 2022 and March 31, 2023; and (ii) other impairments. Refer to Note 6 for further details. When a long-lived asset is abandoned its carrying amount is adjusted to its salvage value, if any. In determining the salvage value of our long-lived assets, management considers information from manufacturers, historical data, and industry standards. In certain cases, management may obtain third party appraisals to estimate salvage value. Share-based compensation The Company accounts for share-based compensation using the fair value method. With the exception of a limited number of share-based awards subject to market-based performance conditions that are valued using the Monte Carlo simulation model, the fair value of awards granted is estimated at the date of grant using the Black-Scholes model. The share-based compensation expense is based on the fair value of share-based awards at the grant date and the expense is recognized over the related service period following a graded vesting expense schedule. Forfeitures are estimated at the time of grant and revised in subsequent periods if there is a difference in actual forfeitures and the estimate. Effective April 1, 2018, the Company early-adopted ASU 2018-07 – Compensation - Stock Compensation (Topic 718) , which among other items, aligns the accounting for non-employee awards with that of employee awards. For awards with service and/or non-market based performance conditions, the amount of compensation expense recognized is based on the number of awards expected to vest, reflecting estimated expected forfeitures, and is adjusted to reflect those awards that do ultimately vest. For awards with performance conditions, the Company recognizes the compensation expense if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of achieving the performance condition at each reporting date. Restricted stock units (“RSUs”) that are settled in cash or common stock at the election of the employee are remeasured to fair value at the end of each reporting period until settlement. This fair value is based on the closing price of the Company’s common shares on the last business day before each period end. Income taxes Income taxes are comprised of current and deferred taxes. These taxes are accounted for using the liability method. Current tax is recognized in connection with income for tax purposes, unrealized tax benefits and the recovery of tax paid in a prior period and measured using the enacted tax rates and laws applicable to the taxation period during which the income for tax purposes arose. Deferred tax is recognized on the difference between the carrying amount of an asset or a liability, as reflected in the financial statements, and the corresponding tax base, used in the computation of income for tax purposes (“temporary difference”) and measured using the enacted tax rates and laws as at the balance sheet date that are expected to apply to the income that the Company expects to arise for tax purposes in the period during which the difference is expected to reverse. Management assesses the likelihood that a deferred tax asset will be realized and a valuation allowance is provided to the extent that it is more likely than not that all or a portion of a deferred tax asset will not be realized. The determination of both current and deferred taxes reflects the Company’s interpretation of the relevant tax rules and judgement. An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs. Income taxes are recognized in the consolidated statement of operations, except when they relate to a pre-tax item that is recognized in other comprehensive income (loss) or directly in equity, respectively. Income taxes recognized in other comprehensive income (loss) or equity are reclassified to the consolidated statement of operations if the corresponding pre-tax item is reclassified to the consolidated statement of operations. Where income taxes arise from the initial accounting for a business combination, these are embedded in the pre-tax accounting for the business combination. Interest and penalties in respect of income taxes are not recognized in the consolidated statement of operations as a component of income taxes but as a component of interest expense. Earnings (loss) per share Basic earnings (loss) per share is computed by dividing reported net income (loss) by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share is computed by dividing earnings (loss) by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Diluted earnings (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common shares of the Company during the reporting periods. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of warrants, vested share options, RSUs and the incremental shares issuable upon conversion of the convertible senior notes. As at March 31, 2023, March 31, 2022, and March 31, 2021 , all instruments were anti-dilutive. Fair value measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company calculates the estimated fair value of financial instruments using quoted market prices whenever available. When quoted market prices are not available, the Company uses standard pricing models. For other financial assets measured at fair value that earn interest, the Company has elected to present interest income as part of the fair value change in other income (expense), net.

New Accounting Policies

New Accounting Policies	12 Months Ended
	Mar. 31, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]
New Accounting Policies	4 . NEW ACCOUNTING POLICIES Recently Adopted Accounting Pronouncements Convertible Instruments and Contracts in an Entity’s Own Equity In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for convertible instruments by removing the separation models for convertible debt instruments and convertible preferred stock with (1) cash conversion features, and (2) beneficial conversion features. In addition, ASU 2020-06 enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Company adopted ASU 2020-06 on April 1, 2022, using the modified retrospective approach with the cumulative effect recognized as an adjustment to the opening deficit balance, and, accordingly, prior period balances and disclosures have not been restated. Upon adoption of ASU 2020-06, the Supreme Debentures (as defined below) are accounted for under the separation model for a substantial premium instead of a beneficial conversion feature resulting in an increased debt discount to be amortized over the life of the instrument. The adoption of this guidance resulted in increased additional paid-in capital by $ 4,452 , decreased long-term debt by $ 3,723 , and decreased accumulated deficit by $ 729 for non-cash accretion expense prior to April 1, 2022.

Canopy USA

Canopy USA	12 Months Ended
	Mar. 31, 2023
Reorganizations [Abstract]
Canopy USA	5 . CANOPY USA Reorganization - Creation of Canopy USA On October 24, 2022, Canopy Growth completed a number of strategic transactions in connection with the creation of Canopy USA, LLC ("Canopy USA"), a new U.S.-domiciled holding company (the “Reorganization”). Following the implementation of the Reorganization, Canopy USA, as of October 24, 2022, holds certain U.S. cannabis investments previously held by Canopy Growth, which is expected to enable Canopy USA, following, among other things, the Meeting (as defined below) and the exercise of the Acreage Option (as defined below), including the issuance of the Fixed Shares (as defined below) to Canopy USA, to consummate the acquisitions of Acreage Holdings, Inc. (“Acreage”), Mountain High Products, LLC, Wana Wellness, LLC and The Cima Group, LLC (collectively, “Wana” and each, a “Wana Entity”), and Lemurian, Inc. (“Jetty”). There were no changes recorded in the estimated fair values of the U.S. cannabis investments described below upon implementation of the Reorganization, and their transfer from Canopy Growth to Canopy USA. Following the implementation of the Reorganization, as of October 24, 2022, Canopy USA holds an ownership interest in the following assets, among others: • Wana - The options to acquire 100 % of the membership interests of Wana (the “Wana Options”), a leading cannabis edibles brand in North America. • Jetty - The options to acquire 100 % of the shares of Jetty (the “Jetty Options”), a California-based producer of high-quality cannabis extracts and pioneer of clean vape technology. Canopy Growth currently retains the option to acquire the issued and outstanding Class E subordinate voting shares (the “Fixed Shares”) of Acreage (the “Acreage Option”), representing approximately 70 % of the total shares of Acreage, at a fixed share exchange ratio of 0.3048 of a common share of Canopy Growth per Fixed Share. Concurrently with the closing of the acquisition of the Fixed Shares pursuant to the exercise of the Acreage Option, the Fixed Shares will be issued to Canopy USA. In addition, Canopy USA has agreed to acquire all of the issued and outstanding Class D subordinate voting shares of Acreage (the “Floating Shares”) by way of a court-approved plan of arrangement (the “Floating Share Arrangement”) in exchange for 0.45 of a common share of Canopy Growth for each Floating Share held. Acreage is a leading vertically-integrated multi-state cannabis operator, with its main operations in densely populated states across the Northeast U.S. including New Jersey and New York. In addition, as of October 24, 2022, Canopy USA held direct and indirect interests in the capital of TerrAscend Corp. (“TerrAscend”), a leading North American cannabis operator with vertically integrated operations and a presence in Pennsylvania, New Jersey, Michigan and California as well as licensed cultivation and processing operations in Maryland. Canopy USA’s direct and indirect interests in TerrAscend included: (i) 38,890,570 exchangeable shares in the capital of TerrAscend (the “TerrAscend Exchangeable Shares”), an option to purchase 1,072,450 TerrAscend common shares (the “TerrAscend Common Shares”) for an aggregate purchase price of $ 1.00 (the “TerrAscend Option”) and 22,474,130 TerrAscend Common Share purchase warrants previously held by Canopy Growth (the “TerrAscend Warrants”); and (ii) the debentures and loan agreement between Canopy Growth and certain TerrAscend subsidiaries. On December 9, 2022, Canopy USA and certain limited partnerships that are controlled by Canopy USA entered into a debt settlement agreement with TerrAscend and certain of its subsidiaries whereby all of the debt obligations, including all principal and interest, were extinguished and all of the previously issued TerrAscend Warrants controlled by Canopy USA were cancelled in exchange for the issuance of 24,601,467 TerrAscend Exchangeable Shares and 22,474,130 new TerrAscend Warrants expiring on December 31, 2032 . See Note 12 for further details. Following the implementation of the Reorganization Canopy USA was determined to be a VIE pursuant to ASC 810 - Consolidations and prior to the completion of the Reorganization Amendments (as defined below), Canopy Growth was determined to be the primary beneficiary of Canopy USA. As a result of such determination and in accordance with ASC 810, Canopy Growth consolidated the financial results of Canopy USA. On May 19, 2023, the Company and Canopy USA restructured the Company’s interests in Canopy USA by implementing the Reorganization Amendments such that the Company does not expect to consolidate the financial results of Canopy USA within the Company’s financial statements in accordance with U.S. GAAP. Refer to discussion below for further information regarding the Reorganization Amendments. Ownership of U.S. Cannabis Investments Following the implementation of the Reorganization, the shares and interests in Acreage, Wana, Jetty and TerrAscend are held, directly or indirectly, by Canopy USA, and Canopy Growth no longer holds a direct interest in any shares or interests in such entities, other than the Acreage Option. Canopy Growth holds non-voting and non-participating shares (the “Non-Voting Shares”) in the capital of Canopy USA. The Non-Voting Shares do not carry voting rights, rights to receive dividends or other rights upon dissolution of Canopy USA. Following the Reorganization Amendments, the Non-Voting Shares are convertible into Class B shares of Canopy USA (the “Canopy USA Class B Shares”). The Company also has the right (regardless of the fact that its Non-Voting Shares are non-voting and non-participating) to appoint one member to the Canopy USA board of managers (the "Canopy USA Board"). As of March 31, 2023, a third party investor owned all of the issued and outstanding Class A shares of Canopy USA (the “Canopy USA Common Shares”) and a wholly-owned subsidiary of the Company holds Non-Voting Shares in the capital of Canopy USA, representing approximately more than 99 % of the issued and outstanding shares in Canopy USA on an as-converted basis. On October 24, 2022, Canopy USA and the Company also entered into an agreement with, among others, Nancy Whiteman, the controlling shareholder of Wana, which was amended and restated on May 19, 2023, whereby subsidiaries of Canopy USA agreed to pay additional consideration in order to acquire the Wana Options and the future payments owed in connection with the exercise of the Wana Options (as described in Note 12 ) will be reduced to US$ 3.00 in exchange for the issuance of Canopy USA Common Shares and Canopy Growth common shares (the “Wana Amending Agreement”). In accordance with the terms of the Wana Amending Agreement, Canopy USA Common Shares and Canopy Growth common shares will be issued to the shareholders of Wana, each with a value equal to 7.5 % of the fair market value of Wana as of the later of: (i) the date that the Wana Options are exercised; and (ii) the T1 Investment (as defined below) closing date (the “Wana Valuation Date”) less any net debt of Wana as of the Wana Valuation Date plus any net cash of Wana as of Wana Valuation Date. The value of Wana and the number of Canopy USA Common Shares will be determined based on the fair market value of Wana and the Canopy USA Common Shares, respectively, as determined by an appraiser appointed by the Company and an appraiser appointed by the shareholders of Wana (and, if required, a third appraiser to be appointed by the initial two appraisers). The Canopy USA Common Shares and Canopy Growth common shares will only be issued to Ms. Whiteman, or entities controlled by Ms. Whiteman, on the later of: (i) the date of exercise of the Wana Options and (ii) the date that CBG Holdings LLC (“CBG”) and Greenstar Canada Investment Limited Partnership (“Greenstar”), indirect, wholly-owned subsidiaries of Constellation Brands, Inc. (“CBI”), have converted their Canopy Growth common shares into Exchangeable Shares (as defined below). The Wana Amending Agreement may be terminated and no Canopy USA Common Shares or Canopy Growth common shares will be issued to Ms. Whiteman, or entities controlled by Ms. Whiteman in the event that CBG and Greenstar have not converted their Canopy Growth common shares into Exchangeable Shares by the later of: (i) sixty days after the Meeting; or (ii) March 31, 2023. The Canopy USA Common Shares issuable to Ms. Whiteman, or entities controlled by Ms. Whiteman, will also be subject to a repurchase right exercisable at any time after the 36 month anniversary of the closing of the transaction contemplated by the Wana Amending Agreement (the “Wana Repurchase Right”) to repurchase all Canopy USA Common Shares that have been issued at a price per Canopy USA Common Share equal to the fair market value as determined by an appraiser. As part of this agreement, Canopy USA has granted Ms. Whiteman the right to appoint one member to the Canopy USA Board and a put right on the same terms and conditions as the Wana Repurchase Right. Canopy Growth and Canopy USA have also entered into a protection agreement (the "Protection Agreement") to provide for certain covenants in order to preserve the value of the Non-Voting Shares held by Canopy Growth until such time as the Non-Voting Shares are converted in accordance with their terms, but does not provide Canopy Growth with the ability to direct the business, operations or activities of Canopy USA. The Protection Agreement was amended and restated in connection with the Reorganization Amendments (the "A&R Protection Agreement"). Upon closing of Canopy USA’s acquisition of Acreage, Canopy Growth will receive additional Non-Voting Shares from Canopy USA in consideration for the issuance of common shares of the Company that shareholders of Acreage will receive in accordance with the terms of the Existing Acreage Arrangement Agreement (as defined below) and the Floating Share Arrangement Agreement. Until such time as Canopy Growth converts the Non-Voting Shares into Canopy USA Class B Shares, Canopy Growth will have no economic or voting interest in Canopy USA, Wana, Jetty, TerrAscend, or Acreage. Canopy USA, Wana, Jetty, TerrAscend, and Acreage will continue to operate independently of Canopy Growth. Acreage Agreements On October 24, 2022, Canopy Growth entered into an arrangement agreement with Canopy USA and Acreage, as amended (the “Floating Share Arrangement Agreement”), pursuant to which, subject to approval of the holders of the Floating Shares and the terms and conditions of the Floating Share Arrangement Agreement, Canopy USA will acquire all of the issued and outstanding Floating Shares by way of a court-approved plan on arrangement under the Business Corporations Act (British Columbia) (the “Floating Share Arrangement”) in exchange for 0.45 of a Company common share for each Floating Share held. In connection with the Floating Share Arrangement Agreement, Canopy Growth has irrevocably waived the Acreage Floating Option (as defined below) existing under the Existing Acreage Arrangement Agreement. On October 24, 2022, Canopy Growth and Canopy USA entered into voting support agreements with certain of Acreage’s directors, officers and consultants pursuant to which such persons have agreed, among other things, to vote their Floating Shares in favor of the Floating Share Arrangement, representing approximately 7.3 % of the issued and outstanding Floating Shares. In addition to shareholder and court approvals, the Floating Share Arrangement is subject to approval of the Amendment Proposal (as defined below) and applicable regulatory approvals including, but not limited to, Toronto Stock Exchange (“TSX”) approval and the satisfaction of certain other closing conditions customary in transactions of this nature. The Floating Share Arrangement received the requisite approval from the holders of Floating Shares at the special meeting of Acreage shareholders held on March 15, 2023 and on March 20, 2023 Acreage obtained a final order from the Supreme Court of British Columbia approving the Floating Share Arrangement. On March 17, 2023, the Floating Share Arrangement Agreement was amended to extend the Exercise Outside Date (as defined in the Floating Share Arrangement Agreement) from March 31, 2023 to May 31, 2023 and on May 31, 2023 the Floating Share Arrangement Agreement was further amended to extend the Exercise Outside Date to August 31, 2023. The completion of the Floating Share Arrangement is subject to satisfaction or, if permitted, waiver of certain closing conditions, including, among others, approval of the Amendment Proposal on or prior to the Exercise Outside Date. It is intended that Canopy Growth’s existing option to acquire the Fixed Shares on the basis of 0.3048 of a Company common share per Fixed Share will be exercised after the Meeting in accordance with the terms of the arrangement agreement dated April 18, 2019, as amended on May 15, 2019, September 23, 2020 and November 17, 2020 (the “Existing Acreage Arrangement Agreement”). Canopy Growth will not hold any Fixed Shares or Floating Shares. Completion of the acquisition of the Fixed Shares following exercise of the Acreage Option is subject to the satisfaction of certain conditions set forth in the Existing Acreage Arrangement Agreement. The acquisition of the Floating Shares pursuant to the Floating Share Arrangement is anticipated to occur immediately prior to the acquisition of the Fixed Shares pursuant to the Existing Acreage Arrangement Agreement in late 2023 such that 100 % of the issued and outstanding shares of Acreage will be owned by Canopy USA on closing of the acquisition of both the Fixed Shares and the Floating Shares. In addition, the Company entered into additional agreements related to Acreage that are described in Note 12. Special Shareholder Meeting In connection with the Reorganization, Canopy Growth expects to hold a special meeting of shareholders (the “Meeting”) at which Canopy Growth shareholders will be asked to consider and, if deemed appropriate, to pass a special resolution authorizing an amendment to its articles of incorporation, as amended (the “Amendment Proposal”), in order to: (i) create and authorize the issuance of an unlimited number of a new class of non-voting and non-participating exchangeable shares in the capital of Canopy Growth (the “Exchangeable Shares”); and (ii) restate the rights of the Company’s common shares to provide for a conversion feature whereby each common share may at any time, at the option of the holder, be converted into one Exchangeable Share. The Exchangeable Shares will not carry voting rights, rights to receive dividends or other rights upon dissolution of Canopy Growth but will be convertible into common shares. The Amendment Proposal must be approved by at least 66 ⅔% of the votes cast on a special resolution by Canopy Growth’s shareholders present in person or represented by proxy at the Meeting. On October 24, 2022, CBG and Greenstar entered into a voting and support agreement with Canopy Growth (the “Voting and Support Agreement”). Pursuant to the terms of the Voting and Support Agreement, CBG and Greenstar agreed, subject to the terms and conditions thereof, among other things, to vote all of the Canopy Growth common shares beneficially owned, directed or controlled, directly or indirectly, by them for the Amendment Proposal. In the event the Amendment Proposal is approved, and subject to the conversion by CBI of their Canopy Growth common shares into Exchangeable Shares, Canopy USA is expected to exercise the Wana Options and the Jetty Options. In the event the Amendment Proposal is not approved, Canopy USA will not be permitted to exercise its rights to acquire shares of Wana or Jetty and the Floating Share Arrangement Agreement will be terminated. In such circumstances, Canopy will retain the Acreage Option under the Existing Acreage Arrangement Agreement and Canopy USA will continue to hold the Wana Options and the Jetty Options, as well as the TerrAscend Exchangeable Shares and other securities in the capital of TerrAscend. In addition, the Company is contractually required to cause Canopy USA to exercise its repurchase right to acquire the Canopy USA Common Shares held by the third party investors. Balance Sheet Actions On October 24, 2022, Canopy Growth entered into agreements with certain of its lenders under its term loan credit agreement dated March 18, 2021 (the “Credit Agreement”) pursuant to which Canopy Growth agreed to tender US$ 187,500 of the principal amount outstanding thereunder at a discounted price of US$ 930 per US$ 1,000 or US$ 174,375 in the aggregate (the “Paydown”). The first payment of $ 117,528 (US $ 87,852 ) was made on November 10, 2022 to reduce the principal indebtedness by $ 126,324 (US $ 94,427 ). The second payment of $ 116,847 (US $ 87,213 ) was made on April 17, 2023 to reduce principal indebtedness by $ 125,606 (US $ 93,750 ). See Note 17 for further details. Canopy Growth also agreed with its lenders to amend certain terms of the Credit Agreement (collectively, the “Credit Agreement Amendments”). The Credit Agreement Amendments include, among other things: (i) reductions to the minimum Liquidity (as defined in the Credit Agreement) covenant to US$ 100,000 ; (ii) certain changes to the application of net proceeds from asset sales; (iii) the establishment of a new committed delayed draw term credit facility in an aggregate principal amount of US$ 100,000 ; and (iv) the elimination of the additional US$ 500,000 incremental term loan facility. Relationship with CBI In connection with the Reorganization, CBI has indicated its current intention to convert all of its common shares of the Company into Exchangeable Shares, conditional upon the approval of the Amendment Proposal. However, any decision to convert will be made by CBI in its sole discretion, and CBI is not obligated to effect any such conversion. In connection with the foregoing, on October 24, 2022, Canopy Growth entered into a consent agreement with CBG and Greenstar (the “Third Consent Agreement”), pursuant to which the parties agreed, among other things, that following the conversion by CBG and Greenstar of their respective Canopy Growth common shares into Exchangeable Shares, other than the Third Consent Agreement and the termination rights contained therein and the Canopy Notes held by Greenstar, all agreements between Canopy Growth and CBI, including the Second Amended and Restated Investor Rights Agreement, dated as of April 18, 2019, by and among certain wholly-owned subsidiaries of CBI and Canopy Growth (the “Second Amended and Restated Investor Rights Agreement”), will be terminated. Pursuant to the terms of the Third Consent Agreement, CBG and Greenstar also agreed, among other things, that at the time of the conversion by CBG and Greenstar of their Canopy Growth common shares into Exchangeable Shares, (i) CBG will surrender the warrants held by CBG to purchase 139,745,453 common shares for cancellation for no consideration; and (ii) all nominees of CBI that are currently sitting on the board of directors of Canopy Growth (the “Board”) will resign from the Board. In addition, pursuant to the Third Consent Agreement and following the Reorganization Amendments, Canopy Growth is contractually required to convert its Non-Voting Shares into Canopy USA Class B Shares and cause Canopy USA to repurchase the Canopy USA Common Shares held by certain third-party investors in Canopy USA in the event CBG and Greenstar have not converted their respective common shares into Exchangeable Shares by the later of: (i) sixty days after the Meeting; or (ii) February 28, 2023 (the “Termination Date”). The Third Consent Agreement will automatically terminate on the Termination Date. In the event that CBI does not convert its Canopy Growth common shares into Exchangeable Shares, Canopy USA will not be permitted to exercise its rights to acquire the Fixed Shares from the Company or exercise its rights under the Wana Options or Jetty Options, and the Floating Share Arrangement Agreement will be terminated. In such circumstances, Canopy Growth will retain the Acreage Option under the Existing Acreage Arrangement Agreement and Canopy USA will continue to hold the Wana Options and the Jetty Options, as well as the TerrAscend Exchangeable Shares and other securities in the capital of TerrAscend. If CBI does not convert its Canopy Growth common shares into Exchangeable Shares, the Company is also contractually required to cause Canopy USA to exercise its repurchase right to acquire the Canopy USA Common Shares held by the third party investors. Amendments to Canopy USA Structure The Company is committed to both optimizing the value of Canopy USA and remaining in compliance with the Nasdaq listing requirements. The Company and Canopy USA effectuated certain changes to the initial structure of the Company’s interest in Canopy USA such that the Company does not expect to consolidate the financial results of Canopy USA within the Company’s financial statements. These changes included, among other things, modifying the terms of the Protection Agreement between the Company, its wholly-owned subsidiary and Canopy USA as well as the terms of Canopy USA’s limited liability company agreement and amending the terms of certain agreements with third-party investors in Canopy USA to eliminate any rights to guaranteed returns (collectively, the “Reorganization Amendments”). See Note 37 for further details relating to the Reorganization Amendments.

Asset Impairment and Restructur

Asset Impairment and Restructuring Costs	12 Months Ended
	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Asset Impairment and Restructuring Costs	6 . ASSET IMPAIRMENT AND RESTRUCTURING COSTS Year ended March 31, 2023 Restructuring and other charges In the year ended March 31, 2023, the Company recognized impairment charges associated with its announcement, in the three months ended March 31, 2023, of a series of comprehensive steps to align its Canadian cannabis operations and resources in response to unfavorable market realities. These actions include: • Transitioning to an asset-light model by: (i) exiting cannabis flower cultivation in the Company’s Smiths Falls, Ontario facility; (ii) ceasing the sourcing of cannabis flower from the Company’s Mirabel, Quebec facility; and (iii) consolidating cultivation at the Company’s existing facilities in Kincardine, Ontario and Kelowna, British Columbia; and • Moving to an adaptive third-party sourcing model for all cannabis beverages, edibles, vapes, and extracts which will enable the Company to select and bring to market new product formats without the required investment in research and development and production footprint. As a result of the aforementioned changes, the Company intends to close and sell the 1 Hershey Drive facility in Smiths Falls, Ontario, consolidate flower, pre-rolled joints, softgel, and oil manufacturing in the Company’s current beverage production facility in Smiths Falls, Ontario, and reduced headcount across the business. We also intend to rationalize our cannabis extraction activities across Canada. Additionally, in March 2023, the Company completed the purchase of the remaining 45 % of the common shares of Les Serres Vert Cannabis Inc. (“Vert Mirabel”) for consideration consisting of cash and the Company’s common shares, thereby increasing the Company’s interest in the entity to 100 %. In connection with that acquisition, the Company terminated its lease for the facility in Mirabel, Quebec and is ceasing the sourcing of cannabis flower from the Mirabel, Quebec facility. The Company also recognized impairment charges associated with the divestiture of the Company’s retail operations pursuant to the OEGRC Transaction and the FOUR20 Transaction (as each terms is defined below), as described in Note 30(a) below. Additionally, the Company: (i) recognized incremental costs primarily associated with the restructuring actions completed in the year ended March 31, 2022, including the closure of certain of its Canadian production facilities, and other operational changes initiated in the three months ended March 31, 2022, as described below in our summary of restructuring actions in the year ended March 31, 2022; and (ii) employee-related restructuring charges associated with actions completed in the three months ended December 31, 2022 and three months ended March 31, 2023 as part of the Company’s ongoing program to align general and administrative costs with business objectives, and further streamline the Company’s operations. The Company recorded total inventory write-downs and associated restructuring charges of $ 90,485 in the year ended March 31, 2023, related primarily to: (i) the aforementioned strategic changes to our business that were initiated in the three months ended March 31, 2023, including the closure of our production facility at 1 Hershey Drive in Smiths Falls, Ontario; (ii) the strategic changes to our business initiated in fiscal 2022, including the shift to a contract manufacturing model for certain product formats and the closure of certain of our production facilities; and (ii) charges associated with certain contract manufacturing agreements held by BioSteel that are not expected to occur past the year ended March 31, 2023. As a result of these actions, the Company recognized aggregate pre-tax charges of $ 547,533 in the year ended March 31, 2023, and reduced headcount by approximately 800 full-time positions. Other impairments The other impairment charges described below related to goodwill and intangible assets are in addition to the restructuring and impairment costs described above and which are associated with the Company’s restructuring actions. Goodwill In the year ended March 31, 2023, the Company recognized goodwill impairment charges totaling $ 1,785,080 as follows: (i) $ 1,725,368 was recorded in the three months ended June 30, 2022 in relation to the Company’s cannabis operations reporting unit in the Canada cannabis segment; (ii) $ 57,401 was recorded in the three months ended September 30, 2022 in relation to the Company’s BioSteel reporting unit; and (iii) $ 2,311 was recorded in the three months ended September 30, 2022 in relation to the Company’s This Works reporting unit. Refer to Note 15 for further details. Intangible assets In the year ended March 31, 2023, the Company recognized asset impairment losses totaling $ 14,614 in connection with certain acquired brand intangible assets, primarily within our Canada cannabis segment. A summary of the pre-tax charges totaling $ 2,347,227 recognized in connection with the Company’s restructuring actions and other impairments is as follows: Year ended March 31, 2023 Restructuring and other charges Other impairments Total Costs recorded in cost of goods sold: Inventory write-downs and other charges $ 90,485 $ - $ 90,485 Costs recorded in operating expenses: Impairment of property, plant and equipment 376,176 - 376,176 Impairment of intangible assets 27,399 14,614 42,013 Impairment of goodwill - 1,785,080 1,785,080 Contractual and other settlement obligations 18,427 - 18,427 Employee-related and other restructuring costs 35,046 - 35,046 Asset impairment and restructuring costs 457,048 1,799,694 2,256,742 Total restructuring, asset impairments and related costs $ 547,533 $ 1,799,694 $ 2,347,227 Costs recorded in cost of goods sold In the year ended March 31, 2023, the Company recognized charges of $ 90,485 relating to inventory write-downs and associated restructuring charges, as described above. Costs recorded in operating expenses The Company recognized asset impairment and restructuring costs of $ 457,048 million in the year ended March 31, 2023 as a result of the restructuring actions described above. The Company impaired certain production facilities, right-of-use assets, and operating license and intellectual property intangible assets, and a loss totaling $ 403,575 was recognized in the year ended March 31, 2023, representing the difference between the net book value of the long-lived assets and their estimated salvage or fair value. Of this loss, $ 376,176 related to property, plant and equipment, and related primarily to buildings and greenhouses, production and warehouse equipment, and right-of-use assets, and $ 27,399 related to operating license and intellectual property intangible assets. In the year ended March 31, 2023, the Company recognized contractual and other settlement obligations of $ 18,427 , and employee-related and other restructuring costs of $ 35,046 . Year Ended March 31, 2022 Restructuring and other charges In the year ended March 31, 2022, the Company recorded charges associated with operational changes resulting from its continuing strategic review of its business. The Company recorded charges in the three months ended June 30, 2021 related to a strategic review of the business conducted as a result of acquisitions completed in that period (see Note 29(b)), which resulted in the closure of the Company’s Niagara-on-the-Lake, Ontario and Langley, British Columbia facilities. In the three months ended March 31, 2022, the Company recorded further charges related to further restructuring actions aligned to its strategic review of the business, which included: (i) reducing cultivation costs in the Canadian adult-use cannabis business through cultivation-related efficiencies and facility improvements; (ii) implementing a flexible manufacturing platform, including contract manufacturing for certain product formats; (iii) right-sizing indirect costs and generating efficiencies across the Company’s supply chain and procurement; (iv) aligning general and administrative costs with short-term business expectations; and (v) further streamlining the organization to drive process-related efficiencies. The Company also recorded charges associated with changes in the estimated fair value of certain of the Company’s Canadian sites that were closed in December 2020, and costs associated with the closure of those sites. Refer to discussion below for restructuring actions in the year ended March 31, 2021. The Company recorded total inventory write-downs and associated restructuring charges of $ 123,669 in the year ended March 31, 2022, related primarily to: (i) the aforementioned strategic changes to our business, including the shift to a contract manufacturing model for certain product formats and the closure of certain of our production facilities; and (ii) amounts deemed excess based on current and projected market demand. As a result of these actions, the Company recognized aggregate pre-tax charges of $ 429,810 in the year ended March 31, 2022, and reduced headcount by approximately 250 full-time positions. Other impairments Goodwill The Company performed its annual goodwill impairment test in the three months ended March 31, 2022, and recognized impairment losses totaling $ 40,748 , of which $ 22,355 relates to the KeyLeaf reporting unit and $ 18,393 relates to the This Works reporting unit. Refer to Note 15 for further details. Intangible assets In the year ended March 31, 2022, the Company recognized asset impairment charges totaling $ 26,065 related to certain of its acquired brands and operating licenses. These impairment charges were identified by the Company during its annual impairment testing process, which was conducted in the three months ended March 31, 2022, and reflected in asset impairment and restructuring costs. These other impairment charges related to goodwill and intangible assets are in addition to the restructuring and impairment costs described above and which are associated with the Company’s restructuring actions. A summary of the pre-tax charges totaling $ 496,623 recognized in connection with the Company’s restructuring actions and other impairments is as follows: Year ended March 31, 2022 Restructuring and other charges Other impairments Total Costs recorded in cost of goods sold: Inventory write-downs and other charges $ 123,669 $ - $ 123,669 Costs recorded in operating expenses: Impairment and abandonment of property, plant and equipment 224,726 - 224,726 Impairment and abandonment of intangible assets 41,404 26,065 67,469 Impairment of goodwill - 40,748 40,748 Contractual and other settlement obligations 6,610 - 6,610 Employee-related and other restructuring costs 29,786 - 29,786 Asset impairment and restructuring costs 302,526 66,813 369,339 Acceleration of share-based compensation expense 3,615 - 3,615 Share-based compensation expense 3,615 - 3,615 Total restructuring, asset impairments and related costs $ 429,810 $ 66,813 $ 496,623 Costs recorded in cost of goods sold In the year ended March 31, 2022, the Company recognized charges of $ 123,669 relating to inventory write-downs and associated restructuring charges, as described above. Costs recorded in operating expenses The Company recognized asset impairment and restructuring costs of $ 302,526 in the year ended March 31, 2022 as a result of the restructuring actions described above. The Company impaired and abandoned certain production facilities and brand and intellectual property intangible assets, and a loss totaling $ 266,130 was recognized in the year ended March 31, 2022, representing the difference between the net book value of the long-lived assets and their estimated salvage value or fair value. Of this loss, $ 224,726 related to property, plant and equipment, and related primarily to buildings and greenhouses, and production and warehouse equipment, and $ 41,404 related to brand and intellectual property intangible assets. In the year ended March 31, 2022, the Company recognized contractual and other settlement obligations of $ 6,610 and employee-related and other restructuring costs of $ 29,786 . In the year ended March 31, 2022, as a result of the restructuring actions described above, the Company accelerated share-based compensation expense relating to the unvested milestones associated with acquisitions completed in prior fiscal years. Accordingly, the Company recognized share-based compensation expense of $ 3,615 in the year ended March 31, 2022. Year Ended March 31, 2021 Restructuring and other charges In the three months ended June 30, 2020, the Company completed certain of the restructuring actions that had commenced in the year ended March 31, 2020, including completing the exit of the Company’s operations in South Africa and Lesotho, and the Company recorded final adjustments related to changes in certain estimates recorded at March 31, 2020. In addition, the Company incurred additional costs related primarily to the rationalization of its marketing organization in April 2020. In the three months ended September 30, 2020, the Company recorded: (i) adjustments related to changes in the estimated fair value of certain of its Canadian production facilities from March 31, 2020, and (ii) charges related to rationalizing certain research and development activities. In December 2020, as the partial outcome of an ongoing end-to-end strategic review of its operations, the Company announced a series of Canadian operational changes designed to streamline its operations and further improve its gross margins. The Company has ceased operations at its sites in St. John’s, Newfoundland and Labrador; Fredericton, New Brunswick; Edmonton, Alberta; Bowmanville, Ontario; as well as its outdoor cannabis grow operations in Saskatchewan. As a result of these restructuring actions, the Company reduced headcount by approximately 220 full-time positions, and abandoned or impaired certain of its production facilities and intangible assets. Additionally, the Company: (i) completed the sale of its production facilities in Aldergrove and Delta, British Columbia in December 2020 and January 2021, respectively, for combined proceeds of $ 40,650 ; and (ii) recorded additional charges related to the shifting of the Company’s strategy in Latin America, which the Company commenced in the three months ended March 31, 2020. In addition to recording adjustments associated with changes in certain estimates related to the closure of its Canadian production facilities, in the three months ended March 31, 2021, the Company recognized costs associated with the closure of the production facilities, and rationalizing certain licensing arrangements. This included: (i) the impairment of the Company’s equity method investment in the More Life Growth Company (“More Life”) in the amount of $ 10,300 ; (ii) the difference between the termination payment made by the Company to More Life, and the remaining minimum royalty obligations owing to More Life that were derecognized (refer to Note 29 (d); and (iii) charges associated with terminating a licensing agreement with a third party (which included derecognizing the remaining minimum royalty obligations owing to the third party in the amount of $ 18,810 ). The Company recorded total inventory write-downs of $ 25,985 in the year ended March 31, 2021 related to the closure of certain of its Canadian and international production facilities. As a result of these actions the Company recognized aggregate pre-tax charges of $ 564,049 in the year ended March 31, 2021. Other impairments In the year ended March 31, 2021, the Company recognized licensed brand intangible asset impairment charges totaling $ 6,634 , which were identified during its annual impairment testing process and reflected in asset impairment and restructuring costs. These other impairment charges are in addition to the restructuring and impairment costs described above and associated with the Company’s restructuring actions. A summary of the pre-tax charges totaling $ 570,683 recognized in connection with the Company’s restructuring actions and other impairments is as follows: Year ended March 31, 2021 Restructuring and other charges Other impairments Total Costs recorded in cost of goods sold: Inventory write-downs $ 25,985 $ - $ 25,985 Costs recorded in operating expenses: Impairment and abandonment of property, plant and equipment 426,748 - 426,748 Impairment and abandonment of intangible assets 54,511 6,634 61,145 Contractual and other settlement obligations 22,352 - 22,352 Employee-related and other restructuring costs 24,153 - 24,153 Asset impairment and restructuring costs 527,764 6,634 534,398 Costs recorded in loss from equity method investments: Impairment of equity method investments 10,300 - 10,300 Total restructuring, asset impairments and related costs $ 564,049 $ 6,634 $ 570,683 Costs recorded in cost of goods sold In the year ended March 31, 2021, the Company recognized charges of $ 25,985 relating to inventory write-downs associated with its restructuring activities, as described above. Costs recorded in operating expenses The Company recognized asset impairment and restructuring costs of $ 527,764 in the year ended March 31, 2021 as a result of the restructuring actions described above. As a result of the restructuring actions described above the Company impaired and abandoned certain production facilities, and operating license intangible assets. A loss totaling $ 481,259 was recognized in the year ended March 31, 2021 representing the difference between the net book value of the long-lived assets and their estimated salvage value or fair value. Of this loss, $ 426,748 related to property, plant and equipment and $ 54,511 related to facility operating license intangible assets. The losses relating to property, plant and equipment were primarily attributable to buildings and greenhouses, and production and warehouse equipment. In the year ended March 31, 2021, the Company recognized contractual and other settlement obligations of $ 22,352 and employee-related and other restructuring costs of $ 24,153 , which included costs associated with the remediation of damages caused by the fire at the Delta facility in November, the closure of the Canadian facilities as described above, and the sale of the British Columbia facilities.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Mar. 31, 2023
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	7 . CASH AND CASH EQUIVALENTS The components of cash and cash equivalents are as follows: March 31, March 31, 2023 2022 Cash $ 462,460 $ 470,682 Cash equivalents 214,547 305,323 $ 677,007 $ 776,005

Short-term Investments

Short-term Investments	12 Months Ended
	Mar. 31, 2023
Short-Term Investments [Abstract]
Short-term Investments	8 . SHORT-TERM INVESTMENTS The components of short-term investments are as follows: March 31, March 31, 2023 2022 Government securities $ 60,226 $ 22,253 Term deposits 30,000 319,092 Commercial paper and other 15,369 254,306 $ 105,595 $ 595,651 The amortized cost of short-term investments at March 31, 2023 is $ 107,661 (March 31, 2022 – $ 599,862 ).

Amounts Receivable, Net

Amounts Receivable, Net	12 Months Ended
	Mar. 31, 2023
Receivables [Abstract]
Amounts Receivable, Net	9 . AMOUNTS RECEIVABLE, NET The components of amounts receivable, net are as follows: March 31, March 31, 2023 2022 (As Restated) Accounts receivable, net $ 66,820 $ 68,197 Indirect taxes receivable 11,544 7,524 Interest receivable 3,966 4,406 Other receivables 11,657 6,454 $ 93,987 $ 86,581 Included in the accounts receivable, net balance at March 31, 2023 is an allowance for doubtful accounts of $ 9,296 (March 31, 2022 – $ 4,764 ).

Inventory

Inventory	12 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventory	10 . INVENTORY The components of inventory are as follows: March 31, March 31, 2023 2022 Raw materials, packaging supplies and consumables $ 28,982 $ 26,821 Work in progress 34,104 65,245 Finished goods 85,815 112,473 $ 148,901 $ 204,539 In the year ended March 31, 2023, the Company recorded write-downs related to inventory in cost of goods sold of $ 82,756 (year ended March 31, 2022 – $ 237,147 ).

Prepaid Expenses and Other Asse

Prepaid Expenses and Other Assets	12 Months Ended
	Mar. 31, 2023
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses and Other Assets	11 . PREPAID EXPENSES AND OTHER ASSETS The components of prepaid expenses and other assets are as follows: March 31, March 31, 2023 2022 Prepaid expenses $ 27,460 $ 22,961 Deposits 1,734 10,145 Prepaid inventory 690 449 Other assets 10,115 19,065 $ 39,999 $ 52,620

Other Financial Assets

Other Financial Assets	12 Months Ended
	Mar. 31, 2023
Schedule of Investments [Abstract]
Other Financial Assets	12 . OTHER FINANCIAL ASSETS The following tables outline changes in other financial assets. Additional details on how the fair value of significant investments are calculated are included in Note 24. Foreign Balance at currency Balance at March 31, Fair value translation March 31, Entity Instrument 2022 Additions changes adjustments Other 2023 Acreage 1 Fixed Shares option and Floating Shares agreement $ - $ - $ 55,382 $ - $ - $ 55,382 TerrAscend Exchangeable Shares Exchangeable shares 229,000 51,000 ( 186,489 ) ( 511 ) - 93,000 TerrAscend Canada - October 2019 Term loan / debenture 10,280 - ( 146 ) - ( 10,134 ) - TerrAscend Canada - March 2020 Term loan / debenture 49,890 - ( 4,804 ) - ( 45,086 ) - Arise Bioscience Term loan / debenture 13,343 - ( 1,767 ) 1,268 ( 12,844 ) - TerrAscend - October 2019 Warrants 3,730 - ( 3,372 ) - ( 358 ) - TerrAscend - March 2020 Warrants 60,740 - ( 46,376 ) - ( 14,364 ) - TerrAscend - December 2020 Warrants 3,460 - ( 2,246 ) - ( 1,214 ) - TerrAscend - December 2022 Warrants - 33,000 ( 7,000 ) - - 26,000 TerrAscend Option 6,300 - ( 4,700 ) - - 1,600 Wana Option 372,343 - ( 154,936 ) 21,671 - 239,078 Jetty Options - 90,120 ( 19,915 ) 4,809 - 75,014 Acreage Hempco 1 Debenture 28,824 - 2,361 2,295 ( 4,218 ) 29,262 Acreage Debt Option Premium Option - 38,048 ( 3,041 ) 472 - 35,479 Acreage Tax Receivable Agreement Other - 41,491 ( 38,035 ) ( 347 ) - 3,109 Other - at fair value through net income (loss) Various 10,396 - ( 9,031 ) 505 - 1,870 Other - classified as held for investment Loan receivable 12,022 - - - ( 3,524 ) 8,498 $ 800,328 $ 253,659 $ ( 424,115 ) $ 30,162 $ ( 91,742 ) $ 568,292 1 Refer to Note 31 for information regarding the Acreage Arrangement and Acreage Hempco. For information regarding the Reorganization, see Note 5. Following the implementation of the Reorganization, Canopy USA, as of October 24, 2022, holds and ownership interest in certain U.S. cannabis investments previously held by the Company, including, among others, interests in the Floating Shares of Acreage, Wana, Jetty and TerrAscend. Foreign Exercise of Balance at currency options / Balance at March 31, Fair value translation Interest disposal March 31, Entity Instrument 2021 Additions changes adjustments income of shares / 2022 TerrAscend Exchangeable Shares Exchangeable shares $ 385,000 $ - $ ( 156,000 ) $ - $ - $ - $ 229,000 TerrAscend Canada - October 2019 Term loan / debenture 10,240 - 835 - ( 795 ) - 10,280 TerrAscend Canada - March 2020 Term loan / debenture 56,330 - ( 1,528 ) - ( 4,912 ) - 49,890 Arise Bioscience Term loan / debenture 13,077 - 308 ( 42 ) - - 13,343 TerrAscend - October 2019 Warrants 17,250 - ( 13,520 ) - - - 3,730 TerrAscend - March 2020 Warrants 152,910 - ( 92,170 ) - - - 60,740 TerrAscend - December 2020 Warrants 13,240 - ( 9,780 ) - - - 3,460 TerrAscend Option 10,600 - ( 4,300 ) - - - 6,300 Wana Option - 442,227 ( 74,639 ) 4,755 - 372,343 Acreage Hempco 1 Debenture 27,448 - 5,337 ( 94 ) ( 3,867 ) - 28,824 Other - at fair value through net income (loss) Various 14,887 6,457 ( 10,652 ) ( 204 ) - ( 92 ) 10,396 Other - classified as held for investment Loan receivable 7,185 5,000 - - - ( 163 ) 12,022 $ 708,167 $ 453,684 $ ( 356,109 ) $ 4,415 $ ( 9,574 ) $ ( 255 ) $ 800,328 1 Refer to Note 31 for information regarding the Acreage Arrangement and Acreage Hempco. TerrAscend Financial Instruments TerrAscend Exchangeable Shares TerrAscend is a publicly traded licensed producer. The TerrAscend Exchangeable Shares will only become convertible into common shares following changes in U.S. federal laws regarding the cultivation, distribution or possession of cannabis, the compliance of TerrAscend with such laws and the approval of the various securities exchanges upon which the issuer’s securities are listed. The TerrAscend Exchangeable Shares are not transferrable or monetizable until exchanged into common shares. In the interim, the Company will not be entitled to voting rights, dividends or other rights upon dissolution of TerrAscend. As a result, the Company does not have significant influence over TerrAscend and accounts for the TerrAscend Exchangeable Shares as a financial asset at estimated fair value with any changes recorded in other income (expense), net. At March 31, 2023 the estimated fair value of the TerrAscend Exchangeable Shares, including the 24,601,467 TerrAscend Exchangeable Shares received as part of the TerrAscend Arrangement (as described below), was $ 93,000 (March 31, 2022 – $ 229,000 ). TerrAscend Canada Term Loan, Debenture, and TerrAscend Warrants – October 2019 On October 2, 2019, RIV Capital completed a $ 13,243 (US$ 10,000 ) investment in TerrAscend Canada Inc. (“TerrAscend Canada”), a wholly-owned subsidiary of TerrAscend. The investment included a term loan (the “TerrAscend Canada October 2019 Term Loan”) pursuant to a secured debenture and 2,559,437 TerrAscend Warrants. As part of the completion of the plan of arrangement with RIV Capital, as described in Note 30(c), Canopy Growth acquired the TerrAscend Canada October 2019 Term Loan and associated TerrAscend Warrants from RIV Capital’s wholly-owned subsidiary, RIV Capital Corporation (formerly Canopy Rivers Corporation) (“RCC”). On December 9, 2022, the date on which the TerrAscend Arrangement (as described below) was completed, the estimated fair value of the TerrAscend Canada October 2019 Term Loan was $ 10,749 (March 31, 2022 – $ 10,280 ), and the estimated fair value of the associated TerrAscend Warrants was $ 380 (March 31, 2022 – $ 3,730 ). TerrAscend Canada Term Loan, Debenture, and TerrAscend Warrants – March 2020 On March 11, 2020, Canopy Growth completed an $ 80,526 investment in TerrAscend Canada. The investment included a term loan pursuant (the “TerrAscend Canada March 2020 Term Loan”) to a secured debenture with an estimated fair value at inception of $ 54,800 and 17,808,975 TerrAscend Warrants with an estimated fair value at inception of $ 25,626 . On December 9, 2022, the date on which the TerrAscend Arrangement (as described below) was completed, the estimated fair value of the TerrAscend Canada March 2020 Term Loan was $ 47,820 (March 31, 2022 – $ 49,890 ) and the associated TerrAscend Warrants had an estimated fair value of $ 15,235 (March 31, 2022 – $ 60,740 ). Arise Bioscience Term Loan, Debenture, and TerrAscend Warrants – December 2020 On December 10, 2020, the Company entered into a loan financing agreement with Arise Bioscience, Inc. (“Arise Bioscience”), a wholly owned subsidiary of TerrAscend, in the amount of $ 25,478 (US$ 20,000 ). The investment included a term loan (the “Arise Term Loan”) pursuant to a secured debenture with an estimated fair value at inception of $ 11,758 and 2,105,718 TerrAscend Warrants with an estimated fair value at inception of $ 13,720 . On December 9, 2022, the date on which the TerrAscend Arrangement (as described below) was completed, the estimated fair value of the Arise Term Loan was $ 13,622 (March 31, 2022 - $ 13,343 and the associated TerrAscend Warrants had an estimated fair value of $ 1,288 (March 31, 2022 – $ 3,460 ). Until December 9, 2022, the date on which the TerrAscend Arrangement (as described below) was completed, the Company accounted for the TerrAscend Canada October 2019 Term Loan, the TerrAscend Canada March 2020 Term Loan, and the Arise Term Loan and associated TerrAscend Warrants as financial assets at estimated fair value, with any changes recorded in other income (expense), net. TerrAscend Option On January 13, 2021, the Company entered into the TerrAscend Option for aggregate consideration of US$ 10,529 ($ 13,445 ). The Company accounts for this instrument as a financial asset at estimated fair value, with any changes recorded in other income (expense), net. At March 31, 2023 the estimated fair value of the TerrAscend Option was $ 1,600 (March 31, 2022 – $ 6,300 ). TerrAscend Arrangement On December 9, 2022, Canopy USA and certain limited partnerships that are controlled by Canopy USA entered into a debt settlement agreement (the “TerrAscend Settlement Agreement”) with TerrAscend, TerrAscend Canada and Arise Bioscience (together with TerrAscend and TerrAscend Canada, the “TerrAscend Entities”) whereby $ 125,467 in aggregate loans, including accrued interest thereon, payable by TerrAscend Canada and Arise Bioscience pursuant to: (i) the TerrAscend Canada October 2019 Term Loan; (ii) the TerrAscend Canada March 2020 Term Loan; and (iii) the Arise Term Loan were extinguished and 22,474,130 TerrAscend Warrants, being all of the previously issued TerrAscend Warrants controlled by Canopy USA (the “Prior Warrants”) were cancelled in exchange for the issuance of: (i) 24,601,467 TerrAscend Exchangeable Shares at a notional price of $ 5.10 per TerrAscend Exchangeable Share; and (ii) 22,474,130 new TerrAscend Warrants (the “New Warrants” and, together with the TerrAscend Exchangeable Shares, the “New TerrAscend Securities”) with a weighted average exercise price of $ 6.07 per TerrAscend Common Share and expiring on December 31, 2032 (collectively, the “TerrAscend Arrangement”). Following the issuance of the New TerrAscend Securities, Canopy USA beneficially owns: (i) 63,492,037 TerrAscend Exchangeable Shares; (ii) 22,474,130 New Warrants; and (iii) the TerrAscend Option. The TerrAscend Exchangeable Shares can be converted into TerrAscend Common Shares at Canopy USA’s option, subject to the terms of the Protection Agreement. On December 9, 2022, the estimated fair value of the financial instruments that were derecognized from these consolidated financial statements was $ 89,094 , consisting of: (i) the aggregate term loans or debentures that were extinguished, including accrued interest, with an estimated fair value of $ 72,191 ; and (ii) the Prior Warrants that were cancelled, with an estimated fair value of $ 16,903 . Changes in the estimated fair value of these financial instruments up to December 9, 2022 were recorded in other income (expense), net. On December 9, 2022, the estimated fair value of the financial instruments that were received from the TerrAscend Entities was $ 84,000 , consisting of: (i) 24,601,467 TerrAscend Exchangeable Shares with an estimated fair value of $ 51,000 ; and (ii) the New Warrants, with an estimated fair value of $ 33,000 . At March 31, 2023, the estimated fair value of the New Warrants was $ 26,000 . Changes in estimated fair value of these financial instruments from initial recognition to March 31, 2023 were recorded in other income (expense), net. The loss of $ 5,094 resulting from the difference, on December 9, 2022, between the carrying amounts of the derecognized financial instruments and the fair value of the financial assets received, was also recorded in other income (expense), net. The See Note 24 for additional details on how the fair value of the aforementioned TerrAscend financial instruments are calculated on a recurring basis. See Note 5 for information regarding the Reorganization. Following the implementation of the Reorganization, as of October 24, 2022, Canopy USA holds certain U.S. cannabis investments previously held by the Company, including the aforementioned direct and indirect interests in the capital of TerrAscend. Wana On October 14, 2021, the Company and Wana entered into definitive agreements (the “Wana Agreements”) providing the Company with the right, upon the occurrence or waiver (at the Company’s discretion) of changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana, or to remove the regulation of such activities from the federal laws of the United States (the “Triggering Event”), to acquire 100 % of the outstanding membership interests of Wana. Wana manufactures and sells gummies in the state of Colorado and licenses its intellectual property to partners, who manufacture, distribute, and sell Wana-branded gummies across the United States and Canada. The Wana Agreements are structured as three separate option agreements whereby the Company has a call option (the “Wana Call Option”) to acquire 100 % of the membership interests in each Wana Entity. As consideration for entering into the Wana Agreements, the Company made an upfront cash payment (the “Wana Upfront Payment”) in the aggregate amount of $ 368,067 (US$ 297,500 ). Upon the Company’s exercise of its right to acquire Wana, the Company will make payments equal to 15 % of the fair market value of Wana at the time the options are exercised (the “Call Option Payments”). As additional consideration for the right to acquire Wana, the Company expects to make additional deferred payments (the “Wana Deferred Payments”) in respect of Wana as of the 2.5- and 5-year anniversary of the Wana Upfront Payment, computed based on a pre-determined contractual formula as follows: • Deferred Payment 1: 25 % of the amount computed as the estimated fair value of Wana at the 2.5 -year anniversary, less: (i) the Wana Upfront Payment, (ii) Wana debt, and (iii) certain other deductions; plus Wana cash, all at the 2.5-year anniversary. • Deferred Payment 2: 25 % of the amount computed as the estimated fair value of Wana at the 5 -year anniversary, less: (i) the greater of (a) the Wana Upfront Payment and (b) the estimated fair value of Wana at the 2.5-year anniversary, (ii) Wana debt, and (iii) certain other deductions, all at the 5-year anniversary; plus the difference in Wana cash between the 5-year and 2.5-year anniversaries. Payment of the Wana Deferred Payments is not contingent upon the occurrence or waiver (at the Company’s discretion) of the Triggering Event or the exercise of the Call Option. At the Company’s option, the Call Option Payments and the Wana Deferred Payments may be satisfied in cash, common shares or a combination thereof at the Company’s sole discretion. Upon initial recognition, the Company estimated the fair value of the Wana financial instrument to be $ 442,227 , consisting of: (i) the Wana Upfront Payment as noted above; and (ii) the present value of the estimated Wana Deferred Payments, totaling $ 74,160 (see Note 18 ). The Wana financial instrument, in effect, represents a call option to purchase 100 % of Wana for a payment equal to 15 % of Wana’s fair market value at the time the option is exercised. At March 31, 2023, the estimated fair value of the Wana financial instrument was $ 239,078 (March 31, 2022 - $ 372,343 ), with the change from initial recognition recorded in other income (expense), net. See Note 24 for additional details on how the fair value of the Wana financial instrument is calculated on a recurring basis. See Note 5 for information regarding the Reorganization. Following the implementation of the Reorganization, Canopy USA, as of October 24, 2022, holds certain U.S. cannabis investments previously held by the Company, which is expected to enable Canopy USA, following, among other things, the Meeting, to consummate the acquisition of Wana. Until such time as Canopy USA elects to exercise its right to acquire Wana and the Company converts the Non-Voting Shares into Canopy USA Class B Shares, the Company will have no economic or voting interest in Wana, the Company will not directly or indirectly control Wana, and the Company and Wana will continue to operate independently of one another. Jetty On May 17, 2022, the Company and Jetty entered into definitive agreements (the “Jetty Agreements”) providing the Company with the right to acquire up to 100 % of the outstanding equity interests in Jetty (i) upon the occurrence of changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana, or to remove the regulation of such activities from the federal laws of the United States; or (ii) an earlier date at the Company’s sole discretion (the “Jetty Triggering Event”). The Jetty Agreements are structured as two separate option agreements whereby the Company has the right to acquire up to 100 % of the equity interests in Jetty. As consideration for entering into the Jetty Agreements, the Company (i) made an upfront cash payment in the amount of $ 29,226 (US$ 22,911 ), and (ii) issued 8,426,539 common shares with a fair value on closing of $ 59,123 (US$ 45,928 ), for total consideration of $ 88,349 (collectively, the “Jetty Upfront Payment”). The first option agreement is exercisable in two tranches, with the first tranche providing the Company with the option to acquire 52.78 % of Jetty’s equity interests, exercisable following the occurrence of the Jetty Triggering Event. The second tranche provides the Company with the option to acquire 25 % of Jetty’s equity interests for their fair market value, subject to certain adjustments. Additionally, the Company expects to make deferred payments (the “Jetty Deferred Payments”) computed based on a pre-determined contractual formula. The second option agreement provides the Company with the option to acquire 22.22 % of Jetty’s equity interests, exercisable following the occurrence of the Jetty Triggering Event. Upon initial recognition, the Company estimated the fair value of the Jetty financial instrument to be $ 90,120 , consisting of (i) the Jetty Upfront Payment as noted above; and (ii) the present value of the estimated Jetty Deferred Payments. At March 31, 2023, the estimated fair value of the Jetty financial instruments was $ 75,014 , with the change in estimated fair value from initial recognition recorded in other income (expense), net. See Note 24 for additional details on how the fair value of the Jetty financial instruments is calculated on a recurring basis. Until such time as Canopy USA elects to exercise its rights to acquire Jetty and the Company converts the Non-Voting Shares into Canopy USA Class B Shares, the Company will have no direct or indirect economic or voting interests in Jetty, the Company will not directly or indirectly control Jetty, and the Company and Jetty will continue to operate independently of one another. See Note 5 for information regarding the Reorganization. Following the implementation of the Reorganization, Canopy USA, as of October 24, 2022, holds certain U.S. cannabis investments previously held by the Company, which is expected to enable Canopy USA, following, among other things, the Meeting, to consummate the acquisition of Jetty. Acreage-Related Agreements Tax Receivable Agreement On October 24, 2022, the Company and Canopy USA entered into a third amendment to the tax receivable agreement (the “Amended TRA”) with, among others, certain current or former unitholders (the “Holders”) of High Street Capital Partners, LLC, a subsidiary of Acreage (“HSCP”), pursuant to HSCP’s amended tax receivable agreement (the “TRA”) and related tax receivable bonus plans with Acreage. Pursuant to the Amended TRA, the Company, on behalf of Canopy USA, agreed to issue common shares of the Company with a fair value of US$ 30,441 to certain Holders as consideration for the assignment of such Holder’s rights under the TRA to Canopy USA. As a result of the Amended TRA, Canopy USA is the sole member and beneficiary under the TRA. In connection with the foregoing, the Company: (i) issued 5,648,927 common shares with a value of $ 20,630 (US$ 15,220 ) to certain Holders on November 4, 2022 as the first installment under the Amended TRA; and (iii) issued 7,102,081 common shares with a value of $ 20,572 (US$ 15,220 ) to certain Holders on March 17, 2023 as the second installment. The aggregate amount paid by the Company in common shares in relation to the assignment of rights in favor of Canopy USA in accordance with the Amended TRA represents a financial instrument. The Company accounts for this instrument as a financial asset at estimated fair value, with any changes recorded in other income (expense), net. At March 31, 2023, the estimated fair value of the financial instrument associated with the Acreage TRA rights was $ 3,109 , with the change in estimated fair value from initial recognition recorded in other income (expense), net. See Note 24 for additional details on how the fair value of the Acreage TRA rights financial instrument is calculated on a recurring basis. The Company, on behalf of Canopy USA, also agreed to issue common shares of the Company with a value of approximately US$ 19,559 to certain eligible participants pursuant to HSCP’s existing tax receivable bonus plans to be issued immediately prior to completion of the Floating Share Arrangement. No accounting recognition was given to this payment in the year ended March 31, 2023 as such payment is contingent upon the completion of the Floating Share Arrangement or, if the Floating Share Arrangement is not completed, upon the closing of the acquisition of the Fixed Shares under the Existing Acreage Arrangement Agreement. Acreage Debt Option Premium On November 15, 2022, a wholly-owned subsidiary of Canopy Growth (the “Acreage Debt Optionholder”) and Acreage’s existing lenders (the “Lenders”) entered into an option agreement, which superseded the letter agreement dated October 24, 2022 between the parties, pursuant to which the Acreage Debt Optionholder was granted the right to purchase the outstanding principal, including all accrued and unpaid interest thereon, of Acreage’s debt, being an amount up to US$ 150,000 (the “Acreage Debt”) from the Lenders in exchange for an option premium payment of $ 38,048 (US$ 28,500 ) (the “Option Premium”), which was deposited into an escrow account on November 17, 2022. The Acreage Debt Optionholder has the right to exercise the option at its discretion, and if the option is exercised, the Option Premium will be used to reduce the purchase price to be paid for the outstanding Acreage Debt. In the event that Acreage repays the Acreage Debt on or prior to maturity, the Option Premium will be returned to the Acreage Debt Optionholder. In the event that Acreage defaults on the Acreage Debt and the Acreage Debt Optionholder does not exercise its option to acquire the Acreage Debt, the Option Premium will be released to the Lenders. The Option Premium represents a financial instrument. The Company accounts for this instrument as a financial asset at estimated fair value, with any changes recorded in other income (expense), net. At March 31, 2023, the estimated fair value of the financial instrument associated with the Option Premium was $ 35,479 , with the change in estimated fair value from initial recognition recorded in other income (expense), net. See Note 24 for additional details on how the fair value of the Option Premium financial instrument is calculated on a recurring basis.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	13 . PROPERTY, PLANT AND EQUIPMENT The components of property, plant and equipment are as follows: March 31, March 31, 2023 2022 Buildings and greenhouses $ 413,832 $ 766,931 Production and warehouse equipment 101,326 159,314 Leasehold improvements 15,529 69,304 Office and lab equipment 13,857 29,879 Computer equipment 8,697 22,293 Land 16,781 18,917 Right-of-use-assets Buildings and greenhouses 37,533 89,228 Production and warehouse equipment 637 55 Assets in process 3,281 19,771 611,473 1,175,692 Less: Accumulated depreciation ( 112,007 ) ( 232,912 ) $ 499,466 $ 942,780 Depreciation expense included in cost of goods sold for the year ended March 31, 2023 is $ 46,164 (year ended March 31, 2022 – $ 50,200 ; year ended March 31, 2021 – $ 51,737 ). Depreciation expense included in selling, general and administrative expenses for the year ended March 31, 2023 is $ 10,572 (year ended March 31, 2022 – $ 26,047 ; year ended March 31, 2021 – $ 19,177 ). See Note 6 for information on the impairment and abandonment of property, plant and equipment that resulted in charges in the amount of $ 376,176 that the Company recognized as part of its restructuring actions in the year ended March 31, 2023 (year ended March 31, 2022 – $ 224,726; year ended March 31, 2021 – $ 426,748 ).

Intangible Assets

Intangible Assets	12 Months Ended
	Mar. 31, 2023
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Intangible Assets	14 . INTANGIBLE ASSETS The components of intangible assets are as follows: March 31, 2023 March 31, 2022 Gross Net Gross Net Carrying Carrying Carrying Carrying Amount Amount Amount Amount Finite lived intangible assets Intellectual property $ 119,283 $ 70,588 $ 138,170 $ 97,638 Distribution channel 73,024 21,258 72,642 24,834 Operating licenses 24,400 19,012 24,400 22,052 Software and domain names 35,100 14,664 29,822 14,206 Brands 16,253 13,249 5,547 3,680 Amortizable intangibles in process 508 508 5,476 5,476 Total $ 268,568 $ 139,279 $ 276,057 $ 167,886 Indefinite lived intangible assets Acquired brands $ 49,440 $ 74,809 Operating licenses - 10,000 Total intangible assets $ 188,719 $ 252,695 Amortization expense included in cost of goods sold for the year ended March 31, 2023 is $ 60 (year ended March 31, 2022 – $ 81 ; year ended March 31, 2021 – $ 80 ). Amortization expense included in selling, general and administrative expenses for the year ended March 31, 2023 is $ 27,721 (year ended March 31, 2022 – $ 38,090 ; year ended March 31, 2021 – $ 56,124 ). At March 31, 2023, the Company reclassified certain acquired brands from indefinite lived intangible assets to finite lived intangible assets as additional information became available that the related brands had a limited useful life to the Company. After the reclassification, the brands are now being amortized based on the useful life policies in Note 3. Estimated amortization expense for each of the five succeeding fiscal years and thereafter is as follows: 2024 $ 28,654 2025 $ 27,276 2026 $ 22,846 2027 $ 20,642 2028 $ 19,518 Thereafter $ 20,343 See Note 6 for information on: (i) the impairment and abandonment of intangible assets that resulted in charges in the amount of $ 27,399 that the Company recognized as part of its restructuring actions in the year ended March 31, 2023 (year ended March 31, 2022 - $ 41,404 ; year ended March 31, 2021 –$ 54,511 ) and (ii) impairment charges of $ 14,614 in the year ended March 31, 2023 (year ended March 31, 2022 - $ 26,065 ; year ended March 31, 2021 – $ 6,634 ).

Goodwill

Goodwill	12 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	15 . GOODWILL The changes in the carrying amount of goodwill are as follows: Balance, March 31, 2021 $ 1,889,354 Purchase accounting allocations 105,323 Disposal of consolidated entities ( 58,786 ) Impairment losses ( 40,748 ) Foreign currency translation adjustments ( 28,640 ) Balance, March 31, 2022 $ 1,866,503 Disposal of consolidated entities ( 227 ) Impairment losses ( 1,785,080 ) Foreign currency translation adjustments 4,367 Balance, March 31, 2023 $ 85,563 Year ended March 31, 2022 At March 31, 2022, the Company performed its annual goodwill impairment analysis using the quantitative assessment. The Company concluded that the carrying values of its KeyLeaf and This Works reporting units were higher than their respective estimated fair values as determined using the income valuation method, and a goodwill impairment loss totaling $ 40,748 was recognized in the year ended March 31, 2022 (year ended March 31, 2021 - $ nil ). The goodwill impairment loss was comprised of: (i) $ 22,355 related to the KeyLeaf reporting unit, representing the entirety of the goodwill assigned to the KeyLeaf reporting unit; and (ii) $ 18,393 related to the This Works reporting unit. Certain negative trends, including slower growth rates, resulted in updated long-term financial forecasts indicating lower forecasted revenue and cash flow generation for the KeyLeaf and This Works reporting units. No impairment was noted for any of the Company’s other reporting units, as the estimated fair value of each of the other reporting units with goodwill exceeded their carrying value. The estimated fair value of the cannabis operations reporting unit in the global cannabis segment was determined using the market valuation method, with the most significant assumptions used in applying this method being: (i) the price of the Company’s common shares; and (ii) the estimated control premium associated with ownership of the Company’s common shares. The estimated fair values of all other reporting units (KeyLeaf, This Works, BioSteel and Storz & Bickel) were determined using the income valuation method, with the most significant assumptions used in applying this method being: (i) the discount rate; (ii) the expected long-term growth rate; and (iii) the annual cash flow projections. These methodologies are consistent with those used by the Company for its annual impairment test conducted at March 31, 2021, and for the quantitative interim goodwill assessment conducted by the Company for the cannabis operations reporting unit at December 31, 2021. The carrying value at March 31, 2022 of the goodwill associated with the Company’s cannabis operations reporting unit was $ 1,727,848 . For the cannabis operations reporting unit, if all other assumptions were held constant and the estimated control premium was decreased by 500 basis points, the estimated fair value would decrease by 7 % and result in an impairment charge. If all other assumptions were held constant and the share price decreased by 10 %, the estimated fair value would decrease by 15 % and result in an impairment charge. The carrying value at March 31, 2022 of the goodwill associated with the Company’s BioSteel reporting unit was $ 57,339 . For the BioSteel reporting unit, if all other assumptions were held constant and the discount rate was increased by 50 basis points, the estimated fair value would decrease by 8 %. If all other assumptions were held constant and the long-term growth rate was decreased by 50 basis points, the estimated fair value would decrease by 3 %. If all other assumptions were held constant and the annual cash flow projections were decreased by 250 basis points, the estimated fair value would decrease by 5 %. The carrying value at March 31, 2022 of the goodwill associated with the Company’s Storz & Bickel reporting unit was $ 79,027 . For the Storz & Bickel reporting unit, if all other assumptions were held constant and the discount rate was increased by 50 basis points, the estimated fair value would decrease by 6 %. If all other assumptions were held constant and the long-term growth rate was decreased by 50 basis points, the estimated fair value would decrease by 4 %. If all other assumptions were held constant and the annual cash flow projections were decreased by 250 basis points, the estimated fair value would decrease by 3 %. At March 31, 2022, the fair value of the cannabis operations reporting unit to which goodwill was assigned exceeded its carrying value by approximately 5 % to 10 %. Accordingly, the goodwill assigned to the cannabis operations reporting unit was at risk for impairment in future periods. The carrying value at March 31, 2022 of the goodwill associated with the Company’s This Works reporting unit was $ 2,289 . Year ended March 31, 2023 As a result of the continued decline in the price of the Company’s common shares in the three months ended June 30, 2022, the Company determined there to be an indicator of impairment for the cannabis operations reporting unit in the global cannabis segment, which was a reportable segment in the three months ended June 30, 2022. As a result, the Company performed a quantitative interim goodwill impairment assessment for the cannabis operations reporting unit as of June 30, 2022. The Company concluded that the carrying value of the cannabis operations reporting unit was higher than its estimated fair value, and a goodwill impairment loss totaling $ 1,725,368 was recognized in the three months ended June 30, 2022, representing the entirety of the goodwill assigned to the cannabis operations reporting unit. The estimated fair value of the cannabis operations reporting unit was determined using the market valuation method, which is consistent with the methodology used by the Company for its annual impairment test conducted at March 31, 2022. The most significant assumptions used in applying this method were: (i) the price of the Company’s common shares; and (ii) the estimated control premium associated with ownership of the Company’s common shares. While the Company changed its reportable segments in the three months ended September 30, 2022 (see Note 35), there were no changes to the composition of the Company’s reporting units to which goodwill remained assigned at September 30, 2022. In the three months ended September 30, 2022, the Company determined there to be indicators of impairment for both its BioSteel and This Works reporting units, as slower growth rates resulted in updated long-term financial forecasts indicating lower forecasted revenue and cash flow generation. As a result, the Company performed a quantitative interim goodwill impairment test for its BioSteel and This Works reporting units as of September 30, 2022 and concluded that the carrying values of these reporting units were higher than their estimated fair values, as determined using the income valuation method. The Company recognized goodwill impairment losses totaling $ 59,712 in the three months ended September 30, 2022, representing: (i) the entirety of the goodwill assigned to its BioSteel reporting unit of $ 57,401 ; and (ii) the entirety of the goodwill assigned to its This Works reporting unit of $ 2,311 . At March 31, 2023, the Company performed its annual goodwill impairment analysis using the quantitative assessment. No impairment was noted for the Company’s Storz & Bickel reporting unit, as the estimated fair value of the Storz & Bickel reporting unit exceeded its carrying value. The estimated fair value of the Storz & Bickel reporting unit was determined using the income valuation method, with the most significant assumptions used in applying this method being: (i) the discount rate; (ii) the expected long-term growth rate; (iii) revenue growth rate projections; and (iv) annual cash flow projections. This methodology is consistent with that used by the Company for its annual impairment test conducted at March 31, 2022. The carrying value, at March 31, 2023, of the goodwill associated with the Storz & Bickel reporting unit was $ 85,563 . For the Storz & Bickel reporting unit, if all other assumptions were held constant and the discount rate was increased by 50 basis points, the estimated fair value would decrease by 5 % and result in an impairment charge. If all other assumptions were held constant and the long-term growth rate was decreased by 50 basis points, the estimated fair value would decrease by 4 % and result in an impairment charge. If all other assumptions were held constant and the revenue growth rate projections were decreased by 250 basis points, the estimated fair value would decrease by 11 % and result in an impairment charge. If all other assumptions were held constant and the annual cash flow projections were decreased by 250 basis points, the estimated fair value would decrease by 3 %. At March 31, 2023, the fair value of the Storz & Bickel reporting unit to which goodwill is assigned exceeded its carrying value by approximately 3 %. Accordingly, the goodwill assigned to the Storz & Bickel reporting unit is at risk for impairment in future periods. The Company may be required to perform a quantitative goodwill impairment assessment in future periods for the Storz & Bickel reporting unit, to the extent the Company experiences declines in the expected long-term growth rate, revenue growth rate projections or annual cash flow projections, or if discount rates increase, or if other indicators of impairment arise.

Other Accrued Expenses and Liab

Other Accrued Expenses and Liabilities	12 Months Ended
	Mar. 31, 2023
Accounts Payable and Accrued Liabilities, Current [Abstract]
Other Accrued Expenses and Liabilities	16 . OTHER ACCRUED EXPENSES AND LIABILITIES The components of other accrued expenses and liabilities are as follows: March 31, March 31, 2023 2022 Employee compensation $ 30,816 $ 24,873 Inventory 323 10,096 Professional fees 6,343 7,640 Taxes and government fees 5,734 7,144 Other 32,775 25,525 $ 75,991 $ 75,278

Debt

Debt	12 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Debt	17 . DEBT The components of debt are as follows: March 31, March 31, Maturity Date 2023 2022 Unsecured senior notes at 4.25 % interest with July 15, 2023 Principal amount $ 337,380 $ 600,000 Accrued interest 3,148 5,958 Non-credit risk fair value adjustment 26,214 7,140 Credit risk fair value adjustment ( 35,492 ) ( 49,140 ) 331,250 563,958 Supreme convertible debentures September 10, 2025 31,503 32,858 Accretion debentures September 10, 2025 8,780 7,720 Credit facility March 18, 2026 840,058 893,647 Equity-settled convertible debentures February 28, 2028 93,228 - Other revolving debt facility, loan, and financings 2,062 2,808 1,306,881 1,500,991 Less: current portion ( 556,890 ) ( 9,296 ) Long-term portion $ 749,991 $ 1,491,695 Credit Facility On March 18, 2021, the Company entered into the Credit Agreement providing for a five-year , first lien senior secured term loan facility in an aggregate principal amount of US$ 750,000 (the “Credit Facility”). The Company had the ability to obtain up to an additional US$ 500,000 of incremental senior secured debt pursuant to the Credit Agreement. As described in Note 5 , in connection with the balance sheet actions completed as part of the creation of Canopy USA, the Company entered into agreements with certain of its lenders under the Credit Agreement to complete the Paydown, which will result in the Company tendering US$ 187,500 of principal amount outstanding thereunder at a discounted price of US$ 930 per US$ 1,000 or US$ 174,375 in the aggregate. The first payment, which was oversubscribed, in the amount of $ 117,528 (US $ 87,852 ) was made on November 10, 2022 to reduce the principal indebtedness by $ 126,324 (US $ 94,427 ). The second payment of $ 116,847 (US $ 87,213 ) was made on April 17, 2023 to reduce principal indebtedness by $ 125,606 (US $ 93,750 ) . The Company also agreed to the Credit Agreement Amendments which, among other things, resulted in: (i) reductions to the minimum Liquidity (as defined in the Credit Agreement) covenant to US$ 100,000 ; (ii) certain changes to the application of net proceeds from asset sales; (iii) the establishment of a new committed delayed draw term credit facility in an aggregate principal amount of US$ 100,000 ; and (iv) the elimination of the additional US$ 500,000 incremental term loan facility. The Credit Facility has no principal payments, matures on March 18, 2026 , has a coupon of LIBOR plus 8.50 % and is subject to a LIBOR floor of 1.00 %. In the event that LIBOR can no longer be adequately ascertained or is no longer available, an alternative rate as permitted under the Credit Agreement will be used. The Company’s obligations under the Credit Facility are guaranteed by material wholly-owned Canadian and U.S. subsidiaries of the Company. The Credit Facility is secured by substantially all of these assets, including material real property, of the borrowers and each of the guarantors. The Credit Agreement contains representations and warranties, and affirmative and negative covenants, including a financial covenant requiring minimum liquidity of US$ 100,000 at the end of each fiscal quarter, which is to be reduced as payments are made in accordance with the Paydown. The proceeds from the Credit Facility were $ 893,160 , and the carrying amount is reflected net of financing costs. Unsecured Senior Notes On June 20, 2018, the Company issued the Canopy Notes with an aggregate principal amount of $ 600,000 . The Canopy Notes bear interest at a rate of 4.25 % per annum, payable semi-annually on January 15th and July 15th of each year commencing from January 15, 2019 . The Canopy Notes will mature on July 15, 2023 . The Canopy Notes are subordinated in right of payment to any existing and future senior indebtedness. The Canopy Notes will rank senior in right of payment to any future subordinated borrowings. The Canopy Notes are effectively junior to any secured indebtedness and the Canopy Notes are structurally subordinated to all indebtedness and other liabilities of the Company’s subsidiaries. On June 29, 2022 and June 30, 2022, the Company entered into privately negotiated exchange agreements (the “Exchange Agreements”) with a limited number of holders of the Canopy Notes including Greenstar (collectively, the “Noteholders”). Pursuant to the Exchange Agreements, the Company agreed to acquire and cancel approximately $ 262,620 of aggregate principal amount of the Canopy Notes from the Noteholders (the “Exchange Transaction”) for an aggregate purchase price (excluding $ 5,383 paid to the Noteholders in cash for accrued and unpaid interest) of $ 259,994 (the “Purchase Price”), which was payable in the Company’s common shares. On the initial closings, 35,662,420 common shares were to be issued to the Noteholders, other than Greenstar, based on a price equal to US$ 3.50 per common share, which was the closing price of the common shares on the Nasdaq Global Select Market on June 29, 2022. The Company satisfied the Purchase Price as follows: • On June 30, 2022, 14,069,353 common shares were issued to Noteholders, representing the Company’s acquisition and cancellation of an aggregate principal amount of Canopy Notes of $ 63,098 , which were recorded at a fair value of $ 50,866 . • In July 2022, 21,593,067 common shares were issued to Noteholders, representing an aggregate principal amount of Canopy Notes of $ 99,522 , which were recorded at a fair value of $ 76,424 upon acquisition and cancellation. • On the final closing on July 18, 2022 (the “Final Closing”), 11,896,536 common shares were issued to Noteholders other than Greenstar, based on the volume-weighted average trading price of the common shares on the Nasdaq Global Select Market for the 10 consecutive trading days beginning on, and including, June 30, 2022, being US$ 2.6245 (the “Averaging Price”). • In addition, on the Final Closing on July 18, 2022, 29,245,456 common shares were issued to Greenstar based on a price per common share equal to the Averaging Price. Pursuant to the Exchange Transaction, the Company agreed to acquire and cancel $ 100,000 in aggregate principal amount, which was recorded at a fair value of $ 98,078 upon acquisition and cancellation. Prior to the completion of the Exchange Transaction, Greenstar held $ 200,000 in aggregate principal amount of the Canopy Notes. In total, 62,735,059 common shares were issued in July 2022, representing the Company’s acquisition and cancellation of an aggregate principal amount of Canopy Notes of $ 199,522 , and a total of 76,804,412 common shares were issued in June and July 2022, representing the Company’s acquisition and cancellation of an aggregate principal amount of Canopy Notes of $ 262,620 . The Canopy Notes were issued pursuant to an indenture dated June 20, 2018, as supplemented on April 30, 2019 and June 29, 2022 (collectively, the “Canopy Notes Indenture”). As a result of a supplement to the Canopy Notes Indenture dated June 29, 2022 (the “Second Supplemental Indenture”), the Company irrevocably surrendered its right to settle the conversion of any Canopy Note with its common shares. As a result, all conversions of Canopy Notes following the execution of the Second Supplemental Indenture will be settled entirely in cash. The Canopy Notes were initially recognized at fair value on the balance sheet and continue to be recorded at fair value. All subsequent changes in fair value, excluding the impact of the change in fair value related to the Company’s own credit risk, are recorded in other income (ex pense), net. The changes in fair value related to the Company’s own credit risk are recorded through other comprehensive income (loss). During the year ended March 31, 2023, the Company acquired and cancelled an aggregate principal amount of Canopy Notes of $ 262,620 , which resulted in a release of accumulated other comprehensive income into other income (expense), net of $ 44,370 . The related tax impact of $ 14,862 for the year ended March 31, 2023 associated with the aggregate principal amount acquired and ca ncelled was also released from accumulated other comprehensive income into deferred income tax expense. Refer to Note 22. In connection with the Exchange Transaction, in the three months ended June 30, 2022, the Company recognized a derivative liability of $ 26,594 in connection with the incremental common shares that were potentially issuable to Noteholders, other than Greenstar, as at June 30, 2022 at the Averaging Price on the Final Closing. The derivative liability, and associated fair value changes in the year ended March 31, 2023, were recorded through other income (expense), net. The derivative liability with a fair value of $ 39,896 was derecognized upon Final Closing on July 18, 2022. The overall change in fair value of the Canopy Notes during the years ended March 31, 2023 and March 31, 2022, was a decrease of $ 232,708 and a decrease of $ 123,456 , respectively, which included contractual interest of $ 16,956 and $ 25,794 , respectively, and principal redemption of $ 262,620 and $ nil , respectively. Upon redemption, the principal redeemed during the year ended March 31, 2023 had a fair value of $ 225,369 . Refer to Note 24 for additional details on how the fair value of the Canopy Notes is calculated. Convertible Debentures On February 21, 2023, the Company entered into a subscription agreement (the “Convertible Debenture Agreement”) with an institutional investor (the “Institutional Investor”) pursuant to which the Institutional Investor agreed to purchase up to US$ 150,000 aggregate principal amount of senior unsecured convertible debentures (“Convertible Debentures”) in a registered direct offering. The Convertible Debentures were issued pursuant to the indenture dated February 21, 2023 (the “Indenture”) between the Company and Computershare Trust Company of Canada, as trustee. Pursuant to the Convertible Debenture Agreement, an initial $ 135,160 (US$ 100,000 ) aggregate principal amount of the Convertible Debentures were sold to the Institutional Investor on February 21, 2023, and the remaining US$ 50,000 aggregate principal amount of the Convertible Debentures will be issued and paid for in the event that certain conditions outlined in the Indenture are satisfied or waived. The Convertible Debentures bear interest at a rate of 5.0 % per annum from the date of issuance, payable at the earlier of: (i) the time of conversion of the Convertible Debentures; or (ii) February 28, 2028 (the “Maturity Date”) , in each case, in common shares of Canopy Growth . No cash payment or any other property of the Company will be payable by the Company to the Institutional Investor in connection with, or as a result of, the issuance, conversion or repayment of the Convertible Debentures. The Convertible Debentures are convertible into the Company’s common shares at the option of the Institutional Investor at any time or times prior to the Maturity Date, at a conversion price equal to 92.5 % of the volume-weighted average price of the Company’s common shares during the three consecutive trading days ending on the business day immediately prior to the date of conversion. On the Maturity Date, the principal amount of the Convertible Debentures, including any accrued but unpaid interest, will also be paid in the Company’s common shares. For the year ended March 31, 2023 , US$ 27,200 in aggregate principal amount of the Convertible Debentures were converted for 14,142,066 common shares. For additional information, refer to Note 20 . Supreme Cannabis Convertible Debentures and Accretion Debentures On October 19, 2018, The Supreme Cannabis Company, Inc. (“Supreme Cannabis”) entered into an indenture with Computershare Trust Company of Canada (the “Trustee”) pursuant to which Supreme Cannabis issued 6.0 % senior unsecured convertible debentures (the “Supreme Debentures”) for gross proceeds of $ 100,000 . On September 9, 2020, Supreme Cannabis and the Trustee entered into a supplemental indenture to effect certain amendments to the Supreme Debentures, which included among other things: (i) the cancellation of $ 63,500 of principal amount of the Supreme Debentures; (ii) an increase in the interest rate to 8 % per annum; (iii) the extension of the maturity date to September 10, 2025 ; and (iv) a reduction in the conversion price to $ 0.285 . In addition, on September 9, 2020, Supreme Cannabis issued new senior unsecured non-convertible debentures (the “Accretion Debentures”). The principal amount began at $nil and accretes at a rate of 11.06 % per annum based on the remaining principal amount of the Supreme Debentures of $ 36,500 to a maximum of $ 13,500 , compounding on a semi-annual basis commencing on September 9, 2020, and ending on September 9, 2023. The Accretion Debentures are payable in cash, but do not bear cash interest and are not convertible into the common shares of Supreme Cannabis (the “Supreme Shares”). The principal amount of the Accretion Debentures will amortize, or be paid, at 1.0 % per month over the 24 months prior to maturity. As a result of the completion of an arrangement, on June 22, 2021 by the Company and Supreme Cannabis, pursuant to which the Company acquired 100 % of the issued and outstanding Supreme Shares (the “Supreme Arrangement”), the Supreme Debentures remain outstanding as securities of Supreme Cannabis, which, upon conversion will entitle the holder thereof to receive, in lieu of the number of Supreme Shares to which such holder was theretofore entitled, the consideration payable under the Supreme Arrangement that such holder would have been entitled to be issued and receive if, immediately prior to the effective time of the Supreme Arrangement, such holder had been the registered holder of the number of Supreme Shares to which such holder was theretofore entitled. In connection with the Supreme Arrangement, the Company, Supreme Cannabis and the Trustee entered into a supplemental indenture whereby the Company agreed to issue common shares upon conversion of any Supreme Debenture. In addition, the Company may force conversion of the Supreme Debentures outstanding with 30 days’ notice if the daily volume weighted average trading price of the Company’s common shares is greater than $38.59 for any 10 consecutive trading days. The Company, Supreme Cannabis and the Trustee entered into a further supplemental indenture whereby the Company agreed to guarantee the obligations of Supreme Cannabis pursuant to the Supreme Debentures and the Accretion Debentures. Prior to September 9, 2023, the Supreme Debentures are not redeemable. Beginning on and after September 9, 2023, Supreme Cannabis may from time to time, upon providing 60 days prior written notice to the Trustee, redeem the Convertible Debentures outstanding, provided that the Accretion Debentures have already been redeemed in full. Debt payments As of March 31, 2023, the required principal repayments under long-term debt obligations, excluding equity-settled convertible debentures, for each of the five succeeding fiscal years and thereafter are as follows: 2024 $ 467,957 2025 6,865 2026 787,956 2027 - 2028 - Thereafter - $ 1,262,778

Other Liabilities

Other Liabilities	12 Months Ended
	Mar. 31, 2023
Other Liabilities Disclosure [Abstract]
Other Liabilities	18 . OTHER LIABILITIES The components of other liabilities are as follows: As at March 31, 2023 As at March 31, 2022 Current Long-term Total Current Long-term Total Lease liabilities $ 28,684 $ 80,625 $ 109,309 $ 38,035 $ 101,125 $ 139,160 Acquisition consideration 25,945 30,323 56,268 4,020 77,834 81,854 Refund liability 7,123 - 7,123 3,729 - 3,729 Settlement liabilities and 32,975 13,938 46,913 18,562 11,090 29,652 $ 94,727 $ 124,886 $ 219,613 $ 64,346 $ 190,049 $ 254,395 The estimated Wana Deferred Payments recognized within acquisition consideration and other investment related liabilities at March 31, 2023 is $ 26,370 (March 31, 2022 - $ 70,066 ) (see Note 12). See Note 24 for additional details on how the fair value of the estimated Wana Deferred Payments is calculated on a recurring basis.

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interest	12 Months Ended
	Mar. 31, 2023
Temporary Equity Disclosure [Abstract]
Redeemable Noncontrolling Interest	19 . REDEEMABLE NONCONTROLLING INTEREST The net change in the redeemable noncontrolling interests is as follows: Vert BioSteel Total (As Restated) As at March 31, 2020 $ 20,250 $ 49,500 $ 69,750 Net loss attributable to redeemable noncontrolling interest ( 11,906 ) ( 6,171 ) ( 18,077 ) Adjustments to redemption amount 3,156 80,471 83,627 As at March 31, 2021 11,500 123,800 135,300 Net loss attributable to redeemable noncontrolling interest ( 3,165 ) ( 16,152 ) ( 19,317 ) Adjustments to redemption amount ( 7,335 ) ( 71,039 ) ( 78,374 ) Redemption of redeemable noncontrolling interest - ( 5,109 ) ( 5,109 ) As at March 31, 2022 1,000 31,500 32,500 Net loss attributable to redeemable noncontrolling interest ( 53 ) ( 29,491 ) ( 29,544 ) Adjustments to redemption amount 53 9,667 9,720 Redemption of redeemable noncontrolling interest ( 1,000 ) ( 11,676 ) ( 12,676 ) As at March 31, 2023 $ - $ - $ -

Share Capital

Share Capital	12 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Share Capital	20 . SHARE CAPITAL CANOPY GROWTH Authorized An unlimited number of common shares. (i) Equity financings There were no equity financings during the years ended March 31, 2023, March 31, 2022 and March 31, 2021. (ii) Other issuances of common shares During the year ended March 31, 2023, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of common shares Share Share Settlement of Convertible Debentures 14,142,066 $ 38,781 $ - HSCP Holders pursuant to Amended TRA 12,751,008 41,202 - Jetty Agreements 8,426,539 59,013 - Completion of acquisition milestones 222,421 1,379 ( 1,379 ) Other issuances 299,853 1,621 ( 572 ) Total 35,841,887 $ 141,996 $ ( 1,951 ) For the year ended March 31, 2023 , the Company also issued 8,692,128 common shares with a value of $ 26,506 relating to its redemption of the redeemable noncontrolling interest in BioSteel. The redemption increases the Company’s interest in BioSteel from 78.6 % to 90.4 %. During the year ended March 31, 2022, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of common shares Share Share Acquisition of Supreme Cannabis 9,013,400 $ 260,668 $ - Completion of acquisition milestones 1,295,285 29,276 ( 29,721 ) Other issuances 492,741 8,201 ( 736 ) Total 10,801,426 $ 298,145 $ ( 30,457 ) During the year ended March 31, 2021, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of common shares Share Share Completion of acquisition milestones 2,598,978 $ 46,903 $ ( 19,059 ) Other issuances 449,729 14,906 ( 14,894 ) Total 3,048,707 $ 61,809 $ ( 33,953 ) (iii) Warrants Number of Average Warrant Balance outstanding at March 31, 2020 1 146,299,443 $ 52.44 $ 2,638,951 Exercise of warrants ( 18,882,927 ) 12.98 ( 70,513 ) Expiry of warrants ( 343,380 ) 41.49 - Balance outstanding at March 31, 2021 1 127,073,136 $ 58.33 $ 2,568,438 Supreme Cannabis warrants 1,265,742 25.61 13,350 Expiry of warrants ( 145,831 ) 32.61 - Balance outstanding at March 31, 2022 1 128,193,047 $ 58.04 $ 2,581,788 Expiry of warrants - - - Balance outstanding at March 31, 2023 1 128,193,047 $ 58.04 $ 2,581,788 1 This balance excludes the Tranche C Warrants, which represent a derivative liability and have nominal value, see Note 31 . RIV CAPITAL Completion of RIV Arrangement On December 21, 2020, Canopy Growth entered into an arrangement agreement with its wholly-owned subsidiary The Tweed Tree Lot Inc. (“Tweed NB”), RIV Capital and RCC, pursuant to which Canopy Growth acquired certain assets from RCC in exchange for cash, Canopy Growth common shares and the surrender of all shares in the capital of RIV Capital held by Canopy Growth in accordance with a plan of arrangement under the Business Corporations Act (Ontario) (the “RIV Arrangement”). Refer to Note 30 (c) for further details regarding the RIV Arrangement. The RIV Arrangement was completed on February 23, 2021. Pursuant to the RIV Arrangement, among other things, Canopy Growth surrendered 36,468,318 Class B multiple voting shares (“MVS”) and 15,223,938 Class A subordinate voting shares (“SVS”) in the capital of RIV Capital and as a result holds no MVS and no SVS. The Company’s MVS and SVS holdings at March 31, 2020 represented a 27.3 % ownership interest and 84.4 % voting interest in RIV Capital at that time. The voting rights allowed the Company to direct the relevant activities of RIV Capital such that the Company had control over RIV Capital until the completion of the RIV Arrangement on February 23, 2021, and RIV Capital was consolidated in these financial statements until that date. Upon completion of the RIV Arrangement, the Company no longer controlled RIV Capital, and the Company derecognized RIV Capital’s consolidated assets and liabilities from its consolidated financial statements. Share buyback On April 2, 2020, RIV Capital received approval from the TSX to commence a normal course issuer bid (“NCIB”) to purchase up to 10,409,961 SVS, representing 10 % of RIV Capital’s issued and outstanding SVS, in the open market or as otherwise permitted by the TSX, subject to the normal terms and limitations of such bids. The NCIB expired on April 1, 2021 . Daily purchases were limited to 70,653 SVS, representing 25 % of the average daily trading volume on the TSX over a specified period. The NCIB was utilized at the sole discretion of RIV Capital, with no contractual obligation to purchase any specified number of shares. All SVS purchases made by RIV Capital under the NCIB were funded out of RIV Capital’s working capital and were cancelled immediately. During the period from April 1, 2020 to February 23, 2021, RIV Capital repurchased and cancelled a total of 273,300 SVS under the NCIB program for $ 307 , at a weighted average acquisition price of $ 1.11 per share. Financings Period from April 1, 2020 to February 23, 2021 There were no financings during the period from April 1, 2020 to February 23, 2021.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	21 . SHARE-BASED COMPENSATION CANOPY GROWTH CORPORATION SHARE-BASED COMPENSATION PLAN Canopy Growth’s eligible employees participate in a share-based compensation plan as noted below. On September 21, 2020, the Company’s shareholders approved amendments to the Company’s Amended and Restated Omnibus Incentive Plan (as amended and restated, the “Omnibus Plan”) pursuant to which the Company can issue share-based long-term incentives. The Omnibus Plan approved by the shareholders extended the maximum term of each Option (as defined below) to be granted by the Company to ten years from the date of grant rather than six years from the date of grant. On May 27, 2021, the Board of Directors of the Company approved certain amendments to the Omnibus Plan in order to reduce the maximum number of shares available for issuance under the Omnibus Plan from 15 % of the issued and outstanding shares to 10 % of the issued and outstanding shares from time to time less the number of shares issuable pursuant to other security-based compensation arrangements of the Company. All directors, officers, employees and independent contractors of the Company are eligible to receive awards of common share purchase options (“Options”), RSUs, performance share units (“PSUs”), deferred share units, stock appreciation rights, performance awards, or other shares-based awards (collectively, the “Awards”) under the Omnibus Plan. The maximum number of common shares reserved for Awards is 51,730,555 at March 31, 2023 (March 31, 2022 – 39,442,260 ). As of March 31, 2023, the only Awards issued have been options, RSUs, and PSUs under the Omnibus Plan. The Omnibus Plan is administered by the Corporate Governance, Compensation and Nominating Committee of the Board (the “CGC&N Committee”) which establishes exercise prices, at not less than the market price at the date of grant, and expiry dates. Awards under the Omnibus Plan generally vest in increments with 1/3 vesting on each of the first, second and third anniversaries from the date of grant, with expiry dates set at ten years from issuance, subject to the discretion of the CGC&N Committee pursuant to the Omnibus Plan to provide for an alternative expiry date or vesting period in an award agreement for the grant of Awards, subject to limits contained in the Omnibus Plan. Under the Company’s Employee Share Purchase Plan (the “Purchase Plan”) the aggregate number of common shares that may be issued is 600,000 , and the maximum number of common shares which may be issued in any one fiscal year shall not exceed 300,000 . As of March 31, 2023, the Company has issued a total of 535,666 common shares under the Purchase Plan (March 31, 2022 – 235,813 ) with 299,853 being issued in the current fiscal year (March 31, 2022 – 198,501 ). The following is a summary of the changes in the Company’s Omnibus Plan employee options during the years ended March 31, 2021, 2022 and 2023: Options Weighted Balance outstanding at March 31, 2020 32,508,395 $ 34.89 Options granted 478,215 28.15 Options exercised ( 7,062,317 ) 22.22 Options forfeited ( 8,219,982 ) 41.27 Balance outstanding at March 31, 2021 17,704,311 $ 36.79 Options granted 2,537,290 17.40 Replacement options issued as a result of the acquisition of Supreme Cannabis 140,159 80.53 Options exercised ( 445,680 ) 12.27 Options forfeited ( 3,153,118 ) 42.03 Balance outstanding at March 31, 2022 16,782,962 $ 33.89 Options granted 4,658,797 4.93 Options exercised ( 79,586 ) 3.53 Options forfeited ( 7,611,285 ) 28.80 Balance outstanding at March 31, 2023 13,750,888 $ 27.12 The following is a summary of the outstanding stock options as at March 31, 2023: Options Outstanding Options Exercisable Weighted Average Weighted Average Remaining Remaining Outstanding at Contractual Life Exercisable at Contractual Life Range of Exercise Prices March 31, 2023 (years) March 31, 2023 (years) $ 0.06 - $ 24.62 5,333,314 4.63 1,300,821 2.61 $ 24.63 - $ 33.53 3,062,535 2.36 1,841,655 2.03 $ 33.54 - $ 36.80 1,448,009 1.69 1,448,009 1.69 $ 36.81 - $ 42.84 1,626,478 1.64 1,620,201 1.62 $ 42.85 - $ 67.64 2,280,552 1.85 2,280,552 1.85 13,750,888 3.00 8,491,238 1.93 At March 31, 2023, the weighted average exercise price of options outstanding and options exercisable was $ 27.12 and $ 37.28 , respectively (March 31, 2022 – $ 33.89 and $ 38.33 , respectively). The Company recorded $ 6,878 in share-based compensation expense related to Options issued to employees and contractors for the year ended March 31, 2023 (for the year ended March 31, 2022 – $ 27,163 ; for the year ended March 31, 2021 – $ 67,737 ). The share-based compensation expense for the year ended March 31, 2023 includes an amount related to 1,078,748 options being provided in exchange for services which are subject to performance conditions (for the year ended March 31, 2022 – 1,336,249 ; for the year ended March 31, 2021 – 2,152,938 ). The Company issued replacement options to employees in relation to the acquisition of Supreme Cannabis (Note 29 (b)) and during the year ended March 31, 2022, recorded share-based compensation expense $ 823 . With the exception of nil options which are subject to market-based performance conditions (March 31, 2022 – nil; March 31, 2021 – 17,559 ) and valued using the Monte Carlo simulation model, the Company uses the Black-Scholes option pricing model to establish the fair value of options granted during the years ended March 31, 2023, 2022 and 2021 on their measurement date by applying the following assumptions: March 31, March 31, March 31, 2023 2022 2021 Risk-free interest rate 3.45 % 1.09 % 0.36 % Expected life of options (years) 3 - 5 3 - 5 1 - 7 Expected volatility 77 % 75 % 76 % Expected forfeiture rate 19 % 18 % 17 % Expected dividend yield nil nil nil Black-Scholes value of each option $ 2.92 $ 9.69 $ 15.24 Volatility was estimated by using the historical volatility of the Company. The expected life in years represents the period of time that Options granted are expected to be outstanding. The risk-free rate was based on zero coupon Canada government bonds with a remaining term equal to the expected life of the Options. During the year ended March 31, 2023, 79,586 Options were exercised ranging in price from $ 0.06 to $ 8.18 for gross proceeds of $ 281 (for the year ended March 31, 2022 – 445,680 Options were exercised ranging in price from $ 0.06 to $ 36.34 for gross proceeds of $ 5,567 ; for the year ended March 31, 2021 – 7,062,317 Options were exercised ranging in prices from $ 0.06 to $ 67.64 for gross proceeds of $ 156,897 ). For the year ended March 31, 2023, the Company recorded $ 18,444 in share-based compensation expense related to RSUs and PSUs (for the year ended March 31, 2022 – $ 10,709 , for the year ended March 31, 2021 – $ 11,448 ). The following is a summary of changes in the Company’s RSUs and PSUs during the years ended March 31, 2021, 2022 and 2023: Number of RSUs Balance outstanding at March 31, 2020 883,009 RSUs granted 142,826 RSUs released ( 120,399 ) RSUs cancelled and forfeited ( 152,126 ) Balance outstanding at March 31, 2021 753,310 RSUs and PSUs granted 3,253,671 RSUs and PSUs released ( 300,319 ) RSUs and PSUs cancelled and forfeited ( 229,370 ) Balance outstanding at March 31, 2022 3,477,292 RSUs and PSUs granted 3,143,098 RSUs and PSUs released ( 1,464,934 ) RSUs and PSUs cancelled and forfeited ( 2,572,242 ) Balance outstanding at March 31, 2023 2,583,214 During the year ended March 31, 2023, the Company recorded $ nil in share-based compensation expense related to acquisition milestones (for the year ended March 31, 2022 – $ 7,991 ; for the year ended March 31, 2021 – $ 8,136 ). During the year ended March 31, 2023, 222,421 shares (during the year ended March 31, 2022 – 1,295,285 , during the year ended March 31, 2021 – 2,598,978 ) were released on completion of acquisition milestones. At March 31, 2023, there were up to 125,489 shares to be issued on the completion of acquisition and asset purchase milestones. In certain cases, the number of shares to be issued is based on the volume weighted average share price at the time the milestones are met. The number of shares has been estimated assuming the milestones were met at March 31, 2023. The number of shares excludes shares that are to be issued on July 4, 2023 to the previous shareholders of Spectrum Cannabis Colombia S.A.S. and Canindica Capital Ltd. based on the fair market value of the Company’s Latin American business on that date. BioSteel share-based payments On October 1, 2019, the Company purchased 72 % of the outstanding shares of BioSteel. BioSteel has a stock option plan under which non-transferable options to purchase common shares of BioSteel may be granted to directors, officers, employees, or independent contractors of the BioSteel. As at March 31, 2023, the Company had 614,778 (March 31, 2022 – 1,565,300 , March 31, 2021 – 1,581,000 ) options outstanding which vest in equal tranches over a 5 -year period. In determining the amount of share-based compensation related to these options, BioSteel used the Black-Scholes option pricing model to establish the fair value of options on their measurement date. The Company recorded $ 1,143 of share-based compensation expense related to the BioSteel options during the year ended March 31, 2023 with a corresponding increase in noncontrolling interest (year ended March 31, 2022 – $ 839 , March 31, 2021 – $ 1,169 ). RIV Capital share-based payments For the period from April 1, 2020 to February 23, 2021, the Company recorded $ 2,659 in share-based compensation expense related to its former subsidiary, RIV Capital. As described in Note 30 (c), the Company disposed of its investment in RIV Capital on February 23, 2021.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	12 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	22 . ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Accumulated other comprehensive income includes the following components: Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2020 $ 126,723 $ 94,176 $ 220,899 Other comprehensive income ( 154,969 ) ( 100,170 ) ( 255,139 ) As at March 31, 2021 ( 28,246 ) ( 5,994 ) ( 34,240 ) Disposal of consolidated entities 16,130 - 16,130 Other comprehensive income (loss) ( 45,352 ) 21,180 ( 24,172 ) As at March 31, 2022 ( 57,468 ) 15,186 ( 42,282 ) Settlement of unsecured senior notes, net of deferred income tax - ( 29,507 ) ( 29,507 ) Other comprehensive income 27,207 30,722 57,929 As at March 31, 2023 $ ( 30,261 ) $ 16,401 $ ( 13,860 )

Noncontrolling Interests

Noncontrolling Interests	12 Months Ended
	Mar. 31, 2023
Noncontrolling Interest [Abstract]
Noncontrolling Interests	23 . NONCONTROLLING INTERESTS The net change in the noncontrolling interests is as follows: RIV 1 Vert BioSteel Other Total (As Restated) As at March 31, 2020 $ 211,086 $ 7,132 $ 489 $ 3,051 $ 221,758 Comprehensive income (loss) 94,532 ( 14,261 ) ( 6,171 ) - 74,100 Net loss attributable to redeemable - 11,906 6,171 - 18,077 Share-based compensation 2,659 - 1,169 - 3,828 Ownership changes ( 308,527 ) ( 4,777 ) - - ( 313,304 ) Warrants 250 - - - 250 As at March 31, 2021 - - 1,658 3,051 4,709 Comprehensive loss - ( 3,165 ) ( 16,152 ) ( 1,207 ) ( 20,524 ) Net loss attributable to redeemable - 3,165 16,152 - 19,317 Share-based compensation - - 839 - 839 As at March 31, 2022 - - 2,497 1,844 4,341 Comprehensive loss - ( 53 ) ( 29,491 ) ( 1,844 ) ( 31,388 ) Net loss attributable to - 53 29,491 - 29,544 Share-based compensation - - 570 - 570 Ownership changes - - - 140 140 Redemption of redeemable - - ( 1,620 ) - ( 1,620 ) As at March 31, 2023 $ - $ - $ 1,447 $ 140 $ 1,587 1 Refer to Note 30(c) for information regarding the completion of the plan of arrangement with RIV Capital.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	24 . FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value measurements are made using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value: • Level 1 - defined as observable inputs such as quoted prices in active markets; • Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and • Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The fair value measurement is categorized in its entirety by reference to its lowest level of significant input. The Company records cash, accounts receivable, interest receivable and, accounts payable, and other accrued expenses and liabilities at cost. The carrying values of these instruments approximate their fair value due to their short-term maturities. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments. Assets and liabilities recognized or disclosed at fair value on a nonrecurring basis may include items such as property, plant and equipment, goodwill and other intangible assets, equity and other investments and other assets. We determine the fair value of these items using Level 3 inputs, as described in the related sections below. The following table represents our financial assets and liabilities measured at estimated fair value on a recurring basis: Fair value measurement using Quoted Significant prices in other Significant active observable unobservable markets inputs inputs (Level 1) (Level 2) (Level 3) Total March 31, 2023 Assets: Short-term investments $ 105,595 $ - $ - $ 105,595 Restricted short-term investments 11,765 - - 11,765 Other financial assets 269 - 559,525 559,794 Liabilities: Unsecured senior notes - 331,250 - 331,250 Other liabilities - - 29,952 29,952 March 31, 2022 Assets: Short-term investments $ 595,651 $ - $ - $ 595,651 Restricted short-term investments 12,216 - - 12,216 Other financial assets 490 - 787,816 788,306 Liabilities: Unsecured senior notes - 563,958 - 563,958 Liability arising from Acreage Arrangement - - 47,000 47,000 Warrant derivative liability - - 26,920 26,920 Other liabilities - - 70,066 70,066 The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 2 financial instruments: Financial asset / financial liability Valuation techniques Key inputs Unsecured senior notes Senior note pricing model Quoted prices in over-the-counter broker market The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 3 financial instruments: Financial asset / financial liability Valuation techniques Significant unobservable inputs Relationship of unobservable inputs to fair value Acreage financial instrument Probability weighted expected return Probability of each scenario Change in probability of occurrence in each scenario will result in a change in fair value model Number of common shares to be issued Increase or decrease in value and number of common shares will result in a decrease or increase in fair value Intrinsic value of Acreage Increase or decrease in intrinsic value will result in an increase or decrease in fair value Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Estimated premium on US legalization Increase or decrease in estimated premium on US legalization will result in an increase or decrease in fair value Control premium Increase or decrease in estimated control premium will result in an increase or decrease in fair value Market access premium Increase or decrease in estimated market access premium will result in an increase or decrease in fair value TerrAscend Exchangeable Shares, TerrAscend Option Put option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Hempco Debenture Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value TerrAscend warrants - December 2022 Black-Sholes option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Wana financial instrument - Call Discounted cash flow Expected future Wana cash flows Increase or decrease in expected future Wana cash flows will result in an increase or decrease in fair value Options Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Wana financial instrument - Deferred Payments Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Volatility of Wana equity Increase or decrease in volatility will result in an increase or decrease in fair value Jetty financial instrument - Discounted cash flow Expected future Jetty cash flows Increase or decrease in expected future Jetty cash flows will result in an increase or decrease in fair value Call Options Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Jetty financial instrument - Deferred Payments Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Volatility of Jetty equity and revenue Increase or decrease in volatility will result in an increase or decrease in fair value Warrant derivative liability Monte Carlo simulation model Volatility of Canopy Growth share price Increase or decrease in volatility will result in an increase or decrease in fair value BioSteel redeemable noncontrolling Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value interest Expected future BioSteel cash flows Increase or decrease in expected future BioSteel cash flows will result in an increase or decrease in fair value Acreage Debt Option Premium Monte Carlo simulation model Volatility of Acreage share price Increase or decrease in volatility will result in a decrease or increase in fair value Acreage Tax Receivable Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Agreement Probability-weighted expected return Probability of each scenario Change in probability of occurrence in each scenario will result in a change in fair value model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value 25 . REVENUE Revenue is disaggregated as follows: Years ended March 31, March 31, March 31, 2023 2022 2021 (As Restated) Canada cannabis Canadian adult-use cannabis Business-to-business 1 $ 95,026 $ 143,732 $ 163,585 Business-to-consumer 36,243 61,570 66,016 131,269 205,302 229,601 Canadian medical cannabis 2 55,798 52,608 55,448 $ 187,067 $ 257,910 $ 285,049 Rest-of-world cannabis C 3 - 36,113 62,335 Other rest-of-world cannabis 38,949 43,193 31,296 $ 38,949 $ 79,306 $ 93,631 Storz & Bickel $ 64,845 $ 85,410 $ 80,998 BioSteel $ 69,649 $ 34,622 $ 28,530 This Works $ 26,029 $ 32,296 $ 33,314 Other 16,365 20,777 25,127 Net revenue $ 402,904 $ 510,321 $ 546,649 1 Canadian adult-use business-to-business net revenue reflects excise taxes of $ 43,071 (year ended March 31, 2022 - $ 56,666 ; and year ended March 31, 2021 - $ 54,928 ). 2 Canadian medical cannabis net revenue reflects excise taxes of $ 4,926 (year ended March 31, 2022 - $ 5,227 ; and year ended March 31, 2021 - $ 5,621 ). The Company recognizes variable consideration related to estimated future product returns and price adjustments as a reduction of the transaction price at the time revenue for the corresponding product sale is recognized. Net revenue reflects actual returns and variable consideration related to estimated returns and price adjustments in the amount of $ 26,233 for the year ended March 31, 2023 (year ended March 31, 2022 – $ 21,464 ; and year ended March 31, 2021 – $ 23,935 ). As of March 31, 2023, the liability for estimated returns and price adjustments was $ 7,123 (March 31, 2022 – $ 3,729 ). 26 . PHARMHOUSE PharmHouse Inc. (“PharmHouse”), a joint venture formed on May 7, 2018 , between RIV Capital and 2615975 Ontario Limited (the “PharmHouse JV Partner”), is a company licensed to cultivate cannabis under the Cannabis Act. Upon completion of the RIV Arrangement on February 23, 2021, the Company no longer controlled RIV Capital and RIV Capital’s consolidated assets and liabilities were derecognized from the Company’s consolidated financial statements. The assets and liabilities that were derecognized include those described below in relation to RIV Capital’s investments in, and obligations with respect to, PharmHouse. Refer to Note 30(c) for further details on the RIV Arrangement. CCAA Proceedings During the year ended March 31, 2021, PharmHouse determined that the previously anticipated timeline to generate cash flows from its offtake agreements with the Company and TerrAscend Canada would not be met, and the ultimate timing and receipt of cash inflows pursuant to these agreements became uncertain. As a result of this, as well as broader sector-wide challenges impacting the Canadian cannabis industry, PharmHouse did not have sufficient liquidity and capital resources to meet its business objectives and became unable to meet its financial obligations as they became due. Accordingly, on September 15, 2020, PharmHouse obtained an order (the “Initial Order”) from the Ontario Superior Court of Justice (the “Court”) granting PharmHouse creditor protection under the Companies’ Creditors Arrangement Act (“CCAA”) (the “CCAA Proceedings”). The Court appointed an independent professional services firm to act as the Monitor of PharmHouse in the CCAA Proceedings while PharmHouse explored a restructuring of its business and operations (the “PharmHouse Restructuring”). On October 29, 2020, PharmHouse received approval from the Court to commence its Sale and Investor Solicitation Process (“SISP”). The SISP process concluded in March 2021, subsequent to the completion of the RIV Arrangement, when PharmHouse entered into a binding asset purchase agreement to sell various operating assets including its facility and certain equipment at the facility. The asset purchase agreement was approved by the Court in March 2021. PharmHouse Recoverability Assessment As a result of the CCAA Proceedings and the Restructuring, RIV Capital determined that there were indicators of impairment present for its investments in various PharmHouse-related financial assets. RIV Capital performed impairment testing for its various PharmHouse-related financial assets by estimating the fair value of PharmHouse en bloc. Due to the lack of profitable operating history for PharmHouse as a cannabis entity, RIV Capital estimated the fair value of PharmHouse en bloc using an asset-based approach to value PharmHouse’s assets under an orderly liquidation scenario where cannabis operations are not continued at PharmHouse’s facility and the greenhouse is sold for purposes other than cannabis cultivation. This amount was then compared to the carrying values of the various PharmHouse-related financial instruments held by RIV Capital, in sequence based on the priority of claims on PharmHouse’s assets (the “PharmHouse Recoverability Assessment”). The significant components of this fair value analysis included PharmHouse’s greenhouse facility and retrofits, separable machinery and equipment, saleable inventory, and cash. Significant unobservable inputs used by RIV Capital to determine the fair value of PharmHouse’s assets include the selling price per square foot for PharmHouse’s greenhouse facility; the recoverability percentage on the liquidation of PharmHouse’s property, plant and equipment; the selling price per gram of PharmHouse’s existing cannabis inventory; and adjustments for the risk of fair value changes and liquidity. Based on the foregoing, the Company estimated the recoverable value of PharmHouse’s assets in an orderly liquidation scenario to be approximately $ 57,500 . The impact of the PharmHouse Recoverability Assessment on RIV Capital’s various PharmHouse-related financial instruments is described below. PharmHouse Financial Guarantee Prior to February 23, 2021, PharmHouse had entered into a syndicated credit agreement (as amended, the “PharmHouse Credit Agreement”) with a number of Canadian banks (the “PharmHouse Lenders”) to provide PharmHouse with a committed, non-revolving credit facility (the “PharmHouse Credit Facility”) with a maximum principal amount of $ 90,000 , which was fully drawn. The obligations of PharmHouse under the PharmHouse Credit Facility were secured by guarantees of RIV Capital and RCC, and a pledge by RCC of all of the shares of PharmHouse held by it (the “PharmHouse Financial Guarantee”). Accordingly, if PharmHouse was unable to generate sufficient cash flows to service its obligations pursuant to the PharmHouse Credit Facility, RIV Capital and RCC were required to compensate the PharmHouse Lenders for their loss incurred on the PharmHouse Credit Facility. The PharmHouse Credit Agreement also contains other covenants applicable to RIV Capital and RCC. Based on the PharmHouse Recoverability Assessment described above, the Company determined that the fair value of PharmHouse’s assets under an orderly liquidation scenario where the facility is not used for cannabis operations may be less than the principal amount owed by PharmHouse pursuant to the PharmHouse Credit Facility. Accordingly, the Company estimated that, prior to February 23, 2021, it had a financial liability related to the PharmHouse Financial Guarantee, reflecting the estimated shortfall between the recoverable amount of PharmHouse en bloc and the Company’s exposure to the PharmHouse Credit Facility. As at February 23, 2021, the Company estimated the current expected credit loss related to its contingent obligation under the PharmHouse Financial Guarantee to be $ 32,500 , and recognized a financial liability for this amount in the consolidated balance sheet. Upon completion of the RIV Arrangement on February 23, 2021, this liability was derecognized from the Company’s consolidated balance sheet. During the year ended March 31, 2021, the Company recognized an associated current expected credit loss of $ 32,500 in net income (loss). Other financial assets, including loans receivable Prior to February 23, 2021, RCC had advanced to PharmHouse: (i) $ 40,000 of secured debt financing pursuant to a shareholder loan agreement; (ii) $ 2,450 pursuant to a secured demand promissory note; and (iii) $ 1,206 between August 4, 2020, and September 8, 2020 pursuant to an unsecured promissory note. The Company recognized these instruments as financial assets, initially recorded them at fair value and subsequently measured them at amortized cost. Additionally, pursuant to the Initial Order, RCC entered into an agreement to provide a super-priority, debtor-in-possession interim, non-revolving credit facility to PharmHouse (the “DIP Financing”), with a maximum principal amount available to be drawn by PharmHouse of $ 9,700 , and a maturity date of February 28, 2021. As at February 23, 2021, RCC had advanced $ 9,300 pursuant to the DIP Financing. As a result of the PharmHouse Recoverability Assessment described above, the Company recognized a current expected credit loss of $ 32,500 in the year ended March 31, 2021, related to its contingent obligation under the PharmHouse Financial Guarantee that existed prior to the completion of the RIV Arrangement on February 23, 2021 and the resulting derecognition of RIV Capital’s consolidated assets and liabilities. The Company also concluded that the following amounts, as described above, may not be recoverable: (i) $ 9,300 advanced pursuant to DIP Financing; (ii) $ 40,000 advanced under the shareholder loan agreement; (iii) $ 2,450 advanced under the secured demand promissory note; (iv) $ 1,206 advanced under the unsecured demand promissory note; and (v) $ 8,989 in interest receivable in relation to these financial instruments. Additionally, it was determined that certain advances in the amount of $ 15,000 provided to PharmHouse by the Company may not be recoverable, and costs of $ 35 were incurred associated with the PharmHouse Restructuring in the year ended March 31, 2021. Accordingly, the Company recorded expected credit losses on financial assets and related charges of $ 109,480 for the year ended March 31, 2021. PharmHouse equity method investment As at February 23, 2021, RCC owned 10,998,660 common shares of PharmHouse, representing a 49 % equity interest on a non-diluted basis. RCC had not yet received any distributions on account of its common share investment in PharmHouse. As a result of the PharmHouse Recoverability Assessment described above, the Company determined that there was an other-than-temporary-impairment and recognized an impairment charge for the full amount of its equity method investment of $ 32,369 . 27 . OTHER INCOME (EXPENSE), NET Other income (expense), net is disaggregated as follows: Years ended March 31, March 31, March 31, 2023 2022 2021 Fair value changes on other financial assets $ ( 424,115 ) $ ( 356,109 ) $ 435,107 Fair value changes on liability arising from Acreage 47,000 553,000 ( 399,849 ) Fair value changes on unsecured senior notes ( 43,104 ) 76,776 ( 162,540 ) Fair value changes on warrant derivative liability 26,920 588,655 ( 293,084 ) Fair value changes on acquisition related contingent 38,890 4,417 39,608 Gain and charges related to settlement of debt 582 - - Interest income 24,282 6,601 21,367 Interest expense ( 126,160 ) ( 103,944 ) ( 8,459 ) Foreign currency gain (loss) ( 8,534 ) 5,415 ( 18,013 ) Gain (loss) on disposal/acquisition of consolidated entity 2,414 ( 6,762 ) 634 Other income (expense), net ( 4,200 ) ( 14,708 ) ( 2,647 ) $ ( 466,025 ) $ 753,341 $ ( 387,876 ) 28 . INCOME TAXES Net loss before income taxes was generated as follows: Years ended March 31, March 31, March 31, 2023 2022 2021 (As Restated) Domestic - Canada $ ( 2,513,026 ) $ ( 173,970 ) $ ( 1,611,210 ) Foreign - outside of Canada ( 801,294 ) ( 165,545 ) ( 72,751 ) $ ( 3,314,320 ) $ ( 339,515 ) $ ( 1,683,961 ) The income tax recovery (expense) consists of the following: Years ended March 31, March 31, March 31, 2023 2022 2021 Current Domestic - Canada $ 4,783 $ 895 $ ( 19,318 ) Foreign - outside of Canada ( 676 ) 1,476 ( 2,091 ) $ 4,107 $ 2,371 $ ( 21,409 ) Deferred Domestic - Canada $ ( 3,603 ) $ 6,353 $ 36,505 Foreign - outside of Canada 4,270 224 ( 1,955 ) 667 6,577 34,550 Income tax recovery $ 4,774 $ 8,948 $ 13,141 As more fully described in Note 3, income taxes that are required to be reflected in equity, instead of in the consolidated statements of operations, are included in the consolidated statements of shareholders’ equity, if applicable. Current and deferred income tax referred to above is recognized based on the Company’s best estimate of the tax rates expected to apply to the income, loss or temporary difference. The Company is subject to income tax in numerous jurisdictions with varying tax rates. During the current year ended, there were no material changes to the enacted statutory tax rates in the jurisdictions where the majority of the Company’s income for tax purposes was earned or where its material temporary differences or losses are expected to be realized or settled, however the impact of commercial decisions and market forces result in changes to the distribution of income for tax purposes amongst taxing jurisdictions that may result in a change of the effective tax rate applicable to such income, loss or temporary difference. A reconciliation of the amount of income taxes reflected above compared to the expected income taxes calculated at the combined Canadian federal and provincial enacted statutory tax rate of 26.5 % for each of the three years ended March 31, 2023, 2022 and 2021 is as follows: Years ended March 31, March 31, March 31, 2023 2022 2021 (As Restated) Net loss before income taxes $ ( 3,314,320 ) $ ( 339,515 ) $ ( 1,683,961 ) Expected tax rate 26.5 % 26.5 % 26.5 % Expected income tax recovery 878,295 89,971 446,250 Non-deductible and non-taxable items ( 29,385 ) 17,557 81,883 Fair value changes on Acreage Arrangement 12,386 146,545 ( 105,960 ) Fair value changes on warrant derivative liability 6,294 155,964 ( 77,663 ) Settlement of unsecured senior notes ( 14,862 ) - - Share-based compensation ( 2,126 ) ( 9,908 ) ( 21,121 ) Goodwill impairment ( 473,702 ) - - Change in valuation allowance ( 313,583 ) ( 363,954 ) ( 358,964 ) Effect of tax rates outside of Canada ( 4,596 ) 8,459 10,870 Non-taxable portion of capital gains and losses ( 48,573 ) ( 38,440 ) 38,705 Other ( 5,374 ) 2,754 ( 859 ) Income tax recovery $ 4,774 $ 8,948 $ 13,141 Current income taxes payable in the amount of $ 1,592 (March 31, 2022 – $ 1,927 ) is included in accounts payable and current income taxes receivable in the amount of $ 5,446 (March 31, 2022 – $ 6,018 ) is included in other accounts receivable. The Company continues to believe the amount of unrealized tax benefits appropriately reflects the uncertainty of items that are or may in the future be under discussion, audit, dispute or appeal with a tax authority or which otherwise result in uncertainty in the determination of income for tax purposes. If appropriate, an unrealized tax benefit will be realized in the year in which the Company determines that realization is not in doubt. Where the final determined outcome is different from the Company’s estimate, such difference will impact the Company’s income taxes in the year during which such determination is made. Significant components of deferred income tax assets (liabilities) consist of the following: Years ended March 31, March 31, 2023 2022 (As Restated) Deferred income tax assets Property, plant and equipment $ 104,043 $ 78,023 Intangible assets 11,202 671 Inventory reserves and write-downs 18,749 40,324 Other reserves and accruals 10,554 5,939 Losses carried forward 1,142,607 919,955 Equity method investments and other financial assets 72,881 10,512 Deferred financing costs 4,597 2,740 Other 10,415 5,635 Gross deferred income tax assets 1,375,048 1,063,799 Valuation allowances ( 1,355,385 ) ( 1,041,802 ) Total deferred income tax assets, net $ 19,663 $ 21,997 Deferred income tax liabilities Property, plant and equipment $ ( 3,475 ) $ ( 4,182 ) Intangible assets ( 15,200 ) ( 29,832 ) Deferred financing costs ( 1,345 ) ( 3,353 ) Other - ( 621 ) Total deferred income tax liabilities ( 20,020 ) ( 37,988 ) Net deferred income tax liabilities $ ( 357 ) $ ( 15,991 ) In evaluating whether it is more likely than not that all or a portion of a deferred income tax asset will be realized consideration is given to the estimated reversal of deferred income tax liabilities and future taxable income. The Company has recognized valuation allowances for operating losses carried forward, capital losses carried forward and other deferred income tax assets when it is believed that it is more likely than not that these items will not be realized. As at March 31, 2023, the Company had temporary differences associated with investments in foreign subsidiaries for which no deferred income tax liabilities have been recognized, as the Company is able to control the timing of the reversal of these temporary differences and material undistributed earnings are considered permanently invested. Determination of the amount of the unrecognized deferred income tax liability is not practicable due to the inherent complexity of the multi-jurisdictional operations of the Company. As at March 31, 2023, the Company has the following losses carried forward available to reduce future years’ taxable income, which losses expire as follows: Expiring within 5 years $ - Expiring between 5 and 10 years 3,321 Expiring between 10 and 15 years 367,213 Expiring between 15 and 20 years 2,829,026 Indefinite 510,831 $ 3,710,391 Total in Canada $ 3,195,923 Total in United States 451,258 Total in Europe 58,731 Total in other jurisdictions 4,479 $ 3,710,391 Total operating losses $ 3,710,391 Total capital losses (carried forward indefinitely) 1,177,195 $ 4,887,586 29 . ACQUISITIONS (a) Year ended March 31, 2023 The following table summarizes the consolidated balance sheet impact at acquisition of the Company’s business combinations that occurred in the year ended March 31, 2023. Verona Facility Property, plant and equipment $ 28,771 Debt and other liabilities ( 2,373 ) Net assets acquired $ 26,398 Consideration paid in cash $ 24,223 Other consideration 2,175 Total consideration $ 26,398 Consideration paid in cash $ 24,223 Less: Cash and cash equivalents acquired - Net cash outflow $ 24,223 The table above summarizes the fair value of the consideration given and the fair values assigned to the assets acquired and liabilities assumed for the acquisition completed in the year ended March 31, 2023. Acquisition of Verona Facility On November 8, 2022, the Company, through its affiliate BioSteel, completed the acquisition (the “Verona Acquisition”) of a manufacturing facility located in Verona, Virginia (the “Verona Facility”) from Flow Beverage Corp. (“Flow”), one of BioSteel’s contract manufacturers. Consideration was $ 26,398 (US$ 19,477 ), consisting of cash paid of $ 15,685 (US$ 11,573 ) and $ 8,538 (US$ 6,299 ) related to the repayment of debt and the retirement of certain lease obligations, and $ 2,175 (US$ 1,605 ) in remediation and indemnity holdbacks to be retained by the Company and paid within one year of the closing of the Verona Acquisition. BioSteel and Flow have also entered into a co-manufacturing agreement whereby, in addition to the production of BioSteel-branded sports hydration beverages, BioSteel will produce Flow’s portfolio of branded water at the Verona Facility. Due to the timing of the Verona Acquisition, the purchase price allocation for the Verona Acquisition is provisional. The fair value assigned to the consideration paid and net assets acquired is based on management’s best estimate using the information currently available and may be revised by the Company as additional information is received. (b) Acquisitions completed in the year ended March 31, 2022 The following table summarized the consolidated balance sheet impact at acquisition of the Company's business combinations that occurred in the year ended March 31, 2022. Ace Supreme Valley Cannabis (i) (ii) Other Total Cash and cash equivalents $ 1,544 $ 41,306 $ 1,227 $ 44,077 Inventory 878 33,426 362 34,666 Other current assets 2,249 14,791 335 17,375 Property, plant and equipment 105 187,407 1,510 189,022 Intangible assets Brands 14,000 22,800 - 36,800 Distribution channel - 3,500 - 3,500 Operating licenses - 24,400 2,000 26,400 Goodwill 39,152 58,842 7,329 105,323 Accounts payable and other accrued expenses and liabilities ( 1,724 ) ( 12,935 ) ( 30 ) ( 14,689 ) Debt and other liabilities - ( 88,324 ) ( 1,037 ) ( 89,361 ) Deferred income tax liabilities ( 1,899 ) ( 5,545 ) ( 540 ) ( 7,984 ) Net assets acquired $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Consideration paid in shares - 260,668 4,052 264,720 Replacement options - 629 - 629 Replacement warrants - 13,350 - 13,350 Other consideration 2,469 4,937 - 7,406 Total consideration $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Less: Cash and cash equivalents acquired ( 1,544 ) ( 41,306 ) ( 1,227 ) ( 44,077 ) Net cash outflow (inflow) $ 50,292 $ ( 41,222 ) $ 5,877 $ 14,947 The table above summarizes the fair value of the consideration given and the fair values assigned to the assets acquired and liabilities assumed for each acquisition. Goodwill arose in these acquisitions because the cost of acquisition included a control premium. In addition, the consideration paid for the combination reflected the benefit of expected revenue growth and future market development. These benefits were not recognized separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets. Except for some of the goodwill arising in respect of the Ace Valley (as defined below) and Supreme Cannabis acquisition, none of the goodwill arising on these acquisitions is expected to be deductible in the computation of income for tax purposes. (i) Ace Valley On April 1, 2021 , the Company entered into a share purchase agreement (the “AV Share Purchase Agreement”) with Tweed Inc., AV Cannabis Inc. (“Ace Valley”), and the shareholders of Ace Valley (the “AV Vendors”) pursuant to which the Company indirectly acquired 100 % of the issued and outstanding shares of Ace Valley for cash consideration of $ 51,836 . Ace Valley is an Ontario-based cannabis brand with a focus on premium, ready-to-enjoy products including vapes, pre-roll joints and gummies. Pursuant to the terms of the AV Share Purchase Agreement, the Company may be required to make certain earn-out payments to the AV Vendors, which may result in an additional cash payment or the issuance of common shares, subject to the fulfillment of certain conditions by April 1, 2023. This represents liability-classified contingent consideration. Management has estimated the fair value of this consideration to be $ 2,469 by assessing the probability and timing of the fulfillment of the specified conditions and discounting the expected cash outflows to present value. In the year ended March 31, 2022, the Company finalized the purchase price allocation to the individual assets acquired and liabilities assumed using the acquisition method (ii) Supreme Cannabis On June 22, 2021 , the Company and Supreme Cannabis completed an arrangement (the “Supreme Arrangement”) pursuant to which the Company acquired 100 % of the issued and outstanding common shares of Supreme Cannabis (the “Supreme Shares”). Supreme Cannabis is a producer of adult-use, wholesale and medical cannabis products, with a diversified portfolio of distinct cannabis companies, products and brands. Pursuant to the Supreme Arrangement, the Company issued 9,013,400 common shares with a fair value on closing of $ 260,668 and made a cash payment of $ 84 to former Supreme Cannabis shareholders in consideration for their Supreme Shares. The Company also assumed the obligation to issue 1,265,742 common shares upon the exercise of outstanding warrants of Supreme Cannabis and issued 140,159 replacement options. The fair value of the obligation upon the exercise of the outstanding warrants of Supreme Cannabis was estimated to be $ 13,350 using a Black-Scholes model. The replacement options’ fair value totaled $ 1,452 , calculated using a Black-Scholes model, of which $ 629 was included in consideration paid as it related to pre-combination services and the residual $ 823 fair value was recognized immediately in share-based compensation expense after the completion of the acquisition. On June 22, 2021, Supreme Cannabis had convertible debentures outstanding with a principal amount of $ 27,045 which were convertible into 94,895,649 Supreme Shares. As a result of the acquisition the conversion feature was adjusted in accordance with an exchange ratio of 0.011659 . The fair value of these convertible debentures on June 22, 2021 was estimated to be $ 36,593 , of which $ 4,937 was allocated to the conversion feature and $ 31,656 to the debt component. In the year ended March 31, 2023, the Company finalized the purchase price allocation to the individual assets acquired and liabilities assumed using the acquisition method. (c) Acquisitions completed in the year ended March 31, 2021 There were no acquisitions during the year ended March 31, 2021 . (d) More Life On November 7, 2019 the Company entered into agreements with certain entities that are controlled by Aubrey “Drake” Graham to launch More Life. Under the agreements Canopy Growth sold 100 % of the shares of 1955625 Ontario Inc., a wholly owned subsidiary of Canopy Growth that holds the Health Canada license for a facility located in Scarborough, Ontari

Revenue

Revenue	12 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue	25 . REVENUE Revenue is disaggregated as follows: Years ended March 31, March 31, March 31, 2023 2022 2021 (As Restated) Canada cannabis Canadian adult-use cannabis Business-to-business 1 $ 95,026 $ 143,732 $ 163,585 Business-to-consumer 36,243 61,570 66,016 131,269 205,302 229,601 Canadian medical cannabis 2 55,798 52,608 55,448 $ 187,067 $ 257,910 $ 285,049 Rest-of-world cannabis C 3 - 36,113 62,335 Other rest-of-world cannabis 38,949 43,193 31,296 $ 38,949 $ 79,306 $ 93,631 Storz & Bickel $ 64,845 $ 85,410 $ 80,998 BioSteel $ 69,649 $ 34,622 $ 28,530 This Works $ 26,029 $ 32,296 $ 33,314 Other 16,365 20,777 25,127 Net revenue $ 402,904 $ 510,321 $ 546,649 1 Canadian adult-use business-to-business net revenue reflects excise taxes of $ 43,071 (year ended March 31, 2022 - $ 56,666 ; and year ended March 31, 2021 - $ 54,928 ). 2 Canadian medical cannabis net revenue reflects excise taxes of $ 4,926 (year ended March 31, 2022 - $ 5,227 ; and year ended March 31, 2021 - $ 5,621 ). The Company recognizes variable consideration related to estimated future product returns and price adjustments as a reduction of the transaction price at the time revenue for the corresponding product sale is recognized. Net revenue reflects actual returns and variable consideration related to estimated returns and price adjustments in the amount of $ 26,233 for the year ended March 31, 2023 (year ended March 31, 2022 – $ 21,464 ; and year ended March 31, 2021 – $ 23,935 ). As of March 31, 2023, the liability for estimated returns and price adjustments was $ 7,123 (March 31, 2022 – $ 3,729 ).

Pharmhouse

Pharmhouse	12 Months Ended
	Mar. 31, 2023
Business Combinations [Abstract]
Pharmhouse	26 . PHARMHOUSE PharmHouse Inc. (“PharmHouse”), a joint venture formed on May 7, 2018 , between RIV Capital and 2615975 Ontario Limited (the “PharmHouse JV Partner”), is a company licensed to cultivate cannabis under the Cannabis Act. Upon completion of the RIV Arrangement on February 23, 2021, the Company no longer controlled RIV Capital and RIV Capital’s consolidated assets and liabilities were derecognized from the Company’s consolidated financial statements. The assets and liabilities that were derecognized include those described below in relation to RIV Capital’s investments in, and obligations with respect to, PharmHouse. Refer to Note 30(c) for further details on the RIV Arrangement. CCAA Proceedings During the year ended March 31, 2021, PharmHouse determined that the previously anticipated timeline to generate cash flows from its offtake agreements with the Company and TerrAscend Canada would not be met, and the ultimate timing and receipt of cash inflows pursuant to these agreements became uncertain. As a result of this, as well as broader sector-wide challenges impacting the Canadian cannabis industry, PharmHouse did not have sufficient liquidity and capital resources to meet its business objectives and became unable to meet its financial obligations as they became due. Accordingly, on September 15, 2020, PharmHouse obtained an order (the “Initial Order”) from the Ontario Superior Court of Justice (the “Court”) granting PharmHouse creditor protection under the Companies’ Creditors Arrangement Act (“CCAA”) (the “CCAA Proceedings”). The Court appointed an independent professional services firm to act as the Monitor of PharmHouse in the CCAA Proceedings while PharmHouse explored a restructuring of its business and operations (the “PharmHouse Restructuring”). On October 29, 2020, PharmHouse received approval from the Court to commence its Sale and Investor Solicitation Process (“SISP”). The SISP process concluded in March 2021, subsequent to the completion of the RIV Arrangement, when PharmHouse entered into a binding asset purchase agreement to sell various operating assets including its facility and certain equipment at the facility. The asset purchase agreement was approved by the Court in March 2021. PharmHouse Recoverability Assessment As a result of the CCAA Proceedings and the Restructuring, RIV Capital determined that there were indicators of impairment present for its investments in various PharmHouse-related financial assets. RIV Capital performed impairment testing for its various PharmHouse-related financial assets by estimating the fair value of PharmHouse en bloc. Due to the lack of profitable operating history for PharmHouse as a cannabis entity, RIV Capital estimated the fair value of PharmHouse en bloc using an asset-based approach to value PharmHouse’s assets under an orderly liquidation scenario where cannabis operations are not continued at PharmHouse’s facility and the greenhouse is sold for purposes other than cannabis cultivation. This amount was then compared to the carrying values of the various PharmHouse-related financial instruments held by RIV Capital, in sequence based on the priority of claims on PharmHouse’s assets (the “PharmHouse Recoverability Assessment”). The significant components of this fair value analysis included PharmHouse’s greenhouse facility and retrofits, separable machinery and equipment, saleable inventory, and cash. Significant unobservable inputs used by RIV Capital to determine the fair value of PharmHouse’s assets include the selling price per square foot for PharmHouse’s greenhouse facility; the recoverability percentage on the liquidation of PharmHouse’s property, plant and equipment; the selling price per gram of PharmHouse’s existing cannabis inventory; and adjustments for the risk of fair value changes and liquidity. Based on the foregoing, the Company estimated the recoverable value of PharmHouse’s assets in an orderly liquidation scenario to be approximately $ 57,500 . The impact of the PharmHouse Recoverability Assessment on RIV Capital’s various PharmHouse-related financial instruments is described below. PharmHouse Financial Guarantee Prior to February 23, 2021, PharmHouse had entered into a syndicated credit agreement (as amended, the “PharmHouse Credit Agreement”) with a number of Canadian banks (the “PharmHouse Lenders”) to provide PharmHouse with a committed, non-revolving credit facility (the “PharmHouse Credit Facility”) with a maximum principal amount of $ 90,000 , which was fully drawn. The obligations of PharmHouse under the PharmHouse Credit Facility were secured by guarantees of RIV Capital and RCC, and a pledge by RCC of all of the shares of PharmHouse held by it (the “PharmHouse Financial Guarantee”). Accordingly, if PharmHouse was unable to generate sufficient cash flows to service its obligations pursuant to the PharmHouse Credit Facility, RIV Capital and RCC were required to compensate the PharmHouse Lenders for their loss incurred on the PharmHouse Credit Facility. The PharmHouse Credit Agreement also contains other covenants applicable to RIV Capital and RCC. Based on the PharmHouse Recoverability Assessment described above, the Company determined that the fair value of PharmHouse’s assets under an orderly liquidation scenario where the facility is not used for cannabis operations may be less than the principal amount owed by PharmHouse pursuant to the PharmHouse Credit Facility. Accordingly, the Company estimated that, prior to February 23, 2021, it had a financial liability related to the PharmHouse Financial Guarantee, reflecting the estimated shortfall between the recoverable amount of PharmHouse en bloc and the Company’s exposure to the PharmHouse Credit Facility. As at February 23, 2021, the Company estimated the current expected credit loss related to its contingent obligation under the PharmHouse Financial Guarantee to be $ 32,500 , and recognized a financial liability for this amount in the consolidated balance sheet. Upon completion of the RIV Arrangement on February 23, 2021, this liability was derecognized from the Company’s consolidated balance sheet. During the year ended March 31, 2021, the Company recognized an associated current expected credit loss of $ 32,500 in net income (loss). Other financial assets, including loans receivable Prior to February 23, 2021, RCC had advanced to PharmHouse: (i) $ 40,000 of secured debt financing pursuant to a shareholder loan agreement; (ii) $ 2,450 pursuant to a secured demand promissory note; and (iii) $ 1,206 between August 4, 2020, and September 8, 2020 pursuant to an unsecured promissory note. The Company recognized these instruments as financial assets, initially recorded them at fair value and subsequently measured them at amortized cost. Additionally, pursuant to the Initial Order, RCC entered into an agreement to provide a super-priority, debtor-in-possession interim, non-revolving credit facility to PharmHouse (the “DIP Financing”), with a maximum principal amount available to be drawn by PharmHouse of $ 9,700 , and a maturity date of February 28, 2021. As at February 23, 2021, RCC had advanced $ 9,300 pursuant to the DIP Financing. As a result of the PharmHouse Recoverability Assessment described above, the Company recognized a current expected credit loss of $ 32,500 in the year ended March 31, 2021, related to its contingent obligation under the PharmHouse Financial Guarantee that existed prior to the completion of the RIV Arrangement on February 23, 2021 and the resulting derecognition of RIV Capital’s consolidated assets and liabilities. The Company also concluded that the following amounts, as described above, may not be recoverable: (i) $ 9,300 advanced pursuant to DIP Financing; (ii) $ 40,000 advanced under the shareholder loan agreement; (iii) $ 2,450 advanced under the secured demand promissory note; (iv) $ 1,206 advanced under the unsecured demand promissory note; and (v) $ 8,989 in interest receivable in relation to these financial instruments. Additionally, it was determined that certain advances in the amount of $ 15,000 provided to PharmHouse by the Company may not be recoverable, and costs of $ 35 were incurred associated with the PharmHouse Restructuring in the year ended March 31, 2021. Accordingly, the Company recorded expected credit losses on financial assets and related charges of $ 109,480 for the year ended March 31, 2021. PharmHouse equity method investment As at February 23, 2021, RCC owned 10,998,660 common shares of PharmHouse, representing a 49 % equity interest on a non-diluted basis. RCC had not yet received any distributions on account of its common share investment in PharmHouse. As a result of the PharmHouse Recoverability Assessment described above, the Company determined that there was an other-than-temporary-impairment and recognized an impairment charge for the full amount of its equity method investment of $ 32,369 .

Other Income (Expense), Net

Other Income (Expense), Net	12 Months Ended
	Mar. 31, 2023
Other Income and Expenses [Abstract]
Other Income (Expense), Net	27 . OTHER INCOME (EXPENSE), NET Other income (expense), net is disaggregated as follows: Years ended March 31, March 31, March 31, 2023 2022 2021 Fair value changes on other financial assets $ ( 424,115 ) $ ( 356,109 ) $ 435,107 Fair value changes on liability arising from Acreage 47,000 553,000 ( 399,849 ) Fair value changes on unsecured senior notes ( 43,104 ) 76,776 ( 162,540 ) Fair value changes on warrant derivative liability 26,920 588,655 ( 293,084 ) Fair value changes on acquisition related contingent 38,890 4,417 39,608 Gain and charges related to settlement of debt 582 - - Interest income 24,282 6,601 21,367 Interest expense ( 126,160 ) ( 103,944 ) ( 8,459 ) Foreign currency gain (loss) ( 8,534 ) 5,415 ( 18,013 ) Gain (loss) on disposal/acquisition of consolidated entity 2,414 ( 6,762 ) 634 Other income (expense), net ( 4,200 ) ( 14,708 ) ( 2,647 ) $ ( 466,025 ) $ 753,341 $ ( 387,876 )

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	28 . INCOME TAXES Net loss before income taxes was generated as follows: Years ended March 31, March 31, March 31, 2023 2022 2021 (As Restated) Domestic - Canada $ ( 2,513,026 ) $ ( 173,970 ) $ ( 1,611,210 ) Foreign - outside of Canada ( 801,294 ) ( 165,545 ) ( 72,751 ) $ ( 3,314,320 ) $ ( 339,515 ) $ ( 1,683,961 ) The income tax recovery (expense) consists of the following: Years ended March 31, March 31, March 31, 2023 2022 2021 Current Domestic - Canada $ 4,783 $ 895 $ ( 19,318 ) Foreign - outside of Canada ( 676 ) 1,476 ( 2,091 ) $ 4,107 $ 2,371 $ ( 21,409 ) Deferred Domestic - Canada $ ( 3,603 ) $ 6,353 $ 36,505 Foreign - outside of Canada 4,270 224 ( 1,955 ) 667 6,577 34,550 Income tax recovery $ 4,774 $ 8,948 $ 13,141 As more fully described in Note 3, income taxes that are required to be reflected in equity, instead of in the consolidated statements of operations, are included in the consolidated statements of shareholders’ equity, if applicable. Current and deferred income tax referred to above is recognized based on the Company’s best estimate of the tax rates expected to apply to the income, loss or temporary difference. The Company is subject to income tax in numerous jurisdictions with varying tax rates. During the current year ended, there were no material changes to the enacted statutory tax rates in the jurisdictions where the majority of the Company’s income for tax purposes was earned or where its material temporary differences or losses are expected to be realized or settled, however the impact of commercial decisions and market forces result in changes to the distribution of income for tax purposes amongst taxing jurisdictions that may result in a change of the effective tax rate applicable to such income, loss or temporary difference. A reconciliation of the amount of income taxes reflected above compared to the expected income taxes calculated at the combined Canadian federal and provincial enacted statutory tax rate of 26.5 % for each of the three years ended March 31, 2023, 2022 and 2021 is as follows: Years ended March 31, March 31, March 31, 2023 2022 2021 (As Restated) Net loss before income taxes $ ( 3,314,320 ) $ ( 339,515 ) $ ( 1,683,961 ) Expected tax rate 26.5 % 26.5 % 26.5 % Expected income tax recovery 878,295 89,971 446,250 Non-deductible and non-taxable items ( 29,385 ) 17,557 81,883 Fair value changes on Acreage Arrangement 12,386 146,545 ( 105,960 ) Fair value changes on warrant derivative liability 6,294 155,964 ( 77,663 ) Settlement of unsecured senior notes ( 14,862 ) - - Share-based compensation ( 2,126 ) ( 9,908 ) ( 21,121 ) Goodwill impairment ( 473,702 ) - - Change in valuation allowance ( 313,583 ) ( 363,954 ) ( 358,964 ) Effect of tax rates outside of Canada ( 4,596 ) 8,459 10,870 Non-taxable portion of capital gains and losses ( 48,573 ) ( 38,440 ) 38,705 Other ( 5,374 ) 2,754 ( 859 ) Income tax recovery $ 4,774 $ 8,948 $ 13,141 Current income taxes payable in the amount of $ 1,592 (March 31, 2022 – $ 1,927 ) is included in accounts payable and current income taxes receivable in the amount of $ 5,446 (March 31, 2022 – $ 6,018 ) is included in other accounts receivable. The Company continues to believe the amount of unrealized tax benefits appropriately reflects the uncertainty of items that are or may in the future be under discussion, audit, dispute or appeal with a tax authority or which otherwise result in uncertainty in the determination of income for tax purposes. If appropriate, an unrealized tax benefit will be realized in the year in which the Company determines that realization is not in doubt. Where the final determined outcome is different from the Company’s estimate, such difference will impact the Company’s income taxes in the year during which such determination is made. Significant components of deferred income tax assets (liabilities) consist of the following: Years ended March 31, March 31, 2023 2022 (As Restated) Deferred income tax assets Property, plant and equipment $ 104,043 $ 78,023 Intangible assets 11,202 671 Inventory reserves and write-downs 18,749 40,324 Other reserves and accruals 10,554 5,939 Losses carried forward 1,142,607 919,955 Equity method investments and other financial assets 72,881 10,512 Deferred financing costs 4,597 2,740 Other 10,415 5,635 Gross deferred income tax assets 1,375,048 1,063,799 Valuation allowances ( 1,355,385 ) ( 1,041,802 ) Total deferred income tax assets, net $ 19,663 $ 21,997 Deferred income tax liabilities Property, plant and equipment $ ( 3,475 ) $ ( 4,182 ) Intangible assets ( 15,200 ) ( 29,832 ) Deferred financing costs ( 1,345 ) ( 3,353 ) Other - ( 621 ) Total deferred income tax liabilities ( 20,020 ) ( 37,988 ) Net deferred income tax liabilities $ ( 357 ) $ ( 15,991 ) In evaluating whether it is more likely than not that all or a portion of a deferred income tax asset will be realized consideration is given to the estimated reversal of deferred income tax liabilities and future taxable income. The Company has recognized valuation allowances for operating losses carried forward, capital losses carried forward and other deferred income tax assets when it is believed that it is more likely than not that these items will not be realized. As at March 31, 2023, the Company had temporary differences associated with investments in foreign subsidiaries for which no deferred income tax liabilities have been recognized, as the Company is able to control the timing of the reversal of these temporary differences and material undistributed earnings are considered permanently invested. Determination of the amount of the unrecognized deferred income tax liability is not practicable due to the inherent complexity of the multi-jurisdictional operations of the Company. As at March 31, 2023, the Company has the following losses carried forward available to reduce future years’ taxable income, which losses expire as follows: Expiring within 5 years $ - Expiring between 5 and 10 years 3,321 Expiring between 10 and 15 years 367,213 Expiring between 15 and 20 years 2,829,026 Indefinite 510,831 $ 3,710,391 Total in Canada $ 3,195,923 Total in United States 451,258 Total in Europe 58,731 Total in other jurisdictions 4,479 $ 3,710,391 Total operating losses $ 3,710,391 Total capital losses (carried forward indefinitely) 1,177,195 $ 4,887,586

Acquisitions

Acquisitions	12 Months Ended
	Mar. 31, 2023
Business Combinations [Abstract]
Acquisitions	29 . ACQUISITIONS (a) Year ended March 31, 2023 The following table summarizes the consolidated balance sheet impact at acquisition of the Company’s business combinations that occurred in the year ended March 31, 2023. Verona Facility Property, plant and equipment $ 28,771 Debt and other liabilities ( 2,373 ) Net assets acquired $ 26,398 Consideration paid in cash $ 24,223 Other consideration 2,175 Total consideration $ 26,398 Consideration paid in cash $ 24,223 Less: Cash and cash equivalents acquired - Net cash outflow $ 24,223 The table above summarizes the fair value of the consideration given and the fair values assigned to the assets acquired and liabilities assumed for the acquisition completed in the year ended March 31, 2023. Acquisition of Verona Facility On November 8, 2022, the Company, through its affiliate BioSteel, completed the acquisition (the “Verona Acquisition”) of a manufacturing facility located in Verona, Virginia (the “Verona Facility”) from Flow Beverage Corp. (“Flow”), one of BioSteel’s contract manufacturers. Consideration was $ 26,398 (US$ 19,477 ), consisting of cash paid of $ 15,685 (US$ 11,573 ) and $ 8,538 (US$ 6,299 ) related to the repayment of debt and the retirement of certain lease obligations, and $ 2,175 (US$ 1,605 ) in remediation and indemnity holdbacks to be retained by the Company and paid within one year of the closing of the Verona Acquisition. BioSteel and Flow have also entered into a co-manufacturing agreement whereby, in addition to the production of BioSteel-branded sports hydration beverages, BioSteel will produce Flow’s portfolio of branded water at the Verona Facility. Due to the timing of the Verona Acquisition, the purchase price allocation for the Verona Acquisition is provisional. The fair value assigned to the consideration paid and net assets acquired is based on management’s best estimate using the information currently available and may be revised by the Company as additional information is received. (b) Acquisitions completed in the year ended March 31, 2022 The following table summarized the consolidated balance sheet impact at acquisition of the Company's business combinations that occurred in the year ended March 31, 2022. Ace Supreme Valley Cannabis (i) (ii) Other Total Cash and cash equivalents $ 1,544 $ 41,306 $ 1,227 $ 44,077 Inventory 878 33,426 362 34,666 Other current assets 2,249 14,791 335 17,375 Property, plant and equipment 105 187,407 1,510 189,022 Intangible assets Brands 14,000 22,800 - 36,800 Distribution channel - 3,500 - 3,500 Operating licenses - 24,400 2,000 26,400 Goodwill 39,152 58,842 7,329 105,323 Accounts payable and other accrued expenses and liabilities ( 1,724 ) ( 12,935 ) ( 30 ) ( 14,689 ) Debt and other liabilities - ( 88,324 ) ( 1,037 ) ( 89,361 ) Deferred income tax liabilities ( 1,899 ) ( 5,545 ) ( 540 ) ( 7,984 ) Net assets acquired $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Consideration paid in shares - 260,668 4,052 264,720 Replacement options - 629 - 629 Replacement warrants - 13,350 - 13,350 Other consideration 2,469 4,937 - 7,406 Total consideration $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Less: Cash and cash equivalents acquired ( 1,544 ) ( 41,306 ) ( 1,227 ) ( 44,077 ) Net cash outflow (inflow) $ 50,292 $ ( 41,222 ) $ 5,877 $ 14,947 The table above summarizes the fair value of the consideration given and the fair values assigned to the assets acquired and liabilities assumed for each acquisition. Goodwill arose in these acquisitions because the cost of acquisition included a control premium. In addition, the consideration paid for the combination reflected the benefit of expected revenue growth and future market development. These benefits were not recognized separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets. Except for some of the goodwill arising in respect of the Ace Valley (as defined below) and Supreme Cannabis acquisition, none of the goodwill arising on these acquisitions is expected to be deductible in the computation of income for tax purposes. (i) Ace Valley On April 1, 2021 , the Company entered into a share purchase agreement (the “AV Share Purchase Agreement”) with Tweed Inc., AV Cannabis Inc. (“Ace Valley”), and the shareholders of Ace Valley (the “AV Vendors”) pursuant to which the Company indirectly acquired 100 % of the issued and outstanding shares of Ace Valley for cash consideration of $ 51,836 . Ace Valley is an Ontario-based cannabis brand with a focus on premium, ready-to-enjoy products including vapes, pre-roll joints and gummies. Pursuant to the terms of the AV Share Purchase Agreement, the Company may be required to make certain earn-out payments to the AV Vendors, which may result in an additional cash payment or the issuance of common shares, subject to the fulfillment of certain conditions by April 1, 2023. This represents liability-classified contingent consideration. Management has estimated the fair value of this consideration to be $ 2,469 by assessing the probability and timing of the fulfillment of the specified conditions and discounting the expected cash outflows to present value. In the year ended March 31, 2022, the Company finalized the purchase price allocation to the individual assets acquired and liabilities assumed using the acquisition method (ii) Supreme Cannabis On June 22, 2021 , the Company and Supreme Cannabis completed an arrangement (the “Supreme Arrangement”) pursuant to which the Company acquired 100 % of the issued and outstanding common shares of Supreme Cannabis (the “Supreme Shares”). Supreme Cannabis is a producer of adult-use, wholesale and medical cannabis products, with a diversified portfolio of distinct cannabis companies, products and brands. Pursuant to the Supreme Arrangement, the Company issued 9,013,400 common shares with a fair value on closing of $ 260,668 and made a cash payment of $ 84 to former Supreme Cannabis shareholders in consideration for their Supreme Shares. The Company also assumed the obligation to issue 1,265,742 common shares upon the exercise of outstanding warrants of Supreme Cannabis and issued 140,159 replacement options. The fair value of the obligation upon the exercise of the outstanding warrants of Supreme Cannabis was estimated to be $ 13,350 using a Black-Scholes model. The replacement options’ fair value totaled $ 1,452 , calculated using a Black-Scholes model, of which $ 629 was included in consideration paid as it related to pre-combination services and the residual $ 823 fair value was recognized immediately in share-based compensation expense after the completion of the acquisition. On June 22, 2021, Supreme Cannabis had convertible debentures outstanding with a principal amount of $ 27,045 which were convertible into 94,895,649 Supreme Shares. As a result of the acquisition the conversion feature was adjusted in accordance with an exchange ratio of 0.011659 . The fair value of these convertible debentures on June 22, 2021 was estimated to be $ 36,593 , of which $ 4,937 was allocated to the conversion feature and $ 31,656 to the debt component. In the year ended March 31, 2023, the Company finalized the purchase price allocation to the individual assets acquired and liabilities assumed using the acquisition method. (c) Acquisitions completed in the year ended March 31, 2021 There were no acquisitions during the year ended March 31, 2021 . (d) More Life On November 7, 2019 the Company entered into agreements with certain entities that are controlled by Aubrey “Drake” Graham to launch More Life. Under the agreements Canopy Growth sold 100 % of the shares of 1955625 Ontario Inc., a wholly owned subsidiary of Canopy Growth that holds the Health Canada license for a facility located in Scarborough, Ontario to More Life (“More Life Facility”) in exchange for a 40 % interest in More Life. Certain entities that are controlled by Drake hold a 60 % ownership interest in More Life. Following this transaction, the Company no longer controlled 1955625 Ontario Inc. and the Company derecognized the assets and liabilities of 1955625 Ontario Inc. from its consolidated financial statements at their carrying amounts. As consideration for the 60 % interest in More Life, certain entities that are controlled by Drake granted More Life the right to exclusively exploit certain intellectual property and brands in association with the growth, manufacture, production, marketing and sale of cannabis and cannabis-related products, accessories, merchandise and paraphernalia in Canada and internationally. More Life sublicensed such rights in Canada to Canopy Growth in exchange for royalty payments. The Company and More Life agreed to terminate the sublicense agreement between the two parties as of March 1, 2021, and as a result the Company derecognized the remaining minimum royalty obligations owing to More Life in the amount of $ 33,681 . The difference between the termination payment made by the Company to More Life and the remaining minimum royalty obligations was recorded in asset impairment and restructuring costs; refer to Note 6. Through its ownership and other rights, the Company was determined to have significant influence over More Life and accounted for its interest in More Life using the equity method of accounting. As at March 31, 2021, as a result of the termination of the sublicense agreement between the Company and More Life, the Company determined that the fair value of its’ interest in More Life was $nil, and accordingly, the Company recognized an impairment on its equity method investment in the amount of $ 10,300 in the year ended March 31, 2021 as part of the restructuring of its global operations. See Note 6 for further information.

Divestitures

Divestitures	12 Months Ended
	Mar. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]
Divestitures	30 . DIVESTITURES (a) Retail Divestiture The Company entered into the following two agreements to divest its retail business in Canada, which includes the retail stores operating under the Tweed and Tokyo Smoke banners: • An agreement with OEG Retail Cannabis (“OEGRC”), a prior Canopy Growth licensee partner, pursuant to which OEGRC acquired ownership of 23 of the Company’s corporate-owned retail stores in Manitoba, Saskatchewan and Newfoundland and Labrador, as well as all Tokyo Smoke-related intellectual property (the “OEGRC Transaction”). In connection with the OEGRC Transaction, the Tokyo Smoke brand has been transferred to OEGRC and all acquired retail stores branded as Tweed will be rebranded by OEGRC. In addition, the master franchise agreement between the Company and OEGRC, pursuant to which OEGRC licenses the Tokyo Smoke brand in Ontario, was terminated effective on the closing of the OEGRC Transaction. The OEGRC Transaction closed on December 30, 2022. • An agreement (the “FOUR20 Agreement”) with 420 Investments Ltd. (“FOUR20”), a licensed cannabis retailer, pursuant to which FOUR20 acquired ownership of five of the Company’s corporate-owned retail stores in Alberta (the “FOUR20 Transaction”). Pursuant to the FOUR20 Agreement, the stores will be rebranded under FOUR20’s retail banner upon closing of the FOUR20 Transaction. The FOUR20 Transaction closed on October 26, 2022. In the three months ended December 31, 2022, upon closing of the OEGRC Transaction and the FOUR20 Transaction, the Company received a cash payment of $ 88 . At December 31, 2022, the Company was also entitled to deferred consideration of $ 5,500 , and an earn-out payment of $ 6,099 , subject to the achievement of certain revenue targets by the divested retail stores. In the three months ended March 31, 2023, $ 2,500 of deferred consideration was received. Following the divestiture of the retail stores pursuant to the OEGRC Transaction and the FOUR20 Transaction, the Company derecognized the assets and liabilities of the associated retail stores from these consolidated financial statements at their carrying amounts on their respective closing dates, as follows: Current assets $ 6,461 Property, plant and equipment 7,990 Other long-term assets 144 Current liabilities ( 9,492 ) Net assets disposed $ 5,103 Consideration received in cash $ 88 Future cash consideration 11,599 Costs to sell ( 2,442 ) Total consideration $ 9,245 Gain on disposal of consolidated entity $ 4,142 The gain calculated on the derecognition of the assets and liabilities of the retail stores is the difference between the carrying amounts of the derecognized assets and liabilities, and the fair value of consideration received, net of costs to sell. (b) C 3 Divestiture On December 15, 2021, the Company entered into an agreement to divest all of its interest in C 3 to a European pharmaceutical company headquartered in Germany. C 3 develops and manufactures cannabinoid-based pharmaceutical products for distribution in Germany and certain other European countries. The C 3 Divestiture was completed on January 31, 2022, pursuant to which the Company received a cash payment of $ 128,316 (€ 88,698 ), inclusive of cash, working capital and debt adjustments. The Company will also be entitled to an earnout payment of up to € 42,600 , subject to the achievement of certain milestones by C 3 . Following the C 3 Divestiture, the Company no longer controls C 3 and the Company derecognized the assets and liabilities of C 3 from these consolidated financial statements at their carrying amounts, including $ 53,541 of goodwill allocated to the C 3 reporting unit. The derecognized assets and liabilities on January 31, 2022, were as follows: Current assets 1 $ 44,568 Property, plant and equipment 9,216 Intangible assets 15,548 Goodwill 53,541 Current liabilities ( 3,089 ) Deferred income tax liabilities ( 6,029 ) Cumulative translation adjustment 19,178 Net assets disposed $ 132,933 Consideration received in cash $ 128,316 Future cash consideration 7,233 Costs to sell ( 1,153 ) Total consideration $ 134,396 Gain on disposal of consolidated entity $ 1,463 1 Included in current assets is $ 19,338 of cash. The gain calculated on the derecognition of C 3 ’s assets and liabilities is the difference between the carrying amounts of the derecognized assets and liabilities, inclusive of any cumulative translation adjustment amounts, and the fair value of consideration received, net of costs to sell. (c) Plan of arrangement with RIV Capital On December 21, 2020, the Canopy Growth entered into the RIV Arrangement with Tweed NB, RIV Capital and RCC, pursuant to which Canopy Growth acquired certain assets from RCC, as set out below, in exchange for cash, Canopy Growth common shares and the surrender of all shares in the capital of RIV Capital held by Canopy Growth. The RIV Arrangement was completed on February 23, 2021. Pursuant to the RIV Arrangement, Canopy Growth increased its conditional ownership interest in TerrAscend through the acquisition of: (i) 19,445,285 TerrAscend Exchangeable Shares held by RCC; (ii) 2,225,714 TerrAscend Warrants with an exercise price of $ 5.95 per share held by RCC; (iii) 333,723 TerrAscend Warrants with an exercise price of $ 6.49 per share held by RCC; and (iv) a loan receivable owing by TerrAscend Canada to RCC. See Note 5 for information regarding the Reorganization. Following the implementation of the Reorganization, as of October 24, 2022, Canopy USA holds certain U.S. cannabis investments previously held by the Company, including the aforementioned direct and indirect interests in the capital of TerrAscend. Pursuant to the RIV Arrangement, Canopy Growth also acquired: (i) all of the Class A preferred shares in the capital of Les Vert Mirabel held by RCC; and (vi) 143 common shares in the capital of Vert Mirabel, thereby increasing Canopy Growth’s ownership of the issued and outstanding common shares in the capital of Vert Mirabel to approximately 55 %. See Note 6 for information regarding the Company’s restructuring actions initiated in the three months ended March 31, 2023, which included, among other things, the purchase of the remaining 45 % of Vert Mirabel and ceasing the sourcing of cannabis flower from the Mirabel, Quebec facility. In addition, all of the obligations of Tweed NB owing to RCC pursuant to a royalty agreement between the parties were terminated. In exchange for the foregoing, Canopy Growth: (i) surrendered 36,468,318 MVS and 15,223,938 SVS in the capital of RIV Capital; (ii) made a cash payment to RCC of $ 115,000 ; and (iii) issued 3,647,902 Canopy Growth common shares to RCC. As a result, following completion of the RIV Arrangement, Canopy Growth no longer had any equity, debt or other interest in RIV Capital, and no longer had any representation on the RIV Capital board of directors. Following this transaction, Canopy Growth no longer controls RIV Capital, and Canopy Growth derecognized the consolidated assets and liabilities of RIV Capital from its consolidated financial statements at their carrying amounts. The derecognized assets and liabilities on February 23, 2021, were as follows: Acquired assets TerrAscend Exchangeable Shares $ 291,500 TerrAscend warrants 32,000 Preferred shares in Vert Mirabel 22,600 Settlement of Tweed NB obligations to RCC 15,000 TerrAscend loan 10,000 Common shares in Vert Mirabel 9,075 Total acquired assets $ 380,175 Consideration paid in shares ( 170,284 ) Consideration paid in cash ( 115,000 ) $ 94,891 Derecognition of RIV Capital net assets Cash and cash equivalents $ 37,801 Amounts receivable, net 4,327 Prepaid expenses and other assets 995 Equity method investments 5,114 Other financial assets 417,256 Property, plant and equipment 729 Intangible assets 86 Accounts payable ( 22,038 ) Other accrued expenses and liabilities ( 1,703 ) Other current liabilities ( 32,653 ) Other long-term liabilities ( 303 ) Noncontrolling interests and other ( 315,144 ) $ 94,467 Gain on completion of RIV Arrangement $ 424 The gain calculated on the derecognition of RIV Capital’s assets and liabilities is the difference between the carrying amounts of the derecognized assets and liabilities of RIV Capital and the fair value of the consideration transferred, being the cash payment made to RCC in the amount of $ 115,000 , the fair value of the Canopy Growth common shares issued to RCC, and the assets acquired.

Acreage Arrangement and Amendme

Acreage Arrangement and Amendments to Cbi Investor Rights Agreement and Warrants	12 Months Ended
	Mar. 31, 2023
Business Combinations [Abstract]
Acreage Arrangement and Amendments to Cbi Investor Rights Agreement and Warrants	31 . ACREAGE ARRANGEMENT AND AMENDMENTS TO CBI INVESTOR RIGHTS AGREEMENT AND WARRANTS Acreage Arrangement On September 23, 2020, the Company and Acreage entered into a second amendment (the “Acreage Amending Agreement”) to the arrangement agreement (the “Original Acreage Arrangement Agreement”) and plan of arrangement (the “Original Acreage Arrangement”) between the Company and Acreage dated April 18, 2019, as amended on May 15, 2019. In connection with the Acreage Amending Agreement, the Company and Acreage implemented an amended and restated plan of arrangement (the “Acreage Amended Arrangement”) on September 23, 2020. Pursuant to the terms of the Original Acreage Arrangement, shareholders of Acreage and holders of certain securities convertible into the existing Acreage subordinated voting shares as of June 26, 2019, received an immediate aggregate total payment of US$ 300,000 ($ 395,190 ) in exchange for granting Canopy Growth both the right and the obligation to acquire all of the issued and outstanding shares of Acreage following the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event and subject to the satisfaction or waiver of the conditions set out in the Original Acreage Arrangement Agreement. The Acreage Amended Arrangement provides for, among other things, the following: • Following the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event and subject to the satisfaction or waiver of the conditions set out in the Original Acreage Arrangement Agreement (as modified in connection with the Acreage Amending Agreement), Canopy Growth will acquire all of the issued and outstanding Fixed Shares based on an amended exchange ratio equal to 0.3048 of a common share to be received for each Fixed Share held. The foregoing exchange ratio for the Fixed Shares is subject to adjustment in accordance with the Acreage Amended Arrangement if, among other things, Acreage issues greater than the permitted number of Fixed Shares; • Upon the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event, Canopy Growth will have the right (the “Acreage Floating Option”) exercisable for a period of 30 days, to acquire all of the issued and outstanding Floating Shares for cash or common shares or a combination thereof, in Canopy Growth’s sole discretion at a price equal to the 30-day volume weighted average trading price of the Floating Shares on the Canadian Securities Exchange, subject to a minimum call price of US$ 6.41 per Floating Share. The foregoing exchange ratio for the Floating Shares is subject to adjustment in accordance with the Acreage Amended Arrangement if Acreage issues greater than the permitted number of Floating Shares. The acquisition of the Floating Shares, if acquired, will take place concurrently with the closing of the acquisition of the Fixed Shares; • Immediately prior to the acquisition of the Fixed Shares, each issued and outstanding Class F multiple voting share will automatically be exchanged for one Fixed Share and thereafter be acquired by Canopy Growth upon the same terms and conditions as the acquisition of the Fixed Shares; • If the occurrence or waiver of the Triggering Event does not occur by September 23, 2030, Canopy Growth’s rights to acquire both the Fixed Shares and the Floating Shares will terminate; • Upon implementation of the Acreage Amended Arrangement, Canopy Growth made a cash payment to the shareholders of Acreage and holders of certain convertible securities in the aggregate amount of US$ 37,500 ($ 49,849 ); and • Acreage is only permitted to issue an aggregate of up to 32,700,000 Fixed Shares and Floating Shares. See Note 5 for information regarding the Reorganization. In connection with the Reorganization and the Floating Share Arrangement Agreement, Canopy Growth irrevocably waived the Acreage Floating Option and subject to, among other things, the terms of the Floating Share Arrangement Agreement, Canopy USA will acquire all of the issued and outstanding Floating Shares. Following the implementation of the Reorganization, Canopy USA, as of October 24, 2022, holds certain U.S. cannabis investments previously held by the Company, which is expected to enable Canopy USA, following, among other things, the Meeting and the exercise of the Acreage Option, including the issuance of the Fixed Shares to Canopy USA, to consummate the acquisitions of Acreage, Wana and Jetty. At March 31, 2023 , the right and the obligation to: (i) acquire the Fixed Shares pursuant to the Existing Acreage Arrangement Agreement; and (ii) acquire the Floating Shares pursuant to the Floating Share Arrangement Agreement (together, the “Acreage financial instrument”), represents a financial asset of $ 55,382 (March 31, 2022 – liability of $ 47,000 ). At March 31, 2023, the estimated fair value of the Acreage business is more than the estimated fair value of the consideration to be provided upon the exercise of the Acreage financial instrument. Fair value changes on the Acreage financial instrument are recognized in other income (expense), net; see Note 27. The fair value determination includes a high degree of subjectivity and judgment, which results in significant estimation uncertainty. See Note 24 for additional details on how the fair value of the Acreage financial instrument is calculated on a recurring basis. From a measurement perspective, the Company has elected the fair value option under ASC 825. In connection with the Acreage Amended Arrangement, on September 23, 2020, an affiliate of the Company advanced US$ 50,000 ($ 66,995 ) to Universal Hemp, LLC, a wholly owned subsidiary of Acreage (“Acreage Hempco”) pursuant to a secured debenture (“Hempco Debenture”). In accordance with the terms of the Hempco Debenture, the funds advanced to Acreage Hempco cannot be used, directly or indirectly, in connection with or for any cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States. The Hempco Debenture bears interest at a rate of 6.1 % per annum and matures on September 23, 2030, or such earlier date in accordance with the terms of the Hempco Debenture. All interest payments made pursuant to the Hempco Debenture are payable in cash by Acreage Hempco. The Hempco Debenture is not convertible and is not guaranteed by Acreage. In connection with the Reorganization, as described in Note 5, on October 24, 2022, the Company transferred the Hempco Debenture to Canopy USA. The amount advanced on September 23, 2020 pursuant to the Hempco Debenture has been recorded in other financial assets (see Note 12), and the Company has elected the fair value option under ASC 825. At March 31, 2023, the estimated fair value of the Hempco Debenture issued to an affiliate of the Company by Acreage Hempco was $ 29,262 (March 31, 2022 – $ 28,824 ), measured using a discounted cash flow model (see Note 24). Refer to Note 12 for details on fair value changes, foreign currency translation adjustment, and interest received. An additional US$ 50,000 may be advanced pursuant to the Hempco Debenture subject to the satisfaction of certain conditions by Acreage Hempco. Amendment to the CBI Investor Rights Agreement and warrants On April 18, 2019, certain wholly owned subsidiaries of CBI and Canopy Growth entered into the Second Amended and Restated Investor Rights Agreement (the "Amended Investor Rights Agreement") and a consent agreement. In connection with these agreements, on June 27, 2019, Canopy Growth: (i) extended the term of the first tranche of warrants, which allow CBI to acquire 88.5 million additional shares of Canopy Growth for a fixed price of $ 50.40 per share (the “Tranche A Warrants”), to November 1, 2023 ; and (ii) replaced the second tranche of warrants with two new tranches of warrants (the “Tranche B Warrants” and the “Tranche C Warrants”) as follows: • The Tranche B Warrants are exercisable to acquire 38.5 million common shares at a price of C$ 76.68 per common share; and • the Tranche C Warrants are exercisable to acquire 12.8 million common shares at a price equal to the 5-day volume-weighted average price of the common shares immediately prior to exercise. In connection with the Tranche B Warrants and the Tranche C Warrants, Canopy Growth will provide CBI with a share repurchase credit of up to $ 1.583 billion on the aggregate exercise price of the Tranche B Warrants and Tranche C Warrants in the event that Canopy Growth does not purchase for cancellation the lesser of: (i) 27,378,866 common shares; and (ii) common shares with a value of $ 1.583 billion, during the period commencing on April 18, 2019 and ending on the date that is 24 months after the date that CBI exercises all of the Tranche A Warrants. The share repurchase credit feature is accounted for as a derivative liability, with the fair value continuing to be $nil at March 31, 2023. The modifications to the Tranche A Warrants resulted in them meeting the definition of a derivative instrument under ASC 815 - Derivatives and Hedging (“ASC 815”). They continue to be classified in equity as the number of shares and exercise price were both fixed at inception. The Tranche B Warrants are accounted for as derivative instruments (the “Warrant derivative liability”) measured at fair value in accordance with ASC 815. At March 31, 2023, the fair value of the warrant derivative liability was $ nil (March 31, 2022 – $ 26,920 ), and fair value changes are recognized in other income (expense), net; see Note 27. See Note 24 for additional details on how the fair value of the warrant derivative liability is calculated on a recurring basis. The Tranche C Warrants are accounted for as derivative instruments, with the fair value continuing to be $nil at March 31, 2023. As described in Note 5, in connection with the Reorganization, the Company entered into the Third Consent Agreement, pursuant to which CBG and Greenstar agreed, among other things, that in the event that CBG and Greenstar convert their ownership in the Company's common shares into Exchangeable Shares, CBG will surrender the warrants held by CBG to purchase 139,745,453 common shares of the Company for cancellation for no consideration. In addition, following such conversion by CBG and Greenstar of their common shares into Exchangeable Shares, other than the Third Consent Agreement and the termination rights contained therein and the CBI Note (as defined below), all agreements between the Company and CBI will terminate, including the Amended Investor Rights Agreement. In such circumstances it is expected that the CBI nominees that are currently sitting on the board of directors of the Company (the “Board”) (and comprise a majority of the Board) will resign as directors of the Company following the termination of the Amended Investor Rights Agreement.

Leases

Leases	12 Months Ended
	Mar. 31, 2023
Lessee Disclosure [Abstract]
Leases	32 . LEASES The Company primarily leases office and production facilities, warehouses, production equipment and vehicles. The Company assesses service arrangements to determine if an asset is explicitly or implicitly specified in the agreement and if we have the right to control the use of the identified asset. The right-of-use asset is initially measured at cost, which is primarily comprised of the initial amount of the lease liability, plus initial direct costs and lease payments at or before the lease commencement date, less any lease incentives received, and is amortized on a straight-line basis over the remaining lease term. All right-of-use assets are reviewed periodically for impairment. The lease liability is initially measured at the present value of lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the incremental borrowing rate. We elected to recognize expenses for leases with a term of 12 months or less on a straight-line basis over the lease term and not to recognize these short-term leases on the balance sheet. Leases have varying terms with remaining lease terms of up to approximately 30 years. Certain of our lease arrangements provide us with the option to extend or to terminate the lease early. Lease payments included in the measurement of the lease liability comprise (a) fixed payments, including in-substance fixed payments; (b) variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date; (c) amounts expected to be payable under a residual value guarantee; and (d) the exercise price under a purchase option that the Company is reasonably certain to exercise, lease payments in an optional renewal period if the Company is reasonably certain to exercise an extension option, and penalties for early termination of a lease unless the Company is reasonably certain not to terminate early. At inception or reassessment of a contract that contains lease and non-lease components, the Company allocates the consideration in the contract to each lease component on the basis of their relative stand-alone prices. Balance sheet location A summary of lease right-of-use assets and liabilities are as follows: March 31, March 31, 2023 2022 Property, plant and equipment Operating lease $ 20,741 $ 39,571 Finance lease 8,838 34,333 $ 29,579 $ 73,904 Other current liabilities: Operating lease $ 9,143 $ 11,752 Finance lease 19,541 26,283 Other long-term liabilities: Operating lease 40,977 58,031 Finance lease 39,648 43,094 $ 109,309 $ 139,160 Lease expense The components of total lease expense are as follows: Years ended March 31, March 31, 2023 2022 Operating lease expense $ 10,608 $ 5,245 Finance lease expense: Amortization of right-of-use assets 1,494 3,883 Interest on lease liabilities 2,018 1,667 $ 14,120 $ 10,795 Lease maturities As of March 31, 2023, the minimum payments due for lease liabilities for each of the five succeeding fiscal years and thereafter are as follows: Operating Leases Finance Leases 2024 $ 11,661 $ 21,410 2025 12,494 5,313 2026 9,521 33,020 2027 9,016 325 2028 7,714 329 Thereafter 8,066 3,725 Total lease payments $ 58,472 $ 64,122 Less: Interest 8,352 4,933 Total lease liabilities $ 50,120 $ 59,189 As of March 31, 2023, we have additional operating leases that have not yet commenced with immaterial aggregated minimum payments on an undiscounted basis. Supplemental information Years ended March 31, March 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 13,277 $ 12,905 Operating cash flows from finance leases 2,018 1,667 Financing cash flows from finance leases 5,997 1,494 Right-of-use assets obtained in exchange for new lease liabilities: Operating leases $ 3,759 $ 9,019 Finance leases 2,714 3,720 March 31, March 31, 2023 2022 Weighted-average remaining lease term: Operating leases 5 6 Finance leases 3 4 Weighted-average discount rate Operating leases 5.24 % 4.50 % Finance leases 4.50 % 4.50 %

Related Party

Related Party	12 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Related Party	33 . RELATED PARTY Year ended March 31, 2023 Pursuant to the Reorganization, the Company entered into certain agreements with CBI, including the Third Consent Agreement. See “Relationship with CBI” in Note 5. Year ended March 31, 2022 There were no reportable related party transactions in the year ended March 31, 2022. Year ended March 31, 2021 On February 23, 2021, the Company completed the RIV Arrangement with RIV Capital and RCC. Refer to Note 30(c) for a description of the RIV Arrangement. In connection with the Proposal Agreement entered into by the Company and Acreage on June 24, 2020 to amend the terms of the Original Acreage Arrangement, the Company entered into the Second Consent Agreement with CBI and its affiliates.

Commitments

Commitments	12 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments	34 . COMMITMENTS The Company has entered into agreements in which it has committed to purchase a minimum amount of inventory, pay a minimum amount of royalty expenses, incur expenditures for property, plant and equipment and procure various other goods or services. The following summarizes the Company’s annual minimum commitments associated with its contractual agreements as of March 31, 2023. This amount excludes the Company’s debt and lease related commitments which are disclosed elsewhere in Notes 17 and 32, respectively in these consolidated financial statements. 2024 $ 118,211 2025 42,382 2026 28,981 2027 19,676 2028 - Thereafter - $ 209,250

Segmented Information

Segmented Information	12 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Segmented Information	35 . SEGMENTED INFORMATION Reportable segments Prior to the three months ended September 30, 2022, the Company had the following two reportable segments: (i) global cannabis; and (ii) other consumer products. Following the completion of certain restructuring actions which were initiated in the three months ended March 31, 2022, and which were aligned with the Company’s strategic review of its business (see Note 6 for details), the Company has changed the structure of its internal management financial reporting. Accordingly, in the three months ended September 30, 2022, the Company began reporting its financial results for the following five reportable segments: • Canada cannabis - includes the production, distribution and sale of a diverse range of cannabis, hemp and cannabis products in Canada pursuant to the Cannabis Act ; • Rest-of-world cannabis - includes the production, distribution and sale of a diverse range of cannabis, hemp and cannabis products internationally pursuant to applicable international legislation, regulations and permits; • Storz & Bickel - includes the production, distribution and sale of vaporizers; • BioSteel - includes the production, distribution and sale of consumer packaged goods including sports nutrition beverages, hydration mixes, proteins and other specialty nutrition products; and • This Works - includes the production, distribution and sale of beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. These segments reflect how the Company’s operations are managed, how the Company’s Chief Executive Officer, who is the Chief Operating Decision Maker (“CODM”), allocates resources and evaluates performance, and how the Company’s internal management financial reporting is structured. The Company’s CODM evaluates the performance of these segments, with a focus on (i) segment net revenue, and (ii) segment gross margin as the measure of segment profit or loss. Accordingly, information regarding segment net revenue and segment gross margin for the comparative periods has been restated to reflect the aforementioned change in reportable segments. The remainder of the Company’s operations include revenue derived from, and cost of sales associated with, the Company’s non-cannabis extraction activities and other ancillary activities; these are included within "other." The accounting policies of each segment are the same as those disclosed in the summary of significant accounting policies in Note 3. Years ended March 31, March 31, March 31, 2023 2022 2021 (As Restated) Segmented net revenue Canada cannabis $ 187,067 $ 257,910 $ 285,049 Rest-of-world cannabis 38,949 79,306 93,631 Storz & Bickel 64,845 85,410 80,998 BioSteel 69,649 34,622 28,530 This Works 26,029 32,296 33,314 Other 16,365 20,777 25,127 $ 402,904 $ 510,321 $ 546,649 Segmented gross margin: Canada cannabis $ ( 95,291 ) $ ( 212,820 ) $ ( 8,435 ) Rest-of-world cannabis ( 3,322 ) ( 28,875 ) 29,687 Storz & Bickel 26,112 37,284 34,231 BioSteel ( 40,613 ) ( 15,722 ) 1,689 This Works 10,205 14,800 17,350 Other ( 1,231 ) 2,197 ( 7,562 ) ( 104,140 ) ( 203,136 ) 66,960 Selling, general and administrative expenses 456,225 472,756 575,389 Share-based compensation 31,188 47,525 91,149 Expected credit losses on financial assets and relates charges - - 109,480 Asset impairment and restructuring costs 2,256,742 369,339 534,398 Operating loss ( 2,848,295 ) ( 1,092,756 ) ( 1,243,456 ) Loss from equity method investments - ( 100 ) ( 52,629 ) Other income (expense), net ( 466,025 ) 753,341 ( 387,876 ) Loss before incomes taxes $ ( 3,314,320 ) $ ( 339,515 ) $ ( 1,683,961 ) Asset information by segment is not provided to, or reviewed by, the Company’s CODM as it is not used to make strategic decisions, allocate resources, or assess performance. Entity-wide disclosures Disaggregation of net revenue by geographic area: Years ended March 31, March 31, March 31, 2023 2022 2021 (As Restated) Canada $ 268,457 $ 286,365 $ 329,172 Germany 48,701 90,874 116,379 United States 39,042 82,080 64,926 Other 46,704 51,002 36,172 $ 402,904 $ 510,321 $ 546,649 Disaggregation of long-lived tangible assets by geographic area: March 31, March 31, 2023 2022 Canada $ 361,778 $ 827,591 United States 85,772 63,247 Germany 51,341 48,355 Other 575 3,587 $ 499,466 $ 942,780 For the year ended March 31, 2023, no customer represented more than 10% of the Company’s net revenue (years ended March 31, 2022 and 2021, one and no , respectively).

Restatement of Previously Issue

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Unaudited)	12 Months Ended
	Mar. 31, 2023
Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements [Abstract]
Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Unaudited)	36. RESTATEMENT OF PREVIOUSLY ISSUED UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) The following tables include corrections to the prior period results, and present the effect of the Restatement Items described in Note 2, “Basis of Presentation - Restatement of Previously Issued Consolidated Financial Statements” on the Company’s unaudited interim condensed consolidated balance sheets for the periods indicated (in thousands, except number of shares and per share data): June 30, 2022 As Previously Reported Restatement Adjustment As Restated Amounts receivable, net $ 96,626 $ ( 13,827 ) $ 82,799 Inventory 205,513 19 205,532 Prepaid expenses and other assets 62,141 ( 298 ) 61,843 Total current assets 1,593,572 ( 14,106 ) 1,579,466 Total assets 3,517,527 ( 14,106 ) 3,503,421 Other liabilities 86,776 170 86,946 Total current liabilities 404,408 170 404,578 Total liabilities 1,834,607 170 1,834,777 Redeemable noncontrolling interest 37,150 ( 9,000 ) 28,150 Additional paid-in capital 2,515,453 5,881 2,521,334 Deficit ( 8,454,214 ) ( 11,157 ) ( 8,465,371 ) Total Canopy Growth Corporation shareholders' equity 1,641,255 ( 5,276 ) 1,635,979 Total shareholders' equity 1,645,770 ( 5,276 ) 1,640,494 Total liabilities and shareholders' equity 3,517,527 ( 14,106 ) 3,503,421 September 30, 2022 As Previously Reported Restatement Adjustment As Restated Amounts receivable, net $ 108,236 $ ( 25,820 ) $ 82,416 Inventory 211,209 545 211,754 Prepaid expenses and other assets 62,957 ( 216 ) 62,741 Total current assets 1,538,175 ( 25,491 ) 1,512,684 Goodwill 136,513 ( 57,401 ) 79,112 Total assets 3,402,270 ( 82,892 ) 3,319,378 Other liabilities 63,645 16,235 79,880 Total current liabilities 542,401 16,235 558,636 Total liabilities 1,738,241 16,235 1,754,476 Redeemable noncontrolling interest 35,900 ( 23,224 ) 12,676 Additional paid-in capital 2,516,811 21,292 2,538,103 Deficit ( 8,676,020 ) ( 97,195 ) ( 8,773,215 ) Total Canopy Growth Corporation shareholders' equity 1,625,173 ( 75,903 ) 1,549,270 Total shareholders' equity 1,628,129 ( 75,903 ) 1,552,226 Total liabilities and shareholders' equity 3,402,270 ( 82,892 ) 3,319,378 December 31, 2022 As Previously Reported Restatement Adjustment As Restated Amounts receivable, net $ 104,640 $ ( 22,954 ) $ 81,686 Inventory 213,937 108 214,045 Prepaid expenses and other assets 52,151 ( 446 ) 51,705 Total current assets 1,172,910 ( 23,292 ) 1,149,618 Goodwill 142,076 ( 57,401 ) 84,675 Total assets 3,020,155 ( 80,693 ) 2,939,462 Other liabilities 84,134 413 84,547 Total current liabilities 678,741 413 679,154 Total liabilities 1,580,406 413 1,580,819 Redeemable noncontrolling interest 11,408 ( 10,408 ) 1,000 Additional paid-in capital 2,510,086 24,379 2,534,465 Deficit ( 8,937,603 ) ( 95,077 ) ( 9,032,680 ) Total Canopy Growth Corporation shareholders' equity 1,425,545 ( 70,698 ) 1,354,847 Total shareholders' equity 1,428,341 ( 70,698 ) 1,357,643 Total liabilities and shareholders' equity 3,020,155 ( 80,693 ) 2,939,462 The following tables present the effect of the Restatement Items on the Company’s unaudited interim condensed consolidated statements of operations and comprehensive income (loss) for the periods indicated (in thousands, except number of shares and per share data): Three months ended June 30, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 122,862 $ ( 4,195 ) $ 118,667 Net revenue 110,115 ( 4,195 ) 105,920 Cost of goods sold 111,507 ( 1 ) 111,506 Gross margin ( 1,392 ) ( 4,194 ) ( 5,586 ) Operating loss ( 1,838,229 ) ( 4,194 ) ( 1,842,423 ) Loss before income taxes ( 2,083,807 ) ( 4,194 ) ( 2,088,001 ) Net loss ( 2,087,556 ) ( 4,194 ) ( 2,091,750 ) Net loss attributable to noncontrolling interests and ( 4,408 ) ( 899 ) ( 5,307 ) Net loss attributable to Canopy Growth Corporation ( 2,083,148 ) ( 3,295 ) ( 2,086,443 ) Basic and diluted loss per share $ ( 5.23 ) $ ( 0.01 ) $ ( 5.24 ) Comprehensive loss: Net loss $ ( 2,087,556 ) $ ( 4,194 ) $ ( 2,091,750 ) Comprehensive loss ( 2,059,738 ) ( 4,194 ) ( 2,063,932 ) Comprehensive loss attributable to noncontrolling interests ( 4,408 ) ( 899 ) ( 5,307 ) Comprehensive loss attributable to ( 2,055,330 ) ( 3,295 ) ( 2,058,625 ) Three months ended September 30, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 130,359 $ ( 12,445 ) $ 117,914 Net revenue 117,863 ( 12,445 ) 105,418 Cost of goods sold 114,042 ( 669 ) 113,373 Gross margin 3,821 ( 11,776 ) ( 7,955 ) Operating expenses Share-based compensation 9,858 4,723 14,581 Asset impairment and restructuring costs 43,968 57,401 101,369 Total operating expenses 179,668 62,124 241,792 Operating loss ( 175,847 ) ( 73,900 ) ( 249,747 ) Loss before income taxes ( 223,691 ) ( 73,900 ) ( 297,591 ) Net loss ( 231,911 ) ( 73,900 ) ( 305,811 ) Net loss attributable to noncontrolling interests and ( 10,105 ) ( 3,536 ) ( 13,641 ) Net loss attributable to Canopy Growth Corporation ( 221,806 ) ( 70,364 ) ( 292,170 ) Basic and diluted loss per share $ ( 0.47 ) $ ( 0.15 ) $ ( 0.62 ) Comprehensive loss: Net loss $ ( 231,911 ) $ ( 73,900 ) $ ( 305,811 ) Comprehensive loss ( 221,647 ) ( 73,900 ) ( 295,547 ) Comprehensive loss attributable to noncontrolling interests ( 10,105 ) ( 3,536 ) ( 13,641 ) Comprehensive loss attributable to ( 211,542 ) ( 70,364 ) ( 281,906 ) Six months ended September 30, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 253,221 $ ( 16,640 ) $ 236,581 Net revenue 227,978 ( 16,640 ) 211,338 Cost of goods sold 225,549 ( 670 ) 224,879 Gross margin 2,429 ( 15,970 ) ( 13,541 ) Operating expenses Share-based compensation 15,297 4,723 20,020 Asset impairment and restructuring costs 1,771,953 57,401 1,829,354 Total operating expenses 2,016,505 62,124 2,078,629 Operating loss ( 2,014,076 ) ( 78,094 ) ( 2,092,170 ) Loss before income taxes ( 2,307,498 ) ( 78,094 ) ( 2,385,592 ) Net loss ( 2,319,467 ) ( 78,094 ) ( 2,397,561 ) Net loss attributable to noncontrolling interests and ( 14,513 ) ( 4,435 ) ( 18,948 ) Net loss attributable to Canopy Growth Corporation ( 2,304,954 ) ( 73,659 ) ( 2,378,613 ) Basic and diluted loss per share $ ( 5.30 ) $ ( 0.17 ) $ ( 5.47 ) Comprehensive loss: Net loss $ ( 2,319,467 ) $ ( 78,094 ) $ ( 2,397,561 ) Comprehensive loss ( 2,281,385 ) ( 78,094 ) ( 2,359,479 ) Comprehensive loss attributable to noncontrolling interests ( 14,513 ) ( 4,435 ) ( 18,948 ) Comprehensive loss attributable to ( 2,266,872 ) ( 73,659 ) ( 2,340,531 ) Three months ended December 31, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 113,349 $ 2,818 $ 116,167 Net revenue 101,213 2,818 104,031 Cost of goods sold 103,654 472 104,126 Gross margin ( 2,441 ) 2,346 ( 95 ) Operating loss ( 153,764 ) 2,346 ( 151,418 ) Loss before income taxes ( 267,104 ) 2,346 ( 264,758 ) Net loss ( 266,722 ) 2,346 ( 264,376 ) Net loss attributable to noncontrolling interests and ( 5,139 ) 228 ( 4,911 ) Net loss attributable to Canopy Growth Corporation ( 261,583 ) 2,118 ( 259,465 ) Basic and diluted loss per share $ ( 0.54 ) $ 0.01 $ ( 0.53 ) Comprehensive loss: Net loss $ ( 266,722 ) $ 2,346 $ ( 264,376 ) Comprehensive loss ( 247,263 ) 2,346 ( 244,917 ) Comprehensive loss attributable to noncontrolling interests ( 5,139 ) 228 ( 4,911 ) Comprehensive loss attributable to ( 242,124 ) 2,118 ( 240,006 ) Nine months ended December 31, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 366,570 $ ( 13,822 ) $ 352,748 Net revenue 329,191 ( 13,822 ) 315,369 Cost of goods sold 329,203 ( 198 ) 329,005 Gross margin ( 12 ) ( 13,624 ) ( 13,636 ) Operating expenses Share-based compensation 21,725 4,723 26,448 Asset impairment and restructuring costs 1,794,212 57,401 1,851,613 Total operating expenses 2,167,828 62,124 2,229,952 Operating loss ( 2,167,840 ) ( 75,748 ) ( 2,243,588 ) Loss before income taxes ( 2,574,602 ) ( 75,748 ) ( 2,650,350 ) Net loss ( 2,586,189 ) ( 75,748 ) ( 2,661,937 ) Net loss attributable to noncontrolling interests and ( 19,652 ) ( 4,207 ) ( 23,859 ) Net loss attributable to Canopy Growth Corporation ( 2,566,537 ) ( 71,541 ) ( 2,638,078 ) Basic and diluted loss per share $ ( 5.66 ) $ ( 0.16 ) $ ( 5.82 ) Comprehensive loss: Net loss $ ( 2,586,189 ) $ ( 75,748 ) $ ( 2,661,937 ) Comprehensive loss ( 2,528,648 ) ( 75,748 ) ( 2,604,396 ) Comprehensive loss attributable to noncontrolling interests ( 19,652 ) ( 4,207 ) ( 23,859 ) Comprehensive loss attributable to ( 2,508,996 ) ( 71,541 ) ( 2,580,537 ) The following tables present the effect of the Restatement Items on the Company’s unaudited interim condensed consolidated statements of shareholders’ equity for the periods indicated: June 30, 2022 As Previously Reported Restatement Adjustment As Restated Additional paid-in-capital - Redeemable noncontrolling interest $ ( 49,698 ) $ 5,881 $ ( 43,817 ) Deficit ( 8,454,214 ) ( 11,157 ) ( 8,465,371 ) Total shareholders' equity 1,645,770 ( 5,276 ) 1,640,494 September 30, 2022 As Previously Reported Restatement Adjustment As Restated Additional paid-in-capital - Redeemable noncontrolling interest $ ( 56,709 ) $ 16,569 $ ( 40,140 ) Additional paid-in-capital - Ownership changes ( 509,723 ) 4,723 ( 505,000 ) Deficit ( 8,676,020 ) ( 97,195 ) ( 8,773,215 ) Total shareholders' equity 1,628,129 ( 75,903 ) 1,552,226 December 31, 2022 As Previously Reported Restatement Adjustment As Restated Additional paid-in-capital - Redeemable noncontrolling interest $ ( 64,707 ) $ 19,656 $ ( 45,051 ) Additional paid-in-capital - Ownership changes ( 512,419 ) 4,723 ( 507,696 ) Deficit ( 8,937,603 ) ( 95,077 ) ( 9,032,680 ) Total shareholders' equity 1,428,341 ( 70,698 ) 1,357,643 The following tables present the effect of the Restatement Items on the Company’s unaudited interim condensed consolidated statements of cash flows for the periods indicated: Three months ended June 30, 2022 As Previously Restatement As Restated Cash flows from operating activities: Net loss $ ( 2,087,556 ) $ ( 4,194 ) $ ( 2,091,750 ) Change in operating assets and liabilities, net of effects from Amounts receivable ( 183 ) 3,964 3,781 Inventory ( 1,126 ) 133 ( 993 ) Prepaid expenses and other assets ( 9,555 ) 219 ( 9,336 ) Other, including non-cash foreign currency 1,928 ( 122 ) 1,806 Net cash used in operating activities ( 140,515 ) - ( 140,515 ) Six months ended September 30, 2022 As Previously Restatement As Restated Cash flows from operating activities: Net loss $ ( 2,319,467 ) $ ( 78,094 ) $ ( 2,397,561 ) Adjustments to reconcile net loss to net cash used in operating activities: Share-based compensation 15,297 4,723 20,020 Asset impairment and restructuring costs 1,783,784 57,401 1,841,185 Change in operating assets and liabilities, net of effects from Amounts receivable ( 11,793 ) 15,956 4,163 Inventory ( 6,822 ) ( 393 ) ( 7,215 ) Prepaid expenses and other assets ( 17,567 ) 138 ( 17,429 ) Other, including non-cash foreign currency ( 19,006 ) 269 ( 18,737 ) Net cash used in operating activities ( 273,915 ) - ( 273,915 ) Nine months ended December 31, 2022 As Previously Restatement As Restated Net loss $ ( 2,586,189 ) $ ( 75,748 ) $ ( 2,661,937 ) Adjustments to reconcile net loss to net cash used in operating activities: Share-based compensation 21,725 4,723 26,448 Asset impairment and restructuring costs 1,797,854 57,401 1,855,255 Change in operating assets and liabilities, net of effects Amounts receivable ( 8,197 ) 13,090 4,893 Inventory ( 9,550 ) 44 ( 9,506 ) Prepaid expenses and other assets ( 6,866 ) 368 ( 6,498 ) Other, including non-cash foreign currency ( 24,459 ) 122 ( 24,337 ) Net cash used in operating activities ( 417,809 ) - ( 417,809 )

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	37. SUBSEQUENT EVENTS Amendments to Canopy USA Structure On May 19, 2023, the Company and Canopy USA implemented the Reorganization Amendments, which included, entering into the A&R Protection Agreement and amending and restating Canopy USA’s limited liability company agreement (the “A&R LLC Agreement”) in order to: (i) eliminate certain negative covenants that were previously granted by Canopy USA in favor of the Company as well as delegating to the managers of the Canopy USA Board not appointed by Canopy Growth the authority to approve the following key decisions (collectively, the “Key Decisions”): (a) the annual business plan of Canopy USA; (b) decisions regarding the executive officers of Canopy USA and any of its subsidiaries; (c) increasing the compensation, bonus levels or other benefits payable to any current, former or future employees or managers of Canopy USA or any of its subsidiaries; (d) any other executive compensation plan matters of Canopy USA or any of its subsidiaries; and (e) the exercise of the Wana Options or the Jetty Options, which for greater certainty means that the Company’s nominee on the Canopy USA Board will not be permitted to vote on any Key Decisions while the Company owns Non-Voting Shares; (ii) reduce the number of managers on the Canopy USA Board from four to three, including, reducing the Company’s nomination right to a single manager; (iii) amend the share capital of Canopy USA to, among other things, (a) create a new class of Canopy USA Class B Shares, which may not be issued prior to the conversion of the Non-Voting Shares or the Canopy USA Common Shares into Canopy USA Class B Shares; (b) amend the terms of the Non-Voting Shares such that the Non-Voting Shares will be convertible into Canopy USA Class B Shares (as opposed to Canopy USA Common Shares); and (c) amend the terms of the Canopy USA Common Shares such that upon conversion of all of the Non-Voting Shares into Canopy USA Class B Shares, the Canopy USA Common Shares will, subject to their terms, automatically convert into Canopy USA Class B Shares, provided that the number of Canopy USA Class B Shares to be issued to the former holders of the Canopy USA Common Shares will be equal to no less than 10 % of the total issued and outstanding Canopy USA Class B Shares following such issuance. Accordingly, as a result of the Reorganization Amendments, in no circumstances will the Company, at the time of such conversions, own more than 90 % of the Canopy USA Class B Shares. In connection with the Reorganization Amendments, on May 19, 2023, Canopy USA and Huneeus 2017 Irrevocable Trust (the “Trust”) entered into a share purchase agreement (the “Trust SPA”), which sets out the terms of the Trust’s investment in Canopy USA in the aggregate amount of up to US$ 20 million. Agustin Huneeus, Jr. is the trustee of the Trust and is an affiliate of a shareholder of Jetty. Pursuant to the terms of the Trust SPA, the Trust will, subject to certain terms and conditions contained in the Trust SPA be issued Canopy USA Common Shares in two tranches with an aggregate value of up to US$ 10 million along with warrants of Canopy USA to acquire additional Canopy USA Common Shares. In addition, subject to the terms of the Trust SPA, the Trust has also been granted options to acquire additional Voting Shares (as defined in Canopy USA’s A&R LLC Agreement) with a value of up to an additional US$ 10 million and one such additional option includes the issuance of additional warrants of Canopy USA. In addition, subject to the terms and conditions of the A&R Protection Agreement and the terms of the option agreements to acquire Wana and Jetty, as applicable, Canopy Growth may be required to issue additional common shares in satisfaction of certain deferred and/or option exercise payments to the shareholders of Wana and Jetty. Canopy Growth will receive additional Non-Voting Shares from Canopy USA as consideration for any Company common shares issued in the future to the shareholders of Wana and Jetty. Refinancing of $100,000 of Canopy Notes Due in 2023 On April 13, 2023, the Company entered into an exchange agreement (the “April 2023 Exchange Agreement”) with Greenstar in order to extinguish $ 100,000 aggregate principal amount of the Canopy Notes. Pursuant to the April 2023 Exchange Agreement, the Company agreed to acquire and cancel $ 100,000 aggregate principal amount of the Canopy Notes held by Greenstar in exchange for: (i) a cash payment to Greenstar in the amount of the unpaid and accrued interest owing under the Canopy Notes held by Greenstar; and (ii) a promissory note (the “CBI Note”) issuable to Greenstar in the aggregate amount of $ 100,000 payable on December 31, 2024 . The CBI Note will bear interest at a rate of 4.25 % per year, payable on maturity of the CBI Note. As a result, Greenstar no longer holds any Canopy Notes. Agreements with Indiva On May 30, 2023, the Company entered into a license assignment and assumption agreement with Indiva Limited ("Indiva") and its subsidiary, Indiva Inc., providing the Company exclusive rights and interests to manufacture, distribute, and sell Wana branded products in Canada. Simultaneously, the Company and Indiva also entered into a contract manufacturing agreement, under which the Company will grant Indiva the exclusive right to manufacture and supply Wana branded products in Canada for five years , with the ability to renew for an additional five-year term upon mutual agreement of the parties. We also subscribed for 37.2 million common shares of Indiva for an aggregate purchase price of $ 2,156 . In addition, we agreed to make the following cash payments to Indiva: (i) $ 844 on May 30, 2023; and (ii) $ 1,250 on May 30, 2024.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Going Concern	Going Concern The consolidated financial statements have been prepared in accordance with generally accepted accounting principles on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As reflected in the consolidated financial statements, the Company has certain material debt obligations coming due in the short-term, has suffered recurring losses from operations and requires additional financing to fund its business and operations. If the Company is unable to raise additional capital, it is possible that it will be unable to meet certain of its financial obligations. For example, the Company may not be able to satisfy the minimum liquidity covenant under its credit facility during its first quarter of fiscal year 2025, which breach could trigger an acceleration of its senior secured indebtedness. As of March 31, 2023, the Company had $ 467,957 in required principal repayments under debt obligations to be settled in cash due within the next 12 months, and cash flow from operations was negative throughout fiscal 2023. As of March 31, 2023, the Company had cash and cash equivalents of $ 677,007 and short-term investments of $ 105,595 , which are predominantly invested in liquid securities issued by the United States government. These matters, when considered in the aggregate raise substantial doubt about the Company’s ability to continue as a going concern for at least twelve months from the issuance of these consolidated financial statements. In view of these matters, continuation as a going concern is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financial requirements and to raise additional capital, and the success of its future operations. The consolidated financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company not continue as a going concern. Management plans to fund the operations and debt obligations of the Company through existing cash positions and proceeds from the sale of certain of the Company’s facilities. The Company is also currently evaluating several different strategies and intends to pursue actions that are expected to increase its liquidity position, including, but not limited to, pursuing additional actions under the Company's cost-savings plan, seeking additional financing from both the public and private markets through the issuance of equity and/or debt securities, and monetizing additional assets. The Company's management cannot provide assurances that the Company will be successful in accomplishing any of its proposed financing plans. Management also cannot provide any assurance as to unforeseen circumstances that could occur within the next 12 months or, if the Company raises capital, thereafter, which could increase the Company’s need to raise additional capital on an immediate basis, which capital may not be available to the Company.
Restatement of Previously Issued Consolidated Financial Statements	Restatement of Previously Issued Consolidated Financial Statements In connection with the preparation of the Company’s consolidated financial statements for the year ended March 31, 2023, management of the Company identified certain trends in the booking of sales by the BioSteel Sports Nutrition Inc. (“BioSteel”) business unit for further review. The Company, together with independent external counsel and forensic accountants, and under the oversight of the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of the Company, initiated an internal review of the financial reporting matters related to BioSteel (the “BioSteel Review”). On May 4, 2023, the Company, in consultation with the Audit Committee, concluded that the Company’s (i) audited consolidated financial statements for the fiscal year ended March 31, 2022, included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2022 (the “2022 10-K”), and (ii) unaudited consolidated financial statements for the quarterly periods ended June 30, 2022, September 30, 2022 and December 31, 2022, included in the Company’s Quarterly Reports on Form 10-Q for such quarterly periods (collectively, the “Form 10-Qs” and together with the 2022 10-K, the “Prior Financial Statements”), should no longer be relied upon because of certain material misstatements contained in the Prior Financial Statements. The BioSteel Review focused on the timing of revenue recognition in accordance with U.S. GAAP under ASC 606, Revenue from Contracts with Customers, and the correction of the misstatements has reduced certain revenues previously recognized and adjusted related balance sheet items in the Prior Financial Statements, including certain segment disclosures (the “Restatement Items”). A summary of the corrected misstatements is as follows: Revenue Recognition As a result of the BioSteel Review, misstatements in the Company's recognition of revenue pursuant to ASC 606 were identified, primarily in relation to the Company's "business-to-business" sales to customers in international markets, including wholesalers, distributors, and retailers. The Company concluded that revenue was incorrectly recognized in certain situations in which: (i) the product ordered by the customer had not been shipped, and therefore control of the product had not been transferred to the customer; (ii) the product was shipped without a legally enforceable written, oral or implied contract with the customer that specified each party's rights regarding the goods to be transferred and the payment terms; or (iii) product had been shipped, and ultimately not accepted by the customer, because the product did not have the required remaining shelf life to be sold through by the customer in a primary sales channel. Redeemable noncontrolling interest in BioSteel As a result of the misstatements related to BioSteel's recognition of revenue, the Company considered the impact on the redeemable noncontrolling interest in BioSteel and determined that its redemption value would decline for the year ended March 31, 2022, and for the quarterly periods ended June 30, 2022, September 30, 2022 and December 31, 2022. Additionally, the consideration the BioSteel shareholders and option holders received for the first tranche of the redeemable noncontrolling interest in the three months ended December 31, 2022 was based on a multiple of BioSteel's revenue which exceeded the contractual settlement consideration after correcting for the revenue misstatements. The excess has been recognized in the three months ended September 30, 2022 as an increase to the deficit for certain employee and non-employee shareholders, and as share-based compensation expense for certain employee and consultant option holders. No gain contingency has been recognized for the excess. Goodwill In considering the misstatements related to revenue recognition and the associated correction of these misstatements through the reduction of previously recognized revenue for BioSteel, the Company determined there to be an indicator of impairment for the BioSteel reporting unit as of September 30, 2022 and, as a result, the Company performed a quantitative interim goodwill impairment assessment for the BioSteel reporting unit as of September 30, 2022. The Company concluded that the carrying value of the BioSteel reporting unit was higher than its estimated fair value, and a goodwill impairment loss totaling $ 57,401 was recognized in the three months ended September 30, 2022, representing the entirety of the goodwill assigned to the BioSteel reporting unit. Accordingly, the Company has restated its Prior Financial Statements for the quarterly periods ended September 30, 2022 and December 31, 2022.
Impact of Restatement	Impact of Restatement The Company evaluated the materiality of these misstatements both qualitatively and quantitatively in accordance with Staff Accounting Bulletin (“SAB”) No. 99, Materiality , and SAB No. 108, Considering the Effects of Prior Year Misstatements in Current Year Financial Statements , and determined the effect of correcting these misstatements was material to the Prior Financial Statements. As a result of the material misstatements, we have restated our Prior Financial Statements in accordance with Accounting Standards Codification (“ASC”) 250, Accounting Changes and Error Corrections (the “Restated Financial Statements”). A reconciliation from the previously reported amounts in the Prior Financial Statements to the restated amounts in the Restated Financial Statements is provided for the impacted financial statement line items below for: (i) the consolidated balance sheet as of March 31, 2022; (ii) the consolidated statement of operations and comprehensive loss for the year ended March 31, 2022; (iii) the consolidated statement of shareholders’ equity for the year ended March 31, 2022; and (iv) the consolidated statement of cash flows for the year ended March 31, 2022. The previously reported amounts in the Prior Financial Statements are labeled as “As Previously Reported” in the tables below. The amounts labelled “Restatement Adjustments” represent the effects of the restatement described above. Also see Note 36, “Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements.” The following table presents the effect of the Restatement Items on the Company’s consolidated balance sheet as of March 31, 2022 (in thousands, except number of shares and per share data): March 31, 2022 As Previously Reported Restatement Adjustment As Restated Amounts receivable, net $ 96,443 $ ( 9,862 ) $ 86,581 Inventory 204,387 152 204,539 Prepaid expenses and other assets 52,700 ( 80 ) 52,620 Total current assets 1,737,402 ( 9,790 ) 1,727,612 Total assets 5,615,050 ( 9,790 ) 5,605,260 Other liabilities 64,054 292 64,346 Total current liabilities 212,898 292 213,190 Total liabilities 1,984,553 292 1,984,845 Redeemable noncontrolling interest 36,200 ( 3,700 ) 32,500 Additional paid-in capital 2,519,766 1,480 2,521,246 Deficit ( 6,370,337 ) ( 7,862 ) ( 6,378,199 ) Total Canopy Growth Corporation shareholders' equity 3,589,956 ( 6,382 ) 3,583,574 Total shareholders' equity 3,594,297 ( 6,382 ) 3,587,915 Total liabilities and shareholders' equity 5,615,050 ( 9,790 ) 5,605,260 The correction of the revenue misstatement described above resulted in a decrease of $ 9,862 in amounts receivable, net, and a corresponding increase in the deficit. Additionally, the correction of the misstatement described above resulted in a decrease in redeemable noncontrolling interest of $ 3,700 and an increase in additional paid-in-capital of $ 1,480 . The following table presents the effect of the Restatement Items on the Company’s consolidated statement of operations and comprehensive loss for the year ended March 31, 2022 (in thousands, except number of shares and per share data): Year ended March 31, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 582,218 $ ( 10,004 ) $ 572,214 Net revenue 520,325 ( 10,004 ) 510,321 Cost of goods sold 713,379 78 713,457 Gross margin ( 193,054 ) ( 10,082 ) ( 203,136 ) Operating loss ( 1,082,674 ) ( 10,082 ) ( 1,092,756 ) Loss income before income taxes ( 329,433 ) ( 10,082 ) ( 339,515 ) Net loss ( 320,485 ) ( 10,082 ) ( 330,567 ) Net loss attributable to noncontrolling interests and ( 18,304 ) ( 2,220 ) ( 20,524 ) Net loss attributable to Canopy Growth Corporation ( 302,181 ) ( 7,862 ) ( 310,043 ) Basic and diluted loss per share $ ( 0.77 ) $ ( 0.02 ) $ ( 0.79 ) Basic and diluted weighted average common shares outstanding 391,324,285 - 391,324,285 Comprehensive loss: Net loss $ ( 320,485 ) $ ( 10,082 ) $ ( 330,567 ) Comprehensive loss ( 344,657 ) ( 10,082 ) ( 354,739 ) Comprehensive loss attributable to noncontrolling interests and ( 18,304 ) ( 2,220 ) ( 20,524 ) Comprehensive loss attributable to Canopy Growth Corporation ( 326,353 ) ( 7,862 ) ( 334,215 ) The correction of the revenue misstatement described above resulted in a decrease of $ 10,004 in net revenue and an increase in the net loss attributable to noncontrolling interests and redeemable noncontrolling interest of $ 2,220 . As a result, net loss attributable to Canopy Growth Corporation and comprehensive loss attributable to Canopy Growth Corporation were each impacted by $ 7,862 . The following table presents the effect of the Restatement Items on the Company’s consolidated statement of shareholders’ equity for the year ended March 31, 2022: March 31, 2022 As Previously Reported Restatement Adjustment As Restated Additional paid-in-capital - Redeemable noncontrolling interest $ ( 44,340 ) $ 1,480 $ ( 42,860 ) Deficit ( 6,370,337 ) ( 7,862 ) ( 6,378,199 ) Total shareholders' equity 3,594,297 ( 6,382 ) 3,587,915 The correction of the revenue misstatement described above resulted in a decrease of $ 1,480 in additional paid-in-capital - redeemable noncontrolling interest, and an increase of $ 7,862 in the deficit. In total, the impact on total shareholders' equity was a decrease of $ 6,382 . The following table presents the effect of the Restatement Items on the Company’s consolidated statement of cash flows for the year ended March 31, 2022: Year ended March 31, 2022 As Previously Reported Restatement Adjustment As Restated Net loss $ ( 320,485 ) $ ( 10,082 ) $ ( 330,567 ) Change in operating assets and liabilities, net of effects from Amounts receivable 3,741 9,862 13,603 Inventory 173,189 ( 152 ) 173,037 Prepaid expenses and other assets 24,472 80 24,552 Other, including non-cash foreign currency ( 10,189 ) 292 ( 9,897 ) Net cash used in operating activities ( 545,811 ) - ( 545,811 ) The correction of the revenue misstatement described above resulted in no net change to net cash used in operating activities. The following table presents the effect of the Restatement Items on the Company’s segmented information note for the year ended March 31, 2022: Year ended March 31, 2022 As Previously Reported Restatement Adjustment As Restated Segmented net revenue Canada cannabis $ 257,910 $ - $ 257,910 Rest-of-world cannabis 79,306 - 79,306 Storz & Bickel 85,410 - 85,410 BioSteel 44,626 ( 10,004 ) 34,622 This Works 32,296 - 32,296 Other 20,777 - 20,777 $ 520,325 $ ( 10,004 ) $ 510,321 Segmented gross margin: Canada cannabis $ ( 212,820 ) $ - $ ( 212,820 ) Rest-of-world cannabis ( 28,875 ) - ( 28,875 ) Storz & Bickel 37,284 37,284 BioSteel ( 5,640 ) ( 10,082 ) ( 15,722 ) This Works 14,800 14,800 Other 2,197 - 2,197 ( 193,054 ) ( 10,082 ) ( 203,136 ) Operating loss ( 1,082,674 ) ( 10,082 ) ( 1,092,756 ) Loss before incomes taxes $ ( 329,433 ) $ ( 10,082 ) $ ( 339,515 ) The correction of the revenue misstatement described above resulted in a decrease of $ 10,004 in revenue associated with the BioSteel reportable segment. The remainder of the notes to the Company’s consolidated financial statements have been updated and restated, as applicable, to reflect the impacts of the restatement described above.
Principles of consolidation	Principles of consolidation The accompanying consolidated financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation.
Variable interest entities	Variable interest entities A variable interest entity (“VIE”) is an entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured such that equity investors lack the ability to control the entity’s activities or do not substantially participate in the gains and losses of the entity. Upon inception of a contractual agreement, and thereafter, if a reconsideration event occurs, the Company performs an assessment to determine whether the arrangement contains a variable interest in an entity and whether that entity is a VIE. The primary beneficiary of a VIE is the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Under ASC 810 – Consolidations , where the Company concludes that it is the primary beneficiary of a VIE, the Company consolidates the accounts of that VIE.
Equity method investments	Equity method investments Investments accounted for using the equity method include those investments where the Company: (i) can exercise significant influence over the other entity and (ii) holds common stock and/or in-substance common stock of the other entity. Under the equity method, investments are carried at cost, and subsequently adjusted for the Company’s share of net income (loss), comprehensive income (loss) and distributions received from the investee. If the current fair value of an investment falls below its carrying amount, this may indicate that an impairment loss should be recorded. Any impairment losses recognized are not reversed in subsequent periods.
Use of estimates	Use of estimates The preparation of these consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ from those estimates.
Foreign currency translation	Foreign currency translation In preparing the financial statements of individual entities, transactions in currencies other than the entity’s functional currency are recognized at exchange rates in effect on the date of the transactions. At each reporting date monetary assets and liabilities denominated in foreign currencies are re-translated at the exchange rates applicable at that date. Non-monetary items carried at fair value that are denominated in foreign currencies are translated at the rates prevailing at the date when the fair value was determined. Non-monetary assets and liabilities that are measured at historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Realized and unrealized exchange gains and losses are recognized through net income (loss). For the purposes of presenting consolidated financial statements, the assets and liabilities of foreign operations are translated into Canadian dollars at the exchange rates applicable at the balance sheet date. Income and expenses, and cash flows of foreign operations are translated into Canadian dollars using average exchange rates. Exchange differences resulting from translating foreign operations are recognized in accumulated other comprehensive income (loss).
Cash equivalents and short-term investments	Cash equivalents and short-term investments Cash equivalents consist of highly liquid investments with original maturities of three months or less. Investments with maturities or redemption dates greater than 90 days at the date of purchase are included in short-term investments. The Company’s investments in debt securities, which consist primarily of U.S. government securities and U.S. commercial paper, have been classified and accounted for using the fair value option. Unrealized gains and losses on debt securities are recognized in net income (loss). All other short-term investments are recorded at fair value with gains or losses recognized in net income (loss).
Inventory	Inventory Inventory consists of raw materials, supplies and consumables used in the inventory process, merchandise for sale, finished goods and work-in-process such as pre-harvested cannabis plants, by-products to be extracted, oils, gel capsules and edible products. Inventory is valued at the lower of cost and net realizable value. Costs include direct and indirect labor, consumables, materials, packaging supplies, utilities, facilities costs, quality and testing costs, production related depreciation and other overhead costs. The Company records inventory reserves for obsolete and slow-moving inventory. Inventory reserves are based on inventory obsolescence trends, age of inventory, historical experience and application of the specific identification method. The Company classifies cannabis inventory as a current asset, although part of such inventory, because of the duration of the cultivation, drying, and conversion process, ordinarily would not be utilized within one year.
Property, plant and equipment	Property, plant and equipment Property, plant and equipment is recorded at cost less accumulated depreciation. Major additions and improvements are capitalized, while maintenance and repairs are expensed as incurred. When significant parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items or components of property, plant and equipment. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the respective accounts and any related gain or loss is recognized in net income (loss). Depreciation is calculated on a straight-line basis over the expected useful lives of the assets, which are as follows: Years Buildings and greenhouses 20 - 50 Production and warehouse equipment 5 - 30 Leasehold improvements 3 - 20 Office and lab equipment 3 - 10 Computer equipment 3 - 10 Estimates of useful life and residual value, and the method of depreciation, are reviewed only when events or changes in circumstances indicate that the current estimates or depreciation method are no longer appropriate. Any changes are accounted for on a prospective basis as a change in estimate.
Intangible assets	Intangible assets Finite lived intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Amortization is provided on a straight-line basis over the following terms: Years Intellectual property 5 - 15 Distribution channel 5 - 11 Operating licenses 5 - 8 Software and domain names 3 - 5 Brands 2 - 5 The estimated useful life and amortization method are reviewed at the end of each reporting year, with the effect of any changes in estimate being accounted for on a prospective basis.
Goodwill and indefinite lived intangible assets	Goodwill and indefinite lived intangible assets Goodwill is allocated to the reporting unit in which the business that created the goodwill resides. A reporting unit is an operating segment, or a business unit one level below that operating segment, for which discrete financial information is prepared and regularly reviewed by segment management. The Company reviews goodwill and indefinite lived intangible assets annually for impairment in the fourth quarter, or sooner, if events or circumstances indicate that the carrying amount of an asset may not be recoverable. The Company may elect to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If factors indicate this is the case, then a quantitative test is performed and an impairment is recorded for any excess carrying value above the reporting unit’s fair value, not to exceed the amount of goodwill. Year ended March 31, 2021 Until the three months ended March 31, 2021, the Company had two operating segments, which were also its reportable segments: (i) cannabis, hemp and other consumer products; and (ii) RIV Capital Inc. (formerly Canopy Rivers Inc.) (“RIV Capital”). The goodwill associated with all acquisitions was allocated to the one reporting unit within the cannabis, hemp and other consumer products operating and reportable segment, as this reporting unit held the acquired entities. The Company changed the structure of its internal management financial reporting in the three months ended March 31, 2021 (refer to Note 35), and accordingly, identified two operating and reportable segments: (i) global cannabis; and (ii) other consumer products. The reorganization of the Company’s reporting structure changed the composition of its reporting units and required that goodwill be reassigned to the reporting units using a relative fair value allocation approach. Assets and liabilities were also reassigned to the reporting units affected based on the assets that would be employed in, or the liabilities related to, the operations of each reporting unit, and the assets or liabilities that would be considered in determining the fair value of each reporting unit. After this reorganization, the Company’s reporting units with goodwill in the global cannabis segment included: (i) cannabis operations, and (ii) C 3 Cannabinoid Compound Company GmbH (“C 3 ”); and in the other consumer products segment included: (i) Storz & Bickel GmbH (“Storz & Bickel”); (ii) This Works Products Ltd. (“This Works”); and (iii) BioSteel. Year ended March 31, 2022 In the three months ended March 31, 2022, the Company further changed the composition of its reporting units within the global cannabis segment as a result of: (i) the completion of the Company’s divestiture of its interest in C 3 (the “C 3 Divestiture”) (see Note 30(b)); and (ii) a strategic shift in the Company’s KeyLeaf Life Sciences (“KeyLeaf”) business to focus on non-cannabis extraction activities. Accordingly, goodwill was reassigned to the KeyLeaf reporting unit from the cannabis operations reporting unit, using the relative fair value allocation approach. There were no changes to the reporting units included in the Company’s other consumer products segment in the year ended March 31, 2022. The Company performed its annual goodwill impairment test in the three months ended March 31, 2022, and recognized impairment losses in relation to its KeyLeaf and This Works reporting units. Refer to Note 15 for further details. Year ended March 31, 2023 In the three months ended June 30, 2022, the Company recognized a goodwill impairment loss in relation to the cannabis operations reporting unit in the global cannabis segment, representing the entirety of the goodwill assigned to the cannabis operations reporting unit. In the three months ended September 30, 2022, following the completion of certain restructuring actions which were initiated in the three months ended March 31, 2022, and which were aligned with the Company’s strategic review of its business, the Company changed the structure of its internal management financial reporting and began reporting its financial results for the following five reportable segments: (i) Canada cannabis; (ii) Rest-of-world cannabis; (iii) Storz & Bickel; (iv) BioSteel; (v) This Works (see Note 35). There were no changes to the composition of the Company’s reporting units to which goodwill remains assigned resulting from the change in reportable segments. The Company recognized goodwill impairment losses in the three months ended September 30, 2022 in relation to its This Works reporting unit and BioSteel reporting unit. In the three months ended March 31, 2023, the Company performed its annual goodwill impairment test and noted no additional impairments. Refer to Note 15 for further details. Indefinite lived intangible assets are comprised of certain acquired brand names and operating licenses, which are carried at cost less accumulated impairment losses. The Company reviews the classification each reporting period to decide whether the assessment made about the useful life as indefinite or finite is still appropriate. Any change is accounted for on a prospective basis as a change in estimate.
Impairment of long-lived assets	Impairment of long-lived assets The Company evaluates the recoverability of long-lived assets, including property, plant and equipment and finite lived intangible assets whenever events or changes in circumstances indicate a potential impairment exists. The Company groups assets at the lowest level for which cash flows are separately identifiable, referred to as an asset group. When indicators of potential impairment are present the Company prepares a projected undiscounted cash flow analysis for the respective asset or asset group. If the sum of the undiscounted cash flow is less than the carrying value of the asset or asset group, an impairment loss is recognized equal to the excess of the carrying value over the fair value, if any.
Restricted short-term investments	Restricted short-term investments The Company considers short-term investments to be restricted when withdrawal or general use is legally restricted. The Company records restricted short-term investments as current or non-current in the consolidated balance sheets based on the classification of the underlying securities.
Redeemable noncontrolling interest	Redeemable noncontrolling interest Redeemable noncontrolling interest is presented as mezzanine equity. The balance of the redeemable noncontrolling interest is reported at the greater of the initial carrying amount adjusted for the redeemable noncontrolling interest’s share of earnings or losses and other comprehensive income or loss, or its estimated redemption value. The Company adjusts the carrying amount of the redeemable interest to the redemption amount each period, assuming the interest was redeemable at the balance sheet date with changes in fair value recorded in equity.
Revenue recognition	Revenue recognition The Company’s cannabis revenue is comprised of sales of: (i) adult-use cannabis products in Canada, either to government agencies or third-party retailers under a “business-to-business” wholesale model, or directly to consumers through the Company’s network of retail stores and e-commerce platforms; and (ii) medical and other cannabis products in Canada and certain other countries. The Company’s other revenue is comprised of sales of vaporizers, beauty, wellness and sleep products, sports nutrition beverages, merchandise, and revenue from other sources. The Company’s revenue-generating activities have a single performance obligation and revenue is recognized at the point in time when control of the product transfers and the Company’s obligations have been fulfilled. This generally occurs when the product is shipped or delivered to the customer, depending upon the method of distribution and shipping terms set forth in the customer contract. In accordance with contracts with certain of the Company’s Canadian provincial customers, the Company fulfills its obligations only when the customer transfers control of the product to the end consumer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for the sale of the Company’s product. Certain of the Company’s customer contracts, most notably those with the Canadian provincial and territorial agencies, may provide the customer with a right of return. In certain circumstances the Company may also provide a retrospective price adjustment to a customer. These items give rise to variable consideration, which is recognized as a reduction of the transaction price based upon the expected amounts of the product returns and price adjustments at the time revenue for the corresponding product sale is recognized. The determination of the reduction of the transaction price for variable consideration requires that the Company make certain estimates and assumptions that affect the timing and amounts of revenue recognized. The Company estimates this variable consideration by taking into account factors such as historical information, current trends, forecasts, provincial and territorial inventory levels, availability of actual results and expectations of demand. The Company recognizes a liability for sales refunds within other current liabilities, and an asset for the value of inventory which is expected to be returned is recognized within prepaid expenses and other assets on the consolidated balance sheets. Sales of products are for cash or otherwise agreed-upon credit terms. The Company’s payment terms vary by location and customer; however, the time period between when revenue is recognized and when payment is due is not significant. The Company estimates and reserves for its bad debt exposure based on its experience with past due accounts and collectability, write-off history, the aging of accounts receivable and an analysis of customer data.
Cost of goods sold	Cost of goods sold The types of costs included in cost of goods sold are raw materials, packaging materials, manufacturing costs, plant facilities administrative support and overheads, and freight and warehouse costs, including distribution costs.
Advertising	Advertising Advertising costs are expensed as incurred. Advertising expenses totaled $ 134,403 , $ 104,221 and $ 72,377 in the years ended March 31, 2023, 2022, and 2021 , respectively.
Research and development	Research and development Research and development costs are expensed as incurred. Research and development expenses totaled $ 21,718 , $ 32,344 , and $ 57,582 in the years ended March 31, 2023, 2022, and 2021 , respectively.
Asset impairment and restructuring costs	Asset impairment and restructuring costs Asset impairment and restructuring costs consist of property, plant and equipment, intangible asset and goodwill impairment charges, asset abandonment costs, contractual and other settlement costs, and employee-related and other restructuring costs recognized in connection with: (i) the restructuring of the Company’s global operations that commenced in the year ended March 31, 2020 and continued during the years ended March 31, 2021, March 31, 2022 and March 31, 2023; and (ii) other impairments. Refer to Note 6 for further details. When a long-lived asset is abandoned its carrying amount is adjusted to its salvage value, if any. In determining the salvage value of our long-lived assets, management considers information from manufacturers, historical data, and industry standards. In certain cases, management may obtain third party appraisals to estimate salvage value.
Share-based compensation	Share-based compensation The Company accounts for share-based compensation using the fair value method. With the exception of a limited number of share-based awards subject to market-based performance conditions that are valued using the Monte Carlo simulation model, the fair value of awards granted is estimated at the date of grant using the Black-Scholes model. The share-based compensation expense is based on the fair value of share-based awards at the grant date and the expense is recognized over the related service period following a graded vesting expense schedule. Forfeitures are estimated at the time of grant and revised in subsequent periods if there is a difference in actual forfeitures and the estimate. Effective April 1, 2018, the Company early-adopted ASU 2018-07 – Compensation - Stock Compensation (Topic 718) , which among other items, aligns the accounting for non-employee awards with that of employee awards. For awards with service and/or non-market based performance conditions, the amount of compensation expense recognized is based on the number of awards expected to vest, reflecting estimated expected forfeitures, and is adjusted to reflect those awards that do ultimately vest. For awards with performance conditions, the Company recognizes the compensation expense if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of achieving the performance condition at each reporting date. Restricted stock units (“RSUs”) that are settled in cash or common stock at the election of the employee are remeasured to fair value at the end of each reporting period until settlement. This fair value is based on the closing price of the Company’s common shares on the last business day before each period end.
Income taxes	Income taxes Income taxes are comprised of current and deferred taxes. These taxes are accounted for using the liability method. Current tax is recognized in connection with income for tax purposes, unrealized tax benefits and the recovery of tax paid in a prior period and measured using the enacted tax rates and laws applicable to the taxation period during which the income for tax purposes arose. Deferred tax is recognized on the difference between the carrying amount of an asset or a liability, as reflected in the financial statements, and the corresponding tax base, used in the computation of income for tax purposes (“temporary difference”) and measured using the enacted tax rates and laws as at the balance sheet date that are expected to apply to the income that the Company expects to arise for tax purposes in the period during which the difference is expected to reverse. Management assesses the likelihood that a deferred tax asset will be realized and a valuation allowance is provided to the extent that it is more likely than not that all or a portion of a deferred tax asset will not be realized. The determination of both current and deferred taxes reflects the Company’s interpretation of the relevant tax rules and judgement. An unrealized tax benefit may arise in connection with a period that has not yet been reviewed by the relevant tax authority. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs. Income taxes are recognized in the consolidated statement of operations, except when they relate to a pre-tax item that is recognized in other comprehensive income (loss) or directly in equity, respectively. Income taxes recognized in other comprehensive income (loss) or equity are reclassified to the consolidated statement of operations if the corresponding pre-tax item is reclassified to the consolidated statement of operations. Where income taxes arise from the initial accounting for a business combination, these are embedded in the pre-tax accounting for the business combination. Interest and penalties in respect of income taxes are not recognized in the consolidated statement of operations as a component of income taxes but as a component of interest expense.
Earnings (loss) per share	Earnings (loss) per share Basic earnings (loss) per share is computed by dividing reported net income (loss) by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share is computed by dividing earnings (loss) by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Diluted earnings (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common shares of the Company during the reporting periods. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of warrants, vested share options, RSUs and the incremental shares issuable upon conversion of the convertible senior notes. As at March 31, 2023, March 31, 2022, and March 31, 2021 , all instruments were anti-dilutive.
Fair value measurements	Fair value measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company calculates the estimated fair value of financial instruments using quoted market prices whenever available. When quoted market prices are not available, the Company uses standard pricing models. For other financial assets measured at fair value that earn interest, the Company has elected to present interest income as part of the fair value change in other income (expense), net.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements Convertible Instruments and Contracts in an Entity’s Own Equity In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for convertible instruments by removing the separation models for convertible debt instruments and convertible preferred stock with (1) cash conversion features, and (2) beneficial conversion features. In addition, ASU 2020-06 enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Company adopted ASU 2020-06 on April 1, 2022, using the modified retrospective approach with the cumulative effect recognized as an adjustment to the opening deficit balance, and, accordingly, prior period balances and disclosures have not been restated. Upon adoption of ASU 2020-06, the Supreme Debentures (as defined below) are accounted for under the separation model for a substantial premium instead of a beneficial conversion feature resulting in an increased debt discount to be amortized over the life of the instrument. The adoption of this guidance resulted in increased additional paid-in capital by $ 4,452 , decreased long-term debt by $ 3,723 , and decreased accumulated deficit by $ 729 for non-cash accretion expense prior to April 1, 2022.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	12 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Restatement of Previously Issued Consolidated Financial Statements and Prior Period Corrections	The following table presents the effect of the Restatement Items on the Company’s consolidated balance sheet as of March 31, 2022 (in thousands, except number of shares and per share data): March 31, 2022 As Previously Reported Restatement Adjustment As Restated Amounts receivable, net $ 96,443 $ ( 9,862 ) $ 86,581 Inventory 204,387 152 204,539 Prepaid expenses and other assets 52,700 ( 80 ) 52,620 Total current assets 1,737,402 ( 9,790 ) 1,727,612 Total assets 5,615,050 ( 9,790 ) 5,605,260 Other liabilities 64,054 292 64,346 Total current liabilities 212,898 292 213,190 Total liabilities 1,984,553 292 1,984,845 Redeemable noncontrolling interest 36,200 ( 3,700 ) 32,500 Additional paid-in capital 2,519,766 1,480 2,521,246 Deficit ( 6,370,337 ) ( 7,862 ) ( 6,378,199 ) Total Canopy Growth Corporation shareholders' equity 3,589,956 ( 6,382 ) 3,583,574 Total shareholders' equity 3,594,297 ( 6,382 ) 3,587,915 Total liabilities and shareholders' equity 5,615,050 ( 9,790 ) 5,605,260 The correction of the revenue misstatement described above resulted in a decrease of $ 9,862 in amounts receivable, net, and a corresponding increase in the deficit. Additionally, the correction of the misstatement described above resulted in a decrease in redeemable noncontrolling interest of $ 3,700 and an increase in additional paid-in-capital of $ 1,480 . The following table presents the effect of the Restatement Items on the Company’s consolidated statement of operations and comprehensive loss for the year ended March 31, 2022 (in thousands, except number of shares and per share data): Year ended March 31, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 582,218 $ ( 10,004 ) $ 572,214 Net revenue 520,325 ( 10,004 ) 510,321 Cost of goods sold 713,379 78 713,457 Gross margin ( 193,054 ) ( 10,082 ) ( 203,136 ) Operating loss ( 1,082,674 ) ( 10,082 ) ( 1,092,756 ) Loss income before income taxes ( 329,433 ) ( 10,082 ) ( 339,515 ) Net loss ( 320,485 ) ( 10,082 ) ( 330,567 ) Net loss attributable to noncontrolling interests and ( 18,304 ) ( 2,220 ) ( 20,524 ) Net loss attributable to Canopy Growth Corporation ( 302,181 ) ( 7,862 ) ( 310,043 ) Basic and diluted loss per share $ ( 0.77 ) $ ( 0.02 ) $ ( 0.79 ) Basic and diluted weighted average common shares outstanding 391,324,285 - 391,324,285 Comprehensive loss: Net loss $ ( 320,485 ) $ ( 10,082 ) $ ( 330,567 ) Comprehensive loss ( 344,657 ) ( 10,082 ) ( 354,739 ) Comprehensive loss attributable to noncontrolling interests and ( 18,304 ) ( 2,220 ) ( 20,524 ) Comprehensive loss attributable to Canopy Growth Corporation ( 326,353 ) ( 7,862 ) ( 334,215 ) The correction of the revenue misstatement described above resulted in a decrease of $ 10,004 in net revenue and an increase in the net loss attributable to noncontrolling interests and redeemable noncontrolling interest of $ 2,220 . As a result, net loss attributable to Canopy Growth Corporation and comprehensive loss attributable to Canopy Growth Corporation were each impacted by $ 7,862 . The following table presents the effect of the Restatement Items on the Company’s consolidated statement of shareholders’ equity for the year ended March 31, 2022: March 31, 2022 As Previously Reported Restatement Adjustment As Restated Additional paid-in-capital - Redeemable noncontrolling interest $ ( 44,340 ) $ 1,480 $ ( 42,860 ) Deficit ( 6,370,337 ) ( 7,862 ) ( 6,378,199 ) Total shareholders' equity 3,594,297 ( 6,382 ) 3,587,915 The correction of the revenue misstatement described above resulted in a decrease of $ 1,480 in additional paid-in-capital - redeemable noncontrolling interest, and an increase of $ 7,862 in the deficit. In total, the impact on total shareholders' equity was a decrease of $ 6,382 . The following table presents the effect of the Restatement Items on the Company’s consolidated statement of cash flows for the year ended March 31, 2022: Year ended March 31, 2022 As Previously Reported Restatement Adjustment As Restated Net loss $ ( 320,485 ) $ ( 10,082 ) $ ( 330,567 ) Change in operating assets and liabilities, net of effects from Amounts receivable 3,741 9,862 13,603 Inventory 173,189 ( 152 ) 173,037 Prepaid expenses and other assets 24,472 80 24,552 Other, including non-cash foreign currency ( 10,189 ) 292 ( 9,897 ) Net cash used in operating activities ( 545,811 ) - ( 545,811 ) The correction of the revenue misstatement described above resulted in no net change to net cash used in operating activities. The following table presents the effect of the Restatement Items on the Company’s segmented information note for the year ended March 31, 2022: Year ended March 31, 2022 As Previously Reported Restatement Adjustment As Restated Segmented net revenue Canada cannabis $ 257,910 $ - $ 257,910 Rest-of-world cannabis 79,306 - 79,306 Storz & Bickel 85,410 - 85,410 BioSteel 44,626 ( 10,004 ) 34,622 This Works 32,296 - 32,296 Other 20,777 - 20,777 $ 520,325 $ ( 10,004 ) $ 510,321 Segmented gross margin: Canada cannabis $ ( 212,820 ) $ - $ ( 212,820 ) Rest-of-world cannabis ( 28,875 ) - ( 28,875 ) Storz & Bickel 37,284 37,284 BioSteel ( 5,640 ) ( 10,082 ) ( 15,722 ) This Works 14,800 14,800 Other 2,197 - 2,197 ( 193,054 ) ( 10,082 ) ( 203,136 ) Operating loss ( 1,082,674 ) ( 10,082 ) ( 1,092,756 ) Loss before incomes taxes $ ( 329,433 ) $ ( 10,082 ) $ ( 339,515 ) The correction of the revenue misstatement described above resulted in a decrease of $ 10,004 in revenue associated with the BioSteel reportable segment. The remainder of the notes to the Company’s consolidated financial statements have been updated and restated, as applicable, to reflect the impacts of the restatement described above. The following tables include corrections to the prior period results, and present the effect of the Restatement Items described in Note 2, “Basis of Presentation - Restatement of Previously Issued Consolidated Financial Statements” on the Company’s unaudited interim condensed consolidated balance sheets for the periods indicated (in thousands, except number of shares and per share data): June 30, 2022 As Previously Reported Restatement Adjustment As Restated Amounts receivable, net $ 96,626 $ ( 13,827 ) $ 82,799 Inventory 205,513 19 205,532 Prepaid expenses and other assets 62,141 ( 298 ) 61,843 Total current assets 1,593,572 ( 14,106 ) 1,579,466 Total assets 3,517,527 ( 14,106 ) 3,503,421 Other liabilities 86,776 170 86,946 Total current liabilities 404,408 170 404,578 Total liabilities 1,834,607 170 1,834,777 Redeemable noncontrolling interest 37,150 ( 9,000 ) 28,150 Additional paid-in capital 2,515,453 5,881 2,521,334 Deficit ( 8,454,214 ) ( 11,157 ) ( 8,465,371 ) Total Canopy Growth Corporation shareholders' equity 1,641,255 ( 5,276 ) 1,635,979 Total shareholders' equity 1,645,770 ( 5,276 ) 1,640,494 Total liabilities and shareholders' equity 3,517,527 ( 14,106 ) 3,503,421 September 30, 2022 As Previously Reported Restatement Adjustment As Restated Amounts receivable, net $ 108,236 $ ( 25,820 ) $ 82,416 Inventory 211,209 545 211,754 Prepaid expenses and other assets 62,957 ( 216 ) 62,741 Total current assets 1,538,175 ( 25,491 ) 1,512,684 Goodwill 136,513 ( 57,401 ) 79,112 Total assets 3,402,270 ( 82,892 ) 3,319,378 Other liabilities 63,645 16,235 79,880 Total current liabilities 542,401 16,235 558,636 Total liabilities 1,738,241 16,235 1,754,476 Redeemable noncontrolling interest 35,900 ( 23,224 ) 12,676 Additional paid-in capital 2,516,811 21,292 2,538,103 Deficit ( 8,676,020 ) ( 97,195 ) ( 8,773,215 ) Total Canopy Growth Corporation shareholders' equity 1,625,173 ( 75,903 ) 1,549,270 Total shareholders' equity 1,628,129 ( 75,903 ) 1,552,226 Total liabilities and shareholders' equity 3,402,270 ( 82,892 ) 3,319,378 December 31, 2022 As Previously Reported Restatement Adjustment As Restated Amounts receivable, net $ 104,640 $ ( 22,954 ) $ 81,686 Inventory 213,937 108 214,045 Prepaid expenses and other assets 52,151 ( 446 ) 51,705 Total current assets 1,172,910 ( 23,292 ) 1,149,618 Goodwill 142,076 ( 57,401 ) 84,675 Total assets 3,020,155 ( 80,693 ) 2,939,462 Other liabilities 84,134 413 84,547 Total current liabilities 678,741 413 679,154 Total liabilities 1,580,406 413 1,580,819 Redeemable noncontrolling interest 11,408 ( 10,408 ) 1,000 Additional paid-in capital 2,510,086 24,379 2,534,465 Deficit ( 8,937,603 ) ( 95,077 ) ( 9,032,680 ) Total Canopy Growth Corporation shareholders' equity 1,425,545 ( 70,698 ) 1,354,847 Total shareholders' equity 1,428,341 ( 70,698 ) 1,357,643 Total liabilities and shareholders' equity 3,020,155 ( 80,693 ) 2,939,462 The following tables present the effect of the Restatement Items on the Company’s unaudited interim condensed consolidated statements of operations and comprehensive income (loss) for the periods indicated (in thousands, except number of shares and per share data): Three months ended June 30, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 122,862 $ ( 4,195 ) $ 118,667 Net revenue 110,115 ( 4,195 ) 105,920 Cost of goods sold 111,507 ( 1 ) 111,506 Gross margin ( 1,392 ) ( 4,194 ) ( 5,586 ) Operating loss ( 1,838,229 ) ( 4,194 ) ( 1,842,423 ) Loss before income taxes ( 2,083,807 ) ( 4,194 ) ( 2,088,001 ) Net loss ( 2,087,556 ) ( 4,194 ) ( 2,091,750 ) Net loss attributable to noncontrolling interests and ( 4,408 ) ( 899 ) ( 5,307 ) Net loss attributable to Canopy Growth Corporation ( 2,083,148 ) ( 3,295 ) ( 2,086,443 ) Basic and diluted loss per share $ ( 5.23 ) $ ( 0.01 ) $ ( 5.24 ) Comprehensive loss: Net loss $ ( 2,087,556 ) $ ( 4,194 ) $ ( 2,091,750 ) Comprehensive loss ( 2,059,738 ) ( 4,194 ) ( 2,063,932 ) Comprehensive loss attributable to noncontrolling interests ( 4,408 ) ( 899 ) ( 5,307 ) Comprehensive loss attributable to ( 2,055,330 ) ( 3,295 ) ( 2,058,625 ) Three months ended September 30, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 130,359 $ ( 12,445 ) $ 117,914 Net revenue 117,863 ( 12,445 ) 105,418 Cost of goods sold 114,042 ( 669 ) 113,373 Gross margin 3,821 ( 11,776 ) ( 7,955 ) Operating expenses Share-based compensation 9,858 4,723 14,581 Asset impairment and restructuring costs 43,968 57,401 101,369 Total operating expenses 179,668 62,124 241,792 Operating loss ( 175,847 ) ( 73,900 ) ( 249,747 ) Loss before income taxes ( 223,691 ) ( 73,900 ) ( 297,591 ) Net loss ( 231,911 ) ( 73,900 ) ( 305,811 ) Net loss attributable to noncontrolling interests and ( 10,105 ) ( 3,536 ) ( 13,641 ) Net loss attributable to Canopy Growth Corporation ( 221,806 ) ( 70,364 ) ( 292,170 ) Basic and diluted loss per share $ ( 0.47 ) $ ( 0.15 ) $ ( 0.62 ) Comprehensive loss: Net loss $ ( 231,911 ) $ ( 73,900 ) $ ( 305,811 ) Comprehensive loss ( 221,647 ) ( 73,900 ) ( 295,547 ) Comprehensive loss attributable to noncontrolling interests ( 10,105 ) ( 3,536 ) ( 13,641 ) Comprehensive loss attributable to ( 211,542 ) ( 70,364 ) ( 281,906 ) Six months ended September 30, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 253,221 $ ( 16,640 ) $ 236,581 Net revenue 227,978 ( 16,640 ) 211,338 Cost of goods sold 225,549 ( 670 ) 224,879 Gross margin 2,429 ( 15,970 ) ( 13,541 ) Operating expenses Share-based compensation 15,297 4,723 20,020 Asset impairment and restructuring costs 1,771,953 57,401 1,829,354 Total operating expenses 2,016,505 62,124 2,078,629 Operating loss ( 2,014,076 ) ( 78,094 ) ( 2,092,170 ) Loss before income taxes ( 2,307,498 ) ( 78,094 ) ( 2,385,592 ) Net loss ( 2,319,467 ) ( 78,094 ) ( 2,397,561 ) Net loss attributable to noncontrolling interests and ( 14,513 ) ( 4,435 ) ( 18,948 ) Net loss attributable to Canopy Growth Corporation ( 2,304,954 ) ( 73,659 ) ( 2,378,613 ) Basic and diluted loss per share $ ( 5.30 ) $ ( 0.17 ) $ ( 5.47 ) Comprehensive loss: Net loss $ ( 2,319,467 ) $ ( 78,094 ) $ ( 2,397,561 ) Comprehensive loss ( 2,281,385 ) ( 78,094 ) ( 2,359,479 ) Comprehensive loss attributable to noncontrolling interests ( 14,513 ) ( 4,435 ) ( 18,948 ) Comprehensive loss attributable to ( 2,266,872 ) ( 73,659 ) ( 2,340,531 ) Three months ended December 31, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 113,349 $ 2,818 $ 116,167 Net revenue 101,213 2,818 104,031 Cost of goods sold 103,654 472 104,126 Gross margin ( 2,441 ) 2,346 ( 95 ) Operating loss ( 153,764 ) 2,346 ( 151,418 ) Loss before income taxes ( 267,104 ) 2,346 ( 264,758 ) Net loss ( 266,722 ) 2,346 ( 264,376 ) Net loss attributable to noncontrolling interests and ( 5,139 ) 228 ( 4,911 ) Net loss attributable to Canopy Growth Corporation ( 261,583 ) 2,118 ( 259,465 ) Basic and diluted loss per share $ ( 0.54 ) $ 0.01 $ ( 0.53 ) Comprehensive loss: Net loss $ ( 266,722 ) $ 2,346 $ ( 264,376 ) Comprehensive loss ( 247,263 ) 2,346 ( 244,917 ) Comprehensive loss attributable to noncontrolling interests ( 5,139 ) 228 ( 4,911 ) Comprehensive loss attributable to ( 242,124 ) 2,118 ( 240,006 ) Nine months ended December 31, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 366,570 $ ( 13,822 ) $ 352,748 Net revenue 329,191 ( 13,822 ) 315,369 Cost of goods sold 329,203 ( 198 ) 329,005 Gross margin ( 12 ) ( 13,624 ) ( 13,636 ) Operating expenses Share-based compensation 21,725 4,723 26,448 Asset impairment and restructuring costs 1,794,212 57,401 1,851,613 Total operating expenses 2,167,828 62,124 2,229,952 Operating loss ( 2,167,840 ) ( 75,748 ) ( 2,243,588 ) Loss before income taxes ( 2,574,602 ) ( 75,748 ) ( 2,650,350 ) Net loss ( 2,586,189 ) ( 75,748 ) ( 2,661,937 ) Net loss attributable to noncontrolling interests and ( 19,652 ) ( 4,207 ) ( 23,859 ) Net loss attributable to Canopy Growth Corporation ( 2,566,537 ) ( 71,541 ) ( 2,638,078 ) Basic and diluted loss per share $ ( 5.66 ) $ ( 0.16 ) $ ( 5.82 ) Comprehensive loss: Net loss $ ( 2,586,189 ) $ ( 75,748 ) $ ( 2,661,937 ) Comprehensive loss ( 2,528,648 ) ( 75,748 ) ( 2,604,396 ) Comprehensive loss attributable to noncontrolling interests ( 19,652 ) ( 4,207 ) ( 23,859 ) Comprehensive loss attributable to ( 2,508,996 ) ( 71,541 ) ( 2,580,537 ) The following tables present the effect of the Restatement Items on the Company’s unaudited interim condensed consolidated statements of shareholders’ equity for the periods indicated: June 30, 2022 As Previously Reported Restatement Adjustment As Restated Additional paid-in-capital - Redeemable noncontrolling interest $ ( 49,698 ) $ 5,881 $ ( 43,817 ) Deficit ( 8,454,214 ) ( 11,157 ) ( 8,465,371 ) Total shareholders' equity 1,645,770 ( 5,276 ) 1,640,494 September 30, 2022 As Previously Reported Restatement Adjustment As Restated Additional paid-in-capital - Redeemable noncontrolling interest $ ( 56,709 ) $ 16,569 $ ( 40,140 ) Additional paid-in-capital - Ownership changes ( 509,723 ) 4,723 ( 505,000 ) Deficit ( 8,676,020 ) ( 97,195 ) ( 8,773,215 ) Total shareholders' equity 1,628,129 ( 75,903 ) 1,552,226 December 31, 2022 As Previously Reported Restatement Adjustment As Restated Additional paid-in-capital - Redeemable noncontrolling interest $ ( 64,707 ) $ 19,656 $ ( 45,051 ) Additional paid-in-capital - Ownership changes ( 512,419 ) 4,723 ( 507,696 ) Deficit ( 8,937,603 ) ( 95,077 ) ( 9,032,680 ) Total shareholders' equity 1,428,341 ( 70,698 ) 1,357,643 The following tables present the effect of the Restatement Items on the Company’s unaudited interim condensed consolidated statements of cash flows for the periods indicated: Three months ended June 30, 2022 As Previously Restatement As Restated Cash flows from operating activities: Net loss $ ( 2,087,556 ) $ ( 4,194 ) $ ( 2,091,750 ) Change in operating assets and liabilities, net of effects from Amounts receivable ( 183 ) 3,964 3,781 Inventory ( 1,126 ) 133 ( 993 ) Prepaid expenses and other assets ( 9,555 ) 219 ( 9,336 ) Other, including non-cash foreign currency 1,928 ( 122 ) 1,806 Net cash used in operating activities ( 140,515 ) - ( 140,515 ) Six months ended September 30, 2022 As Previously Restatement As Restated Cash flows from operating activities: Net loss $ ( 2,319,467 ) $ ( 78,094 ) $ ( 2,397,561 ) Adjustments to reconcile net loss to net cash used in operating activities: Share-based compensation 15,297 4,723 20,020 Asset impairment and restructuring costs 1,783,784 57,401 1,841,185 Change in operating assets and liabilities, net of effects from Amounts receivable ( 11,793 ) 15,956 4,163 Inventory ( 6,822 ) ( 393 ) ( 7,215 ) Prepaid expenses and other assets ( 17,567 ) 138 ( 17,429 ) Other, including non-cash foreign currency ( 19,006 ) 269 ( 18,737 ) Net cash used in operating activities ( 273,915 ) - ( 273,915 ) Nine months ended December 31, 2022 As Previously Restatement As Restated Net loss $ ( 2,586,189 ) $ ( 75,748 ) $ ( 2,661,937 ) Adjustments to reconcile net loss to net cash used in operating activities: Share-based compensation 21,725 4,723 26,448 Asset impairment and restructuring costs 1,797,854 57,401 1,855,255 Change in operating assets and liabilities, net of effects Amounts receivable ( 8,197 ) 13,090 4,893 Inventory ( 9,550 ) 44 ( 9,506 ) Prepaid expenses and other assets ( 6,866 ) 368 ( 6,498 ) Other, including non-cash foreign currency ( 24,459 ) 122 ( 24,337 ) Net cash used in operating activities ( 417,809 ) - ( 417,809 )

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Expected Useful Life of Property, Plant and Equipment	Depreciation is calculated on a straight-line basis over the expected useful lives of the assets, which are as follows: Years Buildings and greenhouses 20 - 50 Production and warehouse equipment 5 - 30 Leasehold improvements 3 - 20 Office and lab equipment 3 - 10 Computer equipment 3 - 10 The components of property, plant and equipment are as follows: March 31, March 31, 2023 2022 Buildings and greenhouses $ 413,832 $ 766,931 Production and warehouse equipment 101,326 159,314 Leasehold improvements 15,529 69,304 Office and lab equipment 13,857 29,879 Computer equipment 8,697 22,293 Land 16,781 18,917 Right-of-use-assets Buildings and greenhouses 37,533 89,228 Production and warehouse equipment 637 55 Assets in process 3,281 19,771 611,473 1,175,692 Less: Accumulated depreciation ( 112,007 ) ( 232,912 ) $ 499,466 $ 942,780
Summary of Finite Lived Intangible Assets Useful Life	Finite lived intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Amortization is provided on a straight-line basis over the following terms: Years Intellectual property 5 - 15 Distribution channel 5 - 11 Operating licenses 5 - 8 Software and domain names 3 - 5 Brands 2 - 5

Asset Impairment and Restruct_2

Asset Impairment and Restructuring Costs (Tables)	12 Months Ended
	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Summary of Pre-tax Charges Recognized in Restructuring Actions and Other Impairments	A summary of the pre-tax charges totaling $ 2,347,227 recognized in connection with the Company’s restructuring actions and other impairments is as follows: Year ended March 31, 2023 Restructuring and other charges Other impairments Total Costs recorded in cost of goods sold: Inventory write-downs and other charges $ 90,485 $ - $ 90,485 Costs recorded in operating expenses: Impairment of property, plant and equipment 376,176 - 376,176 Impairment of intangible assets 27,399 14,614 42,013 Impairment of goodwill - 1,785,080 1,785,080 Contractual and other settlement obligations 18,427 - 18,427 Employee-related and other restructuring costs 35,046 - 35,046 Asset impairment and restructuring costs 457,048 1,799,694 2,256,742 Total restructuring, asset impairments and related costs $ 547,533 $ 1,799,694 $ 2,347,227 A summary of the pre-tax charges totaling $ 496,623 recognized in connection with the Company’s restructuring actions and other impairments is as follows: Year ended March 31, 2022 Restructuring and other charges Other impairments Total Costs recorded in cost of goods sold: Inventory write-downs and other charges $ 123,669 $ - $ 123,669 Costs recorded in operating expenses: Impairment and abandonment of property, plant and equipment 224,726 - 224,726 Impairment and abandonment of intangible assets 41,404 26,065 67,469 Impairment of goodwill - 40,748 40,748 Contractual and other settlement obligations 6,610 - 6,610 Employee-related and other restructuring costs 29,786 - 29,786 Asset impairment and restructuring costs 302,526 66,813 369,339 Acceleration of share-based compensation expense 3,615 - 3,615 Share-based compensation expense 3,615 - 3,615 Total restructuring, asset impairments and related costs $ 429,810 $ 66,813 $ 496,623 A summary of the pre-tax charges totaling $ 570,683 recognized in connection with the Company’s restructuring actions and other impairments is as follows: Year ended March 31, 2021 Restructuring and other charges Other impairments Total Costs recorded in cost of goods sold: Inventory write-downs $ 25,985 $ - $ 25,985 Costs recorded in operating expenses: Impairment and abandonment of property, plant and equipment 426,748 - 426,748 Impairment and abandonment of intangible assets 54,511 6,634 61,145 Contractual and other settlement obligations 22,352 - 22,352 Employee-related and other restructuring costs 24,153 - 24,153 Asset impairment and restructuring costs 527,764 6,634 534,398 Costs recorded in loss from equity method investments: Impairment of equity method investments 10,300 - 10,300 Total restructuring, asset impairments and related costs $ 564,049 $ 6,634 $ 570,683

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Mar. 31, 2023
Cash and Cash Equivalents [Abstract]
Components of Cash and Cash Equivalents	The components of cash and cash equivalents are as follows: March 31, March 31, 2023 2022 Cash $ 462,460 $ 470,682 Cash equivalents 214,547 305,323 $ 677,007 $ 776,005

Short-term Investments (Tables)

Short-term Investments (Tables)	12 Months Ended
	Mar. 31, 2023
Short-Term Investments [Abstract]
Components of Short-term Investments	The components of short-term investments are as follows: March 31, March 31, 2023 2022 Government securities $ 60,226 $ 22,253 Term deposits 30,000 319,092 Commercial paper and other 15,369 254,306 $ 105,595 $ 595,651

Amounts Receivable, Net (Tables

Amounts Receivable, Net (Tables)	12 Months Ended
	Mar. 31, 2023
Receivables [Abstract]
Components of Amounts Receivable, Net	The components of amounts receivable, net are as follows: March 31, March 31, 2023 2022 (As Restated) Accounts receivable, net $ 66,820 $ 68,197 Indirect taxes receivable 11,544 7,524 Interest receivable 3,966 4,406 Other receivables 11,657 6,454 $ 93,987 $ 86,581

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Components of Inventory	The components of inventory are as follows: March 31, March 31, 2023 2022 Raw materials, packaging supplies and consumables $ 28,982 $ 26,821 Work in progress 34,104 65,245 Finished goods 85,815 112,473 $ 148,901 $ 204,539

Prepaid Expenses and Other As_2

Prepaid Expenses and Other Assets (Tables)	12 Months Ended
	Mar. 31, 2023
Prepaid Expense and Other Assets, Current [Abstract]
Components of Prepaid Expenses and Other Assets	The components of prepaid expenses and other assets are as follows: March 31, March 31, 2023 2022 Prepaid expenses $ 27,460 $ 22,961 Deposits 1,734 10,145 Prepaid inventory 690 449 Other assets 10,115 19,065 $ 39,999 $ 52,620

Other Financial Assets (Tables)

Other Financial Assets (Tables)	12 Months Ended
	Mar. 31, 2023
Schedule of Investments [Abstract]
Summary of Changes in Other Financial Assets	The following tables outline changes in other financial assets. Additional details on how the fair value of significant investments are calculated are included in Note 24. Foreign Balance at currency Balance at March 31, Fair value translation March 31, Entity Instrument 2022 Additions changes adjustments Other 2023 Acreage 1 Fixed Shares option and Floating Shares agreement $ - $ - $ 55,382 $ - $ - $ 55,382 TerrAscend Exchangeable Shares Exchangeable shares 229,000 51,000 ( 186,489 ) ( 511 ) - 93,000 TerrAscend Canada - October 2019 Term loan / debenture 10,280 - ( 146 ) - ( 10,134 ) - TerrAscend Canada - March 2020 Term loan / debenture 49,890 - ( 4,804 ) - ( 45,086 ) - Arise Bioscience Term loan / debenture 13,343 - ( 1,767 ) 1,268 ( 12,844 ) - TerrAscend - October 2019 Warrants 3,730 - ( 3,372 ) - ( 358 ) - TerrAscend - March 2020 Warrants 60,740 - ( 46,376 ) - ( 14,364 ) - TerrAscend - December 2020 Warrants 3,460 - ( 2,246 ) - ( 1,214 ) - TerrAscend - December 2022 Warrants - 33,000 ( 7,000 ) - - 26,000 TerrAscend Option 6,300 - ( 4,700 ) - - 1,600 Wana Option 372,343 - ( 154,936 ) 21,671 - 239,078 Jetty Options - 90,120 ( 19,915 ) 4,809 - 75,014 Acreage Hempco 1 Debenture 28,824 - 2,361 2,295 ( 4,218 ) 29,262 Acreage Debt Option Premium Option - 38,048 ( 3,041 ) 472 - 35,479 Acreage Tax Receivable Agreement Other - 41,491 ( 38,035 ) ( 347 ) - 3,109 Other - at fair value through net income (loss) Various 10,396 - ( 9,031 ) 505 - 1,870 Other - classified as held for investment Loan receivable 12,022 - - - ( 3,524 ) 8,498 $ 800,328 $ 253,659 $ ( 424,115 ) $ 30,162 $ ( 91,742 ) $ 568,292 1 Refer to Note 31 for information regarding the Acreage Arrangement and Acreage Hempco. For information regarding the Reorganization, see Note 5. Following the implementation of the Reorganization, Canopy USA, as of October 24, 2022, holds and ownership interest in certain U.S. cannabis investments previously held by the Company, including, among others, interests in the Floating Shares of Acreage, Wana, Jetty and TerrAscend. Foreign Exercise of Balance at currency options / Balance at March 31, Fair value translation Interest disposal March 31, Entity Instrument 2021 Additions changes adjustments income of shares / 2022 TerrAscend Exchangeable Shares Exchangeable shares $ 385,000 $ - $ ( 156,000 ) $ - $ - $ - $ 229,000 TerrAscend Canada - October 2019 Term loan / debenture 10,240 - 835 - ( 795 ) - 10,280 TerrAscend Canada - March 2020 Term loan / debenture 56,330 - ( 1,528 ) - ( 4,912 ) - 49,890 Arise Bioscience Term loan / debenture 13,077 - 308 ( 42 ) - - 13,343 TerrAscend - October 2019 Warrants 17,250 - ( 13,520 ) - - - 3,730 TerrAscend - March 2020 Warrants 152,910 - ( 92,170 ) - - - 60,740 TerrAscend - December 2020 Warrants 13,240 - ( 9,780 ) - - - 3,460 TerrAscend Option 10,600 - ( 4,300 ) - - - 6,300 Wana Option - 442,227 ( 74,639 ) 4,755 - 372,343 Acreage Hempco 1 Debenture 27,448 - 5,337 ( 94 ) ( 3,867 ) - 28,824 Other - at fair value through net income (loss) Various 14,887 6,457 ( 10,652 ) ( 204 ) - ( 92 ) 10,396 Other - classified as held for investment Loan receivable 7,185 5,000 - - - ( 163 ) 12,022 $ 708,167 $ 453,684 $ ( 356,109 ) $ 4,415 $ ( 9,574 ) $ ( 255 ) $ 800,328 1 Refer to Note 31 for information regarding the Acreage Arrangement and Acreage Hempco.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Summary of Expected Useful Life of Property, Plant and Equipment	Depreciation is calculated on a straight-line basis over the expected useful lives of the assets, which are as follows: Years Buildings and greenhouses 20 - 50 Production and warehouse equipment 5 - 30 Leasehold improvements 3 - 20 Office and lab equipment 3 - 10 Computer equipment 3 - 10 The components of property, plant and equipment are as follows: March 31, March 31, 2023 2022 Buildings and greenhouses $ 413,832 $ 766,931 Production and warehouse equipment 101,326 159,314 Leasehold improvements 15,529 69,304 Office and lab equipment 13,857 29,879 Computer equipment 8,697 22,293 Land 16,781 18,917 Right-of-use-assets Buildings and greenhouses 37,533 89,228 Production and warehouse equipment 637 55 Assets in process 3,281 19,771 611,473 1,175,692 Less: Accumulated depreciation ( 112,007 ) ( 232,912 ) $ 499,466 $ 942,780

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Mar. 31, 2023
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Summary of Components of Intangible Assets	The components of intangible assets are as follows: March 31, 2023 March 31, 2022 Gross Net Gross Net Carrying Carrying Carrying Carrying Amount Amount Amount Amount Finite lived intangible assets Intellectual property $ 119,283 $ 70,588 $ 138,170 $ 97,638 Distribution channel 73,024 21,258 72,642 24,834 Operating licenses 24,400 19,012 24,400 22,052 Software and domain names 35,100 14,664 29,822 14,206 Brands 16,253 13,249 5,547 3,680 Amortizable intangibles in process 508 508 5,476 5,476 Total $ 268,568 $ 139,279 $ 276,057 $ 167,886 Indefinite lived intangible assets Acquired brands $ 49,440 $ 74,809 Operating licenses - 10,000 Total intangible assets $ 188,719 $ 252,695
Summary of Estimated Amortization Expense	Estimated amortization expense for each of the five succeeding fiscal years and thereafter is as follows: 2024 $ 28,654 2025 $ 27,276 2026 $ 22,846 2027 $ 20,642 2028 $ 19,518 Thereafter $ 20,343

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill are as follows: Balance, March 31, 2021 $ 1,889,354 Purchase accounting allocations 105,323 Disposal of consolidated entities ( 58,786 ) Impairment losses ( 40,748 ) Foreign currency translation adjustments ( 28,640 ) Balance, March 31, 2022 $ 1,866,503 Disposal of consolidated entities ( 227 ) Impairment losses ( 1,785,080 ) Foreign currency translation adjustments 4,367 Balance, March 31, 2023 $ 85,563

Other Accrued Expenses and Li_2

Other Accrued Expenses and Liabilities (Tables)	12 Months Ended
	Mar. 31, 2023
Accounts Payable and Accrued Liabilities, Current [Abstract]
Components of Other Accrued Expenses and Liabilities	The components of other accrued expenses and liabilities are as follows: March 31, March 31, 2023 2022 Employee compensation $ 30,816 $ 24,873 Inventory 323 10,096 Professional fees 6,343 7,640 Taxes and government fees 5,734 7,144 Other 32,775 25,525 $ 75,991 $ 75,278

Debt (Tables)

Debt (Tables)	12 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Summary of Components of Debt	The components of debt are as follows: March 31, March 31, Maturity Date 2023 2022 Unsecured senior notes at 4.25 % interest with July 15, 2023 Principal amount $ 337,380 $ 600,000 Accrued interest 3,148 5,958 Non-credit risk fair value adjustment 26,214 7,140 Credit risk fair value adjustment ( 35,492 ) ( 49,140 ) 331,250 563,958 Supreme convertible debentures September 10, 2025 31,503 32,858 Accretion debentures September 10, 2025 8,780 7,720 Credit facility March 18, 2026 840,058 893,647 Equity-settled convertible debentures February 28, 2028 93,228 - Other revolving debt facility, loan, and financings 2,062 2,808 1,306,881 1,500,991 Less: current portion ( 556,890 ) ( 9,296 ) Long-term portion $ 749,991 $ 1,491,695
Summary of Required Principal Repayments Under Long-term Debt Obligations Excluding Equity-settled Convertible Debentures	As of March 31, 2023, the required principal repayments under long-term debt obligations, excluding equity-settled convertible debentures, for each of the five succeeding fiscal years and thereafter are as follows: 2024 $ 467,957 2025 6,865 2026 787,956 2027 - 2028 - Thereafter - $ 1,262,778

Other Liabilities (Tables)

Other Liabilities (Tables)	12 Months Ended
	Mar. 31, 2023
Other Liabilities Disclosure [Abstract]
Components of Other Liabilities	The components of other liabilities are as follows: As at March 31, 2023 As at March 31, 2022 Current Long-term Total Current Long-term Total Lease liabilities $ 28,684 $ 80,625 $ 109,309 $ 38,035 $ 101,125 $ 139,160 Acquisition consideration 25,945 30,323 56,268 4,020 77,834 81,854 Refund liability 7,123 - 7,123 3,729 - 3,729 Settlement liabilities and 32,975 13,938 46,913 18,562 11,090 29,652 $ 94,727 $ 124,886 $ 219,613 $ 64,346 $ 190,049 $ 254,395

Redeemable Noncontrolling Int_2

Redeemable Noncontrolling Interest (Tables)	12 Months Ended
	Mar. 31, 2023
Temporary Equity Disclosure [Abstract]
Summary of Net Change in Redeemable Noncontrolling Interests	The net change in the redeemable noncontrolling interests is as follows: Vert BioSteel Total (As Restated) As at March 31, 2020 $ 20,250 $ 49,500 $ 69,750 Net loss attributable to redeemable noncontrolling interest ( 11,906 ) ( 6,171 ) ( 18,077 ) Adjustments to redemption amount 3,156 80,471 83,627 As at March 31, 2021 11,500 123,800 135,300 Net loss attributable to redeemable noncontrolling interest ( 3,165 ) ( 16,152 ) ( 19,317 ) Adjustments to redemption amount ( 7,335 ) ( 71,039 ) ( 78,374 ) Redemption of redeemable noncontrolling interest - ( 5,109 ) ( 5,109 ) As at March 31, 2022 1,000 31,500 32,500 Net loss attributable to redeemable noncontrolling interest ( 53 ) ( 29,491 ) ( 29,544 ) Adjustments to redemption amount 53 9,667 9,720 Redemption of redeemable noncontrolling interest ( 1,000 ) ( 11,676 ) ( 12,676 ) As at March 31, 2023 $ - $ - $ -

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Summary of Issuances of Stock Other	During the year ended March 31, 2023, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of common shares Share Share Settlement of Convertible Debentures 14,142,066 $ 38,781 $ - HSCP Holders pursuant to Amended TRA 12,751,008 41,202 - Jetty Agreements 8,426,539 59,013 - Completion of acquisition milestones 222,421 1,379 ( 1,379 ) Other issuances 299,853 1,621 ( 572 ) Total 35,841,887 $ 141,996 $ ( 1,951 ) For the year ended March 31, 2023 , the Company also issued 8,692,128 common shares with a value of $ 26,506 relating to its redemption of the redeemable noncontrolling interest in BioSteel. The redemption increases the Company’s interest in BioSteel from 78.6 % to 90.4 %. During the year ended March 31, 2022, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of common shares Share Share Acquisition of Supreme Cannabis 9,013,400 $ 260,668 $ - Completion of acquisition milestones 1,295,285 29,276 ( 29,721 ) Other issuances 492,741 8,201 ( 736 ) Total 10,801,426 $ 298,145 $ ( 30,457 ) During the year ended March 31, 2021, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of common shares Share Share Completion of acquisition milestones 2,598,978 $ 46,903 $ ( 19,059 ) Other issuances 449,729 14,906 ( 14,894 ) Total 3,048,707 $ 61,809 $ ( 33,953 )
Summary of Warrants	Number of Average Warrant Balance outstanding at March 31, 2020 1 146,299,443 $ 52.44 $ 2,638,951 Exercise of warrants ( 18,882,927 ) 12.98 ( 70,513 ) Expiry of warrants ( 343,380 ) 41.49 - Balance outstanding at March 31, 2021 1 127,073,136 $ 58.33 $ 2,568,438 Supreme Cannabis warrants 1,265,742 25.61 13,350 Expiry of warrants ( 145,831 ) 32.61 - Balance outstanding at March 31, 2022 1 128,193,047 $ 58.04 $ 2,581,788 Expiry of warrants - - - Balance outstanding at March 31, 2023 1 128,193,047 $ 58.04 $ 2,581,788 1 This balance excludes the Tranche C Warrants, which represent a derivative liability and have nominal value, see Note 31 .

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Mar. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Outstanding Stock Options	The following is a summary of the outstanding stock options as at March 31, 2023: Options Outstanding Options Exercisable Weighted Average Weighted Average Remaining Remaining Outstanding at Contractual Life Exercisable at Contractual Life Range of Exercise Prices March 31, 2023 (years) March 31, 2023 (years) $ 0.06 - $ 24.62 5,333,314 4.63 1,300,821 2.61 $ 24.63 - $ 33.53 3,062,535 2.36 1,841,655 2.03 $ 33.54 - $ 36.80 1,448,009 1.69 1,448,009 1.69 $ 36.81 - $ 42.84 1,626,478 1.64 1,620,201 1.62 $ 42.85 - $ 67.64 2,280,552 1.85 2,280,552 1.85 13,750,888 3.00 8,491,238 1.93
Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model	the Company uses the Black-Scholes option pricing model to establish the fair value of options granted during the years ended March 31, 2023, 2022 and 2021 on their measurement date by applying the following assumptions: March 31, March 31, March 31, 2023 2022 2021 Risk-free interest rate 3.45 % 1.09 % 0.36 % Expected life of options (years) 3 - 5 3 - 5 1 - 7 Expected volatility 77 % 75 % 76 % Expected forfeiture rate 19 % 18 % 17 % Expected dividend yield nil nil nil Black-Scholes value of each option $ 2.92 $ 9.69 $ 15.24
Summary of Changes in RSUs	The following is a summary of changes in the Company’s RSUs and PSUs during the years ended March 31, 2021, 2022 and 2023: Number of RSUs Balance outstanding at March 31, 2020 883,009 RSUs granted 142,826 RSUs released ( 120,399 ) RSUs cancelled and forfeited ( 152,126 ) Balance outstanding at March 31, 2021 753,310 RSUs and PSUs granted 3,253,671 RSUs and PSUs released ( 300,319 ) RSUs and PSUs cancelled and forfeited ( 229,370 ) Balance outstanding at March 31, 2022 3,477,292 RSUs and PSUs granted 3,143,098 RSUs and PSUs released ( 1,464,934 ) RSUs and PSUs cancelled and forfeited ( 2,572,242 ) Balance outstanding at March 31, 2023 2,583,214
Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Changes in Employee Stock Options	The following is a summary of the changes in the Company’s Omnibus Plan employee options during the years ended March 31, 2021, 2022 and 2023: Options Weighted Balance outstanding at March 31, 2020 32,508,395 $ 34.89 Options granted 478,215 28.15 Options exercised ( 7,062,317 ) 22.22 Options forfeited ( 8,219,982 ) 41.27 Balance outstanding at March 31, 2021 17,704,311 $ 36.79 Options granted 2,537,290 17.40 Replacement options issued as a result of the acquisition of Supreme Cannabis 140,159 80.53 Options exercised ( 445,680 ) 12.27 Options forfeited ( 3,153,118 ) 42.03 Balance outstanding at March 31, 2022 16,782,962 $ 33.89 Options granted 4,658,797 4.93 Options exercised ( 79,586 ) 3.53 Options forfeited ( 7,611,285 ) 28.80 Balance outstanding at March 31, 2023 13,750,888 $ 27.12

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Accumulated Other Comprehensive Income	Accumulated other comprehensive income includes the following components: Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2020 $ 126,723 $ 94,176 $ 220,899 Other comprehensive income ( 154,969 ) ( 100,170 ) ( 255,139 ) As at March 31, 2021 ( 28,246 ) ( 5,994 ) ( 34,240 ) Disposal of consolidated entities 16,130 - 16,130 Other comprehensive income (loss) ( 45,352 ) 21,180 ( 24,172 ) As at March 31, 2022 ( 57,468 ) 15,186 ( 42,282 ) Settlement of unsecured senior notes, net of deferred income tax - ( 29,507 ) ( 29,507 ) Other comprehensive income 27,207 30,722 57,929 As at March 31, 2023 $ ( 30,261 ) $ 16,401 $ ( 13,860 )

Noncontrolling Interests (Table

Noncontrolling Interests (Tables)	12 Months Ended
	Mar. 31, 2023
Noncontrolling Interest [Abstract]
Summary of Net Change in Noncontrolling Interests	The net change in the noncontrolling interests is as follows: RIV 1 Vert BioSteel Other Total (As Restated) As at March 31, 2020 $ 211,086 $ 7,132 $ 489 $ 3,051 $ 221,758 Comprehensive income (loss) 94,532 ( 14,261 ) ( 6,171 ) - 74,100 Net loss attributable to redeemable - 11,906 6,171 - 18,077 Share-based compensation 2,659 - 1,169 - 3,828 Ownership changes ( 308,527 ) ( 4,777 ) - - ( 313,304 ) Warrants 250 - - - 250 As at March 31, 2021 - - 1,658 3,051 4,709 Comprehensive loss - ( 3,165 ) ( 16,152 ) ( 1,207 ) ( 20,524 ) Net loss attributable to redeemable - 3,165 16,152 - 19,317 Share-based compensation - - 839 - 839 As at March 31, 2022 - - 2,497 1,844 4,341 Comprehensive loss - ( 53 ) ( 29,491 ) ( 1,844 ) ( 31,388 ) Net loss attributable to - 53 29,491 - 29,544 Share-based compensation - - 570 - 570 Ownership changes - - - 140 140 Redemption of redeemable - - ( 1,620 ) - ( 1,620 ) As at March 31, 2023 $ - $ - $ 1,447 $ 140 $ 1,587 1 Refer to Note 30(c) for information regarding the completion of the plan of arrangement with RIV Capital.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Mar. 31, 2023
Statement [Line Items]
Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis	The following table represents our financial assets and liabilities measured at estimated fair value on a recurring basis: Fair value measurement using Quoted Significant prices in other Significant active observable unobservable markets inputs inputs (Level 1) (Level 2) (Level 3) Total March 31, 2023 Assets: Short-term investments $ 105,595 $ - $ - $ 105,595 Restricted short-term investments 11,765 - - 11,765 Other financial assets 269 - 559,525 559,794 Liabilities: Unsecured senior notes - 331,250 - 331,250 Other liabilities - - 29,952 29,952 March 31, 2022 Assets: Short-term investments $ 595,651 $ - $ - $ 595,651 Restricted short-term investments 12,216 - - 12,216 Other financial assets 490 - 787,816 788,306 Liabilities: Unsecured senior notes - 563,958 - 563,958 Liability arising from Acreage Arrangement - - 47,000 47,000 Warrant derivative liability - - 26,920 26,920 Other liabilities - - 70,066 70,066
Level 2
Statement [Line Items]
Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 and Level 3 Financial Instruments	The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 2 financial instruments: Financial asset / financial liability Valuation techniques Key inputs Unsecured senior notes Senior note pricing model Quoted prices in over-the-counter broker market
Level 3
Statement [Line Items]
Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 and Level 3 Financial Instruments	The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 3 financial instruments: Financial asset / financial liability Valuation techniques Significant unobservable inputs Relationship of unobservable inputs to fair value Acreage financial instrument Probability weighted expected return Probability of each scenario Change in probability of occurrence in each scenario will result in a change in fair value model Number of common shares to be issued Increase or decrease in value and number of common shares will result in a decrease or increase in fair value Intrinsic value of Acreage Increase or decrease in intrinsic value will result in an increase or decrease in fair value Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Estimated premium on US legalization Increase or decrease in estimated premium on US legalization will result in an increase or decrease in fair value Control premium Increase or decrease in estimated control premium will result in an increase or decrease in fair value Market access premium Increase or decrease in estimated market access premium will result in an increase or decrease in fair value TerrAscend Exchangeable Shares, TerrAscend Option Put option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Hempco Debenture Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value TerrAscend warrants - December 2022 Black-Sholes option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Wana financial instrument - Call Discounted cash flow Expected future Wana cash flows Increase or decrease in expected future Wana cash flows will result in an increase or decrease in fair value Options Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Wana financial instrument - Deferred Payments Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Volatility of Wana equity Increase or decrease in volatility will result in an increase or decrease in fair value Jetty financial instrument - Discounted cash flow Expected future Jetty cash flows Increase or decrease in expected future Jetty cash flows will result in an increase or decrease in fair value Call Options Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Jetty financial instrument - Deferred Payments Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Volatility of Jetty equity and revenue Increase or decrease in volatility will result in an increase or decrease in fair value Warrant derivative liability Monte Carlo simulation model Volatility of Canopy Growth share price Increase or decrease in volatility will result in an increase or decrease in fair value BioSteel redeemable noncontrolling Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value interest Expected future BioSteel cash flows Increase or decrease in expected future BioSteel cash flows will result in an increase or decrease in fair value Acreage Debt Option Premium Monte Carlo simulation model Volatility of Acreage share price Increase or decrease in volatility will result in a decrease or increase in fair value Acreage Tax Receivable Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Agreement Probability-weighted expected return Probability of each scenario Change in probability of occurrence in each scenario will result in a change in fair value model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value 25 . REVENUE Revenue is disaggregated as follows: Years ended March 31, March 31, March 31, 2023 2022 2021 (As Restated) Canada cannabis Canadian adult-use cannabis Business-to-business 1 $ 95,026 $ 143,732 $ 163,585 Business-to-consumer 36,243 61,570 66,016 131,269 205,302 229,601 Canadian medical cannabis 2 55,798 52,608 55,448 $ 187,067 $ 257,910 $ 285,049 Rest-of-world cannabis C 3 - 36,113 62,335 Other rest-of-world cannabis 38,949 43,193 31,296 $ 38,949 $ 79,306 $ 93,631 Storz & Bickel $ 64,845 $ 85,410 $ 80,998 BioSteel $ 69,649 $ 34,622 $ 28,530 This Works $ 26,029 $ 32,296 $ 33,314 Other 16,365 20,777 25,127 Net revenue $ 402,904 $ 510,321 $ 546,649 1 Canadian adult-use business-to-business net revenue reflects excise taxes of $ 43,071 (year ended March 31, 2022 - $ 56,666 ; and year ended March 31, 2021 - $ 54,928 ). 2 Canadian medical cannabis net revenue reflects excise taxes of $ 4,926 (year ended March 31, 2022 - $ 5,227 ; and year ended March 31, 2021 - $ 5,621 ). The Company recognizes variable consideration related to estimated future product returns and price adjustments as a reduction of the transaction price at the time revenue for the corresponding product sale is recognized. Net revenue reflects actual returns and variable consideration related to estimated returns and price adjustments in the amount of $ 26,233 for the year ended March 31, 2023 (year ended March 31, 2022 – $ 21,464 ; and year ended March 31, 2021 – $ 23,935 ). As of March 31, 2023, the liability for estimated returns and price adjustments was $ 7,123 (March 31, 2022 – $ 3,729 ). 26 . PHARMHOUSE PharmHouse Inc. (“PharmHouse”), a joint venture formed on May 7, 2018 , between RIV Capital and 2615975 Ontario Limited (the “PharmHouse JV Partner”), is a company licensed to cultivate cannabis under the Cannabis Act. Upon completion of the RIV Arrangement on February 23, 2021, the Company no longer controlled RIV Capital and RIV Capital’s consolidated assets and liabilities were derecognized from the Company’s consolidated financial statements. The assets and liabilities that were derecognized include those described below in relation to RIV Capital’s investments in, and obligations with respect to, PharmHouse. Refer to Note 30(c) for further details on the RIV Arrangement. CCAA Proceedings During the year ended March 31, 2021, PharmHouse determined that the previously anticipated timeline to generate cash flows from its offtake agreements with the Company and TerrAscend Canada would not be met, and the ultimate timing and receipt of cash inflows pursuant to these agreements became uncertain. As a result of this, as well as broader sector-wide challenges impacting the Canadian cannabis industry, PharmHouse did not have sufficient liquidity and capital resources to meet its business objectives and became unable to meet its financial obligations as they became due. Accordingly, on September 15, 2020, PharmHouse obtained an order (the “Initial Order”) from the Ontario Superior Court of Justice (the “Court”) granting PharmHouse creditor protection under the Companies’ Creditors Arrangement Act (“CCAA”) (the “CCAA Proceedings”). The Court appointed an independent professional services firm to act as the Monitor of PharmHouse in the CCAA Proceedings while PharmHouse explored a restructuring of its business and operations (the “PharmHouse Restructuring”). On October 29, 2020, PharmHouse received approval from the Court to commence its Sale and Investor Solicitation Process (“SISP”). The SISP process concluded in March 2021, subsequent to the completion of the RIV Arrangement, when PharmHouse entered into a binding asset purchase agreement to sell various operating assets including its facility and certain equipment at the facility. The asset purchase agreement was approved by the Court in March 2021. PharmHouse Recoverability Assessment As a result of the CCAA Proceedings and the Restructuring, RIV Capital determined that there were indicators of impairment present for its investments in various PharmHouse-related financial assets. RIV Capital performed impairment testing for its various PharmHouse-related financial assets by estimating the fair value of PharmHouse en bloc. Due to the lack of profitable operating history for PharmHouse as a cannabis entity, RIV Capital estimated the fair value of PharmHouse en bloc using an asset-based approach to value PharmHouse’s assets under an orderly liquidation scenario where cannabis operations are not continued at PharmHouse’s facility and the greenhouse is sold for purposes other than cannabis cultivation. This amount was then compared to the carrying values of the various PharmHouse-related financial instruments held by RIV Capital, in sequence based on the priority of claims on PharmHouse’s assets (the “PharmHouse Recoverability Assessment”). The significant components of this fair value analysis included PharmHouse’s greenhouse facility and retrofits, separable machinery and equipment, saleable inventory, and cash. Significant unobservable inputs used by RIV Capital to determine the fair value of PharmHouse’s assets include the selling price per square foot for PharmHouse’s greenhouse facility; the recoverability percentage on the liquidation of PharmHouse’s property, plant and equipment; the selling price per gram of PharmHouse’s existing cannabis inventory; and adjustments for the risk of fair value changes and liquidity. Based on the foregoing, the Company estimated the recoverable value of PharmHouse’s assets in an orderly liquidation scenario to be approximately $ 57,500 . The impact of the PharmHouse Recoverability Assessment on RIV Capital’s various PharmHouse-related financial instruments is described below. PharmHouse Financial Guarantee Prior to February 23, 2021, PharmHouse had entered into a syndicated credit agreement (as amended, the “PharmHouse Credit Agreement”) with a number of Canadian banks (the “PharmHouse Lenders”) to provide PharmHouse with a committed, non-revolving credit facility (the “PharmHouse Credit Facility”) with a maximum principal amount of $ 90,000 , which was fully drawn. The obligations of PharmHouse under the PharmHouse Credit Facility were secured by guarantees of RIV Capital and RCC, and a pledge by RCC of all of the shares of PharmHouse held by it (the “PharmHouse Financial Guarantee”). Accordingly, if PharmHouse was unable to generate sufficient cash flows to service its obligations pursuant to the PharmHouse Credit Facility, RIV Capital and RCC were required to compensate the PharmHouse Lenders for their loss incurred on the PharmHouse Credit Facility. The PharmHouse Credit Agreement also contains other covenants applicable to RIV Capital and RCC. Based on the PharmHouse Recoverability Assessment described above, the Company determined that the fair value of PharmHouse’s assets under an orderly liquidation scenario where the facility is not used for cannabis operations may be less than the principal amount owed by PharmHouse pursuant to the PharmHouse Credit Facility. Accordingly, the Company estimated that, prior to February 23, 2021, it had a financial liability related to the PharmHouse Financial Guarantee, reflecting the estimated shortfall between the recoverable amount of PharmHouse en bloc and the Company’s exposure to the PharmHouse Credit Facility. As at February 23, 2021, the Company estimated the current expected credit loss related to its contingent obligation under the PharmHouse Financial Guarantee to be $ 32,500 , and recognized a financial liability for this amount in the consolidated balance sheet. Upon completion of the RIV Arrangement on February 23, 2021, this liability was derecognized from the Company’s consolidated balance sheet. During the year ended March 31, 2021, the Company recognized an associated current expected credit loss of $ 32,500 in net income (loss). Other financial assets, including loans receivable Prior to February 23, 2021, RCC had advanced to PharmHouse: (i) $ 40,000 of secured debt financing pursuant to a shareholder loan agreement; (ii) $ 2,450 pursuant to a secured demand promissory note; and (iii) $ 1,206 between August 4, 2020, and September 8, 2020 pursuant to an unsecured promissory note. The Company recognized these instruments as financial assets, initially recorded them at fair value and subsequently measured them at amortized cost. Additionally, pursuant to the Initial Order, RCC entered into an agreement to provide a super-priority, debtor-in-possession interim, non-revolving credit facility to PharmHouse (the “DIP Financing”), with a maximum principal amount available to be drawn by PharmHouse of $ 9,700 , and a maturity date of February 28, 2021. As at February 23, 2021, RCC had advanced $ 9,300 pursuant to the DIP Financing. As a result of the PharmHouse Recoverability Assessment described above, the Company recognized a current expected credit loss of $ 32,500 in the year ended March 31, 2021, related to its contingent obligation under the PharmHouse Financial Guarantee that existed prior to the completion of the RIV Arrangement on February 23, 2021 and the resulting derecognition of RIV Capital’s consolidated assets and liabilities. The Company also concluded that the following amounts, as described above, may not be recoverable: (i) $ 9,300 advanced pursuant to DIP Financing; (ii) $ 40,000 advanced under the shareholder loan agreement; (iii) $ 2,450 advanced under the secured demand promissory note; (iv) $ 1,206 advanced under the unsecured demand promissory note; and (v) $ 8,989 in interest receivable in relation to these financial instruments. Additionally, it was determined that certain advances in the amount of $ 15,000 provided to PharmHouse by the Company may not be recoverable, and costs of $ 35 were incurred associated with the PharmHouse Restructuring in the year ended March 31, 2021. Accordingly, the Company recorded expected credit losses on financial assets and related charges of $ 109,480 for the year ended March 31, 2021. PharmHouse equity method investment As at February 23, 2021, RCC owned 10,998,660 common shares of PharmHouse, representing a 49 % equity interest on a non-diluted basis. RCC had not yet received any distributions on account of its common share investment in PharmHouse. As a result of the PharmHouse Recoverability Assessment described above, the Company determined that there was an other-than-temporary-impairment and recognized an impairment charge for the full amount of its equity method investment of $ 32,369 . 27 . OTHER INCOME (EXPENSE), NET Other income (expense), net is disaggregated as follows: Years ended March 31, March 31, March 31, 2023 2022 2021 Fair value changes on other financial assets $ ( 424,115 ) $ ( 356,109 ) $ 435,107 Fair value changes on liability arising from Acreage 47,000 553,000 ( 399,849 ) Fair value changes on unsecured senior notes ( 43,104 ) 76,776 ( 162,540 ) Fair value changes on warrant derivative liability 26,920 588,655 ( 293,084 ) Fair value changes on acquisition related contingent 38,890 4,417 39,608 Gain and charges related to settlement of debt 582 - - Interest income 24,282 6,601 21,367 Interest expense ( 126,160 ) ( 103,944 ) ( 8,459 ) Foreign currency gain (loss) ( 8,534 ) 5,415 ( 18,013 ) Gain (loss) on disposal/acquisition of consolidated entity 2,414 ( 6,762 ) 634 Other income (expense), net ( 4,200 ) ( 14,708 ) ( 2,647 ) $ ( 466,025 ) $ 753,341 $ ( 387,876 ) 28 . INCOME TAXES Net loss before income taxes was generated as follows: Years ended March 31, March 31, March 31, 2023 2022 2021 (As Restated) Domestic - Canada $ ( 2,513,026 ) $ ( 173,970 ) $ ( 1,611,210 ) Foreign - outside of Canada ( 801,294 ) ( 165,545 ) ( 72,751 ) $ ( 3,314,320 ) $ ( 339,515 ) $ ( 1,683,961 ) The income tax recovery (expense) consists of the following: Years ended March 31, March 31, March 31, 2023 2022 2021 Current Domestic - Canada $ 4,783 $ 895 $ ( 19,318 ) Foreign - outside of Canada ( 676 ) 1,476 ( 2,091 ) $ 4,107 $ 2,371 $ ( 21,409 ) Deferred Domestic - Canada $ ( 3,603 ) $ 6,353 $ 36,505 Foreign - outside of Canada 4,270 224 ( 1,955 ) 667 6,577 34,550 Income tax recovery $ 4,774 $ 8,948 $ 13,141 As more fully described in Note 3, income taxes that are required to be reflected in equity, instead of in the consolidated statements of operations, are included in the consolidated statements of shareholders’ equity, if applicable. Current and deferred income tax referred to above is recognized based on the Company’s best estimate of the tax rates expected to apply to the income, loss or temporary difference. The Company is subject to income tax in numerous jurisdictions with varying tax rates. During the current year ended, there were no material changes to the enacted statutory tax rates in the jurisdictions where the majority of the Company’s income for tax purposes was earned or where its material temporary differences or losses are expected to be realized or settled, however the impact of commercial decisions and market forces result in changes to the distribution of income for tax purposes amongst taxing jurisdictions that may result in a change of the effective tax rate applicable to such income, loss or temporary difference. A reconciliation of the amount of income taxes reflected above compared to the expected income taxes calculated at the combined Canadian federal and provincial enacted statutory tax rate of 26.5 % for each of the three years ended March 31, 2023, 2022 and 2021 is as follows: Years ended March 31, March 31, March 31, 2023 2022 2021 (As Restated) Net loss before income taxes $ ( 3,314,320 ) $ ( 339,515 ) $ ( 1,683,961 ) Expected tax rate 26.5 % 26.5 % 26.5 % Expected income tax recovery 878,295 89,971 446,250 Non-deductible and non-taxable items ( 29,385 ) 17,557 81,883 Fair value changes on Acreage Arrangement 12,386 146,545 ( 105,960 ) Fair value changes on warrant derivative liability 6,294 155,964 ( 77,663 ) Settlement of unsecured senior notes ( 14,862 ) - - Share-based compensation ( 2,126 ) ( 9,908 ) ( 21,121 ) Goodwill impairment ( 473,702 ) - - Change in valuation allowance ( 313,583 ) ( 363,954 ) ( 358,964 ) Effect of tax rates outside of Canada ( 4,596 ) 8,459 10,870 Non-taxable portion of capital gains and losses ( 48,573 ) ( 38,440 ) 38,705 Other ( 5,374 ) 2,754 ( 859 ) Income tax recovery $ 4,774 $ 8,948 $ 13,141 Current income taxes payable in the amount of $ 1,592 (March 31, 2022 – $ 1,927 ) is included in accounts payable and current income taxes receivable in the amount of $ 5,446 (March 31, 2022 – $ 6,018 ) is included in other accounts receivable. The Company continues to believe the amount of unrealized tax benefits appropriately reflects the uncertainty of items that are or may in the future be under discussion, audit, dispute or appeal with a tax authority or which otherwise result in uncertainty in the determination of income for tax purposes. If appropriate, an unrealized tax benefit will be realized in the year in which the Company determines that realization is not in doubt. Where the final determined outcome is different from the Company’s estimate, such difference will impact the Company’s income taxes in the year during which such determination is made. Significant components of deferred income tax assets (liabilities) consist of the following: Years ended March 31, March 31, 2023 2022 (As Restated) Deferred income tax assets Property, plant and equipment $ 104,043 $ 78,023 Intangible assets 11,202 671 Inventory reserves and write-downs 18,749 40,324 Other reserves and accruals 10,554 5,939 Losses carried forward 1,142,607 919,955 Equity method investments and other financial assets 72,881 10,512 Deferred financing costs 4,597 2,740 Other 10,415 5,635 Gross deferred income tax assets 1,375,048 1,063,799 Valuation allowances ( 1,355,385 ) ( 1,041,802 ) Total deferred income tax assets, net $ 19,663 $ 21,997 Deferred income tax liabilities Property, plant and equipment $ ( 3,475 ) $ ( 4,182 ) Intangible assets ( 15,200 ) ( 29,832 ) Deferred financing costs ( 1,345 ) ( 3,353 ) Other - ( 621 ) Total deferred income tax liabilities ( 20,020 ) ( 37,988 ) Net deferred income tax liabilities $ ( 357 ) $ ( 15,991 ) In evaluating whether it is more likely than not that all or a portion of a deferred income tax asset will be realized consideration is given to the estimated reversal of deferred income tax liabilities and future taxable income. The Company has recognized valuation allowances for operating losses carried forward, capital losses carried forward and other deferred income tax assets when it is believed that it is more likely than not that these items will not be realized. As at March 31, 2023, the Company had temporary differences associated with investments in foreign subsidiaries for which no deferred income tax liabilities have been recognized, as the Company is able to control the timing of the reversal of these temporary differences and material undistributed earnings are considered permanently invested. Determination of the amount of the unrecognized deferred income tax liability is not practicable due to the inherent complexity of the multi-jurisdictional operations of the Company. As at March 31, 2023, the Company has the following losses carried forward available to reduce future years’ taxable income, which losses expire as follows: Expiring within 5 years $ - Expiring between 5 and 10 years 3,321 Expiring between 10 and 15 years 367,213 Expiring between 15 and 20 years 2,829,026 Indefinite 510,831 $ 3,710,391 Total in Canada $ 3,195,923 Total in United States 451,258 Total in Europe 58,731 Total in other jurisdictions 4,479 $ 3,710,391 Total operating losses $ 3,710,391 Total capital losses (carried forward indefinitely) 1,177,195 $ 4,887,586 29 . ACQUISITIONS (a) Year ended March 31, 2023 The following table summarizes the consolidated balance sheet impact at acquisition of the Company’s business combinations that occurred in the year ended March 31, 2023. Verona Facility Property, plant and equipment $ 28,771 Debt and other liabilities ( 2,373 ) Net assets acquired $ 26,398 Consideration paid in cash $ 24,223 Other consideration 2,175 Total consideration $ 26,398 Consideration paid in cash $ 24,223 Less: Cash and cash equivalents acquired - Net cash outflow $ 24,223 The table above summarizes the fair value of the consideration given and the fair values assigned to the assets acquired and liabilities assumed for the acquisition completed in the year ended March 31, 2023. Acquisition of Verona Facility On November 8, 2022, the Company, through its affiliate BioSteel, completed the acquisition (the “Verona Acquisition”) of a manufacturing facility located in Verona, Virginia (the “Verona Facility”) from Flow Beverage Corp. (“Flow”), one of BioSteel’s contract manufacturers. Consideration was $ 26,398 (US$ 19,477 ), consisting of cash paid of $ 15,685 (US$ 11,573 ) and $ 8,538 (US$ 6,299 ) related to the repayment of debt and the retirement of certain lease obligations, and $ 2,175 (US$ 1,605 ) in remediation and indemnity holdbacks to be retained by the Company and paid within one year of the closing of the Verona Acquisition. BioSteel and Flow have also entered into a co-manufacturing agreement whereby, in addition to the production of BioSteel-branded sports hydration beverages, BioSteel will produce Flow’s portfolio of branded water at the Verona Facility. Due to the timing of the Verona Acquisition, the purchase price allocation for the Verona Acquisition is provisional. The fair value assigned to the consideration paid and net assets acquired is based on management’s best estimate using the information currently available and may be revised by the Company as additional information is received. (b) Acquisitions completed in the year ended March 31, 2022 The following table summarized the consolidated balance sheet impact at acquisition of the Company's business combinations that occurred in the year ended March 31, 2022. Ace Supreme Valley Cannabis (i) (ii) Other Total Cash and cash equivalents $ 1,544 $ 41,306 $ 1,227 $ 44,077 Inventory 878 33,426 362 34,666 Other current assets 2,249 14,791 335 17,375 Property, plant and equipment 105 187,407 1,510 189,022 Intangible assets Brands 14,000 22,800 - 36,800 Distribution channel - 3,500 - 3,500 Operating licenses - 24,400 2,000 26,400 Goodwill 39,152 58,842 7,329 105,323 Accounts payable and other accrued expenses and liabilities ( 1,724 ) ( 12,935 ) ( 30 ) ( 14,689 ) Debt and other liabilities - ( 88,324 ) ( 1,037 ) ( 89,361 ) Deferred income tax liabilities ( 1,899 ) ( 5,545 ) ( 540 ) ( 7,984 ) Net assets acquired $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Consideration paid in shares - 260,668 4,052 264,720 Replacement options - 629 - 629 Replacement warrants - 13,350 - 13,350 Other consideration 2,469 4,937 - 7,406 Total consideration $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Less: Cash and cash equivalents acquired ( 1,544 ) ( 41,306 ) ( 1,227 ) ( 44,077 ) Net cash outflow (inflow) $ 50,292 $ ( 41,222 ) $ 5,877 $ 14,947 The table above summarizes the fair value of the consideration given and the fair values assigned to the assets acquired and liabilities assumed for each acquisition. Goodwill arose in these acquisitions because the cost of acquisition included a control premium. In addition, the consideration paid for the combination reflected the benefit of expected revenue growth and future market development. These benefits were not recognized separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets. Except for some of the goodwill arising in respect of the Ace Valley (as defined below) and Supreme Cannabis acquisition, none of the goodwill arising on these acquisitions is expected to be deductible in the computation of income for tax purposes. (i) Ace Valley On April 1, 2021 , the Company entered into a share purchase agreement (the “AV Share Purchase Agreement”) with Tweed Inc., AV Cannabis Inc. (“Ace Valley”), and the shareholders of Ace Valley (the “AV Vendors”) pursuant to which the Company indirectly acquired 100 % of the issued and outstanding shares of Ace Valley for cash consideration of $ 51,836 . Ace Valley is an Ontario-based cannabis brand with a focus on premium, ready-to-enjoy products including vapes, pre-roll joints and gummies. Pursuant to the terms of the AV Share Purchase Agreement, the Company may be required to make certain earn-out payments to the AV Vendors, which may result in an additional cash payment or the issuance of common shares, subject to the fulfillment of certain conditions by April 1, 2023. This represents liability-classified contingent consideration. Management has estimated the fair value of this consideration to be $ 2,469 by assessing the probability and timing of the fulfillment of the specified conditions and discounting the expected cash outflows to present value. In the year ended March 31, 2022, the Company finalized the purchase price allocation to the individual assets acquired and liabilities assumed using the acquisition method (ii) Supreme Cannabis On June 22, 2021 , the Company and Supreme Cannabis completed an arrangement (the “Supreme Arrangement”) pursuant to which the Company acquired 100 % of the issued and outstanding common shares of Supreme Cannabis (the “Supreme Shares”). Supreme Cannabis is a producer of adult-use, wholesale and medical cannabis products, with a diversified portfolio of distinct cannabis companies, products and brands. Pursuant to the Supreme Arrangement, the Company issued 9,013,400 common shares with a fair value on closing of $ 260,668 and made a cash payment of $ 84 to former Supreme Cannabis shareholders in consideration for their Supreme Shares. The Company also assumed the obligation to issue 1,265,742 common shares upon the exercise of outstanding warrants of Supreme Cannabis and issued 140,159 replacement options. The fair value of the obligation upon the exercise of the outstanding warrants of Supreme Cannabis was estimated to be $ 13,350 using a Black-Scholes model. The replacement options’ fair value totaled $ 1,452 , calculated using a Black-Scholes model, of which $ 629 was included in consideration paid as it related to pre-combination services and the residual $ 823 fair value was recognized immediately in share-based compensation expense after the completion of the acquisition. On June 22, 2021, Supreme Cannabis had convertible debentures outstanding with a principal amount of $ 27,045 which were convertible into 94,895,649 Supreme Shares. As a result of the acquisition the conversion feature was adjusted in accordance with an exchange ratio of 0.011659 . The fair value of these convertible debentures on June 22, 2021 was estimated to be $ 36,593 , of which $ 4,937 was allocated to the conversion feature and $ 31,656 to the debt component. In the year ended March 31, 2023, the Company finalized the purchase price allocation to the individual assets acquired and liabilities assumed using the acquisition method. (c) Acquisitions completed in the year ended March 31, 2021 There were no acquisitions during the year ended March 31, 2021 . (d) More Life On November 7, 2019 the Company entered into agreements with certain entities that are controlled by Aubrey “Drake” Graham to launch More Life. Under the agreements Canopy Growth sold 100 % of the shares of 1955625 Ontario Inc., a wholly owned subsidiary of Canopy Growth that holds the Health Canada license for a facility located in Scarborough, Ontario to More Life (“More Life Facility”) in exchange for a 40 % interest in More Life. Certain entities that are controlled by Drake hold a 60 % ownership interest in More Life. Following this transaction, the Company no longer controlled 1955625 Ontario Inc. and the Company derecognized the assets and liabilities of 1955625 Ontario Inc. from its consolidated financial statements at their carrying amounts. As consideration for the 60 % interest in More Life, certain entities that are controlled by Drake granted More Life the right to exclusively exploit certain intellectual property and brands in association with the growth, manufacture, production, marketing and sale of cannabis and cannabis-related products, accessories, merchandise and paraphernalia in Canada and internationally. More Life sublicensed such rights in Canada to Canopy Growth in exchange for royalty payments. The Company and More Life agreed to terminate the sublicense agreement between the two parties as of March 1, 2021, and as a result the Company derecognized the remaining minimum royalty obligations owing to More Life in the amount of $ 33,681 . The difference between the termination payment made by the Company to More Life and the remaining minimum royalty obligations was recorded in asset impairment and restructuring costs; refer to Note 6. Through its ownership and other rights, the Company was determined to have significant influence over More Life and accounted for its interest in More Life using the equity method of accounting. As at March 31, 2021, as a result of the termination of the sublicense agreement between the Company and More Life, the Company determined that the fair value of its’ interest in More Life was $nil, and accordingly, the Company recognized an impairment on its equity method investment in the amount of $ 10,300 in the year ended March 31, 2021 as part of the restructuring of its global operations. See Note 6 for further information. 30 . DIVESTITURES (a) Retail Divestiture The Company entered into the following two agreements to divest its retail business in Canada, which includes the retail stores operating under the Tweed and Tokyo Smoke banners: • An agreement with OEG Retail Cannabis (“OEGRC”), a prior Canopy Growth licensee partner, pursuant to which OEGRC acquired ownership of 23 of the Company’s corporate-owned retail stores in Manitoba, Saskatchewan and Newfoundland and Labrador, as well as all Tokyo Smoke-related intellectual property (the “OEGRC Transaction”). In connection with the OEGRC Transaction, the Tokyo Smoke brand has been transferred to OEGRC and all acquired retail stores branded as Twe

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Summary of Disaggregation of Revenue	Revenue is disaggregated as follows: Years ended March 31, March 31, March 31, 2023 2022 2021 (As Restated) Canada cannabis Canadian adult-use cannabis Business-to-business 1 $ 95,026 $ 143,732 $ 163,585 Business-to-consumer 36,243 61,570 66,016 131,269 205,302 229,601 Canadian medical cannabis 2 55,798 52,608 55,448 $ 187,067 $ 257,910 $ 285,049 Rest-of-world cannabis C 3 - 36,113 62,335 Other rest-of-world cannabis 38,949 43,193 31,296 $ 38,949 $ 79,306 $ 93,631 Storz & Bickel $ 64,845 $ 85,410 $ 80,998 BioSteel $ 69,649 $ 34,622 $ 28,530 This Works $ 26,029 $ 32,296 $ 33,314 Other 16,365 20,777 25,127 Net revenue $ 402,904 $ 510,321 $ 546,649 1 Canadian adult-use business-to-business net revenue reflects excise taxes of $ 43,071 (year ended March 31, 2022 - $ 56,666 ; and year ended March 31, 2021 - $ 54,928 ). 2 Canadian medical cannabis net revenue reflects excise taxes of $ 4,926 (year ended March 31, 2022 - $ 5,227 ; and year ended March 31, 2021 - $ 5,621 ).

Other Income (Expense), Net (Ta

Other Income (Expense), Net (Tables)	12 Months Ended
	Mar. 31, 2023
Other Income and Expenses [Abstract]
Schedule of Other Income (Expense), Net	Other income (expense), net is disaggregated as follows: Years ended March 31, March 31, March 31, 2023 2022 2021 Fair value changes on other financial assets $ ( 424,115 ) $ ( 356,109 ) $ 435,107 Fair value changes on liability arising from Acreage 47,000 553,000 ( 399,849 ) Fair value changes on unsecured senior notes ( 43,104 ) 76,776 ( 162,540 ) Fair value changes on warrant derivative liability 26,920 588,655 ( 293,084 ) Fair value changes on acquisition related contingent 38,890 4,417 39,608 Gain and charges related to settlement of debt 582 - - Interest income 24,282 6,601 21,367 Interest expense ( 126,160 ) ( 103,944 ) ( 8,459 ) Foreign currency gain (loss) ( 8,534 ) 5,415 ( 18,013 ) Gain (loss) on disposal/acquisition of consolidated entity 2,414 ( 6,762 ) 634 Other income (expense), net ( 4,200 ) ( 14,708 ) ( 2,647 ) $ ( 466,025 ) $ 753,341 $ ( 387,876 )

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Summary of Net Loss Before Income Taxes	Net loss before income taxes was generated as follows: Years ended March 31, March 31, March 31, 2023 2022 2021 (As Restated) Domestic - Canada $ ( 2,513,026 ) $ ( 173,970 ) $ ( 1,611,210 ) Foreign - outside of Canada ( 801,294 ) ( 165,545 ) ( 72,751 ) $ ( 3,314,320 ) $ ( 339,515 ) $ ( 1,683,961 )
Summary of Income Tax Recovery (Expense)	The income tax recovery (expense) consists of the following: Years ended March 31, March 31, March 31, 2023 2022 2021 Current Domestic - Canada $ 4,783 $ 895 $ ( 19,318 ) Foreign - outside of Canada ( 676 ) 1,476 ( 2,091 ) $ 4,107 $ 2,371 $ ( 21,409 ) Deferred Domestic - Canada $ ( 3,603 ) $ 6,353 $ 36,505 Foreign - outside of Canada 4,270 224 ( 1,955 ) 667 6,577 34,550 Income tax recovery $ 4,774 $ 8,948 $ 13,141
Summary of Reconciliation of Amount of Income Taxes Compared to Expected Income Taxes Calculated at Combined Federal and Provincial Enacted Statutory Tax Rate	A reconciliation of the amount of income taxes reflected above compared to the expected income taxes calculated at the combined Canadian federal and provincial enacted statutory tax rate of 26.5 % for each of the three years ended March 31, 2023, 2022 and 2021 is as follows: Years ended March 31, March 31, March 31, 2023 2022 2021 (As Restated) Net loss before income taxes $ ( 3,314,320 ) $ ( 339,515 ) $ ( 1,683,961 ) Expected tax rate 26.5 % 26.5 % 26.5 % Expected income tax recovery 878,295 89,971 446,250 Non-deductible and non-taxable items ( 29,385 ) 17,557 81,883 Fair value changes on Acreage Arrangement 12,386 146,545 ( 105,960 ) Fair value changes on warrant derivative liability 6,294 155,964 ( 77,663 ) Settlement of unsecured senior notes ( 14,862 ) - - Share-based compensation ( 2,126 ) ( 9,908 ) ( 21,121 ) Goodwill impairment ( 473,702 ) - - Change in valuation allowance ( 313,583 ) ( 363,954 ) ( 358,964 ) Effect of tax rates outside of Canada ( 4,596 ) 8,459 10,870 Non-taxable portion of capital gains and losses ( 48,573 ) ( 38,440 ) 38,705 Other ( 5,374 ) 2,754 ( 859 ) Income tax recovery $ 4,774 $ 8,948 $ 13,141
Summary of Significant Compenents of Deferred Income Tax Assets (Liabilities)	Significant components of deferred income tax assets (liabilities) consist of the following: Years ended March 31, March 31, 2023 2022 (As Restated) Deferred income tax assets Property, plant and equipment $ 104,043 $ 78,023 Intangible assets 11,202 671 Inventory reserves and write-downs 18,749 40,324 Other reserves and accruals 10,554 5,939 Losses carried forward 1,142,607 919,955 Equity method investments and other financial assets 72,881 10,512 Deferred financing costs 4,597 2,740 Other 10,415 5,635 Gross deferred income tax assets 1,375,048 1,063,799 Valuation allowances ( 1,355,385 ) ( 1,041,802 ) Total deferred income tax assets, net $ 19,663 $ 21,997 Deferred income tax liabilities Property, plant and equipment $ ( 3,475 ) $ ( 4,182 ) Intangible assets ( 15,200 ) ( 29,832 ) Deferred financing costs ( 1,345 ) ( 3,353 ) Other - ( 621 ) Total deferred income tax liabilities ( 20,020 ) ( 37,988 ) Net deferred income tax liabilities $ ( 357 ) $ ( 15,991 )
Summary of Losses Carried Forward Available to Reduce Future Years' Taxable Income	As at March 31, 2023, the Company has the following losses carried forward available to reduce future years’ taxable income, which losses expire as follows: Expiring within 5 years $ - Expiring between 5 and 10 years 3,321 Expiring between 10 and 15 years 367,213 Expiring between 15 and 20 years 2,829,026 Indefinite 510,831 $ 3,710,391 Total in Canada $ 3,195,923 Total in United States 451,258 Total in Europe 58,731 Total in other jurisdictions 4,479 $ 3,710,391 Total operating losses $ 3,710,391 Total capital losses (carried forward indefinitely) 1,177,195 $ 4,887,586

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Mar. 31, 2023
Business Combinations [Abstract]
Summary of Consolidated Balance Sheet Impact at Acquisition of Company's Business Combinations	The following table summarizes the consolidated balance sheet impact at acquisition of the Company’s business combinations that occurred in the year ended March 31, 2023. Verona Facility Property, plant and equipment $ 28,771 Debt and other liabilities ( 2,373 ) Net assets acquired $ 26,398 Consideration paid in cash $ 24,223 Other consideration 2,175 Total consideration $ 26,398 Consideration paid in cash $ 24,223 Less: Cash and cash equivalents acquired - Net cash outflow $ 24,223 The following table summarized the consolidated balance sheet impact at acquisition of the Company's business combinations that occurred in the year ended March 31, 2022. Ace Supreme Valley Cannabis (i) (ii) Other Total Cash and cash equivalents $ 1,544 $ 41,306 $ 1,227 $ 44,077 Inventory 878 33,426 362 34,666 Other current assets 2,249 14,791 335 17,375 Property, plant and equipment 105 187,407 1,510 189,022 Intangible assets Brands 14,000 22,800 - 36,800 Distribution channel - 3,500 - 3,500 Operating licenses - 24,400 2,000 26,400 Goodwill 39,152 58,842 7,329 105,323 Accounts payable and other accrued expenses and liabilities ( 1,724 ) ( 12,935 ) ( 30 ) ( 14,689 ) Debt and other liabilities - ( 88,324 ) ( 1,037 ) ( 89,361 ) Deferred income tax liabilities ( 1,899 ) ( 5,545 ) ( 540 ) ( 7,984 ) Net assets acquired $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Consideration paid in shares - 260,668 4,052 264,720 Replacement options - 629 - 629 Replacement warrants - 13,350 - 13,350 Other consideration 2,469 4,937 - 7,406 Total consideration $ 54,305 $ 279,668 $ 11,156 $ 345,129 Consideration paid in cash $ 51,836 $ 84 $ 7,104 $ 59,024 Less: Cash and cash equivalents acquired ( 1,544 ) ( 41,306 ) ( 1,227 ) ( 44,077 ) Net cash outflow (inflow) $ 50,292 $ ( 41,222 ) $ 5,877 $ 14,947 There were no acquisitions during the year ended March 31, 2021 .

Divestitures (Tables)

Divestitures (Tables)	12 Months Ended
	Mar. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Schedule of Derecognized Assets and Liabilities	The derecognized assets and liabilities on February 23, 2021, were as follows: Acquired assets TerrAscend Exchangeable Shares $ 291,500 TerrAscend warrants 32,000 Preferred shares in Vert Mirabel 22,600 Settlement of Tweed NB obligations to RCC 15,000 TerrAscend loan 10,000 Common shares in Vert Mirabel 9,075 Total acquired assets $ 380,175 Consideration paid in shares ( 170,284 ) Consideration paid in cash ( 115,000 ) $ 94,891 Derecognition of RIV Capital net assets Cash and cash equivalents $ 37,801 Amounts receivable, net 4,327 Prepaid expenses and other assets 995 Equity method investments 5,114 Other financial assets 417,256 Property, plant and equipment 729 Intangible assets 86 Accounts payable ( 22,038 ) Other accrued expenses and liabilities ( 1,703 ) Other current liabilities ( 32,653 ) Other long-term liabilities ( 303 ) Noncontrolling interests and other ( 315,144 ) $ 94,467 Gain on completion of RIV Arrangement $ 424
OEGRC and FOUR20
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Summary of Derecognized Assets and Liabilities Transferred	Following the divestiture of the retail stores pursuant to the OEGRC Transaction and the FOUR20 Transaction, the Company derecognized the assets and liabilities of the associated retail stores from these consolidated financial statements at their carrying amounts on their respective closing dates, as follows: Current assets $ 6,461 Property, plant and equipment 7,990 Other long-term assets 144 Current liabilities ( 9,492 ) Net assets disposed $ 5,103 Consideration received in cash $ 88 Future cash consideration 11,599 Costs to sell ( 2,442 ) Total consideration $ 9,245 Gain on disposal of consolidated entity $ 4,142
C3
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Summary of Derecognized Assets and Liabilities Transferred	Following the C 3 Divestiture, the Company no longer controls C 3 and the Company derecognized the assets and liabilities of C 3 from these consolidated financial statements at their carrying amounts, including $ 53,541 of goodwill allocated to the C 3 reporting unit. The derecognized assets and liabilities on January 31, 2022, were as follows: Current assets 1 $ 44,568 Property, plant and equipment 9,216 Intangible assets 15,548 Goodwill 53,541 Current liabilities ( 3,089 ) Deferred income tax liabilities ( 6,029 ) Cumulative translation adjustment 19,178 Net assets disposed $ 132,933 Consideration received in cash $ 128,316 Future cash consideration 7,233 Costs to sell ( 1,153 ) Total consideration $ 134,396 Gain on disposal of consolidated entity $ 1,463 1 Included in current assets is $ 19,338 of cash.

Leases (Tables)

Leases (Tables)	12 Months Ended
	Mar. 31, 2023
Lessee Disclosure [Abstract]
Summary of Lease Right-of-use Assets and Liabilities	A summary of lease right-of-use assets and liabilities are as follows: March 31, March 31, 2023 2022 Property, plant and equipment Operating lease $ 20,741 $ 39,571 Finance lease 8,838 34,333 $ 29,579 $ 73,904 Other current liabilities: Operating lease $ 9,143 $ 11,752 Finance lease 19,541 26,283 Other long-term liabilities: Operating lease 40,977 58,031 Finance lease 39,648 43,094 $ 109,309 $ 139,160
Summary of Components of Total Lease Expense	The components of total lease expense are as follows: Years ended March 31, March 31, 2023 2022 Operating lease expense $ 10,608 $ 5,245 Finance lease expense: Amortization of right-of-use assets 1,494 3,883 Interest on lease liabilities 2,018 1,667 $ 14,120 $ 10,795
Summary of Minimum Payments Due for Lease Liabilities	As of March 31, 2023, the minimum payments due for lease liabilities for each of the five succeeding fiscal years and thereafter are as follows: Operating Leases Finance Leases 2024 $ 11,661 $ 21,410 2025 12,494 5,313 2026 9,521 33,020 2027 9,016 325 2028 7,714 329 Thereafter 8,066 3,725 Total lease payments $ 58,472 $ 64,122 Less: Interest 8,352 4,933 Total lease liabilities $ 50,120 $ 59,189
Summary of Supplemental Information of Leases	Supplemental information Years ended March 31, March 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 13,277 $ 12,905 Operating cash flows from finance leases 2,018 1,667 Financing cash flows from finance leases 5,997 1,494 Right-of-use assets obtained in exchange for new lease liabilities: Operating leases $ 3,759 $ 9,019 Finance leases 2,714 3,720 March 31, March 31, 2023 2022 Weighted-average remaining lease term: Operating leases 5 6 Finance leases 3 4 Weighted-average discount rate Operating leases 5.24 % 4.50 % Finance leases 4.50 % 4.50 %

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Summary of Annual Minimum Commitments Associated with Contractual Agreements	The Company has entered into agreements in which it has committed to purchase a minimum amount of inventory, pay a minimum amount of royalty expenses, incur expenditures for property, plant and equipment and procure various other goods or services. The following summarizes the Company’s annual minimum commitments associated with its contractual agreements as of March 31, 2023. This amount excludes the Company’s debt and lease related commitments which are disclosed elsewhere in Notes 17 and 32, respectively in these consolidated financial statements. 2024 $ 118,211 2025 42,382 2026 28,981 2027 19,676 2028 - Thereafter - $ 209,250

Segmented Information (Tables)

Segmented Information (Tables)	12 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated	Years ended March 31, March 31, March 31, 2023 2022 2021 (As Restated) Segmented net revenue Canada cannabis $ 187,067 $ 257,910 $ 285,049 Rest-of-world cannabis 38,949 79,306 93,631 Storz & Bickel 64,845 85,410 80,998 BioSteel 69,649 34,622 28,530 This Works 26,029 32,296 33,314 Other 16,365 20,777 25,127 $ 402,904 $ 510,321 $ 546,649 Segmented gross margin: Canada cannabis $ ( 95,291 ) $ ( 212,820 ) $ ( 8,435 ) Rest-of-world cannabis ( 3,322 ) ( 28,875 ) 29,687 Storz & Bickel 26,112 37,284 34,231 BioSteel ( 40,613 ) ( 15,722 ) 1,689 This Works 10,205 14,800 17,350 Other ( 1,231 ) 2,197 ( 7,562 ) ( 104,140 ) ( 203,136 ) 66,960 Selling, general and administrative expenses 456,225 472,756 575,389 Share-based compensation 31,188 47,525 91,149 Expected credit losses on financial assets and relates charges - - 109,480 Asset impairment and restructuring costs 2,256,742 369,339 534,398 Operating loss ( 2,848,295 ) ( 1,092,756 ) ( 1,243,456 ) Loss from equity method investments - ( 100 ) ( 52,629 ) Other income (expense), net ( 466,025 ) 753,341 ( 387,876 ) Loss before incomes taxes $ ( 3,314,320 ) $ ( 339,515 ) $ ( 1,683,961 )
Summary of Disaggregation of Net Revenue by Geographic Area	Disaggregation of net revenue by geographic area: Years ended March 31, March 31, March 31, 2023 2022 2021 (As Restated) Canada $ 268,457 $ 286,365 $ 329,172 Germany 48,701 90,874 116,379 United States 39,042 82,080 64,926 Other 46,704 51,002 36,172 $ 402,904 $ 510,321 $ 546,649
Summary of Disaggregation of Long-lived Assets by Geographic Areas	Disaggregation of long-lived tangible assets by geographic area: March 31, March 31, 2023 2022 Canada $ 361,778 $ 827,591 United States 85,772 63,247 Germany 51,341 48,355 Other 575 3,587 $ 499,466 $ 942,780

Restatement of Previously Iss_2

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Unaudited) (Tables)	12 Months Ended
	Mar. 31, 2023
Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements [Abstract]
Summary Impact of Restatement Items to Previously Reported Unaudited Interim Condensed Consolidated Financial Information	The following table presents the effect of the Restatement Items on the Company’s consolidated balance sheet as of March 31, 2022 (in thousands, except number of shares and per share data): March 31, 2022 As Previously Reported Restatement Adjustment As Restated Amounts receivable, net $ 96,443 $ ( 9,862 ) $ 86,581 Inventory 204,387 152 204,539 Prepaid expenses and other assets 52,700 ( 80 ) 52,620 Total current assets 1,737,402 ( 9,790 ) 1,727,612 Total assets 5,615,050 ( 9,790 ) 5,605,260 Other liabilities 64,054 292 64,346 Total current liabilities 212,898 292 213,190 Total liabilities 1,984,553 292 1,984,845 Redeemable noncontrolling interest 36,200 ( 3,700 ) 32,500 Additional paid-in capital 2,519,766 1,480 2,521,246 Deficit ( 6,370,337 ) ( 7,862 ) ( 6,378,199 ) Total Canopy Growth Corporation shareholders' equity 3,589,956 ( 6,382 ) 3,583,574 Total shareholders' equity 3,594,297 ( 6,382 ) 3,587,915 Total liabilities and shareholders' equity 5,615,050 ( 9,790 ) 5,605,260 The correction of the revenue misstatement described above resulted in a decrease of $ 9,862 in amounts receivable, net, and a corresponding increase in the deficit. Additionally, the correction of the misstatement described above resulted in a decrease in redeemable noncontrolling interest of $ 3,700 and an increase in additional paid-in-capital of $ 1,480 . The following table presents the effect of the Restatement Items on the Company’s consolidated statement of operations and comprehensive loss for the year ended March 31, 2022 (in thousands, except number of shares and per share data): Year ended March 31, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 582,218 $ ( 10,004 ) $ 572,214 Net revenue 520,325 ( 10,004 ) 510,321 Cost of goods sold 713,379 78 713,457 Gross margin ( 193,054 ) ( 10,082 ) ( 203,136 ) Operating loss ( 1,082,674 ) ( 10,082 ) ( 1,092,756 ) Loss income before income taxes ( 329,433 ) ( 10,082 ) ( 339,515 ) Net loss ( 320,485 ) ( 10,082 ) ( 330,567 ) Net loss attributable to noncontrolling interests and ( 18,304 ) ( 2,220 ) ( 20,524 ) Net loss attributable to Canopy Growth Corporation ( 302,181 ) ( 7,862 ) ( 310,043 ) Basic and diluted loss per share $ ( 0.77 ) $ ( 0.02 ) $ ( 0.79 ) Basic and diluted weighted average common shares outstanding 391,324,285 - 391,324,285 Comprehensive loss: Net loss $ ( 320,485 ) $ ( 10,082 ) $ ( 330,567 ) Comprehensive loss ( 344,657 ) ( 10,082 ) ( 354,739 ) Comprehensive loss attributable to noncontrolling interests and ( 18,304 ) ( 2,220 ) ( 20,524 ) Comprehensive loss attributable to Canopy Growth Corporation ( 326,353 ) ( 7,862 ) ( 334,215 ) The correction of the revenue misstatement described above resulted in a decrease of $ 10,004 in net revenue and an increase in the net loss attributable to noncontrolling interests and redeemable noncontrolling interest of $ 2,220 . As a result, net loss attributable to Canopy Growth Corporation and comprehensive loss attributable to Canopy Growth Corporation were each impacted by $ 7,862 . The following table presents the effect of the Restatement Items on the Company’s consolidated statement of shareholders’ equity for the year ended March 31, 2022: March 31, 2022 As Previously Reported Restatement Adjustment As Restated Additional paid-in-capital - Redeemable noncontrolling interest $ ( 44,340 ) $ 1,480 $ ( 42,860 ) Deficit ( 6,370,337 ) ( 7,862 ) ( 6,378,199 ) Total shareholders' equity 3,594,297 ( 6,382 ) 3,587,915 The correction of the revenue misstatement described above resulted in a decrease of $ 1,480 in additional paid-in-capital - redeemable noncontrolling interest, and an increase of $ 7,862 in the deficit. In total, the impact on total shareholders' equity was a decrease of $ 6,382 . The following table presents the effect of the Restatement Items on the Company’s consolidated statement of cash flows for the year ended March 31, 2022: Year ended March 31, 2022 As Previously Reported Restatement Adjustment As Restated Net loss $ ( 320,485 ) $ ( 10,082 ) $ ( 330,567 ) Change in operating assets and liabilities, net of effects from Amounts receivable 3,741 9,862 13,603 Inventory 173,189 ( 152 ) 173,037 Prepaid expenses and other assets 24,472 80 24,552 Other, including non-cash foreign currency ( 10,189 ) 292 ( 9,897 ) Net cash used in operating activities ( 545,811 ) - ( 545,811 ) The correction of the revenue misstatement described above resulted in no net change to net cash used in operating activities. The following table presents the effect of the Restatement Items on the Company’s segmented information note for the year ended March 31, 2022: Year ended March 31, 2022 As Previously Reported Restatement Adjustment As Restated Segmented net revenue Canada cannabis $ 257,910 $ - $ 257,910 Rest-of-world cannabis 79,306 - 79,306 Storz & Bickel 85,410 - 85,410 BioSteel 44,626 ( 10,004 ) 34,622 This Works 32,296 - 32,296 Other 20,777 - 20,777 $ 520,325 $ ( 10,004 ) $ 510,321 Segmented gross margin: Canada cannabis $ ( 212,820 ) $ - $ ( 212,820 ) Rest-of-world cannabis ( 28,875 ) - ( 28,875 ) Storz & Bickel 37,284 37,284 BioSteel ( 5,640 ) ( 10,082 ) ( 15,722 ) This Works 14,800 14,800 Other 2,197 - 2,197 ( 193,054 ) ( 10,082 ) ( 203,136 ) Operating loss ( 1,082,674 ) ( 10,082 ) ( 1,092,756 ) Loss before incomes taxes $ ( 329,433 ) $ ( 10,082 ) $ ( 339,515 ) The correction of the revenue misstatement described above resulted in a decrease of $ 10,004 in revenue associated with the BioSteel reportable segment. The remainder of the notes to the Company’s consolidated financial statements have been updated and restated, as applicable, to reflect the impacts of the restatement described above. The following tables include corrections to the prior period results, and present the effect of the Restatement Items described in Note 2, “Basis of Presentation - Restatement of Previously Issued Consolidated Financial Statements” on the Company’s unaudited interim condensed consolidated balance sheets for the periods indicated (in thousands, except number of shares and per share data): June 30, 2022 As Previously Reported Restatement Adjustment As Restated Amounts receivable, net $ 96,626 $ ( 13,827 ) $ 82,799 Inventory 205,513 19 205,532 Prepaid expenses and other assets 62,141 ( 298 ) 61,843 Total current assets 1,593,572 ( 14,106 ) 1,579,466 Total assets 3,517,527 ( 14,106 ) 3,503,421 Other liabilities 86,776 170 86,946 Total current liabilities 404,408 170 404,578 Total liabilities 1,834,607 170 1,834,777 Redeemable noncontrolling interest 37,150 ( 9,000 ) 28,150 Additional paid-in capital 2,515,453 5,881 2,521,334 Deficit ( 8,454,214 ) ( 11,157 ) ( 8,465,371 ) Total Canopy Growth Corporation shareholders' equity 1,641,255 ( 5,276 ) 1,635,979 Total shareholders' equity 1,645,770 ( 5,276 ) 1,640,494 Total liabilities and shareholders' equity 3,517,527 ( 14,106 ) 3,503,421 September 30, 2022 As Previously Reported Restatement Adjustment As Restated Amounts receivable, net $ 108,236 $ ( 25,820 ) $ 82,416 Inventory 211,209 545 211,754 Prepaid expenses and other assets 62,957 ( 216 ) 62,741 Total current assets 1,538,175 ( 25,491 ) 1,512,684 Goodwill 136,513 ( 57,401 ) 79,112 Total assets 3,402,270 ( 82,892 ) 3,319,378 Other liabilities 63,645 16,235 79,880 Total current liabilities 542,401 16,235 558,636 Total liabilities 1,738,241 16,235 1,754,476 Redeemable noncontrolling interest 35,900 ( 23,224 ) 12,676 Additional paid-in capital 2,516,811 21,292 2,538,103 Deficit ( 8,676,020 ) ( 97,195 ) ( 8,773,215 ) Total Canopy Growth Corporation shareholders' equity 1,625,173 ( 75,903 ) 1,549,270 Total shareholders' equity 1,628,129 ( 75,903 ) 1,552,226 Total liabilities and shareholders' equity 3,402,270 ( 82,892 ) 3,319,378 December 31, 2022 As Previously Reported Restatement Adjustment As Restated Amounts receivable, net $ 104,640 $ ( 22,954 ) $ 81,686 Inventory 213,937 108 214,045 Prepaid expenses and other assets 52,151 ( 446 ) 51,705 Total current assets 1,172,910 ( 23,292 ) 1,149,618 Goodwill 142,076 ( 57,401 ) 84,675 Total assets 3,020,155 ( 80,693 ) 2,939,462 Other liabilities 84,134 413 84,547 Total current liabilities 678,741 413 679,154 Total liabilities 1,580,406 413 1,580,819 Redeemable noncontrolling interest 11,408 ( 10,408 ) 1,000 Additional paid-in capital 2,510,086 24,379 2,534,465 Deficit ( 8,937,603 ) ( 95,077 ) ( 9,032,680 ) Total Canopy Growth Corporation shareholders' equity 1,425,545 ( 70,698 ) 1,354,847 Total shareholders' equity 1,428,341 ( 70,698 ) 1,357,643 Total liabilities and shareholders' equity 3,020,155 ( 80,693 ) 2,939,462 The following tables present the effect of the Restatement Items on the Company’s unaudited interim condensed consolidated statements of operations and comprehensive income (loss) for the periods indicated (in thousands, except number of shares and per share data): Three months ended June 30, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 122,862 $ ( 4,195 ) $ 118,667 Net revenue 110,115 ( 4,195 ) 105,920 Cost of goods sold 111,507 ( 1 ) 111,506 Gross margin ( 1,392 ) ( 4,194 ) ( 5,586 ) Operating loss ( 1,838,229 ) ( 4,194 ) ( 1,842,423 ) Loss before income taxes ( 2,083,807 ) ( 4,194 ) ( 2,088,001 ) Net loss ( 2,087,556 ) ( 4,194 ) ( 2,091,750 ) Net loss attributable to noncontrolling interests and ( 4,408 ) ( 899 ) ( 5,307 ) Net loss attributable to Canopy Growth Corporation ( 2,083,148 ) ( 3,295 ) ( 2,086,443 ) Basic and diluted loss per share $ ( 5.23 ) $ ( 0.01 ) $ ( 5.24 ) Comprehensive loss: Net loss $ ( 2,087,556 ) $ ( 4,194 ) $ ( 2,091,750 ) Comprehensive loss ( 2,059,738 ) ( 4,194 ) ( 2,063,932 ) Comprehensive loss attributable to noncontrolling interests ( 4,408 ) ( 899 ) ( 5,307 ) Comprehensive loss attributable to ( 2,055,330 ) ( 3,295 ) ( 2,058,625 ) Three months ended September 30, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 130,359 $ ( 12,445 ) $ 117,914 Net revenue 117,863 ( 12,445 ) 105,418 Cost of goods sold 114,042 ( 669 ) 113,373 Gross margin 3,821 ( 11,776 ) ( 7,955 ) Operating expenses Share-based compensation 9,858 4,723 14,581 Asset impairment and restructuring costs 43,968 57,401 101,369 Total operating expenses 179,668 62,124 241,792 Operating loss ( 175,847 ) ( 73,900 ) ( 249,747 ) Loss before income taxes ( 223,691 ) ( 73,900 ) ( 297,591 ) Net loss ( 231,911 ) ( 73,900 ) ( 305,811 ) Net loss attributable to noncontrolling interests and ( 10,105 ) ( 3,536 ) ( 13,641 ) Net loss attributable to Canopy Growth Corporation ( 221,806 ) ( 70,364 ) ( 292,170 ) Basic and diluted loss per share $ ( 0.47 ) $ ( 0.15 ) $ ( 0.62 ) Comprehensive loss: Net loss $ ( 231,911 ) $ ( 73,900 ) $ ( 305,811 ) Comprehensive loss ( 221,647 ) ( 73,900 ) ( 295,547 ) Comprehensive loss attributable to noncontrolling interests ( 10,105 ) ( 3,536 ) ( 13,641 ) Comprehensive loss attributable to ( 211,542 ) ( 70,364 ) ( 281,906 ) Six months ended September 30, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 253,221 $ ( 16,640 ) $ 236,581 Net revenue 227,978 ( 16,640 ) 211,338 Cost of goods sold 225,549 ( 670 ) 224,879 Gross margin 2,429 ( 15,970 ) ( 13,541 ) Operating expenses Share-based compensation 15,297 4,723 20,020 Asset impairment and restructuring costs 1,771,953 57,401 1,829,354 Total operating expenses 2,016,505 62,124 2,078,629 Operating loss ( 2,014,076 ) ( 78,094 ) ( 2,092,170 ) Loss before income taxes ( 2,307,498 ) ( 78,094 ) ( 2,385,592 ) Net loss ( 2,319,467 ) ( 78,094 ) ( 2,397,561 ) Net loss attributable to noncontrolling interests and ( 14,513 ) ( 4,435 ) ( 18,948 ) Net loss attributable to Canopy Growth Corporation ( 2,304,954 ) ( 73,659 ) ( 2,378,613 ) Basic and diluted loss per share $ ( 5.30 ) $ ( 0.17 ) $ ( 5.47 ) Comprehensive loss: Net loss $ ( 2,319,467 ) $ ( 78,094 ) $ ( 2,397,561 ) Comprehensive loss ( 2,281,385 ) ( 78,094 ) ( 2,359,479 ) Comprehensive loss attributable to noncontrolling interests ( 14,513 ) ( 4,435 ) ( 18,948 ) Comprehensive loss attributable to ( 2,266,872 ) ( 73,659 ) ( 2,340,531 ) Three months ended December 31, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 113,349 $ 2,818 $ 116,167 Net revenue 101,213 2,818 104,031 Cost of goods sold 103,654 472 104,126 Gross margin ( 2,441 ) 2,346 ( 95 ) Operating loss ( 153,764 ) 2,346 ( 151,418 ) Loss before income taxes ( 267,104 ) 2,346 ( 264,758 ) Net loss ( 266,722 ) 2,346 ( 264,376 ) Net loss attributable to noncontrolling interests and ( 5,139 ) 228 ( 4,911 ) Net loss attributable to Canopy Growth Corporation ( 261,583 ) 2,118 ( 259,465 ) Basic and diluted loss per share $ ( 0.54 ) $ 0.01 $ ( 0.53 ) Comprehensive loss: Net loss $ ( 266,722 ) $ 2,346 $ ( 264,376 ) Comprehensive loss ( 247,263 ) 2,346 ( 244,917 ) Comprehensive loss attributable to noncontrolling interests ( 5,139 ) 228 ( 4,911 ) Comprehensive loss attributable to ( 242,124 ) 2,118 ( 240,006 ) Nine months ended December 31, 2022 As Previously Reported Restatement Adjustment As Restated Revenue $ 366,570 $ ( 13,822 ) $ 352,748 Net revenue 329,191 ( 13,822 ) 315,369 Cost of goods sold 329,203 ( 198 ) 329,005 Gross margin ( 12 ) ( 13,624 ) ( 13,636 ) Operating expenses Share-based compensation 21,725 4,723 26,448 Asset impairment and restructuring costs 1,794,212 57,401 1,851,613 Total operating expenses 2,167,828 62,124 2,229,952 Operating loss ( 2,167,840 ) ( 75,748 ) ( 2,243,588 ) Loss before income taxes ( 2,574,602 ) ( 75,748 ) ( 2,650,350 ) Net loss ( 2,586,189 ) ( 75,748 ) ( 2,661,937 ) Net loss attributable to noncontrolling interests and ( 19,652 ) ( 4,207 ) ( 23,859 ) Net loss attributable to Canopy Growth Corporation ( 2,566,537 ) ( 71,541 ) ( 2,638,078 ) Basic and diluted loss per share $ ( 5.66 ) $ ( 0.16 ) $ ( 5.82 ) Comprehensive loss: Net loss $ ( 2,586,189 ) $ ( 75,748 ) $ ( 2,661,937 ) Comprehensive loss ( 2,528,648 ) ( 75,748 ) ( 2,604,396 ) Comprehensive loss attributable to noncontrolling interests ( 19,652 ) ( 4,207 ) ( 23,859 ) Comprehensive loss attributable to ( 2,508,996 ) ( 71,541 ) ( 2,580,537 ) The following tables present the effect of the Restatement Items on the Company’s unaudited interim condensed consolidated statements of shareholders’ equity for the periods indicated: June 30, 2022 As Previously Reported Restatement Adjustment As Restated Additional paid-in-capital - Redeemable noncontrolling interest $ ( 49,698 ) $ 5,881 $ ( 43,817 ) Deficit ( 8,454,214 ) ( 11,157 ) ( 8,465,371 ) Total shareholders' equity 1,645,770 ( 5,276 ) 1,640,494 September 30, 2022 As Previously Reported Restatement Adjustment As Restated Additional paid-in-capital - Redeemable noncontrolling interest $ ( 56,709 ) $ 16,569 $ ( 40,140 ) Additional paid-in-capital - Ownership changes ( 509,723 ) 4,723 ( 505,000 ) Deficit ( 8,676,020 ) ( 97,195 ) ( 8,773,215 ) Total shareholders' equity 1,628,129 ( 75,903 ) 1,552,226 December 31, 2022 As Previously Reported Restatement Adjustment As Restated Additional paid-in-capital - Redeemable noncontrolling interest $ ( 64,707 ) $ 19,656 $ ( 45,051 ) Additional paid-in-capital - Ownership changes ( 512,419 ) 4,723 ( 507,696 ) Deficit ( 8,937,603 ) ( 95,077 ) ( 9,032,680 ) Total shareholders' equity 1,428,341 ( 70,698 ) 1,357,643 The following tables present the effect of the Restatement Items on the Company’s unaudited interim condensed consolidated statements of cash flows for the periods indicated: Three months ended June 30, 2022 As Previously Restatement As Restated Cash flows from operating activities: Net loss $ ( 2,087,556 ) $ ( 4,194 ) $ ( 2,091,750 ) Change in operating assets and liabilities, net of effects from Amounts receivable ( 183 ) 3,964 3,781 Inventory ( 1,126 ) 133 ( 993 ) Prepaid expenses and other assets ( 9,555 ) 219 ( 9,336 ) Other, including non-cash foreign currency 1,928 ( 122 ) 1,806 Net cash used in operating activities ( 140,515 ) - ( 140,515 ) Six months ended September 30, 2022 As Previously Restatement As Restated Cash flows from operating activities: Net loss $ ( 2,319,467 ) $ ( 78,094 ) $ ( 2,397,561 ) Adjustments to reconcile net loss to net cash used in operating activities: Share-based compensation 15,297 4,723 20,020 Asset impairment and restructuring costs 1,783,784 57,401 1,841,185 Change in operating assets and liabilities, net of effects from Amounts receivable ( 11,793 ) 15,956 4,163 Inventory ( 6,822 ) ( 393 ) ( 7,215 ) Prepaid expenses and other assets ( 17,567 ) 138 ( 17,429 ) Other, including non-cash foreign currency ( 19,006 ) 269 ( 18,737 ) Net cash used in operating activities ( 273,915 ) - ( 273,915 ) Nine months ended December 31, 2022 As Previously Restatement As Restated Net loss $ ( 2,586,189 ) $ ( 75,748 ) $ ( 2,661,937 ) Adjustments to reconcile net loss to net cash used in operating activities: Share-based compensation 21,725 4,723 26,448 Asset impairment and restructuring costs 1,797,854 57,401 1,855,255 Change in operating assets and liabilities, net of effects Amounts receivable ( 8,197 ) 13,090 4,893 Inventory ( 9,550 ) 44 ( 9,506 ) Prepaid expenses and other assets ( 6,866 ) 368 ( 6,498 ) Other, including non-cash foreign currency ( 24,459 ) 122 ( 24,337 ) Net cash used in operating activities ( 417,809 ) - ( 417,809 )

Basis of Presentation (Addition

Basis of Presentation (Additional Information) (Details) - CAD ($)	3 Months Ended					6 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Principal repayments under debt obligations to be settled in cash due within the next 12 months	$ 467,957,000							$ 467,957,000
Cash and cash equivalents	677,007,000				$ 776,005,000			677,007,000	$ 776,005,000
Short-term investments	105,595,000				595,651,000			105,595,000	595,651,000
Goodwill impairment loss	0		$ 59,712,000		40,748,000			1,785,080,000	40,748,000	$ 0
Decrease in amounts receivable, net	93,987,000	$ 81,686,000	82,416,000	$ 82,799,000	86,581,000	$ 82,416,000	$ 81,686,000	93,987,000	86,581,000
Decrease in redeemable noncontrolling interest								(51,897,000)	(102,800,000)	65,550,000
Decrease in net revenue		(116,167,000)	(117,914,000)	(118,667,000)		(236,581,000)	(352,748,000)	(450,901,000)	(572,214,000)	(607,198,000)
Net loss attributable to noncontrolling interests and redeemable noncontrolling interest		(4,911,000)	(13,641,000)	(5,307,000)		(18,948,000)	(23,859,000)	(31,388,000)	(20,524,000)	74,100,000
Net loss attributable to Canopy Growth Corporation and comprehensive loss attributable to Canopy Growth Corporation		240,006,000	281,906,000	2,058,625,000		2,340,531,000	2,580,537,000	3,220,229,000	334,215,000	2,000,059,000
Decrease in shareholders' equity	(760,022,000)	(1,357,643,000)	(1,552,226,000)	(1,640,494,000)	(3,587,915,000)	(1,552,226,000)	(1,357,643,000)	(760,022,000)	(3,587,915,000)	(3,486,520,000)	$ (5,108,120,000)
Deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Decrease in shareholders' equity	9,672,761,000	9,032,680,000	8,773,215,000	8,465,371,000	6,378,199,000	8,773,215,000	9,032,680,000	9,672,761,000	6,378,199,000	6,068,156,000	4,323,236,000
Redeemable Noncontrolling Interest | Additional Paid-in capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Decrease in redeemable noncontrolling interest								(17,630,000)	(83,483,000)	83,627,000
Decrease in shareholders' equity	$ 51,492,000	45,051,000	40,140,000	43,817,000	42,860,000	40,140,000	45,051,000	51,492,000	42,860,000	121,234,000	$ 40,134,000
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Decrease in amounts receivable, net		(22,954,000)	(25,820,000)	(13,827,000)	(9,862,000)	(25,820,000)	(22,954,000)		(9,862,000)
Decrease in redeemable noncontrolling interest									3,700,000
Increase in additional paid-in-capital									1,480,000
Decrease in net revenue		(2,818,000)	12,445,000	4,195,000		16,640,000	13,822,000		10,004,000
Net loss attributable to noncontrolling interests and redeemable noncontrolling interest		228,000	(3,536,000)	(899,000)		(4,435,000)	(4,207,000)		(2,220,000)
Net loss attributable to Canopy Growth Corporation and comprehensive loss attributable to Canopy Growth Corporation		(2,118,000)	70,364,000	3,295,000		73,659,000	71,541,000		7,862,000
Decrease in shareholders' equity		70,698,000	75,903,000	5,276,000	6,382,000	75,903,000	70,698,000		6,382,000
Restatement Adjustment | Deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Increase in deficit									(7,862,000)
Decrease in shareholders' equity		95,077,000	97,195,000	11,157,000	7,862,000	97,195,000	95,077,000		7,862,000
Restatement Adjustment | Redeemable Noncontrolling Interest | Additional Paid-in capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Decrease in additional paid-in-capital - redeemable noncontrolling interest									1,480,000
Decrease in shareholders' equity		$ (19,656,000)	(16,569,000)	$ (5,881,000)	$ (1,480,000)	$ (16,569,000)	$ (19,656,000)		(1,480,000)
Bio Steel [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Goodwill impairment loss			$ 57,401,000
Decrease in net revenue								$ (69,649,000)	(34,622,000)	$ (28,530,000)
Bio Steel [Member] | Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Decrease in net revenue									$ (10,004,000)

Basis of Presentation - Schedul

Basis of Presentation - Schedule of Effect of Restatement Items on Consolidated Balance Sheet (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Amounts receivable, net	$ 93,987	$ 81,686	$ 82,416	$ 82,799	$ 86,581
Inventory	148,901	214,045	211,754	205,532	204,539
Prepaid expenses and other assets	39,999	51,705	62,741	61,843	52,620
Total current assets	1,077,254	1,149,618	1,512,684	1,579,466	1,727,612
Total assets	2,439,098	2,939,462	3,319,378	3,503,421	5,605,260
Other liabilities	94,727	84,547	79,880	86,946	64,346
Total current liabilities	803,842	679,154	558,636	404,578	213,190
Total liabilities	1,679,076	1,580,819	1,754,476	1,834,777	1,984,845
Redeemable noncontrolling interest		1,000	12,676	28,150	32,500	$ 135,300	$ 69,750
Additional paid-in capital	2,506,485	2,534,465	2,538,103	2,521,334	2,521,246
Deficit	(9,672,761)	(9,032,680)	(8,773,215)	(8,465,371)	(6,378,199)
Total Canopy Growth Corporation shareholders' equity	758,435	1,354,847	1,549,270	1,635,979	3,583,574
Total shareholders' equity	760,022	1,357,643	1,552,226	1,640,494	3,587,915	$ 3,486,520	$ 5,108,120
Total liabilities and shareholders' equity	$ 2,439,098	2,939,462	3,319,378	3,503,421	5,605,260
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Amounts receivable, net		104,640	108,236	96,626	96,443
Inventory		213,937	211,209	205,513	204,387
Prepaid expenses and other assets		52,151	62,957	62,141	52,700
Total current assets		1,172,910	1,538,175	1,593,572	1,737,402
Total assets		3,020,155	3,402,270	3,517,527	5,615,050
Other liabilities		84,134	63,645	86,776	64,054
Total current liabilities		678,741	542,401	404,408	212,898
Total liabilities		1,580,406	1,738,241	1,834,607	1,984,553
Redeemable noncontrolling interest		11,408	35,900	37,150	36,200
Additional paid-in capital		2,510,086	2,516,811	2,515,453	2,519,766
Deficit		(8,937,603)	(8,676,020)	(8,454,214)	(6,370,337)
Total Canopy Growth Corporation shareholders' equity		1,425,545	1,625,173	1,641,255	3,589,956
Total shareholders' equity		1,428,341	1,628,129	1,645,770	3,594,297
Total liabilities and shareholders' equity		3,020,155	3,402,270	3,517,527	5,615,050
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Amounts receivable, net		(22,954)	(25,820)	(13,827)	(9,862)
Inventory		108	545	19	152
Prepaid expenses and other assets		(446)	(216)	(298)	(80)
Total current assets		(23,292)	(25,491)	(14,106)	(9,790)
Total assets		(80,693)	(82,892)	(14,106)	(9,790)
Other liabilities		413	16,235	170	292
Total current liabilities		413	16,235	170	292
Total liabilities		413	16,235	170	292
Redeemable noncontrolling interest		(10,408)	(23,224)	(9,000)	(3,700)
Additional paid-in capital		24,379	21,292	5,881	1,480
Deficit		(95,077)	(97,195)	(11,157)	(7,862)
Total Canopy Growth Corporation shareholders' equity		(70,698)	(75,903)	(5,276)	(6,382)
Total shareholders' equity		(70,698)	(75,903)	(5,276)	(6,382)
Total liabilities and shareholders' equity		$ (80,693)	$ (82,892)	$ (14,106)	$ (9,790)

Basis of Presentation - Sched_2

Basis of Presentation - Schedule of Effect of Restatement Items on Consolidated Statement of Operations and Comprehensive Loss (Details) - CAD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue	$ 116,167	$ 117,914	$ 118,667	$ 236,581	$ 352,748	$ 450,901	$ 572,214	$ 607,198
Net revenue	104,031	105,418	105,920	211,338	315,369	402,904	510,321	546,649
Cost of goods sold	104,126	113,373	111,506	224,879	329,005	507,044	713,457	479,689
Gross margin	(95)	(7,955)	(5,586)	(13,541)	(13,636)	(104,140)	(203,136)	66,960
Operating loss	(151,418)	(249,747)	(1,842,423)	(2,092,170)	(2,243,588)	(2,848,295)	(1,092,756)	(1,243,456)
Loss before income taxes	(264,758)	(297,591)	(2,088,001)	(2,385,592)	(2,650,350)	(3,314,320)	(339,515)	(1,683,961)
Net loss	(264,376)	(305,811)	(2,091,750)	(2,397,561)	(2,661,937)	(3,309,546)	(330,567)	(1,670,820)
Net (loss) income attributable to noncontrolling interests and redeemable noncontrolling interest	(4,911)	(13,641)	(5,307)	(18,948)	(23,859)	(31,388)	(20,524)	74,100
Net loss attributable to Canopy Growth Corporation	$ (259,465)	$ (292,170)	$ (2,086,443)	$ (2,378,613)	$ (2,638,078)	$ (3,278,158)	$ (310,043)	$ (1,744,920)
Basic loss per share	$ (0.53)	$ (0.62)	$ (5.24)	$ (5.47)	$ (5.82)	$ (7.07)	$ (0.79)	$ (4.69)
Diluted loss per share	$ (0.53)	$ (0.62)	$ (5.24)	$ (5.47)	$ (5.82)	$ (7.07)	$ (0.79)	$ (4.69)
Basic weighted average common shares outstanding						463,724,414	391,324,285	371,662,296
Diluted weighted average common shares outstanding						463,724,414	391,324,285	371,662,296
Comprehensive loss:
Comprehensive loss	$ (244,917)	$ (295,547)	$ (2,063,932)	$ (2,359,479)	$ (2,604,396)	$ (3,251,617)	$ (354,739)	$ (1,925,959)
Comprehensive loss attributable to noncontrolling interests and redeemable noncontrolling interest	(4,911)	(13,641)	(5,307)	(18,948)	(23,859)	(31,388)	(20,524)	74,100
Comprehensive loss attributable to Canopy Growth Corporation	(240,006)	(281,906)	(2,058,625)	(2,340,531)	(2,580,537)	$ (3,220,229)	(334,215)	$ (2,000,059)
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue	113,349	130,359	122,862	253,221	366,570		582,218
Net revenue	101,213	117,863	110,115	227,978	329,191		520,325
Cost of goods sold	103,654	114,042	111,507	225,549	329,203		713,379
Gross margin	(2,441)	3,821	(1,392)	2,429	(12)		(193,054)
Operating loss	(153,764)	(175,847)	(1,838,229)	(2,014,076)	(2,167,840)		(1,082,674)
Loss before income taxes	(267,104)	(223,691)	(2,083,807)	(2,307,498)	(2,574,602)		(329,433)
Net loss	(266,722)	(231,911)	(2,087,556)	(2,319,467)	(2,586,189)		(320,485)
Net (loss) income attributable to noncontrolling interests and redeemable noncontrolling interest	(5,139)	(10,105)	(4,408)	(14,513)	(19,652)		(18,304)
Net loss attributable to Canopy Growth Corporation	$ (261,583)	$ (221,806)	$ (2,083,148)	$ (2,304,954)	$ (2,566,537)		$ (302,181)
Basic loss per share	$ (0.54)	$ (0.47)	$ (5.23)	$ (5.30)	$ (5.66)		$ (0.77)
Diluted loss per share	$ (0.54)	$ (0.47)	$ (5.23)	$ (5.30)	$ (5.66)		$ (0.77)
Basic weighted average common shares outstanding							391,324,285
Diluted weighted average common shares outstanding							391,324,285
Comprehensive loss:
Comprehensive loss	$ (247,263)	$ (221,647)	$ (2,059,738)	$ (2,281,385)	$ (2,528,648)		$ (344,657)
Comprehensive loss attributable to noncontrolling interests and redeemable noncontrolling interest	(5,139)	(10,105)	(4,408)	(14,513)	(19,652)		(18,304)
Comprehensive loss attributable to Canopy Growth Corporation	(242,124)	(211,542)	(2,055,330)	(2,266,872)	(2,508,996)		(326,353)
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue	2,818	(12,445)	(4,195)	(16,640)	(13,822)		(10,004)
Net revenue	2,818	(12,445)	(4,195)	(16,640)	(13,822)		(10,004)
Cost of goods sold	472	(669)	(1)	(670)	(198)		78
Gross margin	2,346	(11,776)	(4,194)	(15,970)	(13,624)		(10,082)
Operating loss	2,346	(73,900)	(4,194)	(78,094)	(75,748)		(10,082)
Loss before income taxes	2,346	(73,900)	(4,194)	(78,094)	(75,748)		(10,082)
Net loss	2,346	(73,900)	(4,194)	(78,094)	(75,748)		(10,082)
Net (loss) income attributable to noncontrolling interests and redeemable noncontrolling interest	228	(3,536)	(899)	(4,435)	(4,207)		(2,220)
Net loss attributable to Canopy Growth Corporation	$ 2,118	$ (70,364)	$ (3,295)	$ (73,659)	$ (71,541)		$ (7,862)
Basic loss per share	$ 0.01	$ (0.15)	$ (0.01)	$ (0.17)	$ (0.16)		$ (0.02)
Diluted loss per share	$ 0.01	$ (0.15)	$ (0.01)	$ (0.17)	$ (0.16)		$ (0.02)
Comprehensive loss:
Comprehensive loss	$ 2,346	$ (73,900)	$ (4,194)	$ (78,094)	$ (75,748)		$ (10,082)
Comprehensive loss attributable to noncontrolling interests and redeemable noncontrolling interest	228	(3,536)	(899)	(4,435)	(4,207)		(2,220)
Comprehensive loss attributable to Canopy Growth Corporation	$ 2,118	$ (70,364)	$ (3,295)	$ (73,659)	$ (71,541)		$ (7,862)

Basis of Presentation - Sched_3

Basis of Presentation - Schedule of Effect of Restatement Items on Consolidated Statement of Shareholders' Equity (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity	$ 760,022	$ 1,357,643	$ 1,552,226	$ 1,640,494	$ 3,587,915	$ 3,486,520	$ 5,108,120
Deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity	(9,672,761)	(9,032,680)	(8,773,215)	(8,465,371)	(6,378,199)	(6,068,156)	(4,323,236)
Noncontrolling Interests
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity	1,587				4,341	4,709	221,758
Redeemable Noncontrolling Interest | Additional Paid-in capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity	$ (51,492)	(45,051)	(40,140)	(43,817)	(42,860)	$ (121,234)	$ (40,134)
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity		1,428,341	1,628,129	1,645,770	3,594,297
As Previously Reported | Deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity		(8,937,603)	(8,676,020)	(8,454,214)	(6,370,337)
As Previously Reported | Redeemable Noncontrolling Interest | Additional Paid-in capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity		(64,707)	(56,709)	(49,698)	(44,340)
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity		(70,698)	(75,903)	(5,276)	(6,382)
Restatement Adjustment | Deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity		(95,077)	(97,195)	(11,157)	(7,862)
Restatement Adjustment | Redeemable Noncontrolling Interest | Additional Paid-in capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity		$ 19,656	$ 16,569	$ 5,881	$ 1,480

Basis of Presentation - Sched_4

Basis of Presentation - Schedule of Effect of Restatement Items on Consolidated Statement of Cash Flows (Details) - CAD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	$ (264,376)	$ (305,811)	$ (2,091,750)	$ (2,397,561)	$ (2,661,937)	$ (3,309,546)	$ (330,567)	$ (1,670,820)
Change in operating assets and liabilities, net of effects from purchases of businesses:
Amounts receivable			3,781	4,163	4,893	(9,906)	13,603	(11,994)
Inventory			(993)	(7,215)	(9,506)	55,638	173,037	23,107
Prepaid expenses and other assets			(9,336)	(17,429)	(6,498)	2,484	24,552	77
Other, including non-cash foreign currency			1,806	(18,737)	(24,337)	(6,592)	(9,897)	(89,843)
Net cash used in operating activities			(140,515)	(273,915)	(417,809)	$ (557,546)	(545,811)	$ (465,729)
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	(266,722)	(231,911)	(2,087,556)	(2,319,467)	(2,586,189)		(320,485)
Change in operating assets and liabilities, net of effects from purchases of businesses:
Amounts receivable			(183)	(11,793)	(8,197)		3,741
Inventory			(1,126)	(6,822)	(9,550)		173,189
Prepaid expenses and other assets			(9,555)	(17,567)	(6,866)		24,472
Other, including non-cash foreign currency			1,928	(19,006)	(24,459)		(10,189)
Net cash used in operating activities			(140,515)	(273,915)	(417,809)		(545,811)
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	$ 2,346	$ (73,900)	(4,194)	(78,094)	(75,748)		(10,082)
Change in operating assets and liabilities, net of effects from purchases of businesses:
Amounts receivable			3,964	15,956	13,090		9,862
Inventory			133	(393)	44		(152)
Prepaid expenses and other assets			219	138	368		80
Other, including non-cash foreign currency			$ (122)	$ 269	$ 122		$ 292

Basis of Presentation - Sched_5

Basis of Presentation - Schedule of Effect of Restatement Items on Segmented Information (Details) - CAD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Net revenue	$ 104,031	$ 105,418	$ 105,920	$ 211,338	$ 315,369	$ 402,904	$ 510,321	$ 546,649
Gross margin	(95)	(7,955)	(5,586)	(13,541)	(13,636)	(104,140)	(203,136)	66,960
Operating loss	(151,418)	(249,747)	(1,842,423)	(2,092,170)	(2,243,588)	(2,848,295)	(1,092,756)	(1,243,456)
Loss before income taxes	(264,758)	(297,591)	(2,088,001)	(2,385,592)	(2,650,350)	(3,314,320)	(339,515)	(1,683,961)
Canada Cannabis
Disaggregation of Revenue [Line Items]
Net revenue							257,910
Gross margin							(212,820)
Rest-of-world Cannabis
Disaggregation of Revenue [Line Items]
Net revenue						38,949	79,306	93,631
Gross margin						$ (3,322)	(28,875)	$ 29,687
Storz & Bickel
Disaggregation of Revenue [Line Items]
Net revenue							85,410
Gross margin							37,284
BioSteel
Disaggregation of Revenue [Line Items]
Net revenue							34,622
Gross margin							(15,722)
This Work
Disaggregation of Revenue [Line Items]
Net revenue							32,296
Gross margin							14,800
Other
Disaggregation of Revenue [Line Items]
Net revenue							20,777
Gross margin							2,197
As Previously Reported
Disaggregation of Revenue [Line Items]
Net revenue	101,213	117,863	110,115	227,978	329,191		520,325
Gross margin	(2,441)	3,821	(1,392)	2,429	(12)		(193,054)
Operating loss	(153,764)	(175,847)	(1,838,229)	(2,014,076)	(2,167,840)		(1,082,674)
Loss before income taxes	(267,104)	(223,691)	(2,083,807)	(2,307,498)	(2,574,602)		(329,433)
As Previously Reported | Canada Cannabis
Disaggregation of Revenue [Line Items]
Net revenue							257,910
Gross margin							(212,820)
As Previously Reported | Rest-of-world Cannabis
Disaggregation of Revenue [Line Items]
Net revenue							79,306
Gross margin							(28,875)
As Previously Reported | Storz & Bickel
Disaggregation of Revenue [Line Items]
Net revenue							85,410
Gross margin							37,284
As Previously Reported | BioSteel
Disaggregation of Revenue [Line Items]
Net revenue							44,626
Gross margin							(5,640)
As Previously Reported | This Work
Disaggregation of Revenue [Line Items]
Net revenue							32,296
Gross margin							14,800
As Previously Reported | Other
Disaggregation of Revenue [Line Items]
Net revenue							20,777
Gross margin							2,197
Restatement Adjustment
Disaggregation of Revenue [Line Items]
Net revenue	2,818	(12,445)	(4,195)	(16,640)	(13,822)		(10,004)
Gross margin	2,346	(11,776)	(4,194)	(15,970)	(13,624)		(10,082)
Operating loss	2,346	(73,900)	(4,194)	(78,094)	(75,748)		(10,082)
Loss before income taxes	$ 2,346	$ (73,900)	$ (4,194)	$ (78,094)	$ (75,748)		(10,082)
Restatement Adjustment | BioSteel
Disaggregation of Revenue [Line Items]
Net revenue							(10,004)
Gross margin							$ (10,082)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Summary of Expected Useful Life of Property, Plant and Equipment (Details)	12 Months Ended
	Mar. 31, 2023
Buildings and Greenhouses | Minimum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	20 years
Buildings and Greenhouses | Maximum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	50 years
Production and Warehouse Equipment | Minimum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	5 years
Production and Warehouse Equipment | Maximum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	30 years
Leasehold Improvements | Minimum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	3 years
Leasehold Improvements | Maximum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	20 years
Office and Lab Equipment | Minimum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	3 years
Office and Lab Equipment | Maximum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	10 years
Computer Equipment | Minimum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	3 years
Computer Equipment | Maximum
Summary Of Significant Accounting Policies [Line Items]
Expected useful life of property, plant and equipment	10 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Finite Lived Intangible Assets Useful Life (Details)	12 Months Ended
	Mar. 31, 2023
Distribution Channel | Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	5 years
Distribution Channel | Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	11 years
Operating Licenses | Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	5 years
Operating Licenses | Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	8 years
Intellectual Property | Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	5 years
Intellectual Property | Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	15 years
Brands | Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	2 years
Brands | Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	5 years
Software and Domain Names | Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	3 years
Software and Domain Names | Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life of intangible assets	5 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended				12 Months Ended
	Mar. 31, 2023 CAD ($)	Sep. 30, 2022 CAD ($) Segment	Mar. 31, 2022 CAD ($)	Mar. 31, 2021 CAD ($) Unit Segment	Mar. 31, 2023 CAD ($)	Mar. 31, 2022 CAD ($)	Mar. 31, 2021 CAD ($)
Summary Of Significant Accounting Policies [Line Items]
Number of operating segments | Segment		2		2
Advertising expenses				$ 72,377,000	$ 134,403,000	$ 104,221,000
Research and development expenses				$ 57,582,000	21,718,000	32,344,000
Goodwill impairment	$ 0	$ 59,712,000	$ 40,748,000		$ 1,785,080,000	$ 40,748,000	$ 0
Cannabis, Hemp and Other Consumer Products
Summary Of Significant Accounting Policies [Line Items]
Number of reporting units | Unit				1

New Accounting Policies - Addit

New Accounting Policies - Additional Information (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Summary Of Significant Accounting Policies [Line Items]
Long-term debt	$ 1,306,881				$ 1,500,991
Accumulated deficit	$ (9,672,761)	$ (9,032,680)	$ (8,773,215)	$ (8,465,371)	(6,378,199)
Cumulative Effect from Adoption of ASU 2020-06
Summary Of Significant Accounting Policies [Line Items]
Additional paid in capital					4,452
Long-term debt					3,723
Accumulated deficit					$ 729

Canopy USA - Additional Informa

Canopy USA - Additional Information (Details)

12 Months Ended

Apr. 17, 2023 CAD ($)

Apr. 17, 2023 USD ($)

Dec. 09, 2022 shares

Nov. 10, 2022 CAD ($)

Nov. 10, 2022 USD ($)

Oct. 24, 2022 USD ($) $ / shares shares

Mar. 18, 2021 USD ($) $ / shares

Jun. 24, 2020

Mar. 31, 2023 CAD ($) shares

Mar. 31, 2022 CAD ($) shares

Mar. 31, 2021 CAD ($)

Apr. 17, 2023 USD ($)

Nov. 10, 2022 USD ($)

Oct. 24, 2022 CAD ($) $ / shares shares

Oct. 24, 2022 USD ($) $ / shares shares

Jun. 29, 2022 CAD ($)

May 17, 2022

Oct. 14, 2021

Apr. 18, 2019

Jun. 20, 2018 CAD ($)

Reorganization [Line Items]

Warrant expiration date

Dec. 31, 2032

Nov. 01, 2023

Common stock, shares issued | shares

517,305,551

394,422,604

Common stock value

$ 7,938,571,000

$ 7,482,809,000

Percentage ownership of wholly owned subsidiaries

100%

Minimum percentage of votes cast for approval of amendment proposal

66%

Debt instrument discounted price

$ 930,000

$ 930,000

Paydown

$ 118,179,000

50,763,000

$ 15,619,000

Description of potential changes in structure

The Company and Canopy USA effectuated certain changes to the initial structure of the Company’s interest in Canopy USA such that the Company does not expect to consolidate the financial results of Canopy USA within the Company’s financial statements. These changes included, among other things, modifying the terms of the Protection Agreement between the Company, its wholly-owned subsidiary and Canopy USA as well as the terms of Canopy USA’s limited liability company agreement and amending the terms of certain agreements with third-party investors in Canopy USA to eliminate any rights to guaranteed returns

Credit Facility

Reorganization [Line Items]

Principal amount

$ 750,000

Debt instrument discounted price per us dollar | $ / shares

$ 1,000

$ 1,000

Paydown

$ 174,375,000

$ 174,375,000

Paydown Agreement [Member]

Reorganization [Line Items]

Principal amount

100,000,000

Minimum liquidity, each fiscal quarter

100,000,000

Additional incremental term loan facility

500,000,000

Paydown Agreement [Member] | Credit Facility

Reorganization [Line Items]

Principal amount

187,500

$ 187,500,000

Paydown

$ 117,528,000

$ 87,852,000

Aggregate principal payment amount

$ 126,324,000

$ 94,427,000

Paydown Agreement [Member] | Credit Facility | Subsequent Event

Reorganization [Line Items]

Paydown

$ 116,847,000

$ 87,213,000

Aggregate principal payment amount

$ 125,606,000

$ 93,750,000

Credit Agreement Amendments

Reorganization [Line Items]

Principal amount

100,000,000

Minimum liquidity, each fiscal quarter

100,000,000

Additional incremental term loan facility

$ 500,000,000

4.25% Senior Notes [Member]

Reorganization [Line Items]

Principal amount

$ 337,380,000

$ 600,000,000

$ 262,620,000

$ 600,000,000

Annual interest rate

4.25%

4.25%

Warrants

Reorganization [Line Items]

Common stock, shares issued | shares

139,745,453

139,745,453

139,745,453

Common stock value

$ 0

TerrAscend Option | Equity Option

Reorganization [Line Items]

Business acquisition additional number of shares issuable | shares

1,072,450

1,072,450

Aggregate purchase price of stock options | $ / shares

$ 1

TerrAscend Exchangeable Shares

Reorganization [Line Items]

Exchangeable shares in the capital | shares

24,601,467

38,890,570

38,890,570

TerrAscend Warrants

Reorganization [Line Items]

Common share purchase warrants in the capital | shares

22,474,130

22,474,130

Wana

Reorganization [Line Items]

Ownership percentage

100%

100%

100%

Aggregate exercise price of common shares | $ / shares

$ 3

Percentage of common share to be issued

7.50%

Jetty

Reorganization [Line Items]

Ownership percentage

100%

100%

100%

Acreage

Reorganization [Line Items]

Common stock value

$ 19,559,000

Maximum | Jetty

Reorganization [Line Items]

Ownership percentage

100%

Minimum

Reorganization [Line Items]

Percentage non-voting shares in capital

99%

Minimum liquidity, each fiscal quarter

$ 100,000,000

Fixed Shares | Acreage

Reorganization [Line Items]

Common stock shares conversion ratio

0.3048

Fixed Shares | Acreage | Class E Subordinated Voting Shares

Reorganization [Line Items]

Percentage of outstanding shares purchased

70%

70%

Common stock shares conversion ratio

0.3048

0.3048

Floating Shares

Reorganization [Line Items]

Number of canopy shares exchanged | shares

0.45

Floating Shares | Acreage

Reorganization [Line Items]

Percentage of variable interest entity ownership

7.30%

Floating Shares | Acreage | Class D Subordinated Voting Shares

Reorganization [Line Items]

Number of canopy shares exchanged | shares

0.45

Asset Impairment and Restruct_3

Asset Impairment and Restructuring Costs - Additional Information (Details)		3 Months Ended					6 Months Ended	9 Months Ended	12 Months Ended
	Mar. 01, 2021 CAD ($)	Mar. 31, 2023 CAD ($)	Sep. 30, 2022 CAD ($)	Jun. 30, 2022 CAD ($)	Mar. 31, 2022 CAD ($)	Mar. 31, 2021 CAD ($)	Sep. 30, 2022 CAD ($)	Dec. 31, 2022 CAD ($)	Mar. 31, 2023 CAD ($) Headcount	Mar. 31, 2022 CAD ($) Headcount	Mar. 31, 2021 CAD ($)	Nov. 07, 2019
Restructuring Cost And Reserve [Line Items]
Inventory write-downs									$ 82,756,000	$ 237,147,000
Aggregate pre-tax charges									$ 547,533,000	$ 429,810,000	$ 564,049,000
Number of full time positions eliminated | Headcount									800	250
Goodwill impairment loss		$ 0	$ 59,712,000		$ 40,748,000				$ 1,785,080,000	$ 40,748,000	0
Total restructuring, asset impairment and related costs									2,347,227,000	496,623,000	570,683,000
Impairment losses									403,575,000
Share-based compensation			14,581,000				$ 20,020,000	$ 26,448,000	$ 31,188,000	47,525,000	91,149,000
Canadian And International Production Facilities
Restructuring Cost And Reserve [Line Items]
Inventory write-downs											25,985,000
Third Party
Restructuring Cost And Reserve [Line Items]
Derecognized royalty obligations						$ 18,810,000
More Life
Restructuring Cost And Reserve [Line Items]
Ownership percentage												60%
Impairment of equity method investments						$ 10,300,000					10,300,000
Derecognized royalty obligations	$ 33,681,000
Mirabel, Quebec
Restructuring Cost And Reserve [Line Items]
Ownership percentage		100%							100%
Vert Mirabel
Restructuring Cost And Reserve [Line Items]
Purchase of remaining ownership interest percentage		45%
Aldergrove and Delta
Restructuring Cost And Reserve [Line Items]
Proceeds from sale of assets											40,650,000
Property, Plant and Equipment
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges									$ 376,176,000	224,726,000	426,748,000
Brand and License
Restructuring Cost And Reserve [Line Items]
Brand and license impairment charges									$ 14,614,000	$ 26,065,000	$ 6,634,000
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]									Restructuring Costs and Asset Impairment Charges		Restructuring Costs and Asset Impairment Charges
BioSteel
Restructuring Cost And Reserve [Line Items]
Goodwill impairment loss			57,401,000
This Work
Restructuring Cost And Reserve [Line Items]
Goodwill impairment loss			$ 2,311,000		18,393,000
KeyLeaf
Restructuring Cost And Reserve [Line Items]
Goodwill impairment loss					$ 22,355,000
KeyLeaf | Brand and License
Restructuring Cost And Reserve [Line Items]
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]										Restructuring Costs and Asset Impairment Charges
Canada Cannabis
Restructuring Cost And Reserve [Line Items]
Goodwill impairment loss				$ 1,725,368,000
Costs Recorded in Cost of Goods Sold
Restructuring Cost And Reserve [Line Items]
Inventory write-downs									$ 90,485,000	$ 123,669,000	$ 25,985,000
Restructuring and other charges									90,485,000	123,669,000	25,985,000
Costs Recorded in Operating Expenses
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges									457,048,000	302,526,000	527,764,000
Impairment losses										266,130,000	481,259,000
Share-based compensation										3,615,000
Costs Recorded in Operating Expenses | Property, Plant and Equipment
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges									376,176,000	224,726,000	426,748,000
Impairment losses									376,176,000	224,726,000	426,748,000
Costs Recorded in Operating Expenses | Operating License and Intellectual Property Intangible Assets
Restructuring Cost And Reserve [Line Items]
Impairment losses									27,399,000
Costs Recorded in Operating Expenses | Brand, Intellectual Property and License Intangible Assets
Restructuring Cost And Reserve [Line Items]
Impairment losses										41,404,000	54,511,000
Costs Recorded in Operating Expenses | Contractual And Other Settlement Obligations
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges									18,427,000	6,610,000	22,352,000
Costs Recorded in Operating Expenses | Employee-related and Other Restructuring Costs
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges									$ 35,046,000	$ 29,786,000	$ 24,153,000

Asset Impairment and Restruct_4

Asset Impairment and Restructuring Costs - Summary of Pre-tax Charges Recognized in Restructuring Actions and Other Impairments (Details) - CAD ($) $ in Thousands	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Restructuring Cost And Reserve [Line Items]
Share-based compensation	$ 14,581	$ 20,020	$ 26,448	$ 31,188	$ 47,525	$ 91,149
Restructuring and share-based compensation				547,533	429,810	564,049
Asset impairment and restructuring costs		1,841,185	1,855,255	2,227,989	332,949	519,209
Other impairments				1,799,694	66,813	6,634
Total asset impairment and restructuring costs	$ 101,369	$ 1,829,354	$ 1,851,613	2,256,742	369,339	534,398
Total restructuring, asset impairment and related costs				2,347,227	496,623	570,683
Property, Plant and Equipment
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges				376,176	224,726	426,748
Intangible Assets
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges				27,399	41,404	54,511
Asset impairment and restructuring costs				14,614	26,065	6,634
Costs Recorded in Cost of Goods Sold
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges				90,485	123,669	25,985
Total asset impairment and restructuring costs				90,485	123,669	25,985
Costs Recorded in Operating Expenses
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges				457,048	302,526	527,764
Share-based compensation					3,615
Asset impairment and restructuring costs				1,799,694	66,813	6,634
Total asset impairment and restructuring costs				2,256,742	369,339	534,398
Costs Recorded in Operating Expenses | Property, Plant and Equipment
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges				376,176	224,726	426,748
Total asset impairment and restructuring costs				376,176	224,726	426,748
Costs Recorded in Operating Expenses | Intangible Assets
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges				27,399	41,404	54,511
Asset impairment and restructuring costs				14,614	26,065	6,634
Total asset impairment and restructuring costs				42,013	67,469	61,145
Costs Recorded in Operating Expenses | Goodwill
Restructuring Cost And Reserve [Line Items]
Asset impairment and restructuring costs				1,785,080	40,748
Total asset impairment and restructuring costs				1,785,080	40,748
Costs Recorded in Operating Expenses | Contractual And Other Settlement Obligations
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges				18,427	6,610	22,352
Total asset impairment and restructuring costs				18,427	6,610	22,352
Costs Recorded in Operating Expenses | Employee-related and Other Restructuring Costs
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges				35,046	29,786	24,153
Total asset impairment and restructuring costs				$ 35,046	29,786	24,153
Costs Recorded in Operating Expenses | Spectrum Columbia and Canindica Acquisitions
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges					3,615
Total asset impairment and restructuring costs					$ 3,615
Costs Recorded in Loss from Equity Method Investments
Restructuring Cost And Reserve [Line Items]
Impairment of equity method investments restructuring						10,300
Impairment of equity method investments cost						$ 10,300

Cash and Cash Equivalents - Com

Cash and Cash Equivalents - Components of Cash and Cash Equivalents (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Cash and Cash Equivalents [Abstract]
Cash	$ 462,460	$ 470,682
Cash equivalents	214,547	305,323
Cash and cash equivalents	$ 677,007	$ 776,005

Short-term Investments - Compon

Short-term Investments - Components of Short-term Investments (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Marketable Securities [Line Items]
Short-term investments	$ 105,595	$ 595,651
Government securities
Marketable Securities [Line Items]
Short-term investments	60,226	22,253
Term Deposits
Marketable Securities [Line Items]
Short-term investments	30,000	319,092
Commercial Paper and Other
Marketable Securities [Line Items]
Short-term investments	$ 15,369	$ 254,306

Short-term Investments - Additi

Short-term Investments - Additional Information (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Short-Term Investments [Abstract]
Amortized cost of short-term investments	$ 107,661	$ 599,862

Amounts Receivable, Net - Compo

Amounts Receivable, Net - Components of Amounts Receivable, Net (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Receivables [Abstract]
Accounts receivable, net	$ 66,820				$ 68,197
Indirect taxes receivable	11,544				7,524
Interest receivable	3,966				4,406
Other receivables	11,657				6,454
Amounts receivable, net	$ 93,987	$ 81,686	$ 82,416	$ 82,799	$ 86,581

Amounts Receivable, Net - Addit

Amounts Receivable, Net - Additional Information (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Receivables [Abstract]
Allowance for doubtful accounts	$ 9,296	$ 4,764

Inventory - Components of Inven

Inventory - Components of Inventory (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Inventory Disclosure [Abstract]
Raw materials, packaging supplies and consumables	$ 28,982				$ 26,821
Work in progress	34,104				65,245
Finished goods	85,815				112,473
Inventory	$ 148,901	$ 214,045	$ 211,754	$ 205,532	$ 204,539

Inventory - Additional Informat

Inventory - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Inventory [Line Items]
Inventory write-downs	$ 82,756	$ 237,147

Prepaid Expenses and Other As_3

Prepaid Expenses and Other Assets - Components of Prepaid Expenses and Other Assets (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid expenses	$ 27,460				$ 22,961
Deposits	1,734				10,145
Prepaid inventory	690				449
Other assets	10,115				19,065
Prepaid and other assets	$ 39,999	$ 51,705	$ 62,741	$ 61,843	$ 52,620

Other Financial Assets - Summar

Other Financial Assets - Summary of Changes in Other Financial Assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Schedule Of Investments [Line Items]
Beginning balance	$ 800,328	$ 708,167
Additions	253,659	453,684
Fair value changes	(424,115)	(356,109)
Foreign currency translation adjustments	30,162	4,415
Other	(91,742)
Interest income		(9,574)
Exercise of options / disposal of shares		(255)
Ending balance	568,292	800,328
Acreage1 | Fixed Shares Option and Floating Shares Agreement
Schedule Of Investments [Line Items]
Fair value changes	55,382
Ending balance	55,382
TerrAscend Exchangeable Shares | Exchangeable Shares
Schedule Of Investments [Line Items]
Beginning balance	229,000	385,000
Additions	51,000
Fair value changes	(186,489)	(156,000)
Foreign currency translation adjustments	(511)
Ending balance	93,000	229,000
TerrAscend Canada - October 2019 | Term loan / debenture
Schedule Of Investments [Line Items]
Beginning balance	10,280	10,240
Fair value changes	(146)	835
Other	(10,134)
Interest income		(795)
Ending balance		10,280
TerrAscend Canada March 2020 | Term loan / debenture
Schedule Of Investments [Line Items]
Beginning balance	49,890	56,330
Fair value changes	(4,804)	(1,528)
Other	(45,086)
Interest income		(4,912)
Ending balance		49,890
Arise Bioscience | Term loan / debenture
Schedule Of Investments [Line Items]
Beginning balance	13,343	13,077
Fair value changes	(1,767)	308
Foreign currency translation adjustments	1,268	(42)
Other	(12,844)
Ending balance		13,343
TerrAscend - October 2019 | Warrants
Schedule Of Investments [Line Items]
Beginning balance	3,730	17,250
Fair value changes	(3,372)	(13,520)
Other	(358)
Ending balance		3,730
TerrAscend - March 2020 | Warrants
Schedule Of Investments [Line Items]
Beginning balance	60,740	152,910
Fair value changes	(46,376)	(92,170)
Other	(14,364)
Ending balance		60,740
TerrAscend - December 2020 | Warrants
Schedule Of Investments [Line Items]
Beginning balance	3,460	13,240
Fair value changes	(2,246)	(9,780)
Other	(1,214)
Ending balance		3,460
TerrAscend - December 2022 | Warrants
Schedule Of Investments [Line Items]
Additions	33,000
Fair value changes	(7,000)
Ending balance	26,000
TerrAscend | Equity Option
Schedule Of Investments [Line Items]
Beginning balance	6,300	10,600
Fair value changes	(4,700)	(4,300)
Ending balance	1,600	6,300
Wana | Equity Option
Schedule Of Investments [Line Items]
Beginning balance	372,343
Additions		442,227
Fair value changes	(154,936)	(74,639)
Foreign currency translation adjustments	21,671	4,755
Ending balance	239,078	372,343
Jetty | Equity Option
Schedule Of Investments [Line Items]
Additions	90,120
Fair value changes	(19,915)
Foreign currency translation adjustments	4,809
Ending balance	75,014
Acreage Hempco1 | Debenture
Schedule Of Investments [Line Items]
Beginning balance	28,824
Fair value changes	2,361
Foreign currency translation adjustments	2,295
Other	(4,218)
Ending balance	29,262	28,824
Acreage Debt Option Premium | Equity Option
Schedule Of Investments [Line Items]
Additions	38,048
Fair value changes	(3,041)
Foreign currency translation adjustments	472
Ending balance	35,479
Acreage Tax Receivable Agreement | Other
Schedule Of Investments [Line Items]
Additions	41,491
Fair value changes	(38,035)
Foreign currency translation adjustments	(347)
Ending balance	3,109
Acreage Hempco2 | Debenture
Schedule Of Investments [Line Items]
Beginning balance	28,824	27,448
Fair value changes		5,337
Foreign currency translation adjustments		(94)
Interest income		(3,867)
Ending balance		28,824
Other At Fair Value Through Net Income (Loss) | Various
Schedule Of Investments [Line Items]
Beginning balance	10,396	14,887
Additions		6,457
Fair value changes	(9,031)	(10,652)
Foreign currency translation adjustments	505	(204)
Exercise of options / disposal of shares		(92)
Ending balance	1,870	10,396
Other - Classified as Held for Investment | Loan Receivable
Schedule Of Investments [Line Items]
Beginning balance	12,022	7,185
Additions		5,000
Other	(3,524)
Exercise of options / disposal of shares		(163)
Ending balance	$ 8,498	$ 12,022

Other Financial Assets -Additio

Other Financial Assets -Additional Information (Details) $ / shares in Units, $ in Thousands, $ in Thousands												12 Months Ended
	Dec. 09, 2022 CAD ($) $ / shares shares	Nov. 15, 2022 CAD ($)	Nov. 15, 2022 USD ($)	Oct. 24, 2022 CAD ($) $ / shares shares	Oct. 24, 2022 USD ($) shares	May 17, 2022 CAD ($) Tranche Number shares	May 17, 2022 USD ($) Tranche shares	Oct. 14, 2021 CAD ($) Number	Dec. 10, 2020 CAD ($) shares	Mar. 11, 2020 CAD ($) shares	Oct. 02, 2019 CAD ($) shares	Mar. 31, 2023 CAD ($) shares	Mar. 31, 2022 CAD ($)	Oct. 24, 2022 USD ($) shares	May 17, 2022 USD ($) Number	Oct. 14, 2021 USD ($) Number	Jan. 13, 2021 CAD ($)	Jan. 13, 2021 USD ($)	Dec. 10, 2020 USD ($)	Oct. 02, 2019 USD ($)
Schedule Of Investments [Line Items]
Number of tranches in which option agreement is exercisable | Tranche						2	2
Debt Instrument, Fair Value Disclosure	$ 89,094					$ 90,120						$ 75,014
Common stock value												7,938,571	$ 7,482,809
Prior Warrants
Schedule Of Investments [Line Items]
Debt Instrument, Fair Value Disclosure	16,903
Acreage
Schedule Of Investments [Line Items]
Number of common shares issued | shares				7,102,081	7,102,081
Common shares issued, fair value					$ 30,441
Number of floating shares issued in first installment | shares				5,648,927	5,648,927
Amount of floating shares issued in first installment				$ 20,630	$ 15,220
Debt Instrument, Fair Value Disclosure				3,109								35,479
Common stock value														$ 19,559
Amount of floating shares issued for second payment				$ 20,572	$ 15,220
Upfront Payment
Schedule Of Investments [Line Items]
Total consideration						$ 88,349
Deferred Payment1
Schedule Of Investments [Line Items]
Percentage of Fair Value at the time of Option Exercised								25%
Estimate Fair Value Anniversary Year								2 years 6 months
Term Loans or Debentures
Schedule Of Investments [Line Items]
Debt Instrument, Fair Value Disclosure	$ 72,191
Floating Shares | Acreage
Schedule Of Investments [Line Items]
Outstanding principal of acreage's debt			$ 150,000
Option premium payment		$ 38,048	$ 28,500
Jetty
Schedule Of Investments [Line Items]
Number of option agreements | Number						2									2
Ownership percentage				100%		100%								100%	100%
Proceeds from Warrant Exercises						$ 29,226									$ 22,911
Common shares issued, fair value						$ 59,123	$ 45,928
Jetty | First Tranche
Schedule Of Investments [Line Items]
Ownership percentage						52.78%									52.78%
Jetty | Jetty Acquisition
Schedule Of Investments [Line Items]
Number of common shares issued | shares						8,426,539	8,426,539
Jetty | Maximum
Schedule Of Investments [Line Items]
Ownership percentage						100%									100%
Wana
Schedule Of Investments [Line Items]
Outstanding Membership Interests								100%								100%
Number of option agreements | Number								3								3
Ownership percentage				100%				100%						100%		100%
Proceeds from Warrant Exercises								$ 368,067								$ 297,500
Percentage of Fair Value at the time of Option Exercised								15%
Debt Instrument, Fair Value Disclosure								$ 442,227
Estimated Deferred Payments								$ 74,160
Percentage Of Outstanding Membership Interest Acquired								100%
Investment in the exchangeable shares fair value												$ 239,078	372,343
Wana | Deferred Payment2
Schedule Of Investments [Line Items]
Percentage of Fair Value at the time of Option Exercised								25%
Estimate Fair Value Anniversary Year								5 years
First Option Agreement | Jetty | Second Tranche
Schedule Of Investments [Line Items]
Ownership percentage						25%									25%
Second Option Agreement | Jetty
Schedule Of Investments [Line Items]
Ownership percentage						22.22%									22.22%
TerrAscend Arrangement
Schedule Of Investments [Line Items]
Conversion of loans from related company into shares of Common Stock, shares | shares	24,601,467											24,601,467
Purchase price of shares | $ / shares	$ 5.10
Conversion of loans from related company into shares of Common Stock	$ 125,467											$ 93,000	229,000
Debt Instrument, Fair Value Disclosure	84,000
Loss on differences in derecognized financial instruments and fair value of financial assets received	$ 5,094
TerrAscend Arrangement | Warrants
Schedule Of Investments [Line Items]
Conversion of loans from related company into shares of Common Stock, shares | shares	22,474,130
Exercise price of warrants | $ / shares	$ 6.07
Debt Instrument, Fair Value Disclosure	$ 33,000											26,000
New TerrAscend Securities
Schedule Of Investments [Line Items]
Conversion of loans from related company into shares of Common Stock, shares | shares	63,492,037
New TerrAscend Securities | Warrants
Schedule Of Investments [Line Items]
Conversion of loans from related company into shares of Common Stock, shares | shares	22,474,130
TerrAscend Canada
Schedule Of Investments [Line Items]
Loans, warrants and options										$ 80,526
TerrAscend Canada | TerrAscend Warrants
Schedule Of Investments [Line Items]
Conversion of loans from related company into shares of Common Stock, shares | shares										17,808,975
Loans, warrants and options										$ 25,626		15,235	60,740
TerrAscend Canada | Term Loan
Schedule Of Investments [Line Items]
Loans, warrants and options										$ 54,800		47,820	49,890
TerrAscend Canada | RIV Capital
Schedule Of Investments [Line Items]
Loans, warrants and options											$ 13,243									$ 10,000
TerrAscend Canada | RIV Capital | TerrAscend Warrants
Schedule Of Investments [Line Items]
Conversion of loans from related company into shares of Common Stock, shares | shares											2,559,437
Loans, warrants and options												380	3,730
TerrAscend Canada | RIV Capital | Term Loan
Schedule Of Investments [Line Items]
Loans, warrants and options												10,749	10,280
Arise Bioscience
Schedule Of Investments [Line Items]
Loans, warrants and options									$ 25,478										$ 20,000
Arise Bioscience | TerrAscend Warrants
Schedule Of Investments [Line Items]
Conversion of loans from related company into shares of Common Stock, shares | shares									2,105,718
Loans, warrants and options									$ 13,720			1,288	3,460
Arise Bioscience | Term Loan
Schedule Of Investments [Line Items]
Loans, warrants and options									$ 11,758			13,622	13,343
TerrAscend Option | Equity Option
Schedule Of Investments [Line Items]
Purchase price of shares | $ / shares				$ 1
Loans, warrants and options																	$ 13,445	$ 10,529
Business acquisition additional number of shares issuable | shares				1,072,450										1,072,450
Investment in subsidiary												$ 1,600	$ 6,300
TerrAscend Exchangeable Shares
Schedule Of Investments [Line Items]
Debt Instrument, Fair Value Disclosure	$ 51,000

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Components of Property, Plant and Equipment (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 611,473	$ 1,175,692
Less: Accumulated depreciation	(112,007)	(232,912)
Property, plant and equipment, net	499,466	942,780
Buildings and Greenhouses
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	413,832	766,931
Buildings and Greenhouses | Right-of-Use-Assets
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	37,533	89,228
Production and Warehouse Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	101,326	159,314
Production and Warehouse Equipment | Right-of-Use-Assets
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	637	55
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	15,529	69,304
Land
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	16,781	18,917
Office and Lab Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	13,857	29,879
Computer Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	8,697	22,293
Assets in Process
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 3,281	$ 19,771

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Property Plant And Equipment [Line Items]
Depreciation of property, plant and equipment	$ 56,736	$ 76,247	$ 70,914
Property, Plant and Equipment
Property Plant And Equipment [Line Items]
Charges associated with strategic review	376,176	224,726	426,748
Costs Recorded in Cost of Goods Sold
Property Plant And Equipment [Line Items]
Depreciation of property, plant and equipment	46,164	50,200	51,737
Charges associated with strategic review	90,485	123,669	25,985
Selling, General and Administrative Expenses
Property Plant And Equipment [Line Items]
Depreciation of property, plant and equipment	$ 10,572	$ 26,047	$ 19,177

Intangible Assets - Summary of

Intangible Assets - Summary of Components of Intangible Assets (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	$ 268,568	$ 276,057
Net Carrying Amount	139,279	167,886
Total intangible assets	188,719	252,695
Intellectual Property
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	119,283	138,170
Net Carrying Amount	70,588	97,638
Distribution Channel
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	73,024	72,642
Net Carrying Amount	21,258	24,834
Software and Domain Names
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	35,100	29,822
Net Carrying Amount	14,664	14,206
Operating Licenses
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	24,400	24,400
Net Carrying Amount	19,012	22,052
Indefinite lived intangible assets		10,000
Brands
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	16,253	5,547
Net Carrying Amount	13,249	3,680
Amortizable Intangibles in Process
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	508	5,476
Net Carrying Amount	508	5,476
Acquired Brands
Intangible Assets Net Excluding Goodwill [Line Items]
Indefinite lived intangible assets	$ 49,440	$ 74,809

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - CAD ($) $ in Thousands	6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets			$ 27,781	$ 38,171	$ 56,204
Asset impairment and restructuring costs	$ 1,841,185	$ 1,855,255	2,227,989	332,949	519,209
Intangible Assets
Finite Lived Intangible Assets [Line Items]
Restructuring and other charges			27,399	41,404	54,511
Asset impairment and restructuring costs			14,614	26,065	6,634
Costs Recorded in Cost of Goods Sold
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets			60	81	80
Restructuring and other charges			90,485	123,669	25,985
Selling, General and Administrative Expenses
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets			$ 27,721	$ 38,090	$ 56,124

Intangible Assets - Summary o_2

Intangible Assets - Summary of Estimated Amortization Expense (Details) $ in Thousands	Mar. 31, 2023 CAD ($)
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
2024	$ 28,654
2025	27,276
2026	22,846
2027	20,642
2028	19,518
Thereafter	$ 20,343

Goodwill - Changes in Carrying

Goodwill - Changes in Carrying Amount of Goodwill (Details) - CAD ($)	3 Months Ended			12 Months Ended
	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Goodwill [Line Items]
Beginning Balance	$ 84,675,000			$ 1,866,503,000	$ 1,889,354,000
Purchase accounting allocations					105,323,000
Impairment losses	0	$ (59,712,000)	$ (40,748,000)	(1,785,080,000)	(40,748,000)	$ 0
Foreign currency translation adjustments				4,367,000	(28,640,000)
Ending Balance	85,563,000	$ 79,112,000	1,866,503,000	85,563,000	1,866,503,000	$ 1,889,354,000
Consolidated Entities
Goodwill [Line Items]
Disposal of consolidated entities	$ (227,000)		$ (58,786,000)	$ (227,000)	$ (58,786,000)

Goodwill - Additional Informati

Goodwill - Additional Information (Details) - CAD ($)	3 Months Ended				12 Months Ended
	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2022
Goodwill [Line Items]
Goodwill impairment loss	$ 0	$ 59,712,000		$ 40,748,000	$ 1,785,080,000	$ 40,748,000	$ 0
Goodwill	$ 85,563,000	79,112,000		1,866,503,000	85,563,000	1,866,503,000	$ 1,889,354,000	$ 84,675,000
Key Leaf Reporting Unit
Goodwill [Line Items]
Goodwill impairment loss						22,355,000
This Works Reporting Unit
Goodwill [Line Items]
Goodwill impairment loss		2,311,000				18,393,000
Goodwill				$ 2,289,000		$ 2,289,000
Cannabis Operations Reporting Unit
Goodwill [Line Items]
Goodwill impairment loss			$ 1,725,368,000
Estimated fair value decrease percentage						15%
Share price decrease percentage						10%
Cannabis Operations Reporting Unit | Minimum
Goodwill [Line Items]
Goodwill percentage of fair value in excess of carrying value				5%		5%
Cannabis Operations Reporting Unit | Maximum
Goodwill [Line Items]
Goodwill percentage of fair value in excess of carrying value				10%		10%
Cannabis Operations Reporting Unit | Estimated Control Premium Decreased by 100 Basis Points
Goodwill [Line Items]
Goodwill				$ 1,727,848,000		$ 1,727,848,000
Decrease in estimated control premium						5%
Estimated fair value decrease percentage						7%
BioSteel Reporting Unit
Goodwill [Line Items]
Goodwill impairment loss		$ 57,401,000
BioSteel Reporting Unit | Discount Rate Increased by 50 Basis Points
Goodwill [Line Items]
Goodwill				57,339,000		$ 57,339,000
Estimated fair value decrease percentage						8%
Increase in discount rate						0.50%
BioSteel Reporting Unit | Annual Cash Flow Projections Decreased By 250 Basis Points
Goodwill [Line Items]
Estimated fair value decrease percentage						5%
Decrease in annual cash flow projections						2.50%
BioSteel Reporting Unit | Long Term Growth Rate Decreased By50 Basis Points
Goodwill [Line Items]
Estimated fair value decrease percentage						3%
Decrease in long-term growth rate						0.50%
Storz & Bickel Reporting Unit
Goodwill [Line Items]
Goodwill impairment loss					$ 0
Goodwill impairment, method for fair value determination					The estimated fair value of the Storz & Bickel reporting unit was determined using the income valuation method, with the most significant assumptions used in applying this method being: (i) the discount rate; (ii) the expected long-term growth rate; (iii) revenue growth rate projections; and (iv) annual cash flow projections. This methodology is consistent with that used by the Company for its annual impairment test conducted at March 31, 2022.
Goodwill percentage of fair value in excess of carrying value	3%				3%
Storz & Bickel Reporting Unit | Discount Rate Increased by 50 Basis Points
Goodwill [Line Items]
Goodwill	$ 85,563,000			$ 79,027,000	$ 85,563,000	$ 79,027,000
Estimated fair value decrease percentage					5%	6%
Increase in discount rate					0.50%	0.50%
Storz & Bickel Reporting Unit | Annual Cash Flow Projections Decreased By 250 Basis Points
Goodwill [Line Items]
Estimated fair value decrease percentage					3%	3%
Decrease in annual cash flow projections					2.50%	2.50%
Storz & Bickel Reporting Unit | Long Term Growth Rate Decreased By50 Basis Points
Goodwill [Line Items]
Estimated fair value decrease percentage					4%	4%
Decrease in long-term growth rate					0.50%	0.50%
Storz & Bickel Reporting Unit | Revenue Growth Decreased by 250 Basis Points
Goodwill [Line Items]
Estimated fair value decrease percentage					11%
Decrease in revenue growth projections					2.50%

Other Accrued Expenses and Li_3

Other Accrued Expenses and Liabilities - Components of Other Accrued Expenses and Liabilities (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Accounts Payable and Accrued Liabilities, Current [Abstract]
Employee compensation	$ 30,816	$ 24,873
Inventory	323	10,096
Professional fees	6,343	7,640
Taxes and government fees	5,734	7,144
Other	32,775	25,525
Other accrued expenses and liabilities	$ 75,991	$ 75,278

Debt - Summary of Components of

Debt - Summary of Components of Debt (Details) - CAD ($) $ in Thousands		12 Months Ended
	Jun. 20, 2018	Mar. 31, 2023	Mar. 31, 2022	Jun. 29, 2022
Debt Instrument [Line Items]
Other revolving debt facility, loan, and financings		$ 2,062	$ 2,808
Long Term Debt		1,306,881	1,500,991
Total debt		1,306,881	1,500,991
Less: current portion		(556,890)	(9,296)
Long-term portion		$ 749,991	1,491,695
4.25% Senior Notes [Member]
Debt Instrument [Line Items]
Debenture maturity date	Jul. 15, 2023	Jul. 15, 2023
Principal amount	$ 600,000	$ 337,380	600,000	$ 262,620
Accrued interest		3,148	5,958
Non-credit risk fair value adjustment		26,214	7,140
Credit risk fair value adjustment		(35,492)	(49,140)
Senior Notes			563,958
Long Term Debt		331,250
Total debt		$ 331,250
Supreme Convertible Debentures
Debt Instrument [Line Items]
Convertible debentures		Sep. 10, 2025
Convertible debentures		$ 31,503	32,858
Equity Settled Convertible Debentures
Debt Instrument [Line Items]
Convertible debentures		Feb. 28, 2028
Equity-settled convertible debentures		$ 93,228
Accretion debentures
Debt Instrument [Line Items]
Convertible debentures		Sep. 10, 2025
Accretion debentures		$ 8,780	7,720
Revolving Credit Facility
Debt Instrument [Line Items]
Convertible debentures		Mar. 18, 2026
Credit facility		$ 840,058	$ 893,647

Debt - Summary of Components _2

Debt - Summary of Components of Debt (Parenthetical) (Details)	Mar. 31, 2023	Jun. 20, 2018
4.25% Senior Notes [Member]
Debt Instrument [Line Items]
Annual interest rate	4.25%	4.25%

Debt - Additional Information (

Debt - Additional Information (Details)

1 Months Ended

3 Months Ended

12 Months Ended

Apr. 17, 2023 CAD ($)

Apr. 17, 2023 USD ($)

Feb. 21, 2023 CAD ($)

Feb. 21, 2023 USD ($)

Nov. 10, 2022 CAD ($)

Nov. 10, 2022 USD ($)

Oct. 24, 2022 USD ($) $ / shares

Jul. 18, 2022 shares

Jun. 29, 2022 CAD ($) shares

Jun. 22, 2022

Mar. 18, 2021 CAD ($)

Mar. 18, 2021 USD ($) $ / shares

Sep. 09, 2020 CAD ($)

Jun. 20, 2018 CAD ($)

Sep. 09, 2020 CAD ($)

Oct. 19, 2018 CAD ($) $ / shares

Jun. 30, 2022 CAD ($) shares

Mar. 31, 2023 CAD ($) shares

Mar. 31, 2022 CAD ($)

Mar. 31, 2021 CAD ($)

Apr. 17, 2023 USD ($)

Mar. 31, 2023 USD ($)

Nov. 10, 2022 USD ($)

Jul. 31, 2022 CAD ($) shares

Jun. 30, 2022 $ / shares

Jun. 29, 2022 $ / shares

Debt Instrument [Line Items]

Issuance of long-term debt

$ 893,160,000

$ 135,160,000

$ 893,160,000

Derivative Liability, Statement of Financial Position [Extensible Enumeration]

Derivative Liability, Noncurrent

Derivative Liability, Noncurrent

Derivative liability

$ 39,896,000

Accretion Rate

11.06%

Conversion Of Outstanding Debentures Description

In addition, the Company may force conversion of the Supreme Debentures outstanding with 30 days’ notice if the daily volume weighted average trading price of the Company’s common shares is greater than $38.59 for any 10 consecutive trading days. The Company, Supreme Cannabis and the Trustee entered into a further supplemental indenture whereby the Company agreed to guarantee the obligations of Supreme Cannabis pursuant to the Supreme Debentures and the Accretion Debentures.

Debt instrument discounted price

$ 930,000

$ 930,000

First repayment of debt

118,179,000

$ 50,763,000

$ 15,619,000

Debt Instrument Fair Value

76,424,000

Debt instrument final closing trading days

10 days

GCILP and Other Notes Holders [Member]

Debt Instrument [Line Items]

Principal amount

$ 199,522,000

Supreme Cannabis

Debt Instrument [Line Items]

Interest at a rate

6%

Proceeds from the Credit Facility

$ 100,000,000

Maturity date

Sep. 10, 2025

Conversion price | $ / shares

$ 0.285

Cancellation of Debt

$ 63,500,000

Monthly Interest Rate

1%

1%

Percentage of shares acquired

100%

Minimum

Debt Instrument [Line Items]

Minimum liquidity, each fiscal quarter

100,000,000

Minimum | Supreme Cannabis

Debt Instrument [Line Items]

Proceeds from the Credit Facility

$ 13,500,000

Maximum | Supreme Cannabis

Debt Instrument [Line Items]

Interest at a rate

8%

Proceeds from the Credit Facility

$ 36,500,000

4.25% Senior Notes [Member]

Debt Instrument [Line Items]

Principal amount

$ 262,620,000

$ 600,000,000

$ 337,380,000

600,000,000

Interest at a rate

4.25%

4.25%

4.25%

Frequency of periodic payment team

semi-annually on January 15th and July 15th of each year commencing from January 15, 2019

Maturity date

Jul. 15, 2023

Jul. 15, 2023

Other income (expense), net

$ 44,370,000

Tax impact on aggregated principal amount

14,862,000

Debt instrument, change in fair value of notes

232,708,000

123,456,000

Debt instrument, change in fair value of notes from contractual interest

16,956,000

25,794,000

Principal redemption

262,620,000

$ 0

Principal redeemed fair value

225,369,000

Accrued and unpaid interest

5,383,000

Aggregate purchase price

$ 259,994,000

Debt instrument cancelled

262,620,000

4.25% Senior Notes [Member] | Common Shares

Debt Instrument [Line Items]

Principal amount

$ 63,098,000

$ 99,522,000

Shares issued | shares

35,662,420

14,069,353

21,593,067

Purchase price of shares | $ / shares

$ 3.50

Debt Instrument Fair Value

$ 50,866,000

4.25% Senior Notes [Member] | Common Shares | Noteholders [Member]

Debt Instrument [Line Items]

Shares issued | shares

11,896,536

Purchase price of shares | $ / shares

$ 2.6245

4.25% Senior Notes [Member] | Common Shares | GCILP [Member]

Debt Instrument [Line Items]

Principal amount

200,000,000

Shares issued | shares

29,245,456

Debt Instrument Fair Value

98,078,000

Debt instrument cancelled

100,000,000

Debt instrument acquired

100,000,000

4.25% Senior Notes [Member] | Common Shares | GCILP and Other Notes Holders [Member]

Debt Instrument [Line Items]

Shares issued | shares

62,735,059

4.25% Senior Notes [Member] | Exchange Transaction

Debt Instrument [Line Items]

Derivative liability

$ 26,594,000

Paydown Agreement [Member]

Debt Instrument [Line Items]

Minimum liquidity, each fiscal quarter

100,000,000

Additional incremental term loan facility

500,000,000

Principal amount

$ 100,000,000

Acquisition and cancellation of notes, Share issued on June and July Twenty Twenty Two [Member]

Debt Instrument [Line Items]

Principal amount

$ 262,620,000

Shares issued | shares

76,804,412

Credit Facility

Debt Instrument [Line Items]

Senior secured debt, Term

5 years

Senior credit facility

$ 500,000

Loan amortization payment

$ 0

Convertible debentures

Mar. 18, 2026

Principal amount

$ 750,000

Debt Instrument Discounted Price Per Us Dollar | $ / shares

$ 1,000

$ 1,000

First repayment of debt

$ 174,375,000

$ 174,375,000

Credit Facility | Paydown Agreement [Member]

Debt Instrument [Line Items]

Principal amount

$ 187,500,000

$ 187,500

First repayment of debt

$ 117,528,000

$ 87,852,000

Aggregate principal payment amount

$ 126,324,000

$ 94,427,000

Credit Facility | Paydown Agreement [Member] | Subsequent Event

Debt Instrument [Line Items]

First repayment of debt

$ 116,847,000

$ 87,213,000

Aggregate principal payment amount

$ 125,606,000

$ 93,750,000

L I B O R Plus

Debt Instrument [Line Items]

Interest at a rate

8.50%

L I B O R Floor

Debt Instrument [Line Items]

Interest at a rate

1%

Convertible Debentures

Debt Instrument [Line Items]

Principal amount

$ 27,200,000

Interest at a rate

5%

5%

Maturity date

Feb. 28, 2028

Cash payment or any other property payable

$ 0

Debt Conversion, Description

The Convertible Debentures bear interest at a rate of 5.0% per annum from the date of issuance, payable at the earlier of: (i) the time of conversion of the Convertible Debentures; or (ii) February 28, 2028 (the “Maturity Date”), in each case, in common shares of Canopy Growth. No cash payment or any other property of the Company will be payable by the Company to the Institutional Investor in connection with, or as a result of, the issuance, conversion or repayment of the Convertible Debentures. The Convertible Debentures are convertible into the Company’s common shares at the option of the Institutional Investor at any time or times prior to the Maturity Date, at a conversion price equal to 92.5% of the volume-weighted average price of the Company’s common shares during the three consecutive trading days ending on the business day immediately prior to the date of conversion. On the Maturity Date, the principal amount of the Convertible Debentures, including any accrued but unpaid interest, will also be paid in the Company’s common shares.For the year ended March 31, 2023, US$27,200 in aggregate principal amount of the Convertible Debentures were converted for 14,142,066 common shares. For additional information, refer to Note 20.

Conversion price percentage

92.50%

92.50%

Convertible debentures converted to common shares | shares

14,142,066

Convertible Debentures | Convertible Debenture Agreement [Member] | Institutional Investor

Debt Instrument [Line Items]

Purchased initial amount of convertible debentures

$ 135,160,000

$ 100,000,000

Additional convertible debentures amount purchased in the event of certain conditions are satified or waived

50,000,000

Convertible Debentures | Convertible Debenture Agreement [Member] | Maximum | Institutional Investor

Debt Instrument [Line Items]

Purchase and sale of aggregate principal amount of senior unsecured convertible debentures

$ 150,000,000

Debt - Summary of Required Prin

Debt - Summary of Required Principal Repayments Under Long-term Debt Obligations Excluding Equity-settled Convertible Debentures (Details) $ in Thousands	Mar. 31, 2023 CAD ($)
Long-Term Debt, Fiscal Year Maturity [Abstract]
2024	$ 467,957
2025	6,865
2026	787,956
Long-term debt obligations	$ 1,262,778

Other Liabilities - Components

Other Liabilities - Components of Other Liabilities (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Current
Lease liabilities	$ 28,684				$ 38,035
Acquisition consideration and other investment related liabilities	25,945				4,020
Refund liability	7,123				3,729
Settlement liabilities and other	32,975				18,562
Other Liabilities Current	94,727	$ 84,547	$ 79,880	$ 86,946	64,346
Long-term
Lease liabilities, long-term	80,625				101,125
Acquisition consideration and other investment related liabilities, long-term	30,323				77,834
Settlement liabilities and other, long-term	13,938				11,090
Other liabilities, long-term	124,886				190,049
Total
Lease liabilities	109,309				139,160
Acquisition consideration and other investment related liabilities	56,268				81,854
Refund liability	7,123				3,729
Settlement liabilities and other	46,913				29,652
Other liabilities	$ 219,613				$ 254,395

Other Liabilities - Additional

Other Liabilities - Additional Information (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Wana
Accelerated Share Repurchases [Line Items]
Estimated fair value of deferred payments	$ 26,370	$ 70,066

Redeemable Noncontrolling Int_3

Redeemable Noncontrolling Interest - Summary of Net Change in Redeemable Noncontrolling Interests (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Redeemable Noncontrolling Interest [Line Items]
Beginning balance	$ 32,500	$ 135,300	$ 69,750
Net loss attributable to redeemable noncontrolling interest	(29,544)	(19,317)	(18,077)
Adjustments to redemption amount	9,720	(78,374)	83,627
Ending balance		32,500	135,300
Redeemable Noncontrolling Interest [Member]
Redeemable Noncontrolling Interest [Line Items]
Redemption of redeemable noncontrolling interest	(12,676)	(5,109)
Vert Mirabel
Redeemable Noncontrolling Interest [Line Items]
Beginning balance	1,000	11,500	20,250
Net loss attributable to redeemable noncontrolling interest	(53)	(3,165)	(11,906)
Adjustments to redemption amount	53	(7,335)	3,156
Ending balance		1,000	11,500
Vert Mirabel | Redeemable Noncontrolling Interest [Member]
Redeemable Noncontrolling Interest [Line Items]
Redemption of redeemable noncontrolling interest	(1,000)
BioSteel
Redeemable Noncontrolling Interest [Line Items]
Beginning balance	31,500	123,800	49,500
Net loss attributable to redeemable noncontrolling interest	(29,491)	(16,152)	(6,171)
Adjustments to redemption amount	9,667	(71,039)	80,471
Ending balance		31,500	$ 123,800
BioSteel | Redeemable Noncontrolling Interest [Member]
Redeemable Noncontrolling Interest [Line Items]
Redemption of redeemable noncontrolling interest	$ (11,676)	$ (5,109)

Share Capital - Additional Info

Share Capital - Additional Information (Details) $ / shares in Units, $ in Thousands		11 Months Ended	12 Months Ended
	Apr. 02, 2020 shares	Feb. 23, 2021 CAD ($) $ / shares shares	Mar. 31, 2023 CAD ($) Equity shares	Mar. 31, 2022 CAD ($) Equity	Mar. 31, 2021 Equity	Mar. 31, 2020
Class Of Stock [Line Items]
Number of equity financings | Equity			0	0	0
Financings | $		$ 0
Redemption of redeemable noncontrolling interest | $			$ (34,012)	$ (2,492)
BioSteel
Class Of Stock [Line Items]
Shares issued relating to redemption of redeemable noncontrolling interest			8,692,128
Redemption of redeemable noncontrolling interest | $			$ 26,506
Percentage of interest before redemption			78.60%
Percentage of interest after redemption			90.40%
Class A Subordinate Voting Shares
Class Of Stock [Line Items]
Daily purchases of common shares, limit	70,653
Average daily trading volume	25%
RIV Capital [Member]
Class Of Stock [Line Items]
Ownership percentage						27.30%
Voting rights percentage						84.40%
RIV Capital [Member] | Class A Subordinate Voting Shares
Class Of Stock [Line Items]
Treasury shares		15,223,938	0
Maximum number of shares authorized to be repurchased	10,409,961
Percentage of subordinated voting shares issuable from treasury	10%
NCIB expiration date	Apr. 01, 2021
Stock repurchased and cancelled, shares		273,300
Stock repurchased and cancelled, value | $		$ 307
Weighted Average price, per share | $ / shares		$ 1.11
RIV Capital [Member] | Class B Multiple Voting Shares
Class Of Stock [Line Items]
Treasury shares		36,468,318	0

Share Capital - Summary of Issu

Share Capital - Summary of Issuances of Stock Other (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Equity Class Of Treasury Stock [Line Items]
Completion of acquisition milestones, Number of shares	222,421	1,295,285	2,598,978
Share Capital
Equity Class Of Treasury Stock [Line Items]
Completion of acquisition milestones	$ 1,379	$ 29,276	$ 46,903
Share-based Reserve
Equity Class Of Treasury Stock [Line Items]
Completion of acquisition milestones	$ (1,379)	$ (29,721)	$ (19,059)
Settlement of Convertible Debentures [Member]
Equity Class Of Treasury Stock [Line Items]
Number of common shares	14,142,066
Share capital	$ 38,781
HSCP Holders Pursuant to Amended TRA [Member]
Equity Class Of Treasury Stock [Line Items]
Number of common shares	12,751,008
Share capital	$ 41,202
Jetty Agreements
Equity Class Of Treasury Stock [Line Items]
Number of common shares	8,426,539
Share capital	$ 59,013
Acquisition Of Supreme Cannabis [Member]
Equity Class Of Treasury Stock [Line Items]
Number of common shares		9,013,400
Share capital		$ 260,668
Other Issuances [Member]
Equity Class Of Treasury Stock [Line Items]
Number of common shares	299,853	492,741	449,729
Share capital	$ 1,621	$ 8,201	$ 14,906
Share based reserve	$ (572)	$ (736)	$ (14,894)
Total [Member]
Equity Class Of Treasury Stock [Line Items]
Number of common shares	35,841,887	10,801,426	3,048,707
Share capital	$ 141,996	$ 298,145	$ 61,809
Share based reserve	$ (1,951)	$ (30,457)	$ (33,953)

Share Capital - Summary of Warr

Share Capital - Summary of Warrants (Details) - CAD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Class Of Warrant Or Right [Line Items]
Number of whole warrants, Beginning balance	128,193,047	127,073,136	146,299,443
Number of whole warrants, Exercise of warrants			(18,882,927)
Number of whole warrants, Supreme Cannabis Warrants		1,265,742
Number of whole warrants, Expiry of warrants	0	(145,831)	(343,380)
Number of whole warrants, Ending balance	128,193,047	128,193,047	127,073,136
Average exercise price, Beginning balance	$ 58.04	$ 58.33	$ 52.44
Average exercise price, Exercise of warrants			12.98
Average exercise price, Supreme Cannabis warrants		25.61
Average exercise price, Expiry of warrants	0	$ 32.61	41.49
Average exercise price, Ending balance	$ 58.04	$ 58.04	$ 58.33
Warrant value, Beginning balance	$ 2,581,788	$ 2,568,438	$ 2,638,951
Warrant value, Exercise of warrants			(70,513)
Warrant Value, Supreme Cannabis warrants		13,350
Warrant value, Expiry of warrants	0	0	0
Warrant value, Ending balance	$ 2,581,788	$ 2,581,788	$ 2,568,438

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) - CAD ($) $ / shares in Units, $ in Thousands			3 Months Ended	6 Months Ended	9 Months Ended	11 Months Ended	12 Months Ended
	May 27, 2021	Sep. 21, 2020	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Feb. 23, 2021	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Jun. 22, 2021	Mar. 31, 2020	Oct. 01, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options extended period		10 years
Options maximum period		6 years
Weighted average exercise price of options outstanding							$ 27.12	$ 33.89
Weighted average exercise price of options exercisable							$ 37.28	$ 38.33
Stock options outstanding							13,750,888
Proceeds from exercise of stock options							$ 281	$ 5,567	$ 156,897
Share-based compensation			$ 14,581	$ 20,020	$ 26,448		$ 31,188	$ 47,525	$ 91,149
Number of common shares released on completion of acquisition milestones							222,421	1,295,285	2,598,978
Number of shares to be issued on completion of acquisition and asset purchase milestones							125,489
RIV Capital [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense						$ 2,659
Acquisition Milestones
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation							$ 0	$ 7,991	$ 8,136
Costs Recorded in Operating Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation								3,615
Supreme Cannabis
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense								$ 823
Acquisition of outstanding capital stock										100%
Bio Steel Sports Nutrition Inc
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options outstanding							614,778	1,565,300	1,581,000
Share-based compensation							$ 1,143	$ 839	$ 1,169
Acquisition of outstanding capital stock												72%
Vesting period									5 years
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense							$ 6,878	$ 27,163	$ 67,737
Stock Option Subject To Performance Conditions
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense, options subject to performance conditions							1,078,748	1,336,249	2,152,938
Options with Market Based Performance Conditions and Valued Using Monte Carlo Simulation Model
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options outstanding									17,559
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense							$ 18,444	$ 10,709	$ 11,448
Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common shares reserved for Awards							51,730,555	39,442,260
Options expiration period		10 years
Weighted average exercise price of options outstanding							$ 27.12	$ 33.89	$ 36.79		$ 34.89
Stock options outstanding							13,750,888	16,782,962	17,704,311		32,508,395
Options exercised							79,586	445,680	7,062,317
Exercise price							$ 3.53	$ 12.27	$ 22.22
Proceeds from exercise of stock options							$ 281	$ 5,567	$ 156,897
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate number of common shares authorized		600,000
Equity shares issued to shareholders							299,853	198,501
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of number of shares issuable from treasury pursuant to awards	15%
Maximum | Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price							$ 8.18	$ 36.34	$ 67.64
Maximum | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity shares issued to shareholders		300,000					535,666	235,813
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of number of shares issuable from treasury pursuant to awards	10%
Minimum | Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price							$ 0.06	$ 0.06	$ 0.06

Share-Based Compensation - Summ

Share-Based Compensation - Summary of the Changes in Omnibus Plan Employee Options (Details) - $ / shares	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, ending balance	13,750,888
Weighted average exercise price outstanding, beginning balance	$ 33.89
Weighted average exercise price outstanding, ending balance	$ 27.12	$ 33.89
Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, beginning balance	16,782,962	17,704,311	32,508,395
Options granted	4,658,797	2,537,290	478,215
Replacement options issued as a result of the acquisition of Supreme Cannabis		140,159
Options exercised	(79,586)	(445,680)	(7,062,317)
Options forfeited	(7,611,285)	(3,153,118)	(8,219,982)
Options outstanding, ending balance	13,750,888	16,782,962	17,704,311
Weighted average exercise price outstanding, beginning balance	$ 33.89	$ 36.79	$ 34.89
Weighted average exercise price, Options granted	4.93	17.40	28.15
Weighted average exercise price, Replacement options issued as a result of the acquisition of Supreme Cannabis		80.53
Weighted average exercise price, Options exercised	3.53	12.27	22.22
Weighted average exercise price, Options forfeited	28.80	42.03	41.27
Weighted average exercise price outstanding, ending balance	$ 27.12	$ 33.89	$ 36.79

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Outstanding Stock Options (Details)	12 Months Ended
	Mar. 31, 2023 $ / shares shares
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Options Outstanding	13,750,888
Options Outstanding, Weighted Average Remaining Contractual Life	3 years
Options Exercisable	8,491,238
Options Exercisable, Weighted Average Remaining Contractual Life	1 year 11 months 4 days
Range One
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 0.06
Range of Exercise Prices, Upper Range | $ / shares	$ 24.62
Options Outstanding	5,333,314
Options Outstanding, Weighted Average Remaining Contractual Life	4 years 7 months 17 days
Options Exercisable	1,300,821
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 7 months 9 days
Range Two
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 24.63
Range of Exercise Prices, Upper Range | $ / shares	$ 33.53
Options Outstanding	3,062,535
Options Outstanding, Weighted Average Remaining Contractual Life	2 years 4 months 9 days
Options Exercisable	1,841,655
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 10 days
Range Three
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 33.54
Range of Exercise Prices, Upper Range | $ / shares	$ 36.80
Options Outstanding	1,448,009
Options Outstanding, Weighted Average Remaining Contractual Life	1 year 8 months 8 days
Options Exercisable	1,448,009
Options Exercisable, Weighted Average Remaining Contractual Life	1 year 8 months 8 days
Range Four
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 36.81
Range of Exercise Prices, Upper Range | $ / shares	$ 42.84
Options Outstanding	1,626,478
Options Outstanding, Weighted Average Remaining Contractual Life	1 year 7 months 20 days
Options Exercisable	1,620,201
Options Exercisable, Weighted Average Remaining Contractual Life	1 year 7 months 13 days
Range Five
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 42.85
Range of Exercise Prices, Upper Range | $ / shares	$ 67.64
Options Outstanding	2,280,552
Options Outstanding, Weighted Average Remaining Contractual Life	1 year 10 months 6 days
Options Exercisable	2,280,552
Options Exercisable, Weighted Average Remaining Contractual Life	1 year 10 months 6 days

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model (Details) - $ / shares	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	3.45%	1.09%	0.36%
Expected volatility	77%	75%	76%
Expected forfeiture rate	19%	18%	17%
Expected dividend yield	0%	0%	0%
Black-Scholes value of each option	$ 2.92	$ 9.69	$ 15.24
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options (years)	3 years	3 years	1 year
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options (years)	5 years	5 years	7 years

Share-Based Compensation - Su_4

Share-Based Compensation - Summary of Changes in RSUs (Details) - RSUs - shares	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance	3,477,292	753,310	883,009
RSUs and PSUs granted	3,143,098	3,253,671	142,826
RSUs and PSUs released	(1,464,934)	(300,319)	(120,399)
RSUs and PSUs cancelled and forfeited	(2,572,242)	(229,370)	(152,126)
Ending balance	2,583,214	3,477,292	753,310

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) - Accumulated Other Comprehensive Income (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	$ 3,587,915	$ 3,486,520	$ 5,108,120
Disposal of consolidated entities		16,130
Ending balance	760,022	3,587,915	3,486,520
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(57,468)	(28,246)	126,723
Disposal of consolidated entities		16,130
Other comprehensive income (loss)	27,207	(45,352)	(154,969)
Ending balance	(30,261)	(57,468)	(28,246)
Changes of Own Credit Risk of Financial Liabilities
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	15,186	(5,994)	94,176
Settlement of unsecured senior notes, net of deferred income tax	(29,507)
Other comprehensive income (loss)	30,722	21,180	(100,170)
Ending balance	16,401	15,186	(5,994)
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(42,282)	(34,240)	220,899
Disposal of consolidated entities		16,130
Settlement of unsecured senior notes, net of deferred income tax	(29,507)
Other comprehensive income (loss)	57,929	(24,172)	(255,139)
Ending balance	$ (13,860)	$ (42,282)	$ (34,240)

Noncontrolling Interests - Summ

Noncontrolling Interests - Summary of Net Change in Noncontrolling Interests (Details) - CAD ($) $ in Thousands		3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
		Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Minority Interest [Line Items]
Beginning balance		$ 1,552,226	$ 1,640,494	$ 3,587,915	$ 3,587,915	$ 3,587,915	$ 3,587,915	$ 3,486,520	$ 5,108,120
Comprehensive income (loss)		(4,911)	(13,641)	(5,307)	(18,948)	(23,859)	(31,388)	(20,524)	74,100
Net (loss) income loss attributable to redeemable noncontrolling interest							29,544	19,317	18,077
Share-based compensation			14,581		20,020	26,448	31,188	47,525	91,149
Redemption of redeemable noncontrolling interest							(34,012)	(2,492)
Ending balance		$ 1,357,643	$ 1,552,226	1,640,494	1,552,226	1,357,643	760,022	3,587,915	3,486,520
Noncontrolling Interests
Minority Interest [Line Items]
Beginning balance				4,341	4,341	4,341	4,341	4,709	221,758
Comprehensive income (loss)							(31,388)	(20,524)	74,100
Net (loss) income loss attributable to redeemable noncontrolling interest							29,544	19,317	18,077
Share-based compensation							570	839	3,828
Ownership changes							(140)		(313,304)
Warrants									250
Redemption of redeemable noncontrolling interest							(1,620)
Ending balance							1,587	4,341	4,709
RIV Capital
Minority Interest [Line Items]
Beginning balance	[1]								211,086
Comprehensive income (loss)	[1]								94,532
Share-based compensation	[1]								2,659
Ownership changes	[1]								(308,527)
Warrants	[1]								250
Vert Mirabel
Minority Interest [Line Items]
Beginning balance									7,132
Comprehensive income (loss)							(53)	(3,165)	(14,261)
Net (loss) income loss attributable to redeemable noncontrolling interest							53	3,165	11,906
Ownership changes									(4,777)
BioSteel
Minority Interest [Line Items]
Beginning balance				2,497	2,497	2,497	2,497	1,658	489
Comprehensive income (loss)							(29,491)	(16,152)	(6,171)
Net (loss) income loss attributable to redeemable noncontrolling interest							29,491	16,152	6,171
Share-based compensation							570	839	1,169
Redemption of redeemable noncontrolling interest							(1,620)
Ending balance							1,447	2,497	1,658
Other
Minority Interest [Line Items]
Beginning balance				$ 1,844	$ 1,844	$ 1,844	1,844	3,051	3,051
Comprehensive income (loss)							(1,844)	(1,207)
Ownership changes							140
Ending balance							$ 140	$ 1,844	$ 3,051
[1] Refer to Note 30(c) for information regarding the completion of the plan of arrangement with RIV Capital.

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis (Details) - Fair Value Measurements Recurring - CAD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Assets:
Short-term investments	$ 105,595	$ 595,651
Restricted short-term investments	11,765	12,216
Other financial assets	559,794	788,306
Liabilities:
Unsecured senior notes	331,250	563,958
Other liabilities	29,952	70,066
Acreage
Liabilities:
Derivative liability		47,000
Warrant
Liabilities:
Derivative liability		26,920
Level 1
Assets:
Short-term investments	105,595	595,651
Restricted short-term investments	11,765	12,216
Other financial assets	269	490
Level 2
Liabilities:
Unsecured senior notes	331,250	563,958
Level 3
Assets:
Other financial assets	559,525	787,816
Liabilities:
Other liabilities	$ 29,952	70,066
Level 3 | Acreage
Liabilities:
Derivative liability		47,000
Level 3 | Warrant
Liabilities:
Derivative liability		$ 26,920

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 Financial Instruments (Details) - Level 2 - Unsecured Senior Notes	12 Months Ended
	Mar. 31, 2023
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Senior note pricing model
Key inputs	Quoted prices in over-the-counter broker market

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 3 Financial Instruments (Details) - Level 3	12 Months Ended
	Mar. 31, 2023
Acreage Financial Instrument Probability of Each Scenario
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Probability weighted expected return model
Significant unobservable inputs	Probability of each scenario
Relationship of unobservable inputs to fair value	Change in probability of occurrence in each scenario will result in a change in fair value
Acreage Financial Instrument Value and Number of Canopy Shares Issued
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Number of common shares to be issued
Relationship of unobservable inputs to fair value	Increase or decrease in value and number of common shares will result in a decrease or increase in fair value
Acreage Financial Instrument Intrinsic Value of Acreage
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Intrinsic value of Acreage
Relationship of unobservable inputs to fair value	Increase or decrease in intrinsic value will result in an increase or decrease in fair value
Acreage Financial Instrument Probability and Timing of US Legalization
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Acreage Financial Instrument Estimated Premium on US Legalization
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Estimated premium on US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in estimated premium on US legalization will result in an increase or decrease in fair value
Acreage Financial Instrument Control Premium
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Control premium
Relationship of unobservable inputs to fair value	Increase or decrease in estimated control premium will result in an increase or decrease in fair value
Acreage Financial Instrument Market Access Premium [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Market access premium
Relationship of unobservable inputs to fair value	Increase or decrease in estimated market access premium will result in an increase or decrease in fair value
TerrAscend Exchangeable Shares, TerrAscend Option
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Put option pricing model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Hempco Debenture
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
TerrAscend warrants - December 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Black-Sholes option pricing model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Wana Financial Instrument - Call Options
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Expected future Wana cash flows
Relationship of unobservable inputs to fair value	Increase or decrease in expected future Wana cash flows will result in an increase or decrease in fair value
Wana Financial Instrument - Call Options, Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
Wana Financial Instrument - Deferred Payments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Monte Carlo simulation model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Wana Financial Instrument Volatility of Wana Equity
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Volatility of Wana equity
Relationship of unobservable inputs to fair value	Increase or decrease in volatility will result in an increase or decrease in fair value
Jetty Financial Instrument - Call Options
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Expected future Jetty cash flows
Relationship of unobservable inputs to fair value	Increase or decrease in expected future Jetty cash flows will result in an increase or decrease in fair value
Jetty Financial Instrument - Call Options, Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
Jetty Financial Instrument - Deferred Payments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Monte Carlo simulation model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Jetty Financial Instrument Volatility of Jetty Equity and Revenue
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Volatility of Jetty equity and revenue
Relationship of unobservable inputs to fair value	Increase or decrease in volatility will result in an increase or decrease in fair value
Warrant Derivative Liability Volatility of Canopy Growth Share Price
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Monte Carlo simulation model
Significant unobservable inputs	Volatility of Canopy Growth share price
Relationship of unobservable inputs to fair value	Increase or decrease in volatility will result in an increase or decrease in fair value
BioSteel Redeemable Noncontrolling Interest Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
BioSteel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Expected future BioSteel cash flows
Relationship of unobservable inputs to fair value	Increase or decrease in expected future BioSteel cash flows will result in an increase or decrease in fair value
Acreage Debt Option Premium
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Monte Carlo simulation model
Significant unobservable inputs	Volatility of Acreage share price
Relationship of unobservable inputs to fair value	Increase or decrease in volatility will result in a decrease or increase in fair value
Acreage Tax Receivable Agreement Discounted Cash Flow
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
Acreage Tax Receivable Agreement Probability-weighted Expected Return Model
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Probability-weighted expected return model
Significant unobservable inputs	Probability of each scenario
Relationship of unobservable inputs to fair value	Change in probability of occurrence in each scenario will result in a change in fair value
Acreage Tax Receivable Agreement Probability and Timing of US Legalization
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value

Revenue - Summary of Disaggrega

Revenue - Summary of Disaggregation of Revenue (Details) - CAD ($) $ in Thousands		3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
		Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Disaggregation Of Revenue [Line Items]
Gross revenue		$ 116,167	$ 117,914	$ 118,667	$ 236,581	$ 352,748	$ 450,901	$ 572,214	$ 607,198
Net revenue		$ 104,031	$ 105,418	$ 105,920	$ 211,338	$ 315,369	402,904	510,321	546,649
Canadian adult-use Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue							131,269	205,302	229,601
Canadian Medical Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue	[1]						55,798	52,608	55,448
Canadian Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue							187,067	257,910	285,049
Net revenue								257,910
Rest-of-world Cannabis
Disaggregation Of Revenue [Line Items]
Gross revenue							38,949	79,306	93,631
Net revenue							38,949	79,306	93,631
C3 | Rest-of-world Cannabis
Disaggregation Of Revenue [Line Items]
Gross revenue								36,113	62,335
Other rest-of-world cannabis | Rest-of-world Cannabis
Disaggregation Of Revenue [Line Items]
Gross revenue							38,949	43,193	31,296
Business to Business | Canadian adult-use Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue	[2]						95,026	143,732	163,585
Business to Consumer | Canadian adult-use Cannabis Net Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue							36,243	61,570	66,016
Storz & Bickel
Disaggregation Of Revenue [Line Items]
Gross revenue							64,845	85,410	80,998
Net revenue								85,410
BioSteel
Disaggregation Of Revenue [Line Items]
Gross revenue							69,649	34,622	28,530
Net revenue								34,622
This Work
Disaggregation Of Revenue [Line Items]
Gross revenue							26,029	32,296	33,314
Net revenue								32,296
Other
Disaggregation Of Revenue [Line Items]
Gross revenue							$ 16,365	20,777	$ 25,127
Net revenue								$ 20,777
[1] Canadian medical cannabis net revenue reflects excise taxes of $ 4,926 (year ended March 31, 2022 - $ 5,227 ; and year ended March 31, 2021 - $ 5,621 ). Canadian adult-use business-to-business net revenue reflects excise taxes of $ 43,071 (year ended March 31, 2022 - $ 56,666 ; and year ended March 31, 2021 - $ 54,928 ).

Revenue - Summary of Disaggre_2

Revenue - Summary of Disaggregation of Revenue (Parenthetical) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Disaggregation Of Revenue [Line Items]
Excise taxes	$ 47,997	$ 61,893	$ 60,549
CANADA | Recreational Cannabis Revenue
Disaggregation Of Revenue [Line Items]
Excise taxes	43,071	56,666	54,928
CANADA | Medical Cannabis Revenue
Disaggregation Of Revenue [Line Items]
Excise taxes	$ 4,926	$ 5,227	$ 5,621

Revenue - Additional Informatio

Revenue - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Allowance for estimated returns and price adjustments	$ 26,233	$ 21,464	$ 23,935
Liability for estimated returns and price adjustments	$ 7,123	$ 3,729

Pharmhouse - Additional informa

Pharmhouse - Additional information (Details) - PharmHouse $ in Thousands	12 Months Ended
	Mar. 31, 2023 CAD ($)
Schedule Of Equity Method Investments [Line Items]
Date of formation of joint venture entity	May 07, 2018
Recoverable amount of assets on liquidation	$ 57,500

Pharmhouse - Pharmhouse financi

Pharmhouse - Pharmhouse financial guarantee - Additional information (Details) - CAD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Feb. 23, 2021
Line Of Credit Facility [Line Items]
Financial liabilities	$ 1,580,819	$ 1,754,476	$ 1,834,777	$ 1,754,476	$ 1,580,819	$ 1,679,076	$ 1,984,845
Expected credit loss in net income (loss)	$ (259,465)	$ (292,170)	$ (2,086,443)	$ (2,378,613)	$ (2,638,078)	$ (3,278,158)	$ (310,043)	$ (1,744,920)
Pharmhouse Credit Agreement
Line Of Credit Facility [Line Items]
Non - revolving credit facility, maximum Principle amount									$ 90,000
Expected credit loss									$ (32,500)
Expected credit loss in net income (loss)								$ 32,500

Pharmhouse - Other financial as

Pharmhouse - Other financial assets, including loans receivable - Additional information (Details) - CAD ($) $ in Thousands		3 Months Ended	12 Months Ended
	Aug. 04, 2020	Mar. 31, 2021	Mar. 31, 2021	Feb. 23, 2021
Schedule Of Equity Method Investments [Line Items]
Expected credit losses on financial assets and related charges			$ 109,480
PharmHouse
Schedule Of Equity Method Investments [Line Items]
Loss in interest receivable in relation to the financial instruments			8,989
Advances written off		$ 35,000	15,000,000
Expected credit losses on financial assets and related charges			109,480
PharmHouse | Shareholder Loan Agreement
Schedule Of Equity Method Investments [Line Items]
Secured debt				$ 40,000
PharmHouse | Debtor In Possession
Schedule Of Equity Method Investments [Line Items]
Line of credit facility, pursuant to the agreement				9,300
Contingent irrecoverable credit losses			9,300
PharmHouse | Pharmhouse Credit Agreement
Schedule Of Equity Method Investments [Line Items]
Expected credit losses on financial assets			32,500
PharmHouse | Shareholder Loan Agreement
Schedule Of Equity Method Investments [Line Items]
Contingent irrecoverable credit losses			40,000
PharmHouse | Secured Demand Promissory Note
Schedule Of Equity Method Investments [Line Items]
Secured debt				2,450
Contingent irrecoverable credit losses			2,450
PharmHouse | Unsecured Demand Promissory Note
Schedule Of Equity Method Investments [Line Items]
Debt financing pursuant to a unsecured demand promisory note	$ 1,206
Contingent irrecoverable credit losses			$ 1,206
PharmHouse | Financial Asset Past Due
Schedule Of Equity Method Investments [Line Items]
Financing increased amount				$ 9,700

Pharmhouse - PharmHouse equity

Pharmhouse - PharmHouse equity method investment - Additional information (Details) - PharmHouse $ in Thousands	Feb. 23, 2021 CAD ($) shares
Schedule Of Equity Method Investments [Line Items]
Common shares owned in joint venture | shares	10,998,660
Ownership percentage	49%
Equity method investments | $	$ 32,369

Other Income (Expense), Net - S

Other Income (Expense), Net - Schedule of Other Income (Expense), Net (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Other Income and Expenses [Abstract]
Fair value changes on other financial assets	$ (424,115)	$ (356,109)	$ 435,107
Fair value changes on liability arising from Acreage Arrangement	47,000	553,000	(399,849)
Fair value changes on unsecured senior notes	(43,104)	76,776	(162,540)
Fair value changes on warrant derivative liability	26,920	588,655	(293,084)
Fair value changes on acquisition related contingent consideration and other	38,890	4,417	39,608
Gain and charges related to settlement of debt	582
Interest income	24,282	6,601	21,367
Interest expense	(126,160)	(103,944)	(8,459)
Foreign currency gain (loss)	(8,534)	5,415	(18,013)
Gain (loss) on disposal/acquisition of consolidated entity	2,414	(6,762)	634
Other income (expense), net	(4,200)	(14,708)	(2,647)
Other income (expense), net	$ (466,025)	$ 753,341	$ (387,876)

Income Taxes - Summary of Net L

Income Taxes - Summary of Net Loss Before Income Taxes (Details) - CAD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Domestic - Canada						$ (2,513,026)	$ (173,970)	$ (1,611,210)
Foreign - outside of Canada						(801,294)	(165,545)	(72,751)
Loss before income taxes	$ (264,758)	$ (297,591)	$ (2,088,001)	$ (2,385,592)	$ (2,650,350)	$ (3,314,320)	$ (339,515)	$ (1,683,961)

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Recovery (Expense) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Domestic - Canada	$ 4,783	$ 895	$ (19,318)
Foreign - outside of Canada	(676)	1,476	(2,091)
Current income tax recovery	4,107	2,371	(21,409)
Domestic - Canada	(3,603)	6,353	36,505
Foreign - outside of Canada	4,270	224	(1,955)
Deferred income tax recovery	667	6,577	34,550
Income tax recovery	$ 4,774	$ 8,948	$ 13,141

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Income Tax Examination [Line Items]
Combined Canadian federal and provincial enacted statutory tax rate	26.50%	26.50%	26.50%
Other Accounts Receivable
Income Tax Examination [Line Items]
Current income taxes receivable	$ 5,446	$ 6,018
Accounts Payable
Income Tax Examination [Line Items]
Current income taxes payable	$ 1,592	$ 1,927

Income Taxes - Summary of Recon

Income Taxes - Summary of Reconciliation of Amount of Income Taxes Compared to Expected Income Taxes Calculated at Combined Federal and Provincial Enacted Statutory Tax Rate (Details) - CAD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Net loss before income taxes	$ (264,758)	$ (297,591)	$ (2,088,001)	$ (2,385,592)	$ (2,650,350)	$ (3,314,320)	$ (339,515)	$ (1,683,961)
Expected tax rate						26.50%	26.50%	26.50%
Expected income tax recovery						$ 878,295	$ 89,971	$ 446,250
Non-deductible and non-taxable items						(29,385)	17,557	81,883
Fair value changes on Acreage Arrangement						12,386	146,545	(105,960)
Fair value changes on warrant derivative liability						6,294	155,964	(77,663)
Settlement of unsecured senior notes						(14,862)
Share-based compensation						(2,126)	(9,908)	(21,121)
Goodwill impairment						(473,702)
Change in valuation allowance						(313,583)	(363,954)	(358,964)
Effect of tax rates outside of Canada						(4,596)	8,459	10,870
Non-taxable portion of capital gains and losses						(48,573)	(38,440)	38,705
Other						(5,374)	2,754	(859)
Income tax recovery						$ 4,774	$ 8,948	$ 13,141

Income Taxes - Summary of Signi

Income Taxes - Summary of Significant Compenents of Deferred Income Tax Assets (Liabilities) (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Deferred income tax assets
Property, plant and equipment	$ 104,043	$ 78,023
Intangible assets	11,202	671
Inventory reserves and write-downs	18,749	40,324
Other reserves and accruals	10,554	5,939
Losses carried forward	1,142,607	919,955
Equity method investments and other financial assets	72,881	10,512
Deferred financing costs	4,597	2,740
Other	10,415	5,635
Gross deferred income tax assets	1,375,048	1,063,799
Valuation allowances	(1,355,385)	(1,041,802)
Total deferred income tax assets, net	19,663	21,997
Deferred income tax liabilities
Property, plant and equipment	(3,475)	(4,182)
Intangible assets	(15,200)	(29,832)
Deferred financing costs	(1,345)	(3,353)
Other		(621)
Total deferred income tax liabilities	(20,020)	(37,988)
Net deferred income tax liabilities	$ (357)	$ (15,991)

Income Taxes - Summary of Losse

Income Taxes - Summary of Losses Carried Forward Available to Reduce Future Years' Taxable Income (Details) $ in Thousands	Mar. 31, 2023 CAD ($)
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	$ 3,710,391
Losses carried forward available to reduce future years' taxable income	4,887,586
Expiring between 5 and 10 Years
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	3,321
Expiring between 10 and 15 Years
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	367,213
Expiring between 15 and 20 years
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	2,829,026
Indefinite
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	510,831
Indefinite | Capital Loss Carry forward
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	1,177,195
CANADA
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	3,195,923
United States
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	451,258
Europe
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	58,731
Other Jurisdictions
Operating Loss Carryforwards [Line Items]
Losses carried forward available to reduce future years' taxable income	$ 4,479

Acquisitions - Summary of Conso

Acquisitions - Summary of Consolidated Balance Sheet Impact at Acquisition of Company's Business Combinations (Details) - CAD ($) $ in Thousands			12 Months Ended
	Jun. 22, 2021	Apr. 01, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2021
Business Acquisition [Line Items]
Goodwill			$ 85,563	$ 1,866,503	$ 84,675	$ 79,112	$ 1,889,354
Verona, Virginia
Business Acquisition [Line Items]
Property, plant and equipment			28,771
Debt and other liabilities			(2,373)
Net assets acquired			26,398
Consideration paid in cash			24,223
Other consideration			2,175
Total consideration			26,398
Net cash outflow (inflow)			$ 24,223
Ace Valley
Business Acquisition [Line Items]
Cash and cash equivalents				1,544
Inventory				878
Other current assets				2,249
Property, plant and equipment				105
Goodwill				39,152
Accounts payable and other accrued expenses and liabilities				(1,724)
Deferred income tax liabilities				(1,899)
Net assets acquired				54,305
Consideration paid in cash				51,836
Other consideration				2,469
Total consideration		$ 51,836		54,305
Less: Cash and cash equivalents acquired				(1,544)
Net cash outflow (inflow)				50,292
Supreme Cannabis
Business Acquisition [Line Items]
Cash and cash equivalents				41,306
Inventory				33,426
Other current assets				14,791
Property, plant and equipment				187,407
Goodwill				58,842
Accounts payable and other accrued expenses and liabilities				(12,935)
Debt and other liabilities				(88,324)
Deferred income tax liabilities				(5,545)
Net assets acquired				279,668
Consideration paid in cash	$ 84			$ 84
Consideration paid in shares				260,668
Replacement options	$ 140,159			$ 629
Replacement warrants				13,350
Other consideration				4,937
Total consideration				279,668
Less: Cash and cash equivalents acquired				(41,306)
Net cash outflow (inflow)				(41,222)
Other
Business Acquisition [Line Items]
Cash and cash equivalents				1,227
Inventory				362
Other current assets				335
Property, plant and equipment				1,510
Goodwill				7,329
Accounts payable and other accrued expenses and liabilities				(30)
Debt and other liabilities				(1,037)
Deferred income tax liabilities				(540)
Net assets acquired				11,156
Consideration paid in cash				$ 7,104
Consideration paid in shares				4,052
Total consideration				$ 11,156
Less: Cash and cash equivalents acquired				(1,227)
Net cash outflow (inflow)				5,877
2022 Acquisitions
Business Acquisition [Line Items]
Cash and cash equivalents				44,077
Inventory				34,666
Other current assets				17,375
Property, plant and equipment				189,022
Goodwill				105,323
Accounts payable and other accrued expenses and liabilities				(14,689)
Debt and other liabilities				(89,361)
Deferred income tax liabilities				(7,984)
Net assets acquired				345,129
Consideration paid in cash				$ 59,024
Consideration paid in shares				264,720
Replacement options				$ 629
Replacement warrants				13,350
Other consideration				7,406
Total consideration				345,129
Less: Cash and cash equivalents acquired				(44,077)
Net cash outflow (inflow)				14,947
Brands | Ace Valley
Business Acquisition [Line Items]
Intangible assets				14,000
Brands | Supreme Cannabis
Business Acquisition [Line Items]
Intangible assets				22,800
Brands | 2022 Acquisitions
Business Acquisition [Line Items]
Intangible assets				36,800
Distribution Channel | Supreme Cannabis
Business Acquisition [Line Items]
Intangible assets				3,500
Distribution Channel | 2022 Acquisitions
Business Acquisition [Line Items]
Intangible assets				3,500
Operating Licenses | Supreme Cannabis
Business Acquisition [Line Items]
Intangible assets				24,400
Operating Licenses | Other
Business Acquisition [Line Items]
Intangible assets				2,000
Operating Licenses | 2022 Acquisitions
Business Acquisition [Line Items]
Intangible assets				$ 26,400

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details) - Verona Facility $ in Thousands, $ in Thousands			12 Months Ended
	Nov. 08, 2022 CAD ($)	Nov. 08, 2022 USD ($)	Mar. 31, 2023 CAD ($)
Business Acquisition [Line Items]
Consideration			$ 26,398
Consideration paid in cash			$ 24,223
Verona, Virginia
Business Acquisition [Line Items]
Consideration	$ 26,398	$ 19,477
Consideration paid in cash	15,685	11,573
Consideration transferred related to repayment of debt and retirement of certain lease obligations	8,538	6,299
Consideration transferred in remediation and indemnity holdbacks	$ 2,175	$ 1,605

Acquisitions - Ace Valley - Add

Acquisitions - Ace Valley - Additional Information (Details) - Ace Valley - CAD ($) $ in Thousands		12 Months Ended
	Apr. 01, 2021	Mar. 31, 2022
Business Acquisition [Line Items]
Business acquisition, acquisition date	Apr. 01, 2021
Percentage of outstanding shares purchased	100%
Business acquisition, total purchase consideration	$ 51,836	$ 54,305
Business Combination, Contingent Consideration, Liability	$ 2,469

Acquisitions - Supreme Cannabis

Acquisitions - Supreme Cannabis - Additional Information (Details) $ in Thousands		12 Months Ended
	Jun. 22, 2021 CAD ($) Instrument shares	Mar. 31, 2022 CAD ($)	Mar. 31, 2023 CAD ($)	Dec. 09, 2022 CAD ($)	May 17, 2022 CAD ($)
Business Acquisition [Line Items]
Debt Instrument, Fair Value Disclosure			$ 75,014	$ 89,094	$ 90,120
Supreme Cannabis
Business Acquisition [Line Items]
Name of acquiree	Supreme Cannabis
Date of acquisition	Jun. 22, 2021
Percentage of outstanding shares purchased	100%
Number of common shares | shares	9,013,400
Shares issued, value	$ 260,668
Consideration paid in cash	84	$ 84
Replacement options	140,159	$ 629
Fair value of outstanding warrant	13,350
Fair value of replacement options	1,452
Fair value of replacement options included as consideration paid	629
Fair value of replacement options recognized as share-based compensation expense	823
Supreme Cannabis | Debentures Subject to Mandatory Redemption
Business Acquisition [Line Items]
Principal amount of convertible debt	$ 27,045
Number of shares convertible | Instrument	94,895,649
Share exchange ratio	0.011659
Debt Instrument, Fair Value Disclosure	$ 36,593
Conversion feature of debt	4,937
Debt component	$ 31,656
Supreme Cannabis | Warrant
Business Acquisition [Line Items]
Number of common shares | shares	1,265,742

Acquisitions - More Life - Addi

Acquisitions - More Life - Additional Information (Details) - CAD ($) $ in Thousands			3 Months Ended	12 Months Ended
	Mar. 01, 2021	Nov. 07, 2019	Mar. 31, 2021	Mar. 31, 2021	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022
Schedule Of Equity Method Investments [Line Items]
Goodwill			$ 1,889,354	$ 1,889,354	$ 85,563	$ 84,675	$ 79,112	$ 1,866,503
More Life
Schedule Of Equity Method Investments [Line Items]
Ownership interest		60%
Derecognized royalty obligations	$ 33,681
Impairment of equity method investments			$ 10,300	$ 10,300
More Life | Drake
Schedule Of Equity Method Investments [Line Items]
Ownership percentage		40%
Ownership interest		60%
More Life | 1955625 Ontario Inc.
Schedule Of Equity Method Investments [Line Items]
Percentage of ownership to be sold		100%

Divestitures - Retail Divestitu

Divestitures - Retail Divestiture - Additional Information (Details) $ in Thousands		3 Months Ended
	Dec. 30, 2022 RetailStore	Dec. 31, 2022 CAD ($)	Mar. 31, 2023 CAD ($)
OEGRC
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of ownership acquired | RetailStore	23
OEGRC and FOUR20
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of businesses		$ 88
Deferred consideration		5,500	$ 2,500
Earnout payment receivable		$ 6,099

Divestitures - C3 - Additional

Divestitures - C3 - Additional Information (Details) - Jan. 31, 2022 - C3 € in Thousands, $ in Thousands	CAD ($)	EUR (€)
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Proceeds from divestiture of businesses	$ 128,316	€ 88,698
Earnout payment receivable | €		€ 42,600
Disposal of consolidated entities | $	$ 53,541

Divestitures - Summary of Derec

Divestitures - Summary of Derecognized Assets and Liabilities Transferred (Details) € in Thousands, $ in Thousands			3 Months Ended
	Jan. 31, 2022 CAD ($)	Jan. 31, 2022 EUR (€)	Dec. 31, 2022 CAD ($)	Feb. 23, 2021 CAD ($)
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Property, plant and equipment				$ 729
OEGRC and FOUR20
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Current assets			$ 6,461
Property, plant and equipment			7,990
Other long-term assets			144
Current liabilities			(9,492)
Net assets disposed			5,103
Consideration received in cash			88
Future cash consideration			11,599
Costs to sell			(2,442)
Total consideration			9,245
Gain on disposal of consolidated entity			$ 4,142
C3
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Current assets	$ 44,568
Property, plant and equipment	9,216
Intangible assets	15,548
Goodwill	53,541
Current liabilities	(3,089)
Deferred income tax liabilities	(6,029)
Cumulative translation adjustment	19,178
Net assets disposed	132,933
Consideration received in cash	128,316	€ 88,698
Future cash consideration	7,233
Costs to sell	(1,153)
Total consideration	134,396
Gain on disposal of consolidated entity	$ 1,463

Divestitures - Summary of Der_2

Divestitures - Summary of Derecognized Assets and Liabilities Transferred (Parenthetical) (Details) - CAD ($) $ in Thousands	Jan. 31, 2022	Feb. 23, 2021
Discontinued Operations and Disposal Groups [Abstract]
Cash and cash equivalents	$ 19,338	$ 37,801

Divestitures - Plan of Arrangem

Divestitures - Plan of Arrangement with RIV Capital - Additional Information (Details) - CAD ($) $ / shares in Units, $ in Thousands		3 Months Ended	12 Months Ended
	Dec. 21, 2020	Mar. 31, 2023	Mar. 31, 2023	Mar. 31, 2022
Class Of Stock [Line Items]
Common stock, shares issued		517,305,551	517,305,551	394,422,604
Cash payment		$ 462,460	$ 462,460	$ 470,682
Canopy Rivers
Class Of Stock [Line Items]
Common stock, shares issued		3,647,902	3,647,902
Cash payment		$ 115,000	$ 115,000
Canopy Rivers | Multiple Voting Shares
Class Of Stock [Line Items]
Exchangeable shares in the capital		36,468,318	36,468,318
Canopy Rivers | Subordinated Voting Shares
Class Of Stock [Line Items]
Exchangeable shares in the capital		15,223,938	15,223,938
RIV Arrangement
Class Of Stock [Line Items]
Exchangeable shares in the capital		19,445,285	19,445,285
Common share purchase warrants in the capital	333,723		2,225,714
Exercise price of warrants	$ 5.95	$ 6.49	$ 6.49
Purchase of remaining ownership interest percentage		45%
Maximum | RIV Arrangement
Class Of Stock [Line Items]
Percentage of ownership increase in common shares outstanding			55%

Divestitures - Schedule of Dere

Divestitures - Schedule of Derecognized Assets and Liabilities (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022	Jan. 31, 2022	Mar. 31, 2021	Feb. 23, 2021	Mar. 31, 2020
Class Of Stock [Line Items]
Warrant value	$ 2,581,788	$ 2,581,788		$ 2,568,438		$ 2,638,951
Preferred shares in Vert Mirabel					$ 22,600
Common shares in Vert Mirabel					9,075
Total acquired assets					380,175
Consideration paid in shares					(170,284)
Consideration paid in cash					(115,000)
Total Assets and Liabilities					94,891
Cash and cash equivalents			$ 19,338		37,801
Amounts receivable, net					4,327
Prepaid expenses and other assets					995
Equity method investments					5,114
Other financial assets					417,256
Property, plant and equipment					729
Intangible assets					86
Accounts payable					(22,038)
Other accrued expenses and liabilities					(1,703)
Other current liabilities					(32,653)
Other long-term liabilities					(303)
Noncontrolling interests and other					(315,144)
Disposal Group, Including Discontinued Operation, Liabilities					94,467
Gain on completion of RIV Arrangement					424
TerrAscend
Class Of Stock [Line Items]
TerrAscend Exchangeable Shares					291,500
Warrant value					32,000
TerrAscend loan					10,000
Tweed N B
Class Of Stock [Line Items]
Settlement of Tweed NB obligations to RCC					$ 15,000

Acreage Arrangement and Amend_2

Acreage Arrangement and Amendments to Cbi Investor Rights Agreement and Warrants - Additional Information (Details) $ / shares in Units, $ / shares in Units, $ in Thousands

12 Months Ended

Oct. 24, 2022 CAD ($) shares

Jun. 24, 2020 CAD ($) shares

Jun. 24, 2020 USD ($) $ / shares shares

Jun. 27, 2019 CAD ($)

Jun. 27, 2019 USD ($)

Mar. 31, 2023 CAD ($) shares

Mar. 31, 2023 USD ($)

Mar. 31, 2022 CAD ($) shares

Mar. 31, 2021 CAD ($)

Dec. 09, 2022 CAD ($)

May 17, 2022 CAD ($)

Apr. 18, 2019 $ / shares shares

Business Acquisition [Line Items]

Derivative, financial liability

$ 26,920,000

Debentures bear interest rate per annum

6.10%

Estimated fair value

$ 75,014,000

$ 89,094,000

$ 90,120,000

Warrant expiration date

Dec. 31, 2032

Nov. 01, 2023

Estimated fair value

$ (26,920,000)

$ (588,655,000)

$ 293,084,000

Common stock, shares issued | shares

517,305,551

394,422,604

Tranche A Warrants

Business Acquisition [Line Items]

Warrants to acquire shares | shares

88,500,000

Exercise price of warrants | $ / shares

$ 50.40

Tranche B Warrants

Business Acquisition [Line Items]

Warrants to acquire shares | shares

38,500,000

Exercise price of warrants | $ / shares

$ 76.68

Tranche C Warrants

Business Acquisition [Line Items]

Warrants to acquire shares | shares

12,800,000

Derivative liability

$ 0

Tranche B and C Warrants | Second Amended and Restated Investor Rights Agreement and Consent Agreement

Business Acquisition [Line Items]

Number of common stock shares to be repurchased to avoid providing repurchase credit | shares

27,378,866

Value of common stock to be repurchased to avoid providing repurchase credit

$ 1,583,000,000

Derivative liability

0

Debenture

Business Acquisition [Line Items]

Payments to acquire investments

66,995,000

$ 50,000

Estimated fair value

29,262,000

$ 28,824,000

Additional payment upon satisfaction of certain conditions

$ 50,000

Warrants

Business Acquisition [Line Items]

Derivative, financial liability

$ 0

$ 26,920,000

Common stock, shares issued | shares

139,745,453

139,745,453

Maximum | Second Amended and Restated Investor Rights Agreement and Consent Agreement

Business Acquisition [Line Items]

Share repurchase credit limit

$ 1,583,000,000

Acreage

Business Acquisition [Line Items]

Aggregate payment

$ 49,849,000

$ 37,500

$ 395,190,000

$ 300,000

Estimated fair value

$ 3,109,000

35,479,000

Acreage | Acreage Financial Instrument

Business Acquisition [Line Items]

Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]

Other Financial Assets

Derivative, financial asset

$ 55,382,000

Derivative, financial liability

$ 47,000,000

Acreage | Maximum

Business Acquisition [Line Items]

Number Of Fixed And Floating Shares Issued | shares

32,700,000

32,700,000

Acreage | Fixed Shares

Business Acquisition [Line Items]

Common stock shares conversion ratio

0.3048

Acreage | Class E Subordinated Voting Shares | Fixed Shares

Business Acquisition [Line Items]

Common stock shares conversion ratio

0.3048

0.3048

0.3048

Acreage | Class D Subordinated Voting Shares | Floating Shares

Business Acquisition [Line Items]

Minimum call price | $ / shares

$ 6.41

Leases - Additional Information

Leases - Additional Information (Details) - Maximum	Mar. 31, 2023
Lessee Lease [Line Items]
Lessee, operating lease, term	30 years
Lessee, finance lease, term	30 years

Leases - Summary of Lease Right

Leases - Summary of Lease Right-of-use Assets and Liabilities (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Lessee Disclosure [Abstract]
Operating lease	$ 20,741	$ 39,571
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant and equipment	Property, plant and equipment
Finance lease	$ 8,838	$ 34,333
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant and equipment	Property, plant and equipment
Operating and finance lease right of use asset	$ 29,579	$ 73,904
Operating lease	$ 9,143	$ 11,752
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities
Finance lease	$ 19,541	$ 26,283
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities
Operating lease	$ 40,977	$ 58,031
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities
Finance lease	$ 39,648	$ 43,094
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities
Total finance lease liability, noncurrent	$ 109,309	$ 139,160

Leases - Summary of Components

Leases - Summary of Components of Total Lease Expense (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Lessee Disclosure [Abstract]
Operating lease expense	$ 10,608	$ 5,245
Amortization of right-of-use assets	1,494	3,883
Interest on lease liabilities	2,018	1,667
Total lease expense	$ 14,120	$ 10,795

Leases - Summary of Minimum Pay

Leases - Summary of Minimum Payments Due for Lease Liabilities (Details) $ in Thousands	Mar. 31, 2023 CAD ($)
Lessee Disclosure [Abstract]
2024	$ 11,661
2025	12,494
2026	9,521
2027	9,016
2028	7,714
Thereafter	8,066
Total lease payments	58,472
Less: Interest	8,352
Total lease liabilities	$ 50,120
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Other Liabilities
2024	$ 21,410
2025	5,313
2026	33,020
2027	325
2028	329
Thereafter	3,725
Total lease payments	64,122
Less: Interest	4,933
Total lease liabilities	$ 59,189

Leases - Summary of Measurement

Leases - Summary of Measurement of Lease Liabilities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Lessee Disclosure [Abstract]
Operating cash flows from operating leases	$ 13,277	$ 12,905
Operating cash flows from finance leases	2,018	1,667
Financing cash flows from finance leases	$ 5,997	$ 1,494

Leases - Summary of Right-of-us

Leases - Summary of Right-of-use Assets Obtained in Exchange for New Lease Liabilities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Lessee Disclosure [Abstract]
Operating leases	$ 3,759	$ 9,019
Finance leases	$ 2,714	$ 3,720

Leases - Summary of Weighted Av

Leases - Summary of Weighted Average Remaining Lease Term (Details)	Mar. 31, 2023	Mar. 31, 2022
Lessee Disclosure [Abstract]
Operating leases	5 years	6 years
Finance leases	3 years	4 years

Leases - Summary of Weighted _2

Leases - Summary of Weighted Average Discount Rate (Details)	Mar. 31, 2023	Mar. 31, 2022
Lessee Disclosure [Abstract]
Operating leases	5.24%	4.50%
Finance leases	4.50%	4.50%

Commitments - Summary of Annual

Commitments - Summary of Annual Minimum Commitments Associated with Contractual Agreements (Details) $ in Thousands	Mar. 31, 2023 CAD ($)
Commitments and Contingencies Disclosure [Abstract]
2024	$ 118,211
2025	42,382
2026	28,981
2027	19,676
Total annual minimum commitment associated with contractual agreements	$ 209,250

Segmented Information - Additio

Segmented Information - Additional Information (Details)	3 Months Ended		12 Months Ended
	Sep. 30, 2022 Segment	Mar. 31, 2021 Segment	Mar. 31, 2023 Customer	Mar. 31, 2022 Customer	Mar. 31, 2021 Customer
Segment Reporting Information [Line Items]
Number of operating segments | Segment	2	2
Customer Concentration Risk | Revenue from Contract with Customer Benchmark
Segment Reporting Information [Line Items]
Concentration risk customer number of customers | Customer			0	1	0

Segmented Information - Summary

Segmented Information - Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) - CAD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
Net revenue	$ 104,031	$ 105,418	$ 105,920	$ 211,338	$ 315,369	$ 402,904	$ 510,321	$ 546,649
Gross margin	(95)	(7,955)	(5,586)	(13,541)	(13,636)	(104,140)	(203,136)	66,960
Selling, general and administrative expenses						456,225	472,756	575,389
Share-based compensation		14,581		20,020	26,448	31,188	47,525	91,149
Expected credit losses on financial assets and related charges								109,480
Asset impairment and restructuring costs		101,369		1,829,354	1,851,613	2,256,742	369,339	534,398
Operating loss	(151,418)	(249,747)	(1,842,423)	(2,092,170)	(2,243,588)	(2,848,295)	(1,092,756)	(1,243,456)
Loss from equity method investments							(100)	(52,629)
Other income (expense), net						(466,025)	753,341	(387,876)
Loss before income taxes	$ (264,758)	$ (297,591)	$ (2,088,001)	$ (2,385,592)	$ (2,650,350)	(3,314,320)	(339,515)	(1,683,961)
Canada Cannabis
Segment Reporting Information [Line Items]
Net revenue						187,067	257,910	285,049
Gross margin						(95,291)	(212,820)	(8,435)
Rest-of-world Cannabis
Segment Reporting Information [Line Items]
Net revenue						38,949	79,306	93,631
Gross margin						(3,322)	(28,875)	29,687
Storz & Bickel
Segment Reporting Information [Line Items]
Net revenue						64,845	85,410	80,998
Gross margin						26,112	37,284	34,231
BioSteel
Segment Reporting Information [Line Items]
Net revenue						69,649	34,622	28,530
Gross margin						(40,613)	(15,722)	1,689
This Works
Segment Reporting Information [Line Items]
Net revenue						26,029	32,296	33,314
Gross margin						10,205	14,800	17,350
Other Consumer Products
Segment Reporting Information [Line Items]
Net revenue						16,365	20,777	25,127
Gross margin						$ (1,231)	$ 2,197	$ (7,562)

Segmented Information - Summa_2

Segmented Information - Summary of Disaggregation of Net Revenue by Geographic Area (Details) - CAD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	$ 104,031	$ 105,418	$ 105,920	$ 211,338	$ 315,369	$ 402,904	$ 510,321	$ 546,649
CANADA
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue						268,457	286,365	329,172
Germany
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue						48,701	90,874	116,379
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue						39,042	82,080	64,926
Other
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue						$ 46,704	$ 51,002	$ 36,172

Segmented Information - Summa_3

Segmented Information - Summary of Disaggregation of Long-lived Tangible Assets by Geographic Areas (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	$ 499,466	$ 942,780
CANADA
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	361,778	827,591
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	85,772	63,247
Germany
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	51,341	48,355
Other
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	$ 575	$ 3,587

Restatement of Previously Iss_3

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Unaudited) - Summary of Effect of Restatement Items on Company's Unaudited Interim Condensed Consolidated Balance Sheets (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Amounts receivable, net	$ 93,987	$ 81,686	$ 82,416	$ 82,799	$ 86,581
Inventory	148,901	214,045	211,754	205,532	204,539
Prepaid expenses and other assets	39,999	51,705	62,741	61,843	52,620
Total current assets	1,077,254	1,149,618	1,512,684	1,579,466	1,727,612
Goodwill	85,563	84,675	79,112		1,866,503	$ 1,889,354
Total assets	2,439,098	2,939,462	3,319,378	3,503,421	5,605,260
Other liabilities	94,727	84,547	79,880	86,946	64,346
Total current liabilities	803,842	679,154	558,636	404,578	213,190
Total liabilities	1,679,076	1,580,819	1,754,476	1,834,777	1,984,845
Redeemable noncontrolling interest		1,000	12,676	28,150	32,500	135,300	$ 69,750
Additional paid-in capital	2,506,485	2,534,465	2,538,103	2,521,334	2,521,246
Deficit	(9,672,761)	(9,032,680)	(8,773,215)	(8,465,371)	(6,378,199)
Total Canopy Growth Corporation shareholders' equity	758,435	1,354,847	1,549,270	1,635,979	3,583,574
Noncontrolling interests	1,587				4,341
Total shareholders' equity	760,022	1,357,643	1,552,226	1,640,494	3,587,915	$ 3,486,520	$ 5,108,120
Total liabilities and shareholders' equity	$ 2,439,098	2,939,462	3,319,378	3,503,421	5,605,260
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Amounts receivable, net		104,640	108,236	96,626	96,443
Inventory		213,937	211,209	205,513	204,387
Prepaid expenses and other assets		52,151	62,957	62,141	52,700
Total current assets		1,172,910	1,538,175	1,593,572	1,737,402
Goodwill		142,076	136,513
Total assets		3,020,155	3,402,270	3,517,527	5,615,050
Other liabilities		84,134	63,645	86,776	64,054
Total current liabilities		678,741	542,401	404,408	212,898
Total liabilities		1,580,406	1,738,241	1,834,607	1,984,553
Redeemable noncontrolling interest		11,408	35,900	37,150	36,200
Additional paid-in capital		2,510,086	2,516,811	2,515,453	2,519,766
Deficit		(8,937,603)	(8,676,020)	(8,454,214)	(6,370,337)
Total Canopy Growth Corporation shareholders' equity		1,425,545	1,625,173	1,641,255	3,589,956
Total shareholders' equity		1,428,341	1,628,129	1,645,770	3,594,297
Total liabilities and shareholders' equity		3,020,155	3,402,270	3,517,527	5,615,050
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Amounts receivable, net		(22,954)	(25,820)	(13,827)	(9,862)
Inventory		108	545	19	152
Prepaid expenses and other assets		(446)	(216)	(298)	(80)
Total current assets		(23,292)	(25,491)	(14,106)	(9,790)
Goodwill		(57,401)	(57,401)
Total assets		(80,693)	(82,892)	(14,106)	(9,790)
Other liabilities		413	16,235	170	292
Total current liabilities		413	16,235	170	292
Total liabilities		413	16,235	170	292
Redeemable noncontrolling interest		(10,408)	(23,224)	(9,000)	(3,700)
Additional paid-in capital		24,379	21,292	5,881	1,480
Deficit		(95,077)	(97,195)	(11,157)	(7,862)
Total Canopy Growth Corporation shareholders' equity		(70,698)	(75,903)	(5,276)	(6,382)
Total shareholders' equity		(70,698)	(75,903)	(5,276)	(6,382)
Total liabilities and shareholders' equity		$ (80,693)	$ (82,892)	$ (14,106)	$ (9,790)

Restatement of Previously Iss_4

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Unaudited) - Summary of Effect of Restatement Items on Company's Unaudited Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Details) - CAD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue	$ 116,167	$ 117,914	$ 118,667	$ 236,581	$ 352,748	$ 450,901	$ 572,214	$ 607,198
Net revenue	104,031	105,418	105,920	211,338	315,369	402,904	510,321	546,649
Cost of goods sold	104,126	113,373	111,506	224,879	329,005	507,044	713,457	479,689
Gross margin	(95)	(7,955)	(5,586)	(13,541)	(13,636)	(104,140)	(203,136)	66,960
Operating expenses
Share-based compensation		14,581		20,020	26,448	31,188	47,525	91,149
Asset impairment and restructuring costs		101,369		1,829,354	1,851,613	2,256,742	369,339	534,398
Total operating expenses		241,792		2,078,629	2,229,952	2,744,155	889,620	1,310,416
Operating loss	(151,418)	(249,747)	(1,842,423)	(2,092,170)	(2,243,588)	(2,848,295)	(1,092,756)	(1,243,456)
Loss before income taxes	(264,758)	(297,591)	(2,088,001)	(2,385,592)	(2,650,350)	(3,314,320)	(339,515)	(1,683,961)
Net income (loss)	(264,376)	(305,811)	(2,091,750)	(2,397,561)	(2,661,937)	(3,309,546)	(330,567)	(1,670,820)
Net loss attributable to noncontrolling interests and redeemable noncontrolling interest	(4,911)	(13,641)	(5,307)	(18,948)	(23,859)	(31,388)	(20,524)	74,100
Net income (loss) attributable to Canopy Growth Corporation	$ (259,465)	$ (292,170)	$ (2,086,443)	$ (2,378,613)	$ (2,638,078)	$ (3,278,158)	$ (310,043)	$ (1,744,920)
Basic earnings (loss) per share	$ (0.53)	$ (0.62)	$ (5.24)	$ (5.47)	$ (5.82)	$ (7.07)	$ (0.79)	$ (4.69)
Diluted earnings (loss) per share	$ (0.53)	$ (0.62)	$ (5.24)	$ (5.47)	$ (5.82)	$ (7.07)	$ (0.79)	$ (4.69)
Comprehensive income (loss):
Comprehensive (loss) income	$ (244,917)	$ (295,547)	$ (2,063,932)	$ (2,359,479)	$ (2,604,396)	$ (3,251,617)	$ (354,739)	$ (1,925,959)
Comprehensive loss attributable to noncontrolling interests and redeemable noncontrolling interest	(4,911)	(13,641)	(5,307)	(18,948)	(23,859)	(31,388)	(20,524)	74,100
Comprehensive (loss) income attributable to Canopy Growth Corporation	(240,006)	(281,906)	(2,058,625)	(2,340,531)	(2,580,537)	$ (3,220,229)	(334,215)	$ (2,000,059)
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue	113,349	130,359	122,862	253,221	366,570		582,218
Net revenue	101,213	117,863	110,115	227,978	329,191		520,325
Cost of goods sold	103,654	114,042	111,507	225,549	329,203		713,379
Gross margin	(2,441)	3,821	(1,392)	2,429	(12)		(193,054)
Operating expenses
Share-based compensation		9,858		15,297	21,725
Asset impairment and restructuring costs		43,968		1,771,953	1,794,212
Total operating expenses		179,668		2,016,505	2,167,828
Operating loss	(153,764)	(175,847)	(1,838,229)	(2,014,076)	(2,167,840)		(1,082,674)
Loss before income taxes	(267,104)	(223,691)	(2,083,807)	(2,307,498)	(2,574,602)		(329,433)
Net income (loss)	(266,722)	(231,911)	(2,087,556)	(2,319,467)	(2,586,189)		(320,485)
Net loss attributable to noncontrolling interests and redeemable noncontrolling interest	(5,139)	(10,105)	(4,408)	(14,513)	(19,652)		(18,304)
Net income (loss) attributable to Canopy Growth Corporation	$ (261,583)	$ (221,806)	$ (2,083,148)	$ (2,304,954)	$ (2,566,537)		$ (302,181)
Basic earnings (loss) per share	$ (0.54)	$ (0.47)	$ (5.23)	$ (5.30)	$ (5.66)		$ (0.77)
Diluted earnings (loss) per share	$ (0.54)	$ (0.47)	$ (5.23)	$ (5.30)	$ (5.66)		$ (0.77)
Comprehensive income (loss):
Comprehensive (loss) income	$ (247,263)	$ (221,647)	$ (2,059,738)	$ (2,281,385)	$ (2,528,648)		$ (344,657)
Comprehensive loss attributable to noncontrolling interests and redeemable noncontrolling interest	(5,139)	(10,105)	(4,408)	(14,513)	(19,652)		(18,304)
Comprehensive (loss) income attributable to Canopy Growth Corporation	(242,124)	(211,542)	(2,055,330)	(2,266,872)	(2,508,996)		(326,353)
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue	2,818	(12,445)	(4,195)	(16,640)	(13,822)		(10,004)
Net revenue	2,818	(12,445)	(4,195)	(16,640)	(13,822)		(10,004)
Cost of goods sold	472	(669)	(1)	(670)	(198)		78
Gross margin	2,346	(11,776)	(4,194)	(15,970)	(13,624)		(10,082)
Operating expenses
Share-based compensation		4,723		4,723	4,723
Asset impairment and restructuring costs		57,401		57,401	57,401
Total operating expenses		62,124		62,124	62,124
Operating loss	2,346	(73,900)	(4,194)	(78,094)	(75,748)		(10,082)
Loss before income taxes	2,346	(73,900)	(4,194)	(78,094)	(75,748)		(10,082)
Net income (loss)	2,346	(73,900)	(4,194)	(78,094)	(75,748)		(10,082)
Net loss attributable to noncontrolling interests and redeemable noncontrolling interest	228	(3,536)	(899)	(4,435)	(4,207)		(2,220)
Net income (loss) attributable to Canopy Growth Corporation	$ 2,118	$ (70,364)	$ (3,295)	$ (73,659)	$ (71,541)		$ (7,862)
Basic earnings (loss) per share	$ 0.01	$ (0.15)	$ (0.01)	$ (0.17)	$ (0.16)		$ (0.02)
Diluted earnings (loss) per share	$ 0.01	$ (0.15)	$ (0.01)	$ (0.17)	$ (0.16)		$ (0.02)
Comprehensive income (loss):
Comprehensive (loss) income	$ 2,346	$ (73,900)	$ (4,194)	$ (78,094)	$ (75,748)		$ (10,082)
Comprehensive loss attributable to noncontrolling interests and redeemable noncontrolling interest	228	(3,536)	(899)	(4,435)	(4,207)		(2,220)
Comprehensive (loss) income attributable to Canopy Growth Corporation	$ 2,118	$ (70,364)	$ (3,295)	$ (73,659)	$ (71,541)		$ (7,862)

Restatement of Previously Iss_5

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Unaudited) - Summary of Effect of Restatement Items on Company's Unaudited Interim Condensed Consolidated Statements of Shareholders' Equity (Details) - CAD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity	$ 760,022	$ 1,357,643	$ 1,552,226	$ 1,640,494	$ 3,587,915	$ 3,486,520	$ 5,108,120
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity		1,428,341	1,628,129	1,645,770	3,594,297
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity		(70,698)	(75,903)	(5,276)	(6,382)
Additional Paid-in capital | Ownership Changes
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity	(521,961)	(507,696)	(505,000)		(509,723)	(512,340)	(501,403)
Additional Paid-in capital | Ownership Changes | As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity		(512,419)	(509,723)
Additional Paid-in capital | Ownership Changes | Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity		4,723	4,723
Additional Paid-in capital | Redeemable Noncontrolling Interest
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity	(51,492)	(45,051)	(40,140)	(43,817)	(42,860)	(121,234)	(40,134)
Additional Paid-in capital | Redeemable Noncontrolling Interest | As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity		(64,707)	(56,709)	(49,698)	(44,340)
Additional Paid-in capital | Redeemable Noncontrolling Interest | Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity		19,656	16,569	5,881	1,480
Deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity	$ (9,672,761)	(9,032,680)	(8,773,215)	(8,465,371)	(6,378,199)	$ (6,068,156)	$ (4,323,236)
Deficit | As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity		(8,937,603)	(8,676,020)	(8,454,214)	(6,370,337)
Deficit | Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total shareholders' equity		$ (95,077)	$ (97,195)	$ (11,157)	$ (7,862)

Restatement of Previously Iss_6

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Unaudited) - Summary of Effect of Restatement Items on Company's Unaudited Interim Condensed Consolidated Statements of Cash Flows (Details) - CAD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (264,376)	$ (305,811)	$ (2,091,750)	$ (2,397,561)	$ (2,661,937)	$ (3,309,546)	$ (330,567)	$ (1,670,820)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation				20,020	26,448	31,188	47,525	91,149
Asset impairment and restructuring costs				1,841,185	1,855,255	2,227,989	332,949	519,209
Change in operating assets and liabilities, net of effects from purchases of businesses:
Amounts receivable			3,781	4,163	4,893	(9,906)	13,603	(11,994)
Inventory			(993)	(7,215)	(9,506)	55,638	173,037	23,107
Prepaid expenses and other assets			(9,336)	(17,429)	(6,498)	2,484	24,552	77
Other, including non-cash foreign currency			1,806	(18,737)	(24,337)	(6,592)	(9,897)	(89,843)
Net cash used in operating activities			(140,515)	(273,915)	(417,809)	(557,546)	(545,811)	(465,729)
Cash and cash equivalents, end of period						$ 677,007	776,005	$ 1,154,653	$ 1,303,176
As Previously Reported
Cash flows from operating activities:
Net loss	(266,722)	(231,911)	(2,087,556)	(2,319,467)	(2,586,189)		(320,485)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation				15,297	21,725
Asset impairment and restructuring costs				1,783,784	1,797,854
Change in operating assets and liabilities, net of effects from purchases of businesses:
Amounts receivable			(183)	(11,793)	(8,197)		3,741
Inventory			(1,126)	(6,822)	(9,550)		173,189
Prepaid expenses and other assets			(9,555)	(17,567)	(6,866)		24,472
Other, including non-cash foreign currency			1,928	(19,006)	(24,459)		(10,189)
Net cash used in operating activities			(140,515)	(273,915)	(417,809)		(545,811)
Restatement Adjustment
Cash flows from operating activities:
Net loss	$ 2,346	$ (73,900)	(4,194)	(78,094)	(75,748)		(10,082)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation				4,723	4,723
Asset impairment and restructuring costs				57,401	57,401
Change in operating assets and liabilities, net of effects from purchases of businesses:
Amounts receivable			3,964	15,956	13,090		9,862
Inventory			133	(393)	44		(152)
Prepaid expenses and other assets			219	138	368		80
Other, including non-cash foreign currency			$ (122)	$ 269	$ 122		$ 292

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) $ in Thousands, shares in Millions	May 30, 2024 CAD ($)	May 30, 2023 CAD ($) shares	May 19, 2023 USD ($)	Apr. 14, 2023 CAD ($)
Assignment Agreement | Indiva Inc | Forecast
Subsequent Event [Line Items]
Cash payment	$ 1,250
Subsequent Event | April 2023 Exchange Agreement
Subsequent Event [Line Items]
Extinguishment of debt, amount				$ 100,000
Principal amount				100,000
Subsequent Event | April 2023 Exchange Agreement | Promissory Note
Subsequent Event [Line Items]
Notes payable				$ 100,000
Annual interest rate				4.25%
Maturity date				Dec. 31, 2024
Subsequent Event | Manufacturing Agreement | Indiva Inc | Canada
Subsequent Event [Line Items]
Agreement term		5 years
Agreement term additional renewal period		5 years
Subsequent Event | Assignment Agreement | Indiva Inc
Subsequent Event [Line Items]
Number of common shares subscribed | shares		37.2
Aggregate purchase price		$ 2,156
Cash payment		$ 844
Subsequent Event | Maximum | Trust SPA
Subsequent Event [Line Items]
Aggregate investment amount			$ 20,000,000
Aggregate value of shares issued in two tranches			10,000,000
Options granted to acquire additional voting shares, value			$ 10,000,000
Subsequent Event | Minimum | Class B Shares | Reorganization Amendments
Subsequent Event [Line Items]
Percentage of common shares to be issued to former holders			10%
Percentage of shares owned			90%